{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "8605a806-a1a1-4bd4-91af-5c29c00592ab",
   "metadata": {},
   "source": [
    "# project log\n",
    "\n",
    "## 20-Jan-2026: \n",
    "### Explored the https://clinicaltrials.gov/data-api/api webstie to investigate the possible functions we could write"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "11f4341c-717a-4b0e-9ce9-df81e7226750",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "No encoding supplied: defaulting to UTF-8.\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<style>\n",
       ".list-inline {list-style: none; margin:0; padding: 0}\n",
       ".list-inline>li {display: inline-block}\n",
       ".list-inline>li:not(:last-child)::after {content: \"\\00b7\"; padding: 0 .5ex}\n",
       "</style>\n",
       "<ol class=list-inline><li>'studies'</li><li>'nextPageToken'</li></ol>\n"
      ],
      "text/latex": [
       "\\begin{enumerate*}\n",
       "\\item 'studies'\n",
       "\\item 'nextPageToken'\n",
       "\\end{enumerate*}\n"
      ],
      "text/markdown": [
       "1. 'studies'\n",
       "2. 'nextPageToken'\n",
       "\n",
       "\n"
      ],
      "text/plain": [
       "[1] \"studies\"       \"nextPageToken\""
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<dl>\n",
       "\t<dt>$protocolSection</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$identificationModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$nctId</dt>\n",
       "\t\t<dd>'NCT04441658'</dd>\n",
       "\t<dt>$orgStudyIdInfo</dt>\n",
       "\t\t<dd><strong>$id</strong> = 'DFSC-2020(CR)-02'</dd>\n",
       "\t<dt>$organization</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$fullName</dt>\n",
       "\t\t<dd>'Shanghai East Hospital'</dd>\n",
       "\t<dt>$class</dt>\n",
       "\t\t<dd>'OTHER'</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$briefTitle</dt>\n",
       "\t\t<dd>'Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus'</dd>\n",
       "\t<dt>$officialTitle</dt>\n",
       "\t\t<dd>'Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus'</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$statusModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$statusVerifiedDate</dt>\n",
       "\t\t<dd>'2020-06'</dd>\n",
       "\t<dt>$overallStatus</dt>\n",
       "\t\t<dd>'UNKNOWN'</dd>\n",
       "\t<dt>$lastKnownStatus</dt>\n",
       "\t\t<dd>'RECRUITING'</dd>\n",
       "\t<dt>$expandedAccessInfo</dt>\n",
       "\t\t<dd><strong>$hasExpandedAccess</strong> = FALSE</dd>\n",
       "\t<dt>$startDateStruct</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$date</dt>\n",
       "\t\t<dd>'2020-04-10'</dd>\n",
       "\t<dt>$type</dt>\n",
       "\t\t<dd>'ACTUAL'</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$primaryCompletionDateStruct</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$date</dt>\n",
       "\t\t<dd>'2022-07'</dd>\n",
       "\t<dt>$type</dt>\n",
       "\t\t<dd>'ESTIMATED'</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$completionDateStruct</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$date</dt>\n",
       "\t\t<dd>'2022-12'</dd>\n",
       "\t<dt>$type</dt>\n",
       "\t\t<dd>'ESTIMATED'</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$studyFirstSubmitDate</dt>\n",
       "\t\t<dd>'2020-06-19'</dd>\n",
       "\t<dt>$studyFirstSubmitQcDate</dt>\n",
       "\t\t<dd>'2020-06-19'</dd>\n",
       "\t<dt>$studyFirstPostDateStruct</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$date</dt>\n",
       "\t\t<dd>'2020-06-22'</dd>\n",
       "\t<dt>$type</dt>\n",
       "\t\t<dd>'ACTUAL'</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$lastUpdateSubmitDate</dt>\n",
       "\t\t<dd>'2020-06-19'</dd>\n",
       "\t<dt>$lastUpdatePostDateStruct</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$date</dt>\n",
       "\t\t<dd>'2020-06-22'</dd>\n",
       "\t<dt>$type</dt>\n",
       "\t\t<dd>'ACTUAL'</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$sponsorCollaboratorsModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$responsibleParty</dt>\n",
       "\t\t<dd><strong>$type</strong> = 'SPONSOR'</dd>\n",
       "\t<dt>$leadSponsor</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$name</dt>\n",
       "\t\t<dd>'Shanghai East Hospital'</dd>\n",
       "\t<dt>$class</dt>\n",
       "\t\t<dd>'OTHER'</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$oversightModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$isFdaRegulatedDrug</dt>\n",
       "\t\t<dd>FALSE</dd>\n",
       "\t<dt>$isFdaRegulatedDevice</dt>\n",
       "\t\t<dd>FALSE</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$descriptionModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$briefSummary</dt>\n",
       "\t\t<dd>'This study is a 24-week single-center, randomized, double-blind, placebo-controlled trial. The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion therapy.'</dd>\n",
       "\t<dt>$detailedDescription</dt>\n",
       "\t\t<dd>'This study is a 24-week single-center, randomized, double-blind, placebo-controlled trial. The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment（including insulin） were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion therapy.'</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$conditionsModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$conditions</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li>'Type 2 Diabetes'</li>\n",
       "\t<li>'Mesenchymal Stem Cells'</li>\n",
       "</ol>\n",
       "</dd>\n",
       "\t<dt>$keywords</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li>'Umbilical Cord Mesenchymal Stem Cells'</li>\n",
       "\t<li>'Type 2 Diabetes'</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$designModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$studyType</dt>\n",
       "\t\t<dd>'INTERVENTIONAL'</dd>\n",
       "\t<dt>$phases</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li>'PHASE1'</li>\n",
       "\t<li>'PHASE2'</li>\n",
       "</ol>\n",
       "</dd>\n",
       "\t<dt>$designInfo</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$allocation</dt>\n",
       "\t\t<dd>'RANDOMIZED'</dd>\n",
       "\t<dt>$interventionModel</dt>\n",
       "\t\t<dd>'PARALLEL'</dd>\n",
       "\t<dt>$primaryPurpose</dt>\n",
       "\t\t<dd>'TREATMENT'</dd>\n",
       "\t<dt>$maskingInfo</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$masking</dt>\n",
       "\t\t<dd>'TRIPLE'</dd>\n",
       "\t<dt>$whoMasked</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li>'PARTICIPANT'</li>\n",
       "\t<li>'CARE_PROVIDER'</li>\n",
       "\t<li>'INVESTIGATOR'</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$enrollmentInfo</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$count</dt>\n",
       "\t\t<dd>30</dd>\n",
       "\t<dt>$type</dt>\n",
       "\t\t<dd>'ESTIMATED'</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$armsInterventionsModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$armGroups</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$label</dt>\n",
       "\t\t<dd>'experimental group'</dd>\n",
       "\t<dt>$type</dt>\n",
       "\t\t<dd>'EXPERIMENTAL'</dd>\n",
       "\t<dt>$description</dt>\n",
       "\t\t<dd>'The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75\\\\*10\\\\^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.'</dd>\n",
       "\t<dt>$interventionNames</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li>'Biological: Umbilical Cord Mesenchymal Stem Cells'</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$label</dt>\n",
       "\t\t<dd>'control group'</dd>\n",
       "\t<dt>$type</dt>\n",
       "\t\t<dd>'PLACEBO_COMPARATOR'</dd>\n",
       "\t<dt>$description</dt>\n",
       "\t\t<dd>'The control group will be given the same dose of saline containing human albumin.'</dd>\n",
       "\t<dt>$interventionNames</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li>'Biological: saline'</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "\t<dt>$interventions</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$type</dt>\n",
       "\t\t<dd>'BIOLOGICAL'</dd>\n",
       "\t<dt>$name</dt>\n",
       "\t\t<dd>'Umbilical Cord Mesenchymal Stem Cells'</dd>\n",
       "\t<dt>$description</dt>\n",
       "\t\t<dd>'human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group'</dd>\n",
       "\t<dt>$armGroupLabels</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li>'experimental group'</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$type</dt>\n",
       "\t\t<dd>'BIOLOGICAL'</dd>\n",
       "\t<dt>$name</dt>\n",
       "\t\t<dd>'saline'</dd>\n",
       "\t<dt>$description</dt>\n",
       "\t\t<dd>'saline containing human albumin will be infused to the control group'</dd>\n",
       "\t<dt>$armGroupLabels</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li>'control group'</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$outcomesModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$primaryOutcomes</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$measure</dt>\n",
       "\t\t<dd>'The changes in HbA1C level'</dd>\n",
       "\t<dt>$description</dt>\n",
       "\t\t<dd>'The changes in HbA1C level after transplantation'</dd>\n",
       "\t<dt>$timeFrame</dt>\n",
       "\t\t<dd>'24 weeks after treatment'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "\t<dt>$secondaryOutcomes</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$measure</dt>\n",
       "\t\t<dd>'Reduction of insulin requirement'</dd>\n",
       "\t<dt>$description</dt>\n",
       "\t\t<dd>'Reduction of insulin requirement after transplantation'</dd>\n",
       "\t<dt>$timeFrame</dt>\n",
       "\t\t<dd>'24 weeks after treatment'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$measure</dt>\n",
       "\t\t<dd>'The changes in blood glucose level'</dd>\n",
       "\t<dt>$description</dt>\n",
       "\t\t<dd>'The changes in blood glucose level after transplantation'</dd>\n",
       "\t<dt>$timeFrame</dt>\n",
       "\t\t<dd>'24 weeks after treatment'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$eligibilityModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$eligibilityCriteria</dt>\n",
       "\t\t<dd>'Inclusion Criteria:\\n\\n1. Type 2 diabetes；\\n2. The course of diabetes is 5-15 years;\\n3. 20kg/m2≤body mass index (BMI)≤30 kg /m2；\\n4. 7.5% ≤HbA1c≤10%；\\n5. Insulin dose and other oral antidiabetic drugs doses should be stable over the 3 months prior to randomization.\\n\\nExclusion Criteria:\\n\\n1. Heavy allergic constitution or an allergy to any component used in cell culture.\\n2. Being treated with drug (Glucocorticoids，Tricyclic Antidepressive Agents,etc.) affect the metabolism of glucose in the past 1 month;\\n3. other causes of diabetes;\\n4. All kinds of acute complications such as diabetic ketoacidosis and non-ketohyperosmotic syndrome were screened in the past 6 months;\\n5. Having evidence of ongoing or frequent/severe hypoglycemia in the past 6 months;\\n6. Severe cardiovascular and cerebral events：occurrence of heart failure NYHA Classification III or IV, myocardial infarction, cerebral infarction, cerebral hemorrhage within 6 months before the observation period;\\n7. Patients with abnormal liver and kidney function: AST and ALT exceeding 2.5 times of the normal upper limit, and serum creatinine exceeding 1.5 mg/dl for men, exceeding 1.4 mg/dl for women;\\n8. Positive results of HbsAg、Anti-HCV、HIV or syphilis;\\n9. Patients suffering from other serious systemic diseases (such as malignancy, central nervous system,cardiovascular system, blood system, digestive system,endocrine system,respiratory system, genitourinary system, immune system and);\\n10. Ongoing pregnancy or absence of effective contraception in women with childbearing potential;\\n11. Patients who had received other stem cell therapy before screening.'</dd>\n",
       "\t<dt>$healthyVolunteers</dt>\n",
       "\t\t<dd>FALSE</dd>\n",
       "\t<dt>$sex</dt>\n",
       "\t\t<dd>'ALL'</dd>\n",
       "\t<dt>$minimumAge</dt>\n",
       "\t\t<dd>'30 Years'</dd>\n",
       "\t<dt>$maximumAge</dt>\n",
       "\t\t<dd>'75 Years'</dd>\n",
       "\t<dt>$stdAges</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li>'ADULT'</li>\n",
       "\t<li>'OLDER_ADULT'</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$contactsLocationsModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$centralContacts</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$name</dt>\n",
       "\t\t<dd>'wang congrong, doctor'</dd>\n",
       "\t<dt>$role</dt>\n",
       "\t\t<dd>'CONTACT'</dd>\n",
       "\t<dt>$phone</dt>\n",
       "\t\t<dd>'+86-021-38804518'</dd>\n",
       "\t<dt>$email</dt>\n",
       "\t\t<dd>'wcr601@163.com'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$name</dt>\n",
       "\t\t<dd>'liu zhongmin, doctor'</dd>\n",
       "\t<dt>$role</dt>\n",
       "\t\t<dd>'CONTACT'</dd>\n",
       "\t<dt>$phone</dt>\n",
       "\t\t<dd>'+86-021-38804518'</dd>\n",
       "\t<dt>$email</dt>\n",
       "\t\t<dd>'liu.zhongmin@tongji.edu.cn'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "\t<dt>$overallOfficials</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$name</dt>\n",
       "\t\t<dd>'wang congrong, doctor'</dd>\n",
       "\t<dt>$affiliation</dt>\n",
       "\t\t<dd>'Shanghai East Hospital, China'</dd>\n",
       "\t<dt>$role</dt>\n",
       "\t\t<dd>'PRINCIPAL_INVESTIGATOR'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "\t<dt>$locations</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$facility</dt>\n",
       "\t\t<dd>'Shanghai East Hospital, Shanghai Tongji University'</dd>\n",
       "\t<dt>$status</dt>\n",
       "\t\t<dd>'RECRUITING'</dd>\n",
       "\t<dt>$city</dt>\n",
       "\t\t<dd>'Shanghai'</dd>\n",
       "\t<dt>$state</dt>\n",
       "\t\t<dd>'Shanghai Municipality'</dd>\n",
       "\t<dt>$zip</dt>\n",
       "\t\t<dd>'200120'</dd>\n",
       "\t<dt>$country</dt>\n",
       "\t\t<dd>'China'</dd>\n",
       "\t<dt>$contacts</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$name</dt>\n",
       "\t\t<dd>'wang congrong, doctor'</dd>\n",
       "\t<dt>$role</dt>\n",
       "\t\t<dd>'CONTACT'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "\t<dt>$geoPoint</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$lat</dt>\n",
       "\t\t<dd>31.22222</dd>\n",
       "\t<dt>$lon</dt>\n",
       "\t\t<dd>121.45806</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$derivedSection</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$miscInfoModule</dt>\n",
       "\t\t<dd><strong>$versionHolder</strong> = '2026-01-20'</dd>\n",
       "\t<dt>$conditionBrowseModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$meshes</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D003924'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Diabetes Mellitus, Type 2'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "\t<dt>$ancestors</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D003920'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Diabetes Mellitus'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D044882'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Glucose Metabolism Disorders'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D008659'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Metabolic Diseases'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D009750'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Nutritional and Metabolic Diseases'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D004700'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Endocrine System Diseases'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$interventionBrowseModule</dt>\n",
       "\t\t<dd><dl>\n",
       "\t<dt>$meshes</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D012965'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Sodium Chloride'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "\t<dt>$ancestors</dt>\n",
       "\t\t<dd><ol>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D002712'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Chlorides'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D006851'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Hydrochloric Acid'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D017606'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Chlorine Compounds'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D007287'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Inorganic Chemicals'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "\t<li><dl>\n",
       "\t<dt>$id</dt>\n",
       "\t\t<dd>'D017670'</dd>\n",
       "\t<dt>$term</dt>\n",
       "\t\t<dd>'Sodium Compounds'</dd>\n",
       "</dl>\n",
       "</li>\n",
       "</ol>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "</dl>\n",
       "</dd>\n",
       "\t<dt>$hasResults</dt>\n",
       "\t\t<dd>FALSE</dd>\n",
       "</dl>\n"
      ],
      "text/latex": [
       "\\begin{description}\n",
       "\\item[\\$protocolSection] \\begin{description}\n",
       "\\item[\\$identificationModule] \\begin{description}\n",
       "\\item[\\$nctId] 'NCT04441658'\n",
       "\\item[\\$orgStudyIdInfo] \\textbf{\\$id} = 'DFSC-2020(CR)-02'\n",
       "\\item[\\$organization] \\begin{description}\n",
       "\\item[\\$fullName] 'Shanghai East Hospital'\n",
       "\\item[\\$class] 'OTHER'\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$briefTitle] 'Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus'\n",
       "\\item[\\$officialTitle] 'Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus'\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$statusModule] \\begin{description}\n",
       "\\item[\\$statusVerifiedDate] '2020-06'\n",
       "\\item[\\$overallStatus] 'UNKNOWN'\n",
       "\\item[\\$lastKnownStatus] 'RECRUITING'\n",
       "\\item[\\$expandedAccessInfo] \\textbf{\\$hasExpandedAccess} = FALSE\n",
       "\\item[\\$startDateStruct] \\begin{description}\n",
       "\\item[\\$date] '2020-04-10'\n",
       "\\item[\\$type] 'ACTUAL'\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$primaryCompletionDateStruct] \\begin{description}\n",
       "\\item[\\$date] '2022-07'\n",
       "\\item[\\$type] 'ESTIMATED'\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$completionDateStruct] \\begin{description}\n",
       "\\item[\\$date] '2022-12'\n",
       "\\item[\\$type] 'ESTIMATED'\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$studyFirstSubmitDate] '2020-06-19'\n",
       "\\item[\\$studyFirstSubmitQcDate] '2020-06-19'\n",
       "\\item[\\$studyFirstPostDateStruct] \\begin{description}\n",
       "\\item[\\$date] '2020-06-22'\n",
       "\\item[\\$type] 'ACTUAL'\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$lastUpdateSubmitDate] '2020-06-19'\n",
       "\\item[\\$lastUpdatePostDateStruct] \\begin{description}\n",
       "\\item[\\$date] '2020-06-22'\n",
       "\\item[\\$type] 'ACTUAL'\n",
       "\\end{description}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$sponsorCollaboratorsModule] \\begin{description}\n",
       "\\item[\\$responsibleParty] \\textbf{\\$type} = 'SPONSOR'\n",
       "\\item[\\$leadSponsor] \\begin{description}\n",
       "\\item[\\$name] 'Shanghai East Hospital'\n",
       "\\item[\\$class] 'OTHER'\n",
       "\\end{description}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$oversightModule] \\begin{description}\n",
       "\\item[\\$isFdaRegulatedDrug] FALSE\n",
       "\\item[\\$isFdaRegulatedDevice] FALSE\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$descriptionModule] \\begin{description}\n",
       "\\item[\\$briefSummary] 'This study is a 24-week single-center, randomized, double-blind, placebo-controlled trial. The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion therapy.'\n",
       "\\item[\\$detailedDescription] 'This study is a 24-week single-center, randomized, double-blind, placebo-controlled trial. The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment（including insulin） were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion therapy.'\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$conditionsModule] \\begin{description}\n",
       "\\item[\\$conditions] \\begin{enumerate}\n",
       "\\item 'Type 2 Diabetes'\n",
       "\\item 'Mesenchymal Stem Cells'\n",
       "\\end{enumerate}\n",
       "\n",
       "\\item[\\$keywords] \\begin{enumerate}\n",
       "\\item 'Umbilical Cord Mesenchymal Stem Cells'\n",
       "\\item 'Type 2 Diabetes'\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$designModule] \\begin{description}\n",
       "\\item[\\$studyType] 'INTERVENTIONAL'\n",
       "\\item[\\$phases] \\begin{enumerate}\n",
       "\\item 'PHASE1'\n",
       "\\item 'PHASE2'\n",
       "\\end{enumerate}\n",
       "\n",
       "\\item[\\$designInfo] \\begin{description}\n",
       "\\item[\\$allocation] 'RANDOMIZED'\n",
       "\\item[\\$interventionModel] 'PARALLEL'\n",
       "\\item[\\$primaryPurpose] 'TREATMENT'\n",
       "\\item[\\$maskingInfo] \\begin{description}\n",
       "\\item[\\$masking] 'TRIPLE'\n",
       "\\item[\\$whoMasked] \\begin{enumerate}\n",
       "\\item 'PARTICIPANT'\n",
       "\\item 'CARE\\_PROVIDER'\n",
       "\\item 'INVESTIGATOR'\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$enrollmentInfo] \\begin{description}\n",
       "\\item[\\$count] 30\n",
       "\\item[\\$type] 'ESTIMATED'\n",
       "\\end{description}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$armsInterventionsModule] \\begin{description}\n",
       "\\item[\\$armGroups] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$label] 'experimental group'\n",
       "\\item[\\$type] 'EXPERIMENTAL'\n",
       "\\item[\\$description] 'The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75\\textbackslash{}\\textbackslash{}*10\\textbackslash{}\\textbackslash{}\\textasciicircum{}6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.'\n",
       "\\item[\\$interventionNames] \\begin{enumerate}\n",
       "\\item 'Biological: Umbilical Cord Mesenchymal Stem Cells'\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$label] 'control group'\n",
       "\\item[\\$type] 'PLACEBO\\_COMPARATOR'\n",
       "\\item[\\$description] 'The control group will be given the same dose of saline containing human albumin.'\n",
       "\\item[\\$interventionNames] \\begin{enumerate}\n",
       "\\item 'Biological: saline'\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\item[\\$interventions] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$type] 'BIOLOGICAL'\n",
       "\\item[\\$name] 'Umbilical Cord Mesenchymal Stem Cells'\n",
       "\\item[\\$description] 'human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group'\n",
       "\\item[\\$armGroupLabels] \\begin{enumerate}\n",
       "\\item 'experimental group'\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$type] 'BIOLOGICAL'\n",
       "\\item[\\$name] 'saline'\n",
       "\\item[\\$description] 'saline containing human albumin will be infused to the control group'\n",
       "\\item[\\$armGroupLabels] \\begin{enumerate}\n",
       "\\item 'control group'\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$outcomesModule] \\begin{description}\n",
       "\\item[\\$primaryOutcomes] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$measure] 'The changes in HbA1C level'\n",
       "\\item[\\$description] 'The changes in HbA1C level after transplantation'\n",
       "\\item[\\$timeFrame] '24 weeks after treatment'\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\item[\\$secondaryOutcomes] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$measure] 'Reduction of insulin requirement'\n",
       "\\item[\\$description] 'Reduction of insulin requirement after transplantation'\n",
       "\\item[\\$timeFrame] '24 weeks after treatment'\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$measure] 'The changes in blood glucose level'\n",
       "\\item[\\$description] 'The changes in blood glucose level after transplantation'\n",
       "\\item[\\$timeFrame] '24 weeks after treatment'\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$eligibilityModule] \\begin{description}\n",
       "\\item[\\$eligibilityCriteria] 'Inclusion Criteria:\\textbackslash{}n\\textbackslash{}n1. Type 2 diabetes；\\textbackslash{}n2. The course of diabetes is 5-15 years;\\textbackslash{}n3. 20kg/m2≤body mass index (BMI)≤30 kg /m2；\\textbackslash{}n4. 7.5\\% ≤HbA1c≤10\\%；\\textbackslash{}n5. Insulin dose and other oral antidiabetic drugs doses should be stable over the 3 months prior to randomization.\\textbackslash{}n\\textbackslash{}nExclusion Criteria:\\textbackslash{}n\\textbackslash{}n1. Heavy allergic constitution or an allergy to any component used in cell culture.\\textbackslash{}n2. Being treated with drug (Glucocorticoids，Tricyclic Antidepressive Agents,etc.) affect the metabolism of glucose in the past 1 month;\\textbackslash{}n3. other causes of diabetes;\\textbackslash{}n4. All kinds of acute complications such as diabetic ketoacidosis and non-ketohyperosmotic syndrome were screened in the past 6 months;\\textbackslash{}n5. Having evidence of ongoing or frequent/severe hypoglycemia in the past 6 months;\\textbackslash{}n6. Severe cardiovascular and cerebral events：occurrence of heart failure NYHA Classification III or IV, myocardial infarction, cerebral infarction, cerebral hemorrhage within 6 months before the observation period;\\textbackslash{}n7. Patients with abnormal liver and kidney function: AST and ALT exceeding 2.5 times of the normal upper limit, and serum creatinine exceeding 1.5 mg/dl for men, exceeding 1.4 mg/dl for women;\\textbackslash{}n8. Positive results of HbsAg、Anti-HCV、HIV or syphilis;\\textbackslash{}n9. Patients suffering from other serious systemic diseases (such as malignancy, central nervous system,cardiovascular system, blood system, digestive system,endocrine system,respiratory system, genitourinary system, immune system and);\\textbackslash{}n10. Ongoing pregnancy or absence of effective contraception in women with childbearing potential;\\textbackslash{}n11. Patients who had received other stem cell therapy before screening.'\n",
       "\\item[\\$healthyVolunteers] FALSE\n",
       "\\item[\\$sex] 'ALL'\n",
       "\\item[\\$minimumAge] '30 Years'\n",
       "\\item[\\$maximumAge] '75 Years'\n",
       "\\item[\\$stdAges] \\begin{enumerate}\n",
       "\\item 'ADULT'\n",
       "\\item 'OLDER\\_ADULT'\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$contactsLocationsModule] \\begin{description}\n",
       "\\item[\\$centralContacts] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$name] 'wang congrong, doctor'\n",
       "\\item[\\$role] 'CONTACT'\n",
       "\\item[\\$phone] '+86-021-38804518'\n",
       "\\item[\\$email] 'wcr601@163.com'\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$name] 'liu zhongmin, doctor'\n",
       "\\item[\\$role] 'CONTACT'\n",
       "\\item[\\$phone] '+86-021-38804518'\n",
       "\\item[\\$email] 'liu.zhongmin@tongji.edu.cn'\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\item[\\$overallOfficials] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$name] 'wang congrong, doctor'\n",
       "\\item[\\$affiliation] 'Shanghai East Hospital, China'\n",
       "\\item[\\$role] 'PRINCIPAL\\_INVESTIGATOR'\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\item[\\$locations] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$facility] 'Shanghai East Hospital, Shanghai Tongji University'\n",
       "\\item[\\$status] 'RECRUITING'\n",
       "\\item[\\$city] 'Shanghai'\n",
       "\\item[\\$state] 'Shanghai Municipality'\n",
       "\\item[\\$zip] '200120'\n",
       "\\item[\\$country] 'China'\n",
       "\\item[\\$contacts] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$name] 'wang congrong, doctor'\n",
       "\\item[\\$role] 'CONTACT'\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\item[\\$geoPoint] \\begin{description}\n",
       "\\item[\\$lat] 31.22222\n",
       "\\item[\\$lon] 121.45806\n",
       "\\end{description}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$derivedSection] \\begin{description}\n",
       "\\item[\\$miscInfoModule] \\textbf{\\$versionHolder} = '2026-01-20'\n",
       "\\item[\\$conditionBrowseModule] \\begin{description}\n",
       "\\item[\\$meshes] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D003924'\n",
       "\\item[\\$term] 'Diabetes Mellitus, Type 2'\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\item[\\$ancestors] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D003920'\n",
       "\\item[\\$term] 'Diabetes Mellitus'\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D044882'\n",
       "\\item[\\$term] 'Glucose Metabolism Disorders'\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D008659'\n",
       "\\item[\\$term] 'Metabolic Diseases'\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D009750'\n",
       "\\item[\\$term] 'Nutritional and Metabolic Diseases'\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D004700'\n",
       "\\item[\\$term] 'Endocrine System Diseases'\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$interventionBrowseModule] \\begin{description}\n",
       "\\item[\\$meshes] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D012965'\n",
       "\\item[\\$term] 'Sodium Chloride'\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\item[\\$ancestors] \\begin{enumerate}\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D002712'\n",
       "\\item[\\$term] 'Chlorides'\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D006851'\n",
       "\\item[\\$term] 'Hydrochloric Acid'\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D017606'\n",
       "\\item[\\$term] 'Chlorine Compounds'\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D007287'\n",
       "\\item[\\$term] 'Inorganic Chemicals'\n",
       "\\end{description}\n",
       "\n",
       "\\item \\begin{description}\n",
       "\\item[\\$id] 'D017670'\n",
       "\\item[\\$term] 'Sodium Compounds'\n",
       "\\end{description}\n",
       "\n",
       "\\end{enumerate}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\end{description}\n",
       "\n",
       "\\item[\\$hasResults] FALSE\n",
       "\\end{description}\n"
      ],
      "text/markdown": [
       "$protocolSection\n",
       ":   $identificationModule\n",
       ":   $nctId\n",
       ":   'NCT04441658'\n",
       "$orgStudyIdInfo\n",
       ":   **$id** = 'DFSC-2020(CR)-02'\n",
       "$organization\n",
       ":   $fullName\n",
       ":   'Shanghai East Hospital'\n",
       "$class\n",
       ":   'OTHER'\n",
       "\n",
       "\n",
       "\n",
       "$briefTitle\n",
       ":   'Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus'\n",
       "$officialTitle\n",
       ":   'Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus'\n",
       "\n",
       "\n",
       "\n",
       "$statusModule\n",
       ":   $statusVerifiedDate\n",
       ":   '2020-06'\n",
       "$overallStatus\n",
       ":   'UNKNOWN'\n",
       "$lastKnownStatus\n",
       ":   'RECRUITING'\n",
       "$expandedAccessInfo\n",
       ":   **$hasExpandedAccess** = FALSE\n",
       "$startDateStruct\n",
       ":   $date\n",
       ":   '2020-04-10'\n",
       "$type\n",
       ":   'ACTUAL'\n",
       "\n",
       "\n",
       "\n",
       "$primaryCompletionDateStruct\n",
       ":   $date\n",
       ":   '2022-07'\n",
       "$type\n",
       ":   'ESTIMATED'\n",
       "\n",
       "\n",
       "\n",
       "$completionDateStruct\n",
       ":   $date\n",
       ":   '2022-12'\n",
       "$type\n",
       ":   'ESTIMATED'\n",
       "\n",
       "\n",
       "\n",
       "$studyFirstSubmitDate\n",
       ":   '2020-06-19'\n",
       "$studyFirstSubmitQcDate\n",
       ":   '2020-06-19'\n",
       "$studyFirstPostDateStruct\n",
       ":   $date\n",
       ":   '2020-06-22'\n",
       "$type\n",
       ":   'ACTUAL'\n",
       "\n",
       "\n",
       "\n",
       "$lastUpdateSubmitDate\n",
       ":   '2020-06-19'\n",
       "$lastUpdatePostDateStruct\n",
       ":   $date\n",
       ":   '2020-06-22'\n",
       "$type\n",
       ":   'ACTUAL'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$sponsorCollaboratorsModule\n",
       ":   $responsibleParty\n",
       ":   **$type** = 'SPONSOR'\n",
       "$leadSponsor\n",
       ":   $name\n",
       ":   'Shanghai East Hospital'\n",
       "$class\n",
       ":   'OTHER'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$oversightModule\n",
       ":   $isFdaRegulatedDrug\n",
       ":   FALSE\n",
       "$isFdaRegulatedDevice\n",
       ":   FALSE\n",
       "\n",
       "\n",
       "\n",
       "$descriptionModule\n",
       ":   $briefSummary\n",
       ":   'This study is a 24-week single-center, randomized, double-blind, placebo-controlled trial. The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion therapy.'\n",
       "$detailedDescription\n",
       ":   'This study is a 24-week single-center, randomized, double-blind, placebo-controlled trial. The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment（including insulin） were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion therapy.'\n",
       "\n",
       "\n",
       "\n",
       "$conditionsModule\n",
       ":   $conditions\n",
       ":   1. 'Type 2 Diabetes'\n",
       "2. 'Mesenchymal Stem Cells'\n",
       "\n",
       "\n",
       "\n",
       "$keywords\n",
       ":   1. 'Umbilical Cord Mesenchymal Stem Cells'\n",
       "2. 'Type 2 Diabetes'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$designModule\n",
       ":   $studyType\n",
       ":   'INTERVENTIONAL'\n",
       "$phases\n",
       ":   1. 'PHASE1'\n",
       "2. 'PHASE2'\n",
       "\n",
       "\n",
       "\n",
       "$designInfo\n",
       ":   $allocation\n",
       ":   'RANDOMIZED'\n",
       "$interventionModel\n",
       ":   'PARALLEL'\n",
       "$primaryPurpose\n",
       ":   'TREATMENT'\n",
       "$maskingInfo\n",
       ":   $masking\n",
       ":   'TRIPLE'\n",
       "$whoMasked\n",
       ":   1. 'PARTICIPANT'\n",
       "2. 'CARE_PROVIDER'\n",
       "3. 'INVESTIGATOR'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$enrollmentInfo\n",
       ":   $count\n",
       ":   30\n",
       "$type\n",
       ":   'ESTIMATED'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$armsInterventionsModule\n",
       ":   $armGroups\n",
       ":   1. $label\n",
       ":   'experimental group'\n",
       "$type\n",
       ":   'EXPERIMENTAL'\n",
       "$description\n",
       ":   'The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75\\\\*10\\\\^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.'\n",
       "$interventionNames\n",
       ":   1. 'Biological: Umbilical Cord Mesenchymal Stem Cells'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "2. $label\n",
       ":   'control group'\n",
       "$type\n",
       ":   'PLACEBO_COMPARATOR'\n",
       "$description\n",
       ":   'The control group will be given the same dose of saline containing human albumin.'\n",
       "$interventionNames\n",
       ":   1. 'Biological: saline'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$interventions\n",
       ":   1. $type\n",
       ":   'BIOLOGICAL'\n",
       "$name\n",
       ":   'Umbilical Cord Mesenchymal Stem Cells'\n",
       "$description\n",
       ":   'human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group'\n",
       "$armGroupLabels\n",
       ":   1. 'experimental group'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "2. $type\n",
       ":   'BIOLOGICAL'\n",
       "$name\n",
       ":   'saline'\n",
       "$description\n",
       ":   'saline containing human albumin will be infused to the control group'\n",
       "$armGroupLabels\n",
       ":   1. 'control group'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$outcomesModule\n",
       ":   $primaryOutcomes\n",
       ":   1. $measure\n",
       ":   'The changes in HbA1C level'\n",
       "$description\n",
       ":   'The changes in HbA1C level after transplantation'\n",
       "$timeFrame\n",
       ":   '24 weeks after treatment'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$secondaryOutcomes\n",
       ":   1. $measure\n",
       ":   'Reduction of insulin requirement'\n",
       "$description\n",
       ":   'Reduction of insulin requirement after transplantation'\n",
       "$timeFrame\n",
       ":   '24 weeks after treatment'\n",
       "\n",
       "\n",
       "\n",
       "2. $measure\n",
       ":   'The changes in blood glucose level'\n",
       "$description\n",
       ":   'The changes in blood glucose level after transplantation'\n",
       "$timeFrame\n",
       ":   '24 weeks after treatment'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$eligibilityModule\n",
       ":   $eligibilityCriteria\n",
       ":   'Inclusion Criteria:\\n\\n1. Type 2 diabetes；\\n2. The course of diabetes is 5-15 years;\\n3. 20kg/m2≤body mass index (BMI)≤30 kg /m2；\\n4. 7.5% ≤HbA1c≤10%；\\n5. Insulin dose and other oral antidiabetic drugs doses should be stable over the 3 months prior to randomization.\\n\\nExclusion Criteria:\\n\\n1. Heavy allergic constitution or an allergy to any component used in cell culture.\\n2. Being treated with drug (Glucocorticoids，Tricyclic Antidepressive Agents,etc.) affect the metabolism of glucose in the past 1 month;\\n3. other causes of diabetes;\\n4. All kinds of acute complications such as diabetic ketoacidosis and non-ketohyperosmotic syndrome were screened in the past 6 months;\\n5. Having evidence of ongoing or frequent/severe hypoglycemia in the past 6 months;\\n6. Severe cardiovascular and cerebral events：occurrence of heart failure NYHA Classification III or IV, myocardial infarction, cerebral infarction, cerebral hemorrhage within 6 months before the observation period;\\n7. Patients with abnormal liver and kidney function: AST and ALT exceeding 2.5 times of the normal upper limit, and serum creatinine exceeding 1.5 mg/dl for men, exceeding 1.4 mg/dl for women;\\n8. Positive results of HbsAg、Anti-HCV、HIV or syphilis;\\n9. Patients suffering from other serious systemic diseases (such as malignancy, central nervous system,cardiovascular system, blood system, digestive system,endocrine system,respiratory system, genitourinary system, immune system and);\\n10. Ongoing pregnancy or absence of effective contraception in women with childbearing potential;\\n11. Patients who had received other stem cell therapy before screening.'\n",
       "$healthyVolunteers\n",
       ":   FALSE\n",
       "$sex\n",
       ":   'ALL'\n",
       "$minimumAge\n",
       ":   '30 Years'\n",
       "$maximumAge\n",
       ":   '75 Years'\n",
       "$stdAges\n",
       ":   1. 'ADULT'\n",
       "2. 'OLDER_ADULT'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$contactsLocationsModule\n",
       ":   $centralContacts\n",
       ":   1. $name\n",
       ":   'wang congrong, doctor'\n",
       "$role\n",
       ":   'CONTACT'\n",
       "$phone\n",
       ":   '+86-021-38804518'\n",
       "$email\n",
       ":   'wcr601@163.com'\n",
       "\n",
       "\n",
       "\n",
       "2. $name\n",
       ":   'liu zhongmin, doctor'\n",
       "$role\n",
       ":   'CONTACT'\n",
       "$phone\n",
       ":   '+86-021-38804518'\n",
       "$email\n",
       ":   'liu.zhongmin@tongji.edu.cn'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$overallOfficials\n",
       ":   1. $name\n",
       ":   'wang congrong, doctor'\n",
       "$affiliation\n",
       ":   'Shanghai East Hospital, China'\n",
       "$role\n",
       ":   'PRINCIPAL_INVESTIGATOR'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$locations\n",
       ":   1. $facility\n",
       ":   'Shanghai East Hospital, Shanghai Tongji University'\n",
       "$status\n",
       ":   'RECRUITING'\n",
       "$city\n",
       ":   'Shanghai'\n",
       "$state\n",
       ":   'Shanghai Municipality'\n",
       "$zip\n",
       ":   '200120'\n",
       "$country\n",
       ":   'China'\n",
       "$contacts\n",
       ":   1. $name\n",
       ":   'wang congrong, doctor'\n",
       "$role\n",
       ":   'CONTACT'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$geoPoint\n",
       ":   $lat\n",
       ":   31.22222\n",
       "$lon\n",
       ":   121.45806\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$derivedSection\n",
       ":   $miscInfoModule\n",
       ":   **$versionHolder** = '2026-01-20'\n",
       "$conditionBrowseModule\n",
       ":   $meshes\n",
       ":   1. $id\n",
       ":   'D003924'\n",
       "$term\n",
       ":   'Diabetes Mellitus, Type 2'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$ancestors\n",
       ":   1. $id\n",
       ":   'D003920'\n",
       "$term\n",
       ":   'Diabetes Mellitus'\n",
       "\n",
       "\n",
       "\n",
       "2. $id\n",
       ":   'D044882'\n",
       "$term\n",
       ":   'Glucose Metabolism Disorders'\n",
       "\n",
       "\n",
       "\n",
       "3. $id\n",
       ":   'D008659'\n",
       "$term\n",
       ":   'Metabolic Diseases'\n",
       "\n",
       "\n",
       "\n",
       "4. $id\n",
       ":   'D009750'\n",
       "$term\n",
       ":   'Nutritional and Metabolic Diseases'\n",
       "\n",
       "\n",
       "\n",
       "5. $id\n",
       ":   'D004700'\n",
       "$term\n",
       ":   'Endocrine System Diseases'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$interventionBrowseModule\n",
       ":   $meshes\n",
       ":   1. $id\n",
       ":   'D012965'\n",
       "$term\n",
       ":   'Sodium Chloride'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$ancestors\n",
       ":   1. $id\n",
       ":   'D002712'\n",
       "$term\n",
       ":   'Chlorides'\n",
       "\n",
       "\n",
       "\n",
       "2. $id\n",
       ":   'D006851'\n",
       "$term\n",
       ":   'Hydrochloric Acid'\n",
       "\n",
       "\n",
       "\n",
       "3. $id\n",
       ":   'D017606'\n",
       "$term\n",
       ":   'Chlorine Compounds'\n",
       "\n",
       "\n",
       "\n",
       "4. $id\n",
       ":   'D007287'\n",
       "$term\n",
       ":   'Inorganic Chemicals'\n",
       "\n",
       "\n",
       "\n",
       "5. $id\n",
       ":   'D017670'\n",
       "$term\n",
       ":   'Sodium Compounds'\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$hasResults\n",
       ":   FALSE\n",
       "\n",
       "\n"
      ],
      "text/plain": [
       "$protocolSection\n",
       "$protocolSection$identificationModule\n",
       "$protocolSection$identificationModule$nctId\n",
       "[1] \"NCT04441658\"\n",
       "\n",
       "$protocolSection$identificationModule$orgStudyIdInfo\n",
       "$protocolSection$identificationModule$orgStudyIdInfo$id\n",
       "[1] \"DFSC-2020(CR)-02\"\n",
       "\n",
       "\n",
       "$protocolSection$identificationModule$organization\n",
       "$protocolSection$identificationModule$organization$fullName\n",
       "[1] \"Shanghai East Hospital\"\n",
       "\n",
       "$protocolSection$identificationModule$organization$class\n",
       "[1] \"OTHER\"\n",
       "\n",
       "\n",
       "$protocolSection$identificationModule$briefTitle\n",
       "[1] \"Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus\"\n",
       "\n",
       "$protocolSection$identificationModule$officialTitle\n",
       "[1] \"Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus\"\n",
       "\n",
       "\n",
       "$protocolSection$statusModule\n",
       "$protocolSection$statusModule$statusVerifiedDate\n",
       "[1] \"2020-06\"\n",
       "\n",
       "$protocolSection$statusModule$overallStatus\n",
       "[1] \"UNKNOWN\"\n",
       "\n",
       "$protocolSection$statusModule$lastKnownStatus\n",
       "[1] \"RECRUITING\"\n",
       "\n",
       "$protocolSection$statusModule$expandedAccessInfo\n",
       "$protocolSection$statusModule$expandedAccessInfo$hasExpandedAccess\n",
       "[1] FALSE\n",
       "\n",
       "\n",
       "$protocolSection$statusModule$startDateStruct\n",
       "$protocolSection$statusModule$startDateStruct$date\n",
       "[1] \"2020-04-10\"\n",
       "\n",
       "$protocolSection$statusModule$startDateStruct$type\n",
       "[1] \"ACTUAL\"\n",
       "\n",
       "\n",
       "$protocolSection$statusModule$primaryCompletionDateStruct\n",
       "$protocolSection$statusModule$primaryCompletionDateStruct$date\n",
       "[1] \"2022-07\"\n",
       "\n",
       "$protocolSection$statusModule$primaryCompletionDateStruct$type\n",
       "[1] \"ESTIMATED\"\n",
       "\n",
       "\n",
       "$protocolSection$statusModule$completionDateStruct\n",
       "$protocolSection$statusModule$completionDateStruct$date\n",
       "[1] \"2022-12\"\n",
       "\n",
       "$protocolSection$statusModule$completionDateStruct$type\n",
       "[1] \"ESTIMATED\"\n",
       "\n",
       "\n",
       "$protocolSection$statusModule$studyFirstSubmitDate\n",
       "[1] \"2020-06-19\"\n",
       "\n",
       "$protocolSection$statusModule$studyFirstSubmitQcDate\n",
       "[1] \"2020-06-19\"\n",
       "\n",
       "$protocolSection$statusModule$studyFirstPostDateStruct\n",
       "$protocolSection$statusModule$studyFirstPostDateStruct$date\n",
       "[1] \"2020-06-22\"\n",
       "\n",
       "$protocolSection$statusModule$studyFirstPostDateStruct$type\n",
       "[1] \"ACTUAL\"\n",
       "\n",
       "\n",
       "$protocolSection$statusModule$lastUpdateSubmitDate\n",
       "[1] \"2020-06-19\"\n",
       "\n",
       "$protocolSection$statusModule$lastUpdatePostDateStruct\n",
       "$protocolSection$statusModule$lastUpdatePostDateStruct$date\n",
       "[1] \"2020-06-22\"\n",
       "\n",
       "$protocolSection$statusModule$lastUpdatePostDateStruct$type\n",
       "[1] \"ACTUAL\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$sponsorCollaboratorsModule\n",
       "$protocolSection$sponsorCollaboratorsModule$responsibleParty\n",
       "$protocolSection$sponsorCollaboratorsModule$responsibleParty$type\n",
       "[1] \"SPONSOR\"\n",
       "\n",
       "\n",
       "$protocolSection$sponsorCollaboratorsModule$leadSponsor\n",
       "$protocolSection$sponsorCollaboratorsModule$leadSponsor$name\n",
       "[1] \"Shanghai East Hospital\"\n",
       "\n",
       "$protocolSection$sponsorCollaboratorsModule$leadSponsor$class\n",
       "[1] \"OTHER\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$oversightModule\n",
       "$protocolSection$oversightModule$isFdaRegulatedDrug\n",
       "[1] FALSE\n",
       "\n",
       "$protocolSection$oversightModule$isFdaRegulatedDevice\n",
       "[1] FALSE\n",
       "\n",
       "\n",
       "$protocolSection$descriptionModule\n",
       "$protocolSection$descriptionModule$briefSummary\n",
       "[1] \"This study is a 24-week single-center, randomized, double-blind, placebo-controlled trial. The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion therapy.\"\n",
       "\n",
       "$protocolSection$descriptionModule$detailedDescription\n",
       "[1] \"This study is a 24-week single-center, randomized, double-blind, placebo-controlled trial. The trial includes a 3-week early screening and lifestyle education period, 6-week treatment period, and 18-week follow-up period. Chinese type 2 diabetic subjects receiving traditional hypoglycemic treatment（including insulin） were randomly assigned to umbilical cord mesenchymal stem cell or placebo infusion therapy to observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion therapy.\"\n",
       "\n",
       "\n",
       "$protocolSection$conditionsModule\n",
       "$protocolSection$conditionsModule$conditions\n",
       "$protocolSection$conditionsModule$conditions[[1]]\n",
       "[1] \"Type 2 Diabetes\"\n",
       "\n",
       "$protocolSection$conditionsModule$conditions[[2]]\n",
       "[1] \"Mesenchymal Stem Cells\"\n",
       "\n",
       "\n",
       "$protocolSection$conditionsModule$keywords\n",
       "$protocolSection$conditionsModule$keywords[[1]]\n",
       "[1] \"Umbilical Cord Mesenchymal Stem Cells\"\n",
       "\n",
       "$protocolSection$conditionsModule$keywords[[2]]\n",
       "[1] \"Type 2 Diabetes\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$designModule\n",
       "$protocolSection$designModule$studyType\n",
       "[1] \"INTERVENTIONAL\"\n",
       "\n",
       "$protocolSection$designModule$phases\n",
       "$protocolSection$designModule$phases[[1]]\n",
       "[1] \"PHASE1\"\n",
       "\n",
       "$protocolSection$designModule$phases[[2]]\n",
       "[1] \"PHASE2\"\n",
       "\n",
       "\n",
       "$protocolSection$designModule$designInfo\n",
       "$protocolSection$designModule$designInfo$allocation\n",
       "[1] \"RANDOMIZED\"\n",
       "\n",
       "$protocolSection$designModule$designInfo$interventionModel\n",
       "[1] \"PARALLEL\"\n",
       "\n",
       "$protocolSection$designModule$designInfo$primaryPurpose\n",
       "[1] \"TREATMENT\"\n",
       "\n",
       "$protocolSection$designModule$designInfo$maskingInfo\n",
       "$protocolSection$designModule$designInfo$maskingInfo$masking\n",
       "[1] \"TRIPLE\"\n",
       "\n",
       "$protocolSection$designModule$designInfo$maskingInfo$whoMasked\n",
       "$protocolSection$designModule$designInfo$maskingInfo$whoMasked[[1]]\n",
       "[1] \"PARTICIPANT\"\n",
       "\n",
       "$protocolSection$designModule$designInfo$maskingInfo$whoMasked[[2]]\n",
       "[1] \"CARE_PROVIDER\"\n",
       "\n",
       "$protocolSection$designModule$designInfo$maskingInfo$whoMasked[[3]]\n",
       "[1] \"INVESTIGATOR\"\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$designModule$enrollmentInfo\n",
       "$protocolSection$designModule$enrollmentInfo$count\n",
       "[1] 30\n",
       "\n",
       "$protocolSection$designModule$enrollmentInfo$type\n",
       "[1] \"ESTIMATED\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$armsInterventionsModule\n",
       "$protocolSection$armsInterventionsModule$armGroups\n",
       "$protocolSection$armsInterventionsModule$armGroups[[1]]\n",
       "$protocolSection$armsInterventionsModule$armGroups[[1]]$label\n",
       "[1] \"experimental group\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$armGroups[[1]]$type\n",
       "[1] \"EXPERIMENTAL\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$armGroups[[1]]$description\n",
       "[1] \"The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75\\\\*10\\\\^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$armGroups[[1]]$interventionNames\n",
       "$protocolSection$armsInterventionsModule$armGroups[[1]]$interventionNames[[1]]\n",
       "[1] \"Biological: Umbilical Cord Mesenchymal Stem Cells\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$armsInterventionsModule$armGroups[[2]]\n",
       "$protocolSection$armsInterventionsModule$armGroups[[2]]$label\n",
       "[1] \"control group\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$armGroups[[2]]$type\n",
       "[1] \"PLACEBO_COMPARATOR\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$armGroups[[2]]$description\n",
       "[1] \"The control group will be given the same dose of saline containing human albumin.\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$armGroups[[2]]$interventionNames\n",
       "$protocolSection$armsInterventionsModule$armGroups[[2]]$interventionNames[[1]]\n",
       "[1] \"Biological: saline\"\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$armsInterventionsModule$interventions\n",
       "$protocolSection$armsInterventionsModule$interventions[[1]]\n",
       "$protocolSection$armsInterventionsModule$interventions[[1]]$type\n",
       "[1] \"BIOLOGICAL\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$interventions[[1]]$name\n",
       "[1] \"Umbilical Cord Mesenchymal Stem Cells\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$interventions[[1]]$description\n",
       "[1] \"human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$interventions[[1]]$armGroupLabels\n",
       "$protocolSection$armsInterventionsModule$interventions[[1]]$armGroupLabels[[1]]\n",
       "[1] \"experimental group\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$armsInterventionsModule$interventions[[2]]\n",
       "$protocolSection$armsInterventionsModule$interventions[[2]]$type\n",
       "[1] \"BIOLOGICAL\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$interventions[[2]]$name\n",
       "[1] \"saline\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$interventions[[2]]$description\n",
       "[1] \"saline containing human albumin will be infused to the control group\"\n",
       "\n",
       "$protocolSection$armsInterventionsModule$interventions[[2]]$armGroupLabels\n",
       "$protocolSection$armsInterventionsModule$interventions[[2]]$armGroupLabels[[1]]\n",
       "[1] \"control group\"\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$outcomesModule\n",
       "$protocolSection$outcomesModule$primaryOutcomes\n",
       "$protocolSection$outcomesModule$primaryOutcomes[[1]]\n",
       "$protocolSection$outcomesModule$primaryOutcomes[[1]]$measure\n",
       "[1] \"The changes in HbA1C level\"\n",
       "\n",
       "$protocolSection$outcomesModule$primaryOutcomes[[1]]$description\n",
       "[1] \"The changes in HbA1C level after transplantation\"\n",
       "\n",
       "$protocolSection$outcomesModule$primaryOutcomes[[1]]$timeFrame\n",
       "[1] \"24 weeks after treatment\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$outcomesModule$secondaryOutcomes\n",
       "$protocolSection$outcomesModule$secondaryOutcomes[[1]]\n",
       "$protocolSection$outcomesModule$secondaryOutcomes[[1]]$measure\n",
       "[1] \"Reduction of insulin requirement\"\n",
       "\n",
       "$protocolSection$outcomesModule$secondaryOutcomes[[1]]$description\n",
       "[1] \"Reduction of insulin requirement after transplantation\"\n",
       "\n",
       "$protocolSection$outcomesModule$secondaryOutcomes[[1]]$timeFrame\n",
       "[1] \"24 weeks after treatment\"\n",
       "\n",
       "\n",
       "$protocolSection$outcomesModule$secondaryOutcomes[[2]]\n",
       "$protocolSection$outcomesModule$secondaryOutcomes[[2]]$measure\n",
       "[1] \"The changes in blood glucose level\"\n",
       "\n",
       "$protocolSection$outcomesModule$secondaryOutcomes[[2]]$description\n",
       "[1] \"The changes in blood glucose level after transplantation\"\n",
       "\n",
       "$protocolSection$outcomesModule$secondaryOutcomes[[2]]$timeFrame\n",
       "[1] \"24 weeks after treatment\"\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$eligibilityModule\n",
       "$protocolSection$eligibilityModule$eligibilityCriteria\n",
       "[1] \"Inclusion Criteria:\\n\\n1. Type 2 diabetes；\\n2. The course of diabetes is 5-15 years;\\n3. 20kg/m2≤body mass index (BMI)≤30 kg /m2；\\n4. 7.5% ≤HbA1c≤10%；\\n5. Insulin dose and other oral antidiabetic drugs doses should be stable over the 3 months prior to randomization.\\n\\nExclusion Criteria:\\n\\n1. Heavy allergic constitution or an allergy to any component used in cell culture.\\n2. Being treated with drug (Glucocorticoids，Tricyclic Antidepressive Agents,etc.) affect the metabolism of glucose in the past 1 month;\\n3. other causes of diabetes;\\n4. All kinds of acute complications such as diabetic ketoacidosis and non-ketohyperosmotic syndrome were screened in the past 6 months;\\n5. Having evidence of ongoing or frequent/severe hypoglycemia in the past 6 months;\\n6. Severe cardiovascular and cerebral events：occurrence of heart failure NYHA Classification III or IV, myocardial infarction, cerebral infarction, cerebral hemorrhage within 6 months before the observation period;\\n7. Patients with abnormal liver and kidney function: AST and ALT exceeding 2.5 times of the normal upper limit, and serum creatinine exceeding 1.5 mg/dl for men, exceeding 1.4 mg/dl for women;\\n8. Positive results of HbsAg、Anti-HCV、HIV or syphilis;\\n9. Patients suffering from other serious systemic diseases (such as malignancy, central nervous system,cardiovascular system, blood system, digestive system,endocrine system,respiratory system, genitourinary system, immune system and);\\n10. Ongoing pregnancy or absence of effective contraception in women with childbearing potential;\\n11. Patients who had received other stem cell therapy before screening.\"\n",
       "\n",
       "$protocolSection$eligibilityModule$healthyVolunteers\n",
       "[1] FALSE\n",
       "\n",
       "$protocolSection$eligibilityModule$sex\n",
       "[1] \"ALL\"\n",
       "\n",
       "$protocolSection$eligibilityModule$minimumAge\n",
       "[1] \"30 Years\"\n",
       "\n",
       "$protocolSection$eligibilityModule$maximumAge\n",
       "[1] \"75 Years\"\n",
       "\n",
       "$protocolSection$eligibilityModule$stdAges\n",
       "$protocolSection$eligibilityModule$stdAges[[1]]\n",
       "[1] \"ADULT\"\n",
       "\n",
       "$protocolSection$eligibilityModule$stdAges[[2]]\n",
       "[1] \"OLDER_ADULT\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$contactsLocationsModule\n",
       "$protocolSection$contactsLocationsModule$centralContacts\n",
       "$protocolSection$contactsLocationsModule$centralContacts[[1]]\n",
       "$protocolSection$contactsLocationsModule$centralContacts[[1]]$name\n",
       "[1] \"wang congrong, doctor\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$centralContacts[[1]]$role\n",
       "[1] \"CONTACT\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$centralContacts[[1]]$phone\n",
       "[1] \"+86-021-38804518\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$centralContacts[[1]]$email\n",
       "[1] \"wcr601@163.com\"\n",
       "\n",
       "\n",
       "$protocolSection$contactsLocationsModule$centralContacts[[2]]\n",
       "$protocolSection$contactsLocationsModule$centralContacts[[2]]$name\n",
       "[1] \"liu zhongmin, doctor\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$centralContacts[[2]]$role\n",
       "[1] \"CONTACT\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$centralContacts[[2]]$phone\n",
       "[1] \"+86-021-38804518\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$centralContacts[[2]]$email\n",
       "[1] \"liu.zhongmin@tongji.edu.cn\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$contactsLocationsModule$overallOfficials\n",
       "$protocolSection$contactsLocationsModule$overallOfficials[[1]]\n",
       "$protocolSection$contactsLocationsModule$overallOfficials[[1]]$name\n",
       "[1] \"wang congrong, doctor\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$overallOfficials[[1]]$affiliation\n",
       "[1] \"Shanghai East Hospital, China\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$overallOfficials[[1]]$role\n",
       "[1] \"PRINCIPAL_INVESTIGATOR\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$contactsLocationsModule$locations\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$facility\n",
       "[1] \"Shanghai East Hospital, Shanghai Tongji University\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$status\n",
       "[1] \"RECRUITING\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$city\n",
       "[1] \"Shanghai\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$state\n",
       "[1] \"Shanghai Municipality\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$zip\n",
       "[1] \"200120\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$country\n",
       "[1] \"China\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$contacts\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$contacts[[1]]\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$contacts[[1]]$name\n",
       "[1] \"wang congrong, doctor\"\n",
       "\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$contacts[[1]]$role\n",
       "[1] \"CONTACT\"\n",
       "\n",
       "\n",
       "\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$geoPoint\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$geoPoint$lat\n",
       "[1] 31.22222\n",
       "\n",
       "$protocolSection$contactsLocationsModule$locations[[1]]$geoPoint$lon\n",
       "[1] 121.4581\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$derivedSection\n",
       "$derivedSection$miscInfoModule\n",
       "$derivedSection$miscInfoModule$versionHolder\n",
       "[1] \"2026-01-20\"\n",
       "\n",
       "\n",
       "$derivedSection$conditionBrowseModule\n",
       "$derivedSection$conditionBrowseModule$meshes\n",
       "$derivedSection$conditionBrowseModule$meshes[[1]]\n",
       "$derivedSection$conditionBrowseModule$meshes[[1]]$id\n",
       "[1] \"D003924\"\n",
       "\n",
       "$derivedSection$conditionBrowseModule$meshes[[1]]$term\n",
       "[1] \"Diabetes Mellitus, Type 2\"\n",
       "\n",
       "\n",
       "\n",
       "$derivedSection$conditionBrowseModule$ancestors\n",
       "$derivedSection$conditionBrowseModule$ancestors[[1]]\n",
       "$derivedSection$conditionBrowseModule$ancestors[[1]]$id\n",
       "[1] \"D003920\"\n",
       "\n",
       "$derivedSection$conditionBrowseModule$ancestors[[1]]$term\n",
       "[1] \"Diabetes Mellitus\"\n",
       "\n",
       "\n",
       "$derivedSection$conditionBrowseModule$ancestors[[2]]\n",
       "$derivedSection$conditionBrowseModule$ancestors[[2]]$id\n",
       "[1] \"D044882\"\n",
       "\n",
       "$derivedSection$conditionBrowseModule$ancestors[[2]]$term\n",
       "[1] \"Glucose Metabolism Disorders\"\n",
       "\n",
       "\n",
       "$derivedSection$conditionBrowseModule$ancestors[[3]]\n",
       "$derivedSection$conditionBrowseModule$ancestors[[3]]$id\n",
       "[1] \"D008659\"\n",
       "\n",
       "$derivedSection$conditionBrowseModule$ancestors[[3]]$term\n",
       "[1] \"Metabolic Diseases\"\n",
       "\n",
       "\n",
       "$derivedSection$conditionBrowseModule$ancestors[[4]]\n",
       "$derivedSection$conditionBrowseModule$ancestors[[4]]$id\n",
       "[1] \"D009750\"\n",
       "\n",
       "$derivedSection$conditionBrowseModule$ancestors[[4]]$term\n",
       "[1] \"Nutritional and Metabolic Diseases\"\n",
       "\n",
       "\n",
       "$derivedSection$conditionBrowseModule$ancestors[[5]]\n",
       "$derivedSection$conditionBrowseModule$ancestors[[5]]$id\n",
       "[1] \"D004700\"\n",
       "\n",
       "$derivedSection$conditionBrowseModule$ancestors[[5]]$term\n",
       "[1] \"Endocrine System Diseases\"\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$derivedSection$interventionBrowseModule\n",
       "$derivedSection$interventionBrowseModule$meshes\n",
       "$derivedSection$interventionBrowseModule$meshes[[1]]\n",
       "$derivedSection$interventionBrowseModule$meshes[[1]]$id\n",
       "[1] \"D012965\"\n",
       "\n",
       "$derivedSection$interventionBrowseModule$meshes[[1]]$term\n",
       "[1] \"Sodium Chloride\"\n",
       "\n",
       "\n",
       "\n",
       "$derivedSection$interventionBrowseModule$ancestors\n",
       "$derivedSection$interventionBrowseModule$ancestors[[1]]\n",
       "$derivedSection$interventionBrowseModule$ancestors[[1]]$id\n",
       "[1] \"D002712\"\n",
       "\n",
       "$derivedSection$interventionBrowseModule$ancestors[[1]]$term\n",
       "[1] \"Chlorides\"\n",
       "\n",
       "\n",
       "$derivedSection$interventionBrowseModule$ancestors[[2]]\n",
       "$derivedSection$interventionBrowseModule$ancestors[[2]]$id\n",
       "[1] \"D006851\"\n",
       "\n",
       "$derivedSection$interventionBrowseModule$ancestors[[2]]$term\n",
       "[1] \"Hydrochloric Acid\"\n",
       "\n",
       "\n",
       "$derivedSection$interventionBrowseModule$ancestors[[3]]\n",
       "$derivedSection$interventionBrowseModule$ancestors[[3]]$id\n",
       "[1] \"D017606\"\n",
       "\n",
       "$derivedSection$interventionBrowseModule$ancestors[[3]]$term\n",
       "[1] \"Chlorine Compounds\"\n",
       "\n",
       "\n",
       "$derivedSection$interventionBrowseModule$ancestors[[4]]\n",
       "$derivedSection$interventionBrowseModule$ancestors[[4]]$id\n",
       "[1] \"D007287\"\n",
       "\n",
       "$derivedSection$interventionBrowseModule$ancestors[[4]]$term\n",
       "[1] \"Inorganic Chemicals\"\n",
       "\n",
       "\n",
       "$derivedSection$interventionBrowseModule$ancestors[[5]]\n",
       "$derivedSection$interventionBrowseModule$ancestors[[5]]$id\n",
       "[1] \"D017670\"\n",
       "\n",
       "$derivedSection$interventionBrowseModule$ancestors[[5]]$term\n",
       "[1] \"Sodium Compounds\"\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "$hasResults\n",
       "[1] FALSE\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "library(httr)\n",
    "library(jsonlite)\n",
    "\n",
    "# 1. Build the URL\n",
    "url <- \"https://clinicaltrials.gov/api/v2/studies?query.term=diabetes&pageSize=5\"\n",
    "\n",
    "# 2. Download the data\n",
    "response <- GET(url)\n",
    "\n",
    "# 3. Convert JSON to R list\n",
    "data <- fromJSON(content(response, \"text\"), simplifyVector = FALSE)\n",
    "\n",
    "# 4. Look at what we got\n",
    "names(data)\n",
    "studies <- data$studies\n",
    "\n",
    "# Look at the first study\n",
    "studies[[1]]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "648a77e9-36ff-4cd9-8fd8-f3b128b14504",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "------------------------\n",
      "NCT ID: NCT04441658 \n",
      "Title: Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus \n",
      "Status: UNKNOWN \n",
      "\n",
      "------------------------\n",
      "NCT ID: NCT03162926 \n",
      "Title: A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus \n",
      "Status: COMPLETED \n",
      "\n",
      "------------------------\n",
      "NCT ID: NCT03797885 \n",
      "Title: A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal \n",
      "Status: COMPLETED \n",
      "\n",
      "------------------------\n",
      "NCT ID: NCT01373476 \n",
      "Title: Multicentre, Randomized, Controlled Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy \n",
      "Status: COMPLETED \n",
      "\n",
      "------------------------\n",
      "NCT ID: NCT01686568 \n",
      "Title: Omega-3 Fatty Acids and Insulin Sensitivity \n",
      "Status: COMPLETED \n"
     ]
    }
   ],
   "source": [
    "\n",
    "for (i in seq_along(studies)) {\n",
    "  study <- studies[[i]]\n",
    "\n",
    "  nct_id <- study$protocolSection$identificationModule$nctId\n",
    "  title  <- study$protocolSection$identificationModule$briefTitle\n",
    "  status <- study$protocolSection$statusModule$overallStatus\n",
    "\n",
    "  cat(\"\\n------------------------\\n\")\n",
    "  cat(\"NCT ID:\", nct_id, \"\\n\")\n",
    "  cat(\"Title:\", title, \"\\n\")\n",
    "  cat(\"Status:\", status, \"\\n\")\n",
    "}\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "02d1c7b1-fdfa-47aa-be01-b06825aea9a0",
   "metadata": {},
   "source": [
    "- Noticed here the Json is organized like a nested list. There are modules that group the similar fields together.\n",
    "- what are the possible modules"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c425f54f-96eb-4838-9250-7079facb8664",
   "metadata": {},
   "source": [
    "## 21-Jan-2026\n",
    "\n",
    "- Collaborated with team members and threw around some ideas.\n",
    "- what fields should we add?\n",
    "- what modules do we add?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "7892f9f9-fa43-471a-9fc8-36c7cb76458f",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Warning message:\n",
      "\"package 'httr' was built under R version 4.5.2\"\n",
      "\n",
      "Attaching package: 'dplyr'\n",
      "\n",
      "\n",
      "The following objects are masked from 'package:stats':\n",
      "\n",
      "    filter, lag\n",
      "\n",
      "\n",
      "The following objects are masked from 'package:base':\n",
      "\n",
      "    intersect, setdiff, setequal, union\n",
      "\n",
      "\n",
      "\n",
      "Attaching package: 'purrr'\n",
      "\n",
      "\n",
      "The following object is masked from 'package:jsonlite':\n",
      "\n",
      "    flatten\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "library(httr)\n",
    "library(jsonlite)\n",
    "library(dplyr)\n",
    "library(purrr)\n",
    "library(tibble)\n",
    "\n",
    "`%||%` <- function(x, y) if (is.null(x)) y else x\n",
    "\n",
    "ct_search_studies <- function(query = NULL,\n",
    "                              condition = NULL,\n",
    "                              intervention = NULL,\n",
    "                              page_size = 100,\n",
    "                              page_token = NULL) {\n",
    "\n",
    "  base_url <- \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "\n",
    "  # Build query parameters\n",
    "  params <- list(\n",
    "    pageSize = page_size,\n",
    "    format = \"json\"\n",
    "  )\n",
    "\n",
    "  if (!is.null(query)) {\n",
    "    params[[\"query.term\"]] <- query\n",
    "  }\n",
    "\n",
    "  if (!is.null(condition)) {\n",
    "    params[[\"query.cond\"]] <- condition\n",
    "  }\n",
    "\n",
    "  if (!is.null(intervention)) {\n",
    "    params[[\"query.intr\"]] <- intervention\n",
    "  }\n",
    "\n",
    "  if (!is.null(page_token)) {\n",
    "    params[[\"pageToken\"]] <- page_token\n",
    "  }\n",
    "\n",
    "  # Send request\n",
    "  resp <- GET(base_url, query = params)\n",
    "  stop_for_status(resp)\n",
    "\n",
    "  txt <- content(resp, as = \"text\", encoding = \"UTF-8\")\n",
    "  json <- fromJSON(txt, simplifyVector = FALSE)\n",
    "\n",
    "  studies <- json$studies %||% list()\n",
    "\n",
    "  # Extract a few useful fields into a tidy table\n",
    "  out <- tibble(\n",
    "    nct_id = map_chr(studies, ~ .x$protocolSection$identificationModule$nctId %||% NA_character_),\n",
    "    title  = map_chr(studies, ~ .x$protocolSection$identificationModule$briefTitle %||% NA_character_),\n",
    "    status = map_chr(studies, ~ .x$protocolSection$statusModule$overallStatus %||% NA_character_),\n",
    "    phase  = map_chr(studies, ~ paste(.x$protocolSection$designModule$phaseList$phase, collapse = \", \") %||% NA_character_),\n",
    "    start_date = map_chr(studies, ~ .x$protocolSection$statusModule$startDateStruct$date %||% NA_character_)\n",
    "  )\n",
    "\n",
    "  list(\n",
    "    data = out,\n",
    "    next_page_token = json$nextPageToken %||% NULL,\n",
    "    total_count = json$totalCount %||% NA_integer_\n",
    "  )\n",
    "}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "6e5f8f52-828a-4cea-adac-4c7eb5b8b3b2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A tibble: 20 × 5</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>nct_id</th><th scope=col>title</th><th scope=col>status</th><th scope=col>phase</th><th scope=col>start_date</th></tr>\n",
       "\t<tr><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td>NCT02951260</td><td>The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation     </td><td>COMPLETED </td><td></td><td>2016-10   </td></tr>\n",
       "\t<tr><td>NCT00286624</td><td>Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation                                                 </td><td>COMPLETED </td><td></td><td>2003-03   </td></tr>\n",
       "\t<tr><td>NCT00859079</td><td>Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients</td><td>COMPLETED </td><td></td><td>2006-06   </td></tr>\n",
       "\t<tr><td>NCT00480779</td><td>Evaluation of Group Lifestyle Balance DVD in Primary Care Practice                                                      </td><td>COMPLETED </td><td></td><td>2007-06   </td></tr>\n",
       "\t<tr><td>NCT03885362</td><td>Assessment of the Accuracy of Continuous Glucose Sensors in People With Diabetes Undergoing Haemodialysis               </td><td>COMPLETED </td><td></td><td>2019-12-11</td></tr>\n",
       "\t<tr><td>NCT04089462</td><td>Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study               </td><td>COMPLETED </td><td></td><td>2019-09-30</td></tr>\n",
       "\t<tr><td>NCT03810846</td><td>Feasibility and Safety of Walking Football in Patients With Type 2 Diabetes                                             </td><td>COMPLETED </td><td></td><td>2018-09-17</td></tr>\n",
       "\t<tr><td>NCT00136188</td><td>Nitric Oxide (NO) Activity and Diabetic Nephropathy                                                                     </td><td>COMPLETED </td><td></td><td>2009-08   </td></tr>\n",
       "\t<tr><td>NCT04919603</td><td>Impact of Exercise Intervention on the Phenome                                                                          </td><td>UNKNOWN   </td><td></td><td>2021-06-15</td></tr>\n",
       "\t<tr><td>NCT00762242</td><td>Metabolomic Profiling of Novel Mediators of Vascular Function                                                           </td><td>TERMINATED</td><td></td><td>2007-05   </td></tr>\n",
       "\t<tr><td>NCT00922194</td><td>Metformin in Overweight Type 2 Diabetes Mellitus                                                                        </td><td>COMPLETED </td><td></td><td>2006-02   </td></tr>\n",
       "\t<tr><td>NCT05295329</td><td>Effect of Compound Danshen Dripping Pills on Diabetic Patients With Coronary Microcirculation Disturbance               </td><td>UNKNOWN   </td><td></td><td>2022-04-01</td></tr>\n",
       "\t<tr><td>NCT05870202</td><td>Treatment Burden Screening Questionnaire Pilot Study                                                                    </td><td>COMPLETED </td><td></td><td>2023-03-07</td></tr>\n",
       "\t<tr><td>NCT05881837</td><td>Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes                                             </td><td>COMPLETED </td><td></td><td>2023-06-13</td></tr>\n",
       "\t<tr><td>NCT05203575</td><td>Building a Behavioural Intervention Programme to Improve Self-Management of Diabetes                                    </td><td>UNKNOWN   </td><td></td><td>2022-03-28</td></tr>\n",
       "\t<tr><td>NCT05548218</td><td>Care Companion Diabetes                                                                                                 </td><td>COMPLETED </td><td></td><td>2022-08-15</td></tr>\n",
       "\t<tr><td>NCT04403789</td><td>Effects of a Workplace Exercise Intervention on Cardio-Metabolic Health                                                 </td><td>COMPLETED </td><td></td><td>2021-03-28</td></tr>\n",
       "\t<tr><td>NCT00296374</td><td>Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease            </td><td>COMPLETED </td><td></td><td>2006-02   </td></tr>\n",
       "\t<tr><td>NCT00353990</td><td>Bioavailability of Insulin Administered in Duodenum                                                                     </td><td>COMPLETED </td><td></td><td>2006-08   </td></tr>\n",
       "\t<tr><td>NCT03603990</td><td>Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema                                              </td><td>WITHDRAWN </td><td></td><td>2018-09-01</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A tibble: 20 × 5\n",
       "\\begin{tabular}{lllll}\n",
       " nct\\_id & title & status & phase & start\\_date\\\\\n",
       " <chr> & <chr> & <chr> & <chr> & <chr>\\\\\n",
       "\\hline\n",
       "\t NCT02951260 & The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation      & COMPLETED  &  & 2016-10   \\\\\n",
       "\t NCT00286624 & Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation                                                  & COMPLETED  &  & 2003-03   \\\\\n",
       "\t NCT00859079 & Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients & COMPLETED  &  & 2006-06   \\\\\n",
       "\t NCT00480779 & Evaluation of Group Lifestyle Balance DVD in Primary Care Practice                                                       & COMPLETED  &  & 2007-06   \\\\\n",
       "\t NCT03885362 & Assessment of the Accuracy of Continuous Glucose Sensors in People With Diabetes Undergoing Haemodialysis                & COMPLETED  &  & 2019-12-11\\\\\n",
       "\t NCT04089462 & Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study                & COMPLETED  &  & 2019-09-30\\\\\n",
       "\t NCT03810846 & Feasibility and Safety of Walking Football in Patients With Type 2 Diabetes                                              & COMPLETED  &  & 2018-09-17\\\\\n",
       "\t NCT00136188 & Nitric Oxide (NO) Activity and Diabetic Nephropathy                                                                      & COMPLETED  &  & 2009-08   \\\\\n",
       "\t NCT04919603 & Impact of Exercise Intervention on the Phenome                                                                           & UNKNOWN    &  & 2021-06-15\\\\\n",
       "\t NCT00762242 & Metabolomic Profiling of Novel Mediators of Vascular Function                                                            & TERMINATED &  & 2007-05   \\\\\n",
       "\t NCT00922194 & Metformin in Overweight Type 2 Diabetes Mellitus                                                                         & COMPLETED  &  & 2006-02   \\\\\n",
       "\t NCT05295329 & Effect of Compound Danshen Dripping Pills on Diabetic Patients With Coronary Microcirculation Disturbance                & UNKNOWN    &  & 2022-04-01\\\\\n",
       "\t NCT05870202 & Treatment Burden Screening Questionnaire Pilot Study                                                                     & COMPLETED  &  & 2023-03-07\\\\\n",
       "\t NCT05881837 & Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes                                              & COMPLETED  &  & 2023-06-13\\\\\n",
       "\t NCT05203575 & Building a Behavioural Intervention Programme to Improve Self-Management of Diabetes                                     & UNKNOWN    &  & 2022-03-28\\\\\n",
       "\t NCT05548218 & Care Companion Diabetes                                                                                                  & COMPLETED  &  & 2022-08-15\\\\\n",
       "\t NCT04403789 & Effects of a Workplace Exercise Intervention on Cardio-Metabolic Health                                                  & COMPLETED  &  & 2021-03-28\\\\\n",
       "\t NCT00296374 & Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease             & COMPLETED  &  & 2006-02   \\\\\n",
       "\t NCT00353990 & Bioavailability of Insulin Administered in Duodenum                                                                      & COMPLETED  &  & 2006-08   \\\\\n",
       "\t NCT03603990 & Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema                                               & WITHDRAWN  &  & 2018-09-01\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A tibble: 20 × 5\n",
       "\n",
       "| nct_id &lt;chr&gt; | title &lt;chr&gt; | status &lt;chr&gt; | phase &lt;chr&gt; | start_date &lt;chr&gt; |\n",
       "|---|---|---|---|---|\n",
       "| NCT02951260 | The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation      | COMPLETED  | <!----> | 2016-10    |\n",
       "| NCT00286624 | Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation                                                  | COMPLETED  | <!----> | 2003-03    |\n",
       "| NCT00859079 | Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients | COMPLETED  | <!----> | 2006-06    |\n",
       "| NCT00480779 | Evaluation of Group Lifestyle Balance DVD in Primary Care Practice                                                       | COMPLETED  | <!----> | 2007-06    |\n",
       "| NCT03885362 | Assessment of the Accuracy of Continuous Glucose Sensors in People With Diabetes Undergoing Haemodialysis                | COMPLETED  | <!----> | 2019-12-11 |\n",
       "| NCT04089462 | Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study                | COMPLETED  | <!----> | 2019-09-30 |\n",
       "| NCT03810846 | Feasibility and Safety of Walking Football in Patients With Type 2 Diabetes                                              | COMPLETED  | <!----> | 2018-09-17 |\n",
       "| NCT00136188 | Nitric Oxide (NO) Activity and Diabetic Nephropathy                                                                      | COMPLETED  | <!----> | 2009-08    |\n",
       "| NCT04919603 | Impact of Exercise Intervention on the Phenome                                                                           | UNKNOWN    | <!----> | 2021-06-15 |\n",
       "| NCT00762242 | Metabolomic Profiling of Novel Mediators of Vascular Function                                                            | TERMINATED | <!----> | 2007-05    |\n",
       "| NCT00922194 | Metformin in Overweight Type 2 Diabetes Mellitus                                                                         | COMPLETED  | <!----> | 2006-02    |\n",
       "| NCT05295329 | Effect of Compound Danshen Dripping Pills on Diabetic Patients With Coronary Microcirculation Disturbance                | UNKNOWN    | <!----> | 2022-04-01 |\n",
       "| NCT05870202 | Treatment Burden Screening Questionnaire Pilot Study                                                                     | COMPLETED  | <!----> | 2023-03-07 |\n",
       "| NCT05881837 | Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes                                              | COMPLETED  | <!----> | 2023-06-13 |\n",
       "| NCT05203575 | Building a Behavioural Intervention Programme to Improve Self-Management of Diabetes                                     | UNKNOWN    | <!----> | 2022-03-28 |\n",
       "| NCT05548218 | Care Companion Diabetes                                                                                                  | COMPLETED  | <!----> | 2022-08-15 |\n",
       "| NCT04403789 | Effects of a Workplace Exercise Intervention on Cardio-Metabolic Health                                                  | COMPLETED  | <!----> | 2021-03-28 |\n",
       "| NCT00296374 | Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease             | COMPLETED  | <!----> | 2006-02    |\n",
       "| NCT00353990 | Bioavailability of Insulin Administered in Duodenum                                                                      | COMPLETED  | <!----> | 2006-08    |\n",
       "| NCT03603990 | Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema                                               | WITHDRAWN  | <!----> | 2018-09-01 |\n",
       "\n"
      ],
      "text/plain": [
       "   nct_id     \n",
       "1  NCT02951260\n",
       "2  NCT00286624\n",
       "3  NCT00859079\n",
       "4  NCT00480779\n",
       "5  NCT03885362\n",
       "6  NCT04089462\n",
       "7  NCT03810846\n",
       "8  NCT00136188\n",
       "9  NCT04919603\n",
       "10 NCT00762242\n",
       "11 NCT00922194\n",
       "12 NCT05295329\n",
       "13 NCT05870202\n",
       "14 NCT05881837\n",
       "15 NCT05203575\n",
       "16 NCT05548218\n",
       "17 NCT04403789\n",
       "18 NCT00296374\n",
       "19 NCT00353990\n",
       "20 NCT03603990\n",
       "   title                                                                                                                   \n",
       "1  The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation     \n",
       "2  Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation                                                 \n",
       "3  Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients\n",
       "4  Evaluation of Group Lifestyle Balance DVD in Primary Care Practice                                                      \n",
       "5  Assessment of the Accuracy of Continuous Glucose Sensors in People With Diabetes Undergoing Haemodialysis               \n",
       "6  Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study               \n",
       "7  Feasibility and Safety of Walking Football in Patients With Type 2 Diabetes                                             \n",
       "8  Nitric Oxide (NO) Activity and Diabetic Nephropathy                                                                     \n",
       "9  Impact of Exercise Intervention on the Phenome                                                                          \n",
       "10 Metabolomic Profiling of Novel Mediators of Vascular Function                                                           \n",
       "11 Metformin in Overweight Type 2 Diabetes Mellitus                                                                        \n",
       "12 Effect of Compound Danshen Dripping Pills on Diabetic Patients With Coronary Microcirculation Disturbance               \n",
       "13 Treatment Burden Screening Questionnaire Pilot Study                                                                    \n",
       "14 Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes                                             \n",
       "15 Building a Behavioural Intervention Programme to Improve Self-Management of Diabetes                                    \n",
       "16 Care Companion Diabetes                                                                                                 \n",
       "17 Effects of a Workplace Exercise Intervention on Cardio-Metabolic Health                                                 \n",
       "18 Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease            \n",
       "19 Bioavailability of Insulin Administered in Duodenum                                                                     \n",
       "20 Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema                                              \n",
       "   status     phase start_date\n",
       "1  COMPLETED        2016-10   \n",
       "2  COMPLETED        2003-03   \n",
       "3  COMPLETED        2006-06   \n",
       "4  COMPLETED        2007-06   \n",
       "5  COMPLETED        2019-12-11\n",
       "6  COMPLETED        2019-09-30\n",
       "7  COMPLETED        2018-09-17\n",
       "8  COMPLETED        2009-08   \n",
       "9  UNKNOWN          2021-06-15\n",
       "10 TERMINATED       2007-05   \n",
       "11 COMPLETED        2006-02   \n",
       "12 UNKNOWN          2022-04-01\n",
       "13 COMPLETED        2023-03-07\n",
       "14 COMPLETED        2023-06-13\n",
       "15 UNKNOWN          2022-03-28\n",
       "16 COMPLETED        2022-08-15\n",
       "17 COMPLETED        2021-03-28\n",
       "18 COMPLETED        2006-02   \n",
       "19 COMPLETED        2006-08   \n",
       "20 WITHDRAWN        2018-09-01"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "res <- ct_search_studies(condition = \"diabetes\", page_size = 20)\n",
    "\n",
    "res$data"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f88b6435-a490-4421-87c0-adb4aa2ea76e",
   "metadata": {},
   "source": [
    "## 28-Jan-2026\n",
    "\n",
    "- Realized filtering dates is very tedious the dates have to be in a specific format or else it will break. \n",
    "- Tested out teammates code and cleaned up the output tables of his API .\n",
    "- I am experimenting with nested tables but i think its too complex and not very user friendly"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "e1f8dbec-c79b-49f0-ae43-a43523eed26d",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[1m\u001b[22m\u001b[36mℹ\u001b[39m Loading \u001b[34mtidytrials\u001b[39m\n",
      "\n",
      "Attaching package: 'dplyr'\n",
      "\n",
      "\n",
      "The following objects are masked from 'package:stats':\n",
      "\n",
      "    filter, lag\n",
      "\n",
      "\n",
      "The following objects are masked from 'package:base':\n",
      "\n",
      "    intersect, setdiff, setequal, union\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "suppressWarnings(devtools::load_all())\n",
    "spec <- list(\n",
    "  query = \"cancer\",\n",
    "  max_records = 10,\n",
    "  phase = \"Phase 2\",\n",
    "  country = \"Canada\",\n",
    "  from_date = \"2022-01-01\",\n",
    "  to_date = \"2023-01-01\",\n",
    "  date_filter = \"StartDate\"\n",
    ")\n",
    "result <- trials_run_spec(spec)\n",
    "# str(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "929506bc-728a-42e2-ab9c-2d732c07d5d2",
   "metadata": {},
   "outputs": [],
   "source": [
    "`%||%` <- function(a, b) if (is.null(a) || length(a) == 0) b else a\n",
    "\n",
    "get_in <- function(x, path, default = NA_character_) {\n",
    "  for (nm in path) {\n",
    "    if (is.null(x[[nm]])) return(default)\n",
    "    x <- x[[nm]]\n",
    "  }\n",
    "  if (is.null(x) || length(x) == 0) return(default)\n",
    "  if (is.atomic(x)) return(as.character(x)[1])\n",
    "  default\n",
    "}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "8dead0ce-47de-4697-a8e5-5cf36d4756eb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A tibble: 6 × 24</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>nct_id</th><th scope=col>org_study_id</th><th scope=col>brief_title</th><th scope=col>official_title</th><th scope=col>overall_status</th><th scope=col>why_stopped</th><th scope=col>start_date</th><th scope=col>primary_completion_date</th><th scope=col>completion_date</th><th scope=col>last_update_posted</th><th scope=col>⋯</th><th scope=col>allocation</th><th scope=col>intervention_model</th><th scope=col>primary_purpose</th><th scope=col>masking</th><th scope=col>enrollment</th><th scope=col>enrollment_type</th><th scope=col>conditions</th><th scope=col>countries</th><th scope=col>n_sites</th><th scope=col>has_results</th></tr>\n",
       "\t<tr><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>⋯</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;lgl&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td>NCT05444894</td><td>EM-301-BThal-001  </td><td>EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)       </td><td>A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)                                   </td><td>ACTIVE_NOT_RECRUITING</td><td>NA              </td><td>2022-04-29</td><td>2025-09   </td><td>2025-12   </td><td>2025-04-02</td><td>⋯</td><td>NA            </td><td>SINGLE_GROUP</td><td>TREATMENT</td><td>NONE     </td><td>9  </td><td>ESTIMATED</td><td>Transfusion Dependent Beta Thalassemia; Hemoglobinopathies; Thalassemia Major; Thalassemia Intermedia                                                                      </td><td>United States; Canada                                                                                                                              </td><td>  8</td><td>FALSE</td></tr>\n",
       "\t<tr><td>NCT07150091</td><td>208887 Sub Study 6</td><td>Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM</td><td>A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination</td><td>ACTIVE_NOT_RECRUITING</td><td>NA              </td><td>2022-07-19</td><td>2025-04-17</td><td>2027-03-11</td><td>2025-09-02</td><td>⋯</td><td>NA            </td><td>SINGLE_GROUP</td><td>TREATMENT</td><td>NONE     </td><td>20 </td><td>ACTUAL   </td><td>Multiple Myeloma                                                                                                                                                           </td><td>United States; Brazil; Canada; France; Germany; Greece; Mexico; South Korea                                                                        </td><td> 12</td><td>FALSE</td></tr>\n",
       "\t<tr><td>NCT05421598</td><td>DRI17509          </td><td>Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                    </td><td>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                                                                                </td><td>COMPLETED            </td><td>NA              </td><td>2022-06-30</td><td>2024-10-11</td><td>2025-03-20</td><td>2025-10-09</td><td>⋯</td><td>RANDOMIZED    </td><td>PARALLEL    </td><td>TREATMENT</td><td>QUADRUPLE</td><td>446</td><td>ACTUAL   </td><td>Asthma                                                                                                                                                                     </td><td>United States; Argentina; Brazil; Canada; Chile; Hungary; Italy; Japan; Mexico; Poland; South Africa; South Korea; Turkey (Türkiye); United Kingdom</td><td>113</td><td>FALSE</td></tr>\n",
       "\t<tr><td>NCT05394350</td><td>1088-002          </td><td>A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)          </td><td>A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors                                                                                                                                                                                          </td><td>TERMINATED           </td><td>Business Reasons</td><td>2022-07-07</td><td>2023-09-07</td><td>2023-09-07</td><td>2024-11-08</td><td>⋯</td><td>NON_RANDOMIZED</td><td>PARALLEL    </td><td>TREATMENT</td><td>NONE     </td><td>27 </td><td>ACTUAL   </td><td>Advanced Solid Tumors                                                                                                                                                      </td><td>United States; Canada; Denmark; Israel; Switzerland                                                                                                </td><td> 13</td><td> TRUE</td></tr>\n",
       "\t<tr><td>NCT04765514</td><td>IIT-0012          </td><td>Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients                                                      </td><td>A Randomized Controlled Trial of Chemo-Radiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail Patients With Newly Diagnosed Glioblastoma                                                                                                                                                                                                                </td><td>RECRUITING           </td><td>NA              </td><td>2022-07-27</td><td>2032-06   </td><td>2032-06   </td><td>2025-06-12</td><td>⋯</td><td>RANDOMIZED    </td><td>PARALLEL    </td><td>TREATMENT</td><td>NONE     </td><td>121</td><td>ESTIMATED</td><td>Glioblastoma Multiforme                                                                                                                                                    </td><td>Canada                                                                                                                                             </td><td>  2</td><td>FALSE</td></tr>\n",
       "\t<tr><td>NCT05432934</td><td>BIO-2549          </td><td>Transversus Abdominis Plane Blocks With and Without Dexamethasone                                                                         </td><td>Transversus Abdominis Plane Blocks With and Without Dexamethasone: A Randomized Clinical Trial in Minimally Invasive Colorectal Surgery                                                                                                                                                                                                                             </td><td>UNKNOWN              </td><td>NA              </td><td>2022-09-01</td><td>2024-03-31</td><td>2024-08-31</td><td>2023-12-07</td><td>⋯</td><td>RANDOMIZED    </td><td>PARALLEL    </td><td>TREATMENT</td><td>DOUBLE   </td><td>60 </td><td>ESTIMATED</td><td>Colorectal Disorders; Regional Anesthesia Morbidity; Analgesia; Local Anesthetic Complication; Pain, Postoperative; Colorectal Cancer; Crohn Disease; Diverticular Diseases</td><td>Canada                                                                                                                                             </td><td>  1</td><td>FALSE</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A tibble: 6 × 24\n",
       "\\begin{tabular}{lllllllllllllllllllll}\n",
       " nct\\_id & org\\_study\\_id & brief\\_title & official\\_title & overall\\_status & why\\_stopped & start\\_date & primary\\_completion\\_date & completion\\_date & last\\_update\\_posted & ⋯ & allocation & intervention\\_model & primary\\_purpose & masking & enrollment & enrollment\\_type & conditions & countries & n\\_sites & has\\_results\\\\\n",
       " <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & ⋯ & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <int> & <lgl>\\\\\n",
       "\\hline\n",
       "\t NCT05444894 & EM-301-BThal-001   & EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)        & A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)                                    & ACTIVE\\_NOT\\_RECRUITING & NA               & 2022-04-29 & 2025-09    & 2025-12    & 2025-04-02 & ⋯ & NA             & SINGLE\\_GROUP & TREATMENT & NONE      & 9   & ESTIMATED & Transfusion Dependent Beta Thalassemia; Hemoglobinopathies; Thalassemia Major; Thalassemia Intermedia                                                                       & United States; Canada                                                                                                                               &   8 & FALSE\\\\\n",
       "\t NCT07150091 & 208887 Sub Study 6 & Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM & A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination & ACTIVE\\_NOT\\_RECRUITING & NA               & 2022-07-19 & 2025-04-17 & 2027-03-11 & 2025-09-02 & ⋯ & NA             & SINGLE\\_GROUP & TREATMENT & NONE      & 20  & ACTUAL    & Multiple Myeloma                                                                                                                                                            & United States; Brazil; Canada; France; Germany; Greece; Mexico; South Korea                                                                         &  12 & FALSE\\\\\n",
       "\t NCT05421598 & DRI17509           & Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                     & A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                                                                                 & COMPLETED             & NA               & 2022-06-30 & 2024-10-11 & 2025-03-20 & 2025-10-09 & ⋯ & RANDOMIZED     & PARALLEL     & TREATMENT & QUADRUPLE & 446 & ACTUAL    & Asthma                                                                                                                                                                      & United States; Argentina; Brazil; Canada; Chile; Hungary; Italy; Japan; Mexico; Poland; South Africa; South Korea; Turkey (Türkiye); United Kingdom & 113 & FALSE\\\\\n",
       "\t NCT05394350 & 1088-002           & A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)           & A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors                                                                                                                                                                                           & TERMINATED            & Business Reasons & 2022-07-07 & 2023-09-07 & 2023-09-07 & 2024-11-08 & ⋯ & NON\\_RANDOMIZED & PARALLEL     & TREATMENT & NONE      & 27  & ACTUAL    & Advanced Solid Tumors                                                                                                                                                       & United States; Canada; Denmark; Israel; Switzerland                                                                                                 &  13 &  TRUE\\\\\n",
       "\t NCT04765514 & IIT-0012           & Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients                                                       & A Randomized Controlled Trial of Chemo-Radiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail Patients With Newly Diagnosed Glioblastoma                                                                                                                                                                                                                 & RECRUITING            & NA               & 2022-07-27 & 2032-06    & 2032-06    & 2025-06-12 & ⋯ & RANDOMIZED     & PARALLEL     & TREATMENT & NONE      & 121 & ESTIMATED & Glioblastoma Multiforme                                                                                                                                                     & Canada                                                                                                                                              &   2 & FALSE\\\\\n",
       "\t NCT05432934 & BIO-2549           & Transversus Abdominis Plane Blocks With and Without Dexamethasone                                                                          & Transversus Abdominis Plane Blocks With and Without Dexamethasone: A Randomized Clinical Trial in Minimally Invasive Colorectal Surgery                                                                                                                                                                                                                              & UNKNOWN               & NA               & 2022-09-01 & 2024-03-31 & 2024-08-31 & 2023-12-07 & ⋯ & RANDOMIZED     & PARALLEL     & TREATMENT & DOUBLE    & 60  & ESTIMATED & Colorectal Disorders; Regional Anesthesia Morbidity; Analgesia; Local Anesthetic Complication; Pain, Postoperative; Colorectal Cancer; Crohn Disease; Diverticular Diseases & Canada                                                                                                                                              &   1 & FALSE\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A tibble: 6 × 24\n",
       "\n",
       "| nct_id &lt;chr&gt; | org_study_id &lt;chr&gt; | brief_title &lt;chr&gt; | official_title &lt;chr&gt; | overall_status &lt;chr&gt; | why_stopped &lt;chr&gt; | start_date &lt;chr&gt; | primary_completion_date &lt;chr&gt; | completion_date &lt;chr&gt; | last_update_posted &lt;chr&gt; | ⋯ ⋯ | allocation &lt;chr&gt; | intervention_model &lt;chr&gt; | primary_purpose &lt;chr&gt; | masking &lt;chr&gt; | enrollment &lt;chr&gt; | enrollment_type &lt;chr&gt; | conditions &lt;chr&gt; | countries &lt;chr&gt; | n_sites &lt;int&gt; | has_results &lt;lgl&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| NCT05444894 | EM-301-BThal-001   | EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)        | A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)                                    | ACTIVE_NOT_RECRUITING | NA               | 2022-04-29 | 2025-09    | 2025-12    | 2025-04-02 | ⋯ | NA             | SINGLE_GROUP | TREATMENT | NONE      | 9   | ESTIMATED | Transfusion Dependent Beta Thalassemia; Hemoglobinopathies; Thalassemia Major; Thalassemia Intermedia                                                                       | United States; Canada                                                                                                                               |   8 | FALSE |\n",
       "| NCT07150091 | 208887 Sub Study 6 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination | ACTIVE_NOT_RECRUITING | NA               | 2022-07-19 | 2025-04-17 | 2027-03-11 | 2025-09-02 | ⋯ | NA             | SINGLE_GROUP | TREATMENT | NONE      | 20  | ACTUAL    | Multiple Myeloma                                                                                                                                                            | United States; Brazil; Canada; France; Germany; Greece; Mexico; South Korea                                                                         |  12 | FALSE |\n",
       "| NCT05421598 | DRI17509           | Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                     | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                                                                                 | COMPLETED             | NA               | 2022-06-30 | 2024-10-11 | 2025-03-20 | 2025-10-09 | ⋯ | RANDOMIZED     | PARALLEL     | TREATMENT | QUADRUPLE | 446 | ACTUAL    | Asthma                                                                                                                                                                      | United States; Argentina; Brazil; Canada; Chile; Hungary; Italy; Japan; Mexico; Poland; South Africa; South Korea; Turkey (Türkiye); United Kingdom | 113 | FALSE |\n",
       "| NCT05394350 | 1088-002           | A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)           | A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors                                                                                                                                                                                           | TERMINATED            | Business Reasons | 2022-07-07 | 2023-09-07 | 2023-09-07 | 2024-11-08 | ⋯ | NON_RANDOMIZED | PARALLEL     | TREATMENT | NONE      | 27  | ACTUAL    | Advanced Solid Tumors                                                                                                                                                       | United States; Canada; Denmark; Israel; Switzerland                                                                                                 |  13 |  TRUE |\n",
       "| NCT04765514 | IIT-0012           | Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients                                                       | A Randomized Controlled Trial of Chemo-Radiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail Patients With Newly Diagnosed Glioblastoma                                                                                                                                                                                                                 | RECRUITING            | NA               | 2022-07-27 | 2032-06    | 2032-06    | 2025-06-12 | ⋯ | RANDOMIZED     | PARALLEL     | TREATMENT | NONE      | 121 | ESTIMATED | Glioblastoma Multiforme                                                                                                                                                     | Canada                                                                                                                                              |   2 | FALSE |\n",
       "| NCT05432934 | BIO-2549           | Transversus Abdominis Plane Blocks With and Without Dexamethasone                                                                          | Transversus Abdominis Plane Blocks With and Without Dexamethasone: A Randomized Clinical Trial in Minimally Invasive Colorectal Surgery                                                                                                                                                                                                                              | UNKNOWN               | NA               | 2022-09-01 | 2024-03-31 | 2024-08-31 | 2023-12-07 | ⋯ | RANDOMIZED     | PARALLEL     | TREATMENT | DOUBLE    | 60  | ESTIMATED | Colorectal Disorders; Regional Anesthesia Morbidity; Analgesia; Local Anesthetic Complication; Pain, Postoperative; Colorectal Cancer; Crohn Disease; Diverticular Diseases | Canada                                                                                                                                              |   1 | FALSE |\n",
       "\n"
      ],
      "text/plain": [
       "  nct_id      org_study_id      \n",
       "1 NCT05444894 EM-301-BThal-001  \n",
       "2 NCT07150091 208887 Sub Study 6\n",
       "3 NCT05421598 DRI17509          \n",
       "4 NCT05394350 1088-002          \n",
       "5 NCT04765514 IIT-0012          \n",
       "6 NCT05432934 BIO-2549          \n",
       "  brief_title                                                                                                                               \n",
       "1 EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)       \n",
       "2 Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM\n",
       "3 Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                    \n",
       "4 A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)          \n",
       "5 Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients                                                      \n",
       "6 Transversus Abdominis Plane Blocks With and Without Dexamethasone                                                                         \n",
       "  official_title                                                                                                                                                                                                                                                                                                                                                      \n",
       "1 A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)                                   \n",
       "2 A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination\n",
       "3 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                                                                                \n",
       "4 A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors                                                                                                                                                                                          \n",
       "5 A Randomized Controlled Trial of Chemo-Radiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail Patients With Newly Diagnosed Glioblastoma                                                                                                                                                                                                                \n",
       "6 Transversus Abdominis Plane Blocks With and Without Dexamethasone: A Randomized Clinical Trial in Minimally Invasive Colorectal Surgery                                                                                                                                                                                                                             \n",
       "  overall_status        why_stopped      start_date primary_completion_date\n",
       "1 ACTIVE_NOT_RECRUITING NA               2022-04-29 2025-09                \n",
       "2 ACTIVE_NOT_RECRUITING NA               2022-07-19 2025-04-17             \n",
       "3 COMPLETED             NA               2022-06-30 2024-10-11             \n",
       "4 TERMINATED            Business Reasons 2022-07-07 2023-09-07             \n",
       "5 RECRUITING            NA               2022-07-27 2032-06                \n",
       "6 UNKNOWN               NA               2022-09-01 2024-03-31             \n",
       "  completion_date last_update_posted ⋯ allocation     intervention_model\n",
       "1 2025-12         2025-04-02         ⋯ NA             SINGLE_GROUP      \n",
       "2 2027-03-11      2025-09-02         ⋯ NA             SINGLE_GROUP      \n",
       "3 2025-03-20      2025-10-09         ⋯ RANDOMIZED     PARALLEL          \n",
       "4 2023-09-07      2024-11-08         ⋯ NON_RANDOMIZED PARALLEL          \n",
       "5 2032-06         2025-06-12         ⋯ RANDOMIZED     PARALLEL          \n",
       "6 2024-08-31      2023-12-07         ⋯ RANDOMIZED     PARALLEL          \n",
       "  primary_purpose masking   enrollment enrollment_type\n",
       "1 TREATMENT       NONE      9          ESTIMATED      \n",
       "2 TREATMENT       NONE      20         ACTUAL         \n",
       "3 TREATMENT       QUADRUPLE 446        ACTUAL         \n",
       "4 TREATMENT       NONE      27         ACTUAL         \n",
       "5 TREATMENT       NONE      121        ESTIMATED      \n",
       "6 TREATMENT       DOUBLE    60         ESTIMATED      \n",
       "  conditions                                                                                                                                                                 \n",
       "1 Transfusion Dependent Beta Thalassemia; Hemoglobinopathies; Thalassemia Major; Thalassemia Intermedia                                                                      \n",
       "2 Multiple Myeloma                                                                                                                                                           \n",
       "3 Asthma                                                                                                                                                                     \n",
       "4 Advanced Solid Tumors                                                                                                                                                      \n",
       "5 Glioblastoma Multiforme                                                                                                                                                    \n",
       "6 Colorectal Disorders; Regional Anesthesia Morbidity; Analgesia; Local Anesthetic Complication; Pain, Postoperative; Colorectal Cancer; Crohn Disease; Diverticular Diseases\n",
       "  countries                                                                                                                                          \n",
       "1 United States; Canada                                                                                                                              \n",
       "2 United States; Brazil; Canada; France; Germany; Greece; Mexico; South Korea                                                                        \n",
       "3 United States; Argentina; Brazil; Canada; Chile; Hungary; Italy; Japan; Mexico; Poland; South Africa; South Korea; Turkey (Türkiye); United Kingdom\n",
       "4 United States; Canada; Denmark; Israel; Switzerland                                                                                                \n",
       "5 Canada                                                                                                                                             \n",
       "6 Canada                                                                                                                                             \n",
       "  n_sites has_results\n",
       "1   8     FALSE      \n",
       "2  12     FALSE      \n",
       "3 113     FALSE      \n",
       "4  13      TRUE      \n",
       "5   2     FALSE      \n",
       "6   1     FALSE      "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "library(tibble)\n",
    "library(purrr)\n",
    "library(dplyr)\n",
    "\n",
    "studies_to_table <- function(studies) {\n",
    "  map_dfr(studies, function(st) {\n",
    "\n",
    "    # pull lists safely\n",
    "    conds <- st$protocolSection$conditionsModule$conditions %||% character(0)\n",
    "    locs  <- st$protocolSection$contactsLocationsModule$locations %||% list()\n",
    "\n",
    "    # collapse conditions\n",
    "    condition_all <- if (length(conds) == 0) NA_character_ else paste(unlist(conds), collapse = \"; \")\n",
    "\n",
    "    # derive countries + site count\n",
    "    countries <- unique(vapply(locs, function(z) z$country %||% NA_character_, character(1)))\n",
    "    countries <- countries[!is.na(countries)]\n",
    "    country_all <- if (length(countries) == 0) NA_character_ else paste(countries, collapse = \"; \")\n",
    "    n_sites <- length(locs)\n",
    "\n",
    "    tibble(\n",
    "      nct_id = get_in(st, c(\"protocolSection\",\"identificationModule\",\"nctId\")),\n",
    "      org_study_id = get_in(st, c(\"protocolSection\",\"identificationModule\",\"orgStudyIdInfo\",\"id\")),\n",
    "      brief_title = get_in(st, c(\"protocolSection\",\"identificationModule\",\"briefTitle\")),\n",
    "      official_title = get_in(st, c(\"protocolSection\",\"identificationModule\",\"officialTitle\")),\n",
    "\n",
    "      overall_status = get_in(st, c(\"protocolSection\",\"statusModule\",\"overallStatus\")),\n",
    "      why_stopped = get_in(st, c(\"protocolSection\",\"statusModule\",\"whyStopped\")),\n",
    "\n",
    "      start_date = get_in(st, c(\"protocolSection\",\"statusModule\",\"startDateStruct\",\"date\")),\n",
    "      primary_completion_date = get_in(st, c(\"protocolSection\",\"statusModule\",\"primaryCompletionDateStruct\",\"date\")),\n",
    "      completion_date = get_in(st, c(\"protocolSection\",\"statusModule\",\"completionDateStruct\",\"date\")),\n",
    "      last_update_posted = get_in(st, c(\"protocolSection\",\"statusModule\",\"lastUpdatePostDateStruct\",\"date\")),\n",
    "\n",
    "      sponsor = get_in(st, c(\"protocolSection\",\"sponsorCollaboratorsModule\",\"leadSponsor\",\"name\")),\n",
    "      sponsor_class = get_in(st, c(\"protocolSection\",\"sponsorCollaboratorsModule\",\"leadSponsor\",\"class\")),\n",
    "\n",
    "      study_type = get_in(st, c(\"protocolSection\",\"designModule\",\"studyType\")),\n",
    "      phase = {\n",
    "        ph <- st$protocolSection$designModule$phases %||% character(0)\n",
    "        if (length(ph) == 0) NA_character_ else paste(unlist(ph), collapse = \", \")\n",
    "      },\n",
    "      allocation = get_in(st, c(\"protocolSection\",\"designModule\",\"designInfo\",\"allocation\")),\n",
    "      intervention_model = get_in(st, c(\"protocolSection\",\"designModule\",\"designInfo\",\"interventionModel\")),\n",
    "      primary_purpose = get_in(st, c(\"protocolSection\",\"designModule\",\"designInfo\",\"primaryPurpose\")),\n",
    "      masking = get_in(st, c(\"protocolSection\",\"designModule\",\"designInfo\",\"maskingInfo\",\"masking\")),\n",
    "\n",
    "      enrollment = get_in(st, c(\"protocolSection\",\"designModule\",\"enrollmentInfo\",\"count\")),\n",
    "      enrollment_type = get_in(st, c(\"protocolSection\",\"designModule\",\"enrollmentInfo\",\"type\")),\n",
    "\n",
    "      conditions = condition_all,\n",
    "      countries = country_all,\n",
    "      n_sites = n_sites,\n",
    "\n",
    "      has_results = st$hasResults %||% NA\n",
    "    )\n",
    "  })\n",
    "}\n",
    "\n",
    "tbl <- studies_to_table(result$studies) |> distinct(nct_id, .keep_all = TRUE)\n",
    "head(tbl)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "d6077ee0-95c9-40c8-b97f-d76748c5e64d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<!doctype html>\n",
       "<html>\n",
       "\t<head>\n",
       "\t\t<meta charset=\"utf-8\">\n",
       "\t\t<link href=\"data:text/css;charset-utf-8;base64,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\" rel=\"stylesheet\" />\n",
       "<script title=\"htmlwidgets\" src=\"data:application/javascript;base64,(function() {
  // If window.HTMLWidgets is already defined, then use it; otherwise create a
  // new object. This allows preceding code to set options that affect the
  // initialization process (though none currently exist).
  window.HTMLWidgets = window.HTMLWidgets || {};

  // See if we're running in a viewer pane. If not, we're in a web browser.
  var viewerMode = window.HTMLWidgets.viewerMode =
      /\bviewer_pane=1\b/.test(window.location);

  // See if we're running in Shiny mode. If not, it's a static document.
  // Note that static widgets can appear in both Shiny and static modes, but
  // obviously, Shiny widgets can only appear in Shiny apps/documents.
  var shinyMode = window.HTMLWidgets.shinyMode =
      typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings;

  // We can't count on jQuery being available, so we implement our own
  // version if necessary.
  function querySelectorAll(scope, selector) {
    if (typeof(jQuery) !== "undefined" && scope instanceof jQuery) {
      return scope.find(selector);
    }
    if (scope.querySelectorAll) {
      return scope.querySelectorAll(selector);
    }
  }

  function asArray(value) {
    if (value === null)
      return [];
    if ($.isArray(value))
      return value;
    return [value];
  }

  // Implement jQuery's extend
  function extend(target /*, ... */) {
    if (arguments.length == 1) {
      return target;
    }
    for (var i = 1; i < arguments.length; i++) {
      var source = arguments[i];
      for (var prop in source) {
        if (source.hasOwnProperty(prop)) {
          target[prop] = source[prop];
        }
      }
    }
    return target;
  }

  // IE8 doesn't support Array.forEach.
  function forEach(values, callback, thisArg) {
    if (values.forEach) {
      values.forEach(callback, thisArg);
    } else {
      for (var i = 0; i < values.length; i++) {
        callback.call(thisArg, values[i], i, values);
      }
    }
  }

  // Replaces the specified method with the return value of funcSource.
  //
  // Note that funcSource should not BE the new method, it should be a function
  // that RETURNS the new method. funcSource receives a single argument that is
  // the overridden method, it can be called from the new method. The overridden
  // method can be called like a regular function, it has the target permanently
  // bound to it so "this" will work correctly.
  function overrideMethod(target, methodName, funcSource) {
    var superFunc = target[methodName] || function() {};
    var superFuncBound = function() {
      return superFunc.apply(target, arguments);
    };
    target[methodName] = funcSource(superFuncBound);
  }

  // Add a method to delegator that, when invoked, calls
  // delegatee.methodName. If there is no such method on
  // the delegatee, but there was one on delegator before
  // delegateMethod was called, then the original version
  // is invoked instead.
  // For example:
  //
  // var a = {
  //   method1: function() { console.log('a1'); }
  //   method2: function() { console.log('a2'); }
  // };
  // var b = {
  //   method1: function() { console.log('b1'); }
  // };
  // delegateMethod(a, b, "method1");
  // delegateMethod(a, b, "method2");
  // a.method1();
  // a.method2();
  //
  // The output would be "b1", "a2".
  function delegateMethod(delegator, delegatee, methodName) {
    var inherited = delegator[methodName];
    delegator[methodName] = function() {
      var target = delegatee;
      var method = delegatee[methodName];

      // The method doesn't exist on the delegatee. Instead,
      // call the method on the delegator, if it exists.
      if (!method) {
        target = delegator;
        method = inherited;
      }

      if (method) {
        return method.apply(target, arguments);
      }
    };
  }

  // Implement a vague facsimilie of jQuery's data method
  function elementData(el, name, value) {
    if (arguments.length == 2) {
      return el["htmlwidget_data_" + name];
    } else if (arguments.length == 3) {
      el["htmlwidget_data_" + name] = value;
      return el;
    } else {
      throw new Error("Wrong number of arguments for elementData: " +
        arguments.length);
    }
  }

  // http://stackoverflow.com/questions/3446170/escape-string-for-use-in-javascript-regex
  function escapeRegExp(str) {
    return str.replace(/[\-\[\]\/\{\}\(\)\*\+\?\.\\\^\$\|]/g, "\\$&");
  }

  function hasClass(el, className) {
    var re = new RegExp("\\b" + escapeRegExp(className) + "\\b");
    return re.test(el.className);
  }

  // elements - array (or array-like object) of HTML elements
  // className - class name to test for
  // include - if true, only return elements with given className;
  //   if false, only return elements *without* given className
  function filterByClass(elements, className, include) {
    var results = [];
    for (var i = 0; i < elements.length; i++) {
      if (hasClass(elements[i], className) == include)
        results.push(elements[i]);
    }
    return results;
  }

  function on(obj, eventName, func) {
    if (obj.addEventListener) {
      obj.addEventListener(eventName, func, false);
    } else if (obj.attachEvent) {
      obj.attachEvent(eventName, func);
    }
  }

  function off(obj, eventName, func) {
    if (obj.removeEventListener)
      obj.removeEventListener(eventName, func, false);
    else if (obj.detachEvent) {
      obj.detachEvent(eventName, func);
    }
  }

  // Translate array of values to top/right/bottom/left, as usual with
  // the "padding" CSS property
  // https://developer.mozilla.org/en-US/docs/Web/CSS/padding
  function unpackPadding(value) {
    if (typeof(value) === "number")
      value = [value];
    if (value.length === 1) {
      return {top: value[0], right: value[0], bottom: value[0], left: value[0]};
    }
    if (value.length === 2) {
      return {top: value[0], right: value[1], bottom: value[0], left: value[1]};
    }
    if (value.length === 3) {
      return {top: value[0], right: value[1], bottom: value[2], left: value[1]};
    }
    if (value.length === 4) {
      return {top: value[0], right: value[1], bottom: value[2], left: value[3]};
    }
  }

  // Convert an unpacked padding object to a CSS value
  function paddingToCss(paddingObj) {
    return paddingObj.top + "px " + paddingObj.right + "px " + paddingObj.bottom + "px " + paddingObj.left + "px";
  }

  // Makes a number suitable for CSS
  function px(x) {
    if (typeof(x) === "number")
      return x + "px";
    else
      return x;
  }

  // Retrieves runtime widget sizing information for an element.
  // The return value is either null, or an object with fill, padding,
  // defaultWidth, defaultHeight fields.
  function sizingPolicy(el) {
    var sizingEl = document.querySelector("script[data-for='" + el.id + "'][type='application/htmlwidget-sizing']");
    if (!sizingEl)
      return null;
    var sp = JSON.parse(sizingEl.textContent || sizingEl.text || "{}");
    if (viewerMode) {
      return sp.viewer;
    } else {
      return sp.browser;
    }
  }

  // @param tasks Array of strings (or falsy value, in which case no-op).
  //   Each element must be a valid JavaScript expression that yields a
  //   function. Or, can be an array of objects with "code" and "data"
  //   properties; in this case, the "code" property should be a string
  //   of JS that's an expr that yields a function, and "data" should be
  //   an object that will be added as an additional argument when that
  //   function is called.
  // @param target The object that will be "this" for each function
  //   execution.
  // @param args Array of arguments to be passed to the functions. (The
  //   same arguments will be passed to all functions.)
  function evalAndRun(tasks, target, args) {
    if (tasks) {
      forEach(tasks, function(task) {
        var theseArgs = args;
        if (typeof(task) === "object") {
          theseArgs = theseArgs.concat([task.data]);
          task = task.code;
        }
        var taskFunc = tryEval(task);
        if (typeof(taskFunc) !== "function") {
          throw new Error("Task must be a function! Source:\n" + task);
        }
        taskFunc.apply(target, theseArgs);
      });
    }
  }

  // Attempt eval() both with and without enclosing in parentheses.
  // Note that enclosing coerces a function declaration into
  // an expression that eval() can parse
  // (otherwise, a SyntaxError is thrown)
  function tryEval(code) {
    var result = null;
    try {
      result = eval("(" + code + ")");
    } catch(error) {
      if (!(error instanceof SyntaxError)) {
        throw error;
      }
      try {
        result = eval(code);
      } catch(e) {
        if (e instanceof SyntaxError) {
          throw error;
        } else {
          throw e;
        }
      }
    }
    return result;
  }

  function initSizing(el) {
    var sizing = sizingPolicy(el);
    if (!sizing)
      return;

    var cel = document.getElementById("htmlwidget_container");
    if (!cel)
      return;

    if (typeof(sizing.padding) !== "undefined") {
      document.body.style.margin = "0";
      document.body.style.padding = paddingToCss(unpackPadding(sizing.padding));
    }

    if (sizing.fill) {
      document.body.style.overflow = "hidden";
      document.body.style.width = "100%";
      document.body.style.height = "100%";
      document.documentElement.style.width = "100%";
      document.documentElement.style.height = "100%";
      cel.style.position = "absolute";
      var pad = unpackPadding(sizing.padding);
      cel.style.top = pad.top + "px";
      cel.style.right = pad.right + "px";
      cel.style.bottom = pad.bottom + "px";
      cel.style.left = pad.left + "px";
      el.style.width = "100%";
      el.style.height = "100%";

      return {
        getWidth: function() { return cel.getBoundingClientRect().width; },
        getHeight: function() { return cel.getBoundingClientRect().height; }
      };

    } else {
      el.style.width = px(sizing.width);
      el.style.height = px(sizing.height);

      return {
        getWidth: function() { return cel.getBoundingClientRect().width; },
        getHeight: function() { return cel.getBoundingClientRect().height; }
      };
    }
  }

  // Default implementations for methods
  var defaults = {
    find: function(scope) {
      return querySelectorAll(scope, "." + this.name);
    },
    renderError: function(el, err) {
      var $el = $(el);

      this.clearError(el);

      // Add all these error classes, as Shiny does
      var errClass = "shiny-output-error";
      if (err.type !== null) {
        // use the classes of the error condition as CSS class names
        errClass = errClass + " " + $.map(asArray(err.type), function(type) {
          return errClass + "-" + type;
        }).join(" ");
      }
      errClass = errClass + " htmlwidgets-error";

      // Is el inline or block? If inline or inline-block, just display:none it
      // and add an inline error.
      var display = $el.css("display");
      $el.data("restore-display-mode", display);

      if (display === "inline" || display === "inline-block") {
        $el.hide();
        if (err.message !== "") {
          var errorSpan = $("<span>").addClass(errClass);
          errorSpan.text(err.message);
          $el.after(errorSpan);
        }
      } else if (display === "block") {
        // If block, add an error just after the el, set visibility:none on the
        // el, and position the error to be on top of the el.
        // Mark it with a unique ID and CSS class so we can remove it later.
        $el.css("visibility", "hidden");
        if (err.message !== "") {
          var errorDiv = $("<div>").addClass(errClass).css("position", "absolute")
            .css("top", el.offsetTop)
            .css("left", el.offsetLeft)
            // setting width can push out the page size, forcing otherwise
            // unnecessary scrollbars to appear and making it impossible for
            // the element to shrink; so use max-width instead
            .css("maxWidth", el.offsetWidth)
            .css("height", el.offsetHeight);
          errorDiv.text(err.message);
          $el.after(errorDiv);

          // Really dumb way to keep the size/position of the error in sync with
          // the parent element as the window is resized or whatever.
          var intId = setInterval(function() {
            if (!errorDiv[0].parentElement) {
              clearInterval(intId);
              return;
            }
            errorDiv
              .css("top", el.offsetTop)
              .css("left", el.offsetLeft)
              .css("maxWidth", el.offsetWidth)
              .css("height", el.offsetHeight);
          }, 500);
        }
      }
    },
    clearError: function(el) {
      var $el = $(el);
      var display = $el.data("restore-display-mode");
      $el.data("restore-display-mode", null);

      if (display === "inline" || display === "inline-block") {
        if (display)
          $el.css("display", display);
        $(el.nextSibling).filter(".htmlwidgets-error").remove();
      } else if (display === "block"){
        $el.css("visibility", "inherit");
        $(el.nextSibling).filter(".htmlwidgets-error").remove();
      }
    },
    sizing: {}
  };

  // Called by widget bindings to register a new type of widget. The definition
  // object can contain the following properties:
  // - name (required) - A string indicating the binding name, which will be
  //   used by default as the CSS classname to look for.
  // - initialize (optional) - A function(el) that will be called once per
  //   widget element; if a value is returned, it will be passed as the third
  //   value to renderValue.
  // - renderValue (required) - A function(el, data, initValue) that will be
  //   called with data. Static contexts will cause this to be called once per
  //   element; Shiny apps will cause this to be called multiple times per
  //   element, as the data changes.
  window.HTMLWidgets.widget = function(definition) {
    if (!definition.name) {
      throw new Error("Widget must have a name");
    }
    if (!definition.type) {
      throw new Error("Widget must have a type");
    }
    // Currently we only support output widgets
    if (definition.type !== "output") {
      throw new Error("Unrecognized widget type '" + definition.type + "'");
    }
    // TODO: Verify that .name is a valid CSS classname

    // Support new-style instance-bound definitions. Old-style class-bound
    // definitions have one widget "object" per widget per type/class of
    // widget; the renderValue and resize methods on such widget objects
    // take el and instance arguments, because the widget object can't
    // store them. New-style instance-bound definitions have one widget
    // object per widget instance; the definition that's passed in doesn't
    // provide renderValue or resize methods at all, just the single method
    //   factory(el, width, height)
    // which returns an object that has renderValue(x) and resize(w, h).
    // This enables a far more natural programming style for the widget
    // author, who can store per-instance state using either OO-style
    // instance fields or functional-style closure variables (I guess this
    // is in contrast to what can only be called C-style pseudo-OO which is
    // what we required before).
    if (definition.factory) {
      definition = createLegacyDefinitionAdapter(definition);
    }

    if (!definition.renderValue) {
      throw new Error("Widget must have a renderValue function");
    }

    // For static rendering (non-Shiny), use a simple widget registration
    // scheme. We also use this scheme for Shiny apps/documents that also
    // contain static widgets.
    window.HTMLWidgets.widgets = window.HTMLWidgets.widgets || [];
    // Merge defaults into the definition; don't mutate the original definition.
    var staticBinding = extend({}, defaults, definition);
    overrideMethod(staticBinding, "find", function(superfunc) {
      return function(scope) {
        var results = superfunc(scope);
        // Filter out Shiny outputs, we only want the static kind
        return filterByClass(results, "html-widget-output", false);
      };
    });
    window.HTMLWidgets.widgets.push(staticBinding);

    if (shinyMode) {
      // Shiny is running. Register the definition with an output binding.
      // The definition itself will not be the output binding, instead
      // we will make an output binding object that delegates to the
      // definition. This is because we foolishly used the same method
      // name (renderValue) for htmlwidgets definition and Shiny bindings
      // but they actually have quite different semantics (the Shiny
      // bindings receive data that includes lots of metadata that it
      // strips off before calling htmlwidgets renderValue). We can't
      // just ignore the difference because in some widgets it's helpful
      // to call this.renderValue() from inside of resize(), and if
      // we're not delegating, then that call will go to the Shiny
      // version instead of the htmlwidgets version.

      // Merge defaults with definition, without mutating either.
      var bindingDef = extend({}, defaults, definition);

      // This object will be our actual Shiny binding.
      var shinyBinding = new Shiny.OutputBinding();

      // With a few exceptions, we'll want to simply use the bindingDef's
      // version of methods if they are available, otherwise fall back to
      // Shiny's defaults. NOTE: If Shiny's output bindings gain additional
      // methods in the future, and we want them to be overrideable by
      // HTMLWidget binding definitions, then we'll need to add them to this
      // list.
      delegateMethod(shinyBinding, bindingDef, "getId");
      delegateMethod(shinyBinding, bindingDef, "onValueChange");
      delegateMethod(shinyBinding, bindingDef, "onValueError");
      delegateMethod(shinyBinding, bindingDef, "renderError");
      delegateMethod(shinyBinding, bindingDef, "clearError");
      delegateMethod(shinyBinding, bindingDef, "showProgress");

      // The find, renderValue, and resize are handled differently, because we
      // want to actually decorate the behavior of the bindingDef methods.

      shinyBinding.find = function(scope) {
        var results = bindingDef.find(scope);

        // Only return elements that are Shiny outputs, not static ones
        var dynamicResults = results.filter(".html-widget-output");

        // It's possible that whatever caused Shiny to think there might be
        // new dynamic outputs, also caused there to be new static outputs.
        // Since there might be lots of different htmlwidgets bindings, we
        // schedule execution for later--no need to staticRender multiple
        // times.
        if (results.length !== dynamicResults.length)
          scheduleStaticRender();

        return dynamicResults;
      };

      // Wrap renderValue to handle initialization, which unfortunately isn't
      // supported natively by Shiny at the time of this writing.

      shinyBinding.renderValue = function(el, data) {
        Shiny.renderDependencies(data.deps);
        // Resolve strings marked as javascript literals to objects
        if (!(data.evals instanceof Array)) data.evals = [data.evals];
        for (var i = 0; data.evals && i < data.evals.length; i++) {
          window.HTMLWidgets.evaluateStringMember(data.x, data.evals[i]);
        }
        if (!bindingDef.renderOnNullValue) {
          if (data.x === null) {
            el.style.visibility = "hidden";
            return;
          } else {
            el.style.visibility = "inherit";
          }
        }
        if (!elementData(el, "initialized")) {
          initSizing(el);

          elementData(el, "initialized", true);
          if (bindingDef.initialize) {
            var rect = el.getBoundingClientRect();
            var result = bindingDef.initialize(el, rect.width, rect.height);
            elementData(el, "init_result", result);
          }
        }
        bindingDef.renderValue(el, data.x, elementData(el, "init_result"));
        evalAndRun(data.jsHooks.render, elementData(el, "init_result"), [el, data.x]);
      };

      // Only override resize if bindingDef implements it
      if (bindingDef.resize) {
        shinyBinding.resize = function(el, width, height) {
          // Shiny can call resize before initialize/renderValue have been
          // called, which doesn't make sense for widgets.
          if (elementData(el, "initialized")) {
            bindingDef.resize(el, width, height, elementData(el, "init_result"));
          }
        };
      }

      Shiny.outputBindings.register(shinyBinding, bindingDef.name);
    }
  };

  var scheduleStaticRenderTimerId = null;
  function scheduleStaticRender() {
    if (!scheduleStaticRenderTimerId) {
      scheduleStaticRenderTimerId = setTimeout(function() {
        scheduleStaticRenderTimerId = null;
        window.HTMLWidgets.staticRender();
      }, 1);
    }
  }

  // Render static widgets after the document finishes loading
  // Statically render all elements that are of this widget's class
  window.HTMLWidgets.staticRender = function() {
    var bindings = window.HTMLWidgets.widgets || [];
    forEach(bindings, function(binding) {
      var matches = binding.find(document.documentElement);
      forEach(matches, function(el) {
        var sizeObj = initSizing(el, binding);

        var getSize = function(el) {
          if (sizeObj) {
            return {w: sizeObj.getWidth(), h: sizeObj.getHeight()}
          } else {
            var rect = el.getBoundingClientRect();
            return {w: rect.width, h: rect.height}
          }
        };

        if (hasClass(el, "html-widget-static-bound"))
          return;
        el.className = el.className + " html-widget-static-bound";

        var initResult;
        if (binding.initialize) {
          var size = getSize(el);
          initResult = binding.initialize(el, size.w, size.h);
          elementData(el, "init_result", initResult);
        }

        if (binding.resize) {
          var lastSize = getSize(el);
          var resizeHandler = function(e) {
            var size = getSize(el);
            if (size.w === 0 && size.h === 0)
              return;
            if (size.w === lastSize.w && size.h === lastSize.h)
              return;
            lastSize = size;
            binding.resize(el, size.w, size.h, initResult);
          };

          on(window, "resize", resizeHandler);

          // This is needed for cases where we're running in a Shiny
          // app, but the widget itself is not a Shiny output, but
          // rather a simple static widget. One example of this is
          // an rmarkdown document that has runtime:shiny and widget
          // that isn't in a render function. Shiny only knows to
          // call resize handlers for Shiny outputs, not for static
          // widgets, so we do it ourselves.
          if (window.jQuery) {
            window.jQuery(document).on(
              "shown.htmlwidgets shown.bs.tab.htmlwidgets shown.bs.collapse.htmlwidgets",
              resizeHandler
            );
            window.jQuery(document).on(
              "hidden.htmlwidgets hidden.bs.tab.htmlwidgets hidden.bs.collapse.htmlwidgets",
              resizeHandler
            );
          }

          // This is needed for the specific case of ioslides, which
          // flips slides between display:none and display:block.
          // Ideally we would not have to have ioslide-specific code
          // here, but rather have ioslides raise a generic event,
          // but the rmarkdown package just went to CRAN so the
          // window to getting that fixed may be long.
          if (window.addEventListener) {
            // It's OK to limit this to window.addEventListener
            // browsers because ioslides itself only supports
            // such browsers.
            on(document, "slideenter", resizeHandler);
            on(document, "slideleave", resizeHandler);
          }
        }

        var scriptData = document.querySelector("script[data-for='" + el.id + "'][type='application/json']");
        if (scriptData) {
          var data = JSON.parse(scriptData.textContent || scriptData.text);
          // Resolve strings marked as javascript literals to objects
          if (!(data.evals instanceof Array)) data.evals = [data.evals];
          for (var k = 0; data.evals && k < data.evals.length; k++) {
            window.HTMLWidgets.evaluateStringMember(data.x, data.evals[k]);
          }
          binding.renderValue(el, data.x, initResult);
          evalAndRun(data.jsHooks.render, initResult, [el, data.x]);
        }
      });
    });

    invokePostRenderHandlers();
  }


  function has_jQuery3() {
    if (!window.jQuery) {
      return false;
    }
    var $version = window.jQuery.fn.jquery;
    var $major_version = parseInt($version.split(".")[0]);
    return $major_version >= 3;
  }

  /*
  / Shiny 1.4 bumped jQuery from 1.x to 3.x which means jQuery's
  / on-ready handler (i.e., $(fn)) is now asyncronous (i.e., it now
  / really means $(setTimeout(fn)).
  / https://jquery.com/upgrade-guide/3.0/#breaking-change-document-ready-handlers-are-now-asynchronous
  /
  / Since Shiny uses $() to schedule initShiny, shiny>=1.4 calls initShiny
  / one tick later than it did before, which means staticRender() is
  / called renderValue() earlier than (advanced) widget authors might be expecting.
  / https://github.com/rstudio/shiny/issues/2630
  /
  / For a concrete example, leaflet has some methods (e.g., updateBounds)
  / which reference Shiny methods registered in initShiny (e.g., setInputValue).
  / Since leaflet is privy to this life-cycle, it knows to use setTimeout() to
  / delay execution of those methods (until Shiny methods are ready)
  / https://github.com/rstudio/leaflet/blob/18ec981/javascript/src/index.js#L266-L268
  /
  / Ideally widget authors wouldn't need to use this setTimeout() hack that
  / leaflet uses to call Shiny methods on a staticRender(). In the long run,
  / the logic initShiny should be broken up so that method registration happens
  / right away, but binding happens later.
  */
  function maybeStaticRenderLater() {
    if (shinyMode && has_jQuery3()) {
      window.jQuery(window.HTMLWidgets.staticRender);
    } else {
      window.HTMLWidgets.staticRender();
    }
  }

  if (document.addEventListener) {
    document.addEventListener("DOMContentLoaded", function() {
      document.removeEventListener("DOMContentLoaded", arguments.callee, false);
      maybeStaticRenderLater();
    }, false);
  } else if (document.attachEvent) {
    document.attachEvent("onreadystatechange", function() {
      if (document.readyState === "complete") {
        document.detachEvent("onreadystatechange", arguments.callee);
        maybeStaticRenderLater();
      }
    });
  }


  window.HTMLWidgets.getAttachmentUrl = function(depname, key) {
    // If no key, default to the first item
    if (typeof(key) === "undefined")
      key = 1;

    var link = document.getElementById(depname + "-" + key + "-attachment");
    if (!link) {
      throw new Error("Attachment " + depname + "/" + key + " not found in document");
    }
    return link.getAttribute("href");
  };

  window.HTMLWidgets.dataframeToD3 = function(df) {
    var names = [];
    var length;
    for (var name in df) {
        if (df.hasOwnProperty(name))
            names.push(name);
        if (typeof(df[name]) !== "object" || typeof(df[name].length) === "undefined") {
            throw new Error("All fields must be arrays");
        } else if (typeof(length) !== "undefined" && length !== df[name].length) {
            throw new Error("All fields must be arrays of the same length");
        }
        length = df[name].length;
    }
    var results = [];
    var item;
    for (var row = 0; row < length; row++) {
        item = {};
        for (var col = 0; col < names.length; col++) {
            item[names[col]] = df[names[col]][row];
        }
        results.push(item);
    }
    return results;
  };

  window.HTMLWidgets.transposeArray2D = function(array) {
      if (array.length === 0) return array;
      var newArray = array[0].map(function(col, i) {
          return array.map(function(row) {
              return row[i]
          })
      });
      return newArray;
  };
  // Split value at splitChar, but allow splitChar to be escaped
  // using escapeChar. Any other characters escaped by escapeChar
  // will be included as usual (including escapeChar itself).
  function splitWithEscape(value, splitChar, escapeChar) {
    var results = [];
    var escapeMode = false;
    var currentResult = "";
    for (var pos = 0; pos < value.length; pos++) {
      if (!escapeMode) {
        if (value[pos] === splitChar) {
          results.push(currentResult);
          currentResult = "";
        } else if (value[pos] === escapeChar) {
          escapeMode = true;
        } else {
          currentResult += value[pos];
        }
      } else {
        currentResult += value[pos];
        escapeMode = false;
      }
    }
    if (currentResult !== "") {
      results.push(currentResult);
    }
    return results;
  }
  // Function authored by Yihui/JJ Allaire
  window.HTMLWidgets.evaluateStringMember = function(o, member) {
    var parts = splitWithEscape(member, '.', '\\');
    for (var i = 0, l = parts.length; i < l; i++) {
      var part = parts[i];
      // part may be a character or 'numeric' member name
      if (o !== null && typeof o === "object" && part in o) {
        if (i == (l - 1)) { // if we are at the end of the line then evalulate
          if (typeof o[part] === "string")
            o[part] = tryEval(o[part]);
        } else { // otherwise continue to next embedded object
          o = o[part];
        }
      }
    }
  };

  // Retrieve the HTMLWidget instance (i.e. the return value of an
  // HTMLWidget binding's initialize() or factory() function)
  // associated with an element, or null if none.
  window.HTMLWidgets.getInstance = function(el) {
    return elementData(el, "init_result");
  };

  // Finds the first element in the scope that matches the selector,
  // and returns the HTMLWidget instance (i.e. the return value of
  // an HTMLWidget binding's initialize() or factory() function)
  // associated with that element, if any. If no element matches the
  // selector, or the first matching element has no HTMLWidget
  // instance associated with it, then null is returned.
  //
  // The scope argument is optional, and defaults to window.document.
  window.HTMLWidgets.find = function(scope, selector) {
    if (arguments.length == 1) {
      selector = scope;
      scope = document;
    }

    var el = scope.querySelector(selector);
    if (el === null) {
      return null;
    } else {
      return window.HTMLWidgets.getInstance(el);
    }
  };

  // Finds all elements in the scope that match the selector, and
  // returns the HTMLWidget instances (i.e. the return values of
  // an HTMLWidget binding's initialize() or factory() function)
  // associated with the elements, in an array. If elements that
  // match the selector don't have an associated HTMLWidget
  // instance, the returned array will contain nulls.
  //
  // The scope argument is optional, and defaults to window.document.
  window.HTMLWidgets.findAll = function(scope, selector) {
    if (arguments.length == 1) {
      selector = scope;
      scope = document;
    }

    var nodes = scope.querySelectorAll(selector);
    var results = [];
    for (var i = 0; i < nodes.length; i++) {
      results.push(window.HTMLWidgets.getInstance(nodes[i]));
    }
    return results;
  };

  var postRenderHandlers = [];
  function invokePostRenderHandlers() {
    while (postRenderHandlers.length) {
      var handler = postRenderHandlers.shift();
      if (handler) {
        handler();
      }
    }
  }

  // Register the given callback function to be invoked after the
  // next time static widgets are rendered.
  window.HTMLWidgets.addPostRenderHandler = function(callback) {
    postRenderHandlers.push(callback);
  };

  // Takes a new-style instance-bound definition, and returns an
  // old-style class-bound definition. This saves us from having
  // to rewrite all the logic in this file to accomodate both
  // types of definitions.
  function createLegacyDefinitionAdapter(defn) {
    var result = {
      name: defn.name,
      type: defn.type,
      initialize: function(el, width, height) {
        return defn.factory(el, width, height);
      },
      renderValue: function(el, x, instance) {
        return instance.renderValue(x);
      },
      resize: function(el, width, height, instance) {
        return instance.resize(width, height);
      }
    };

    if (defn.find)
      result.find = defn.find;
    if (defn.renderError)
      result.renderError = defn.renderError;
    if (defn.clearError)
      result.clearError = defn.clearError;

    return result;
  }
})();
\"></script>\n",
       "<link href=\"data:text/css;charset-utf-8;base64,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\" rel=\"stylesheet\" />\n",
       "<script title=\"datatables-binding\" src=\"data:application/javascript;base64,(function() {

// some helper functions: using a global object DTWidget so that it can be used
// in JS() code, e.g. datatable(options = list(foo = JS('code'))); unlike R's
// dynamic scoping, when 'code' is eval'ed, JavaScript does not know objects
// from the "parent frame", e.g. JS('DTWidget') will not work unless it was made
// a global object
var DTWidget = {};

// 123456666.7890 -> 123,456,666.7890
var markInterval = function(d, digits, interval, mark, decMark, precision) {
  x = precision ? d.toPrecision(digits) : d.toFixed(digits);
  if (!/^-?[\d.]+$/.test(x)) return x;
  var xv = x.split('.');
  if (xv.length > 2) return x;  // should have at most one decimal point
  xv[0] = xv[0].replace(new RegExp('\\B(?=(\\d{' + interval + '})+(?!\\d))', 'g'), mark);
  return xv.join(decMark);
};

DTWidget.formatCurrency = function(data, currency, digits, interval, mark, decMark, before, zeroPrint) {
  var d = parseFloat(data);
  if (isNaN(d)) return '';
  if (zeroPrint !== null && d === 0.0) return zeroPrint;
  var res = markInterval(d, digits, interval, mark, decMark);
  res = before ? (/^-/.test(res) ? '-' + currency + res.replace(/^-/, '') : currency + res) :
    res + currency;
  return res;
};

DTWidget.formatString = function(data, prefix, suffix) {
  var d = data;
  if (d === null) return '';
  return prefix + d + suffix;
};

DTWidget.formatPercentage = function(data, digits, interval, mark, decMark, zeroPrint) {
  var d = parseFloat(data);
  if (isNaN(d)) return '';
  if (zeroPrint !== null && d === 0.0) return zeroPrint;
  return markInterval(d * 100, digits, interval, mark, decMark) + '%';
};

DTWidget.formatRound = function(data, digits, interval, mark, decMark, zeroPrint) {
  var d = parseFloat(data);
  if (isNaN(d)) return '';
  if (zeroPrint !== null && d === 0.0) return zeroPrint;
  return markInterval(d, digits, interval, mark, decMark);
};

DTWidget.formatSignif = function(data, digits, interval, mark, decMark, zeroPrint) {
  var d = parseFloat(data);
  if (isNaN(d)) return '';
  if (zeroPrint !== null && d === 0.0) return zeroPrint;
  return markInterval(d, digits, interval, mark, decMark, true);
};

DTWidget.formatDate = function(data, method, params) {
  var d = data;
  if (d === null) return '';
  // (new Date('2015-10-28')).toDateString() may return 2015-10-27 because the
  // actual time created could be like 'Tue Oct 27 2015 19:00:00 GMT-0500 (CDT)',
  // i.e. the date-only string is treated as UTC time instead of local time
  if ((method === 'toDateString' || method === 'toLocaleDateString') && /^\d{4,}\D\d{2}\D\d{2}$/.test(d)) {
    d = d.split(/\D/);
    d = new Date(d[0], d[1] - 1, d[2]);
  } else {
    d = new Date(d);
  }
  return d[method].apply(d, params);
};

window.DTWidget = DTWidget;

// A helper function to update the properties of existing filters
var setFilterProps = function(td, props) {
  // Update enabled/disabled state
  var $input = $(td).find('input').first();
  var searchable = $input.data('searchable');
  $input.prop('disabled', !searchable || props.disabled);

  // Based on the filter type, set its new values
  var type = td.getAttribute('data-type');
  if (['factor', 'logical'].includes(type)) {
    // Reformat the new dropdown options for use with selectize
    var new_vals = props.params.options.map(function(item) {
      return { text: item, value: item };
    });

    // Find the selectize object
    var dropdown = $(td).find('.selectized').eq(0)[0].selectize;

    // Note the current values
    var old_vals = dropdown.getValue();

    // Remove the existing values
    dropdown.clearOptions();

    // Add the new options
    dropdown.addOption(new_vals);

    // Preserve the existing values
    dropdown.setValue(old_vals);

  } else if (['number', 'integer', 'date', 'time'].includes(type)) {
    // Apply internal scaling to new limits. Updating scale not yet implemented.
    var slider = $(td).find('.noUi-target').eq(0);
    var scale = Math.pow(10, Math.max(0, +slider.data('scale') || 0));
    var new_vals = [props.params.min * scale, props.params.max * scale];

    // Note what the new limits will be just for this filter
    var new_lims = new_vals.slice();

    // Determine the current values and limits
    var old_vals = slider.val().map(Number);
    var old_lims = slider.noUiSlider('options').range;
    old_lims = [old_lims.min, old_lims.max];

    // Preserve the current values if filters have been applied; otherwise, apply no filtering
    if (old_vals[0] != old_lims[0]) {
      new_vals[0] = Math.max(old_vals[0], new_vals[0]);
    }

    if (old_vals[1] != old_lims[1]) {
      new_vals[1] = Math.min(old_vals[1], new_vals[1]);
    }

    // Update the endpoints of the slider
    slider.noUiSlider({
      start: new_vals,
      range: {'min': new_lims[0], 'max': new_lims[1]}
    }, true);
  }
};

var transposeArray2D = function(a) {
  return a.length === 0 ? a : HTMLWidgets.transposeArray2D(a);
};

var crosstalkPluginsInstalled = false;

function maybeInstallCrosstalkPlugins() {
  if (crosstalkPluginsInstalled)
    return;
  crosstalkPluginsInstalled = true;

  $.fn.dataTable.ext.afnFiltering.push(
    function(oSettings, aData, iDataIndex) {
      var ctfilter = oSettings.nTable.ctfilter;
      if (ctfilter && !ctfilter[iDataIndex])
        return false;

      var ctselect = oSettings.nTable.ctselect;
      if (ctselect && !ctselect[iDataIndex])
        return false;

      return true;
    }
  );
}

HTMLWidgets.widget({
  name: "datatables",
  type: "output",
  renderOnNullValue: true,
  initialize: function(el, width, height) {
    // in order that the type=number inputs return a number
    $.valHooks.number = {
      get: function(el) {
        var value = parseFloat(el.value);
        return isNaN(value) ? "" : value;
      }
    };
    $(el).html('&nbsp;');
    return {
      data: null,
      ctfilterHandle: new crosstalk.FilterHandle(),
      ctfilterSubscription: null,
      ctselectHandle: new crosstalk.SelectionHandle(),
      ctselectSubscription: null
    };
  },
  renderValue: function(el, data, instance) {
    if ((el.offsetWidth === 0 || el.offsetHeight === 0) && data.lazyRender !== false) {
      instance.data = data;
      return;
    }
    instance.data = null;
    var $el = $(el);
    $el.empty();

    if (data === null) {
      $el.append('&nbsp;');
      // clear previous Shiny inputs (if any)
      for (var i in instance.clearInputs) instance.clearInputs[i]();
      instance.clearInputs = {};
      return;
    }

    var crosstalkOptions = data.crosstalkOptions;
    if (!crosstalkOptions) crosstalkOptions = {
      'key': null, 'group': null
    };
    if (crosstalkOptions.group) {
      maybeInstallCrosstalkPlugins();
      instance.ctfilterHandle.setGroup(crosstalkOptions.group);
      instance.ctselectHandle.setGroup(crosstalkOptions.group);
    }

    // if we are in the viewer then we always want to fillContainer and
    // and autoHideNavigation (unless the user has explicitly set these)
    if (window.HTMLWidgets.viewerMode) {
      if (!data.hasOwnProperty("fillContainer"))
        data.fillContainer = true;
      if (!data.hasOwnProperty("autoHideNavigation"))
        data.autoHideNavigation = true;
    }

    // propagate fillContainer to instance (so we have it in resize)
    instance.fillContainer = data.fillContainer;

    var cells = data.data;

    if (cells instanceof Array) cells = transposeArray2D(cells);

    $el.append(data.container);
    var $table = $el.find('table');
    if (data.class) $table.addClass(data.class);
    if (data.caption) $table.prepend(data.caption);

    if (!data.selection) data.selection = {
      mode: 'none', selected: null, target: 'row', selectable: null
    };
    if (HTMLWidgets.shinyMode && data.selection.mode !== 'none' &&
        data.selection.target === 'row+column') {
      if ($table.children('tfoot').length === 0) {
        $table.append($('<tfoot>'));
        $table.find('thead tr').clone().appendTo($table.find('tfoot'));
      }
    }

    // column filters
    var filterRow;
    switch (data.filter) {
      case 'top':
        $table.children('thead').append(data.filterHTML);
        filterRow = $table.find('thead tr:last td');
        break;
      case 'bottom':
        if ($table.children('tfoot').length === 0) {
          $table.append($('<tfoot>'));
        }
        $table.children('tfoot').prepend(data.filterHTML);
        filterRow = $table.find('tfoot tr:first td');
        break;
    }

    var options = { searchDelay: 1000 };
    if (cells !== null) $.extend(options, {
      data: cells
    });

    // options for fillContainer
    var bootstrapActive = typeof($.fn.popover) != 'undefined';
    if (instance.fillContainer) {

      // force scrollX/scrollY and turn off autoWidth
      options.scrollX = true;
      options.scrollY = "100px"; // can be any value, we'll adjust below

      // if we aren't paginating then move around the info/filter controls
      // to save space at the bottom and rephrase the info callback
      if (data.options.paging === false) {

        // we know how to do this cleanly for bootstrap, not so much
        // for other themes/layouts
        if (bootstrapActive) {
          options.dom = "<'row'<'col-sm-4'i><'col-sm-8'f>>" +
                        "<'row'<'col-sm-12'tr>>";
        }

        options.fnInfoCallback = function(oSettings, iStart, iEnd,
                                           iMax, iTotal, sPre) {
          return Number(iTotal).toLocaleString() + " records";
        };
      }
    }

    // auto hide navigation if requested
    // Note, this only works on client-side processing mode as on server-side,
    // cells (data.data) is null; In addition, we require the pageLength option
    // being provided explicitly to enable this. Despite we may be able to deduce
    // the default value of pageLength, it may complicate things so we'd rather
    // put this responsiblity to users and warn them on the R side.
    if (data.autoHideNavigation === true && data.options.paging !== false) {
      // strip all nav if length >= cells
      if ((cells instanceof Array) && data.options.pageLength >= cells.length)
        options.dom = bootstrapActive ? "<'row'<'col-sm-12'tr>>" : "t";
      // alternatively lean things out for flexdashboard mobile portrait
      else if (bootstrapActive && window.FlexDashboard && window.FlexDashboard.isMobilePhone())
        options.dom = "<'row'<'col-sm-12'f>>" +
                      "<'row'<'col-sm-12'tr>>"  +
                      "<'row'<'col-sm-12'p>>";
    }

    $.extend(true, options, data.options || {});

    var searchCols = options.searchCols;
    if (searchCols) {
      searchCols = searchCols.map(function(x) {
        return x === null ? '' : x.search;
      });
      // FIXME: this means I don't respect the escapeRegex setting
      delete options.searchCols;
    }

    // server-side processing?
    var server = options.serverSide === true;

    // use the dataSrc function to pre-process JSON data returned from R
    var DT_rows_all = [], DT_rows_current = [];
    if (server && HTMLWidgets.shinyMode && typeof options.ajax === 'object' &&
        /^session\/[\da-z]+\/dataobj/.test(options.ajax.url) && !options.ajax.dataSrc) {
      options.ajax.dataSrc = function(json) {
        DT_rows_all = $.makeArray(json.DT_rows_all);
        DT_rows_current = $.makeArray(json.DT_rows_current);
        var data = json.data;
        if (!colReorderEnabled()) return data;
        var table = $table.DataTable(), order = table.colReorder.order(), flag = true, i, j, row;
        for (i = 0; i < order.length; ++i) if (order[i] !== i) flag = false;
        if (flag) return data;
        for (i = 0; i < data.length; ++i) {
          row = data[i].slice();
          for (j = 0; j < order.length; ++j) data[i][j] = row[order[j]];
        }
        return data;
      };
    }

    var thiz = this;
    if (instance.fillContainer) $table.on('init.dt', function(e) {
      thiz.fillAvailableHeight(el, $(el).innerHeight());
    });
    // If the page contains serveral datatables and one of which enables colReorder,
    // the table.colReorder.order() function will exist but throws error when called.
    // So it seems like the only way to know if colReorder is enabled or not is to
    // check the options.
    var colReorderEnabled = function() { return "colReorder" in options; };
    var table = $table.DataTable(options);
    $el.data('datatable', table);

    if ('rowGroup' in options) {
      // Maintain RowGroup dataSrc when columns are reordered (#1109)
      table.on('column-reorder', function(e, settings, details) {
        var oldDataSrc = table.rowGroup().dataSrc();
        var newDataSrc = details.mapping[oldDataSrc];
        table.rowGroup().dataSrc(newDataSrc);
      });
    }

    // Unregister previous Crosstalk event subscriptions, if they exist
    if (instance.ctfilterSubscription) {
      instance.ctfilterHandle.off("change", instance.ctfilterSubscription);
      instance.ctfilterSubscription = null;
    }
    if (instance.ctselectSubscription) {
      instance.ctselectHandle.off("change", instance.ctselectSubscription);
      instance.ctselectSubscription = null;
    }

    if (!crosstalkOptions.group) {
      $table[0].ctfilter = null;
      $table[0].ctselect = null;
    } else {
      var key = crosstalkOptions.key;
      function keysToMatches(keys) {
        if (!keys) {
          return null;
        } else {
          var selectedKeys = {};
          for (var i = 0; i < keys.length; i++) {
            selectedKeys[keys[i]] = true;
          }
          var matches = {};
          for (var j = 0; j < key.length; j++) {
            if (selectedKeys[key[j]])
              matches[j] = true;
          }
          return matches;
        }
      }

      function applyCrosstalkFilter(e) {
        $table[0].ctfilter = keysToMatches(e.value);
        table.draw();
      }
      instance.ctfilterSubscription = instance.ctfilterHandle.on("change", applyCrosstalkFilter);
      applyCrosstalkFilter({value: instance.ctfilterHandle.filteredKeys});

      function applyCrosstalkSelection(e) {
        if (e.sender !== instance.ctselectHandle) {
          table
            .rows('.' + selClass, {search: 'applied'})
            .nodes()
            .to$()
            .removeClass(selClass);
          if (selectedRows)
            changeInput('rows_selected', selectedRows(), void 0, true);
        }

        if (e.sender !== instance.ctselectHandle && e.value && e.value.length) {
          var matches = keysToMatches(e.value);

          // persistent selection with plotly (& leaflet)
          var ctOpts = crosstalk.var("plotlyCrosstalkOpts").get() || {};
          if (ctOpts.persistent === true) {
            var matches = $.extend(matches, $table[0].ctselect);
          }

          $table[0].ctselect = matches;
          table.draw();
        } else {
          if ($table[0].ctselect) {
            $table[0].ctselect = null;
            table.draw();
          }
        }
      }
      instance.ctselectSubscription = instance.ctselectHandle.on("change", applyCrosstalkSelection);
      // TODO: This next line doesn't seem to work when renderDataTable is used
      applyCrosstalkSelection({value: instance.ctselectHandle.value});
    }

    var inArray = function(val, array) {
      return $.inArray(val, $.makeArray(array)) > -1;
    };

    // search the i-th column
    var searchColumn = function(i, value) {
      var regex = false, ci = true;
      if (options.search) {
        regex = options.search.regex,
        ci = options.search.caseInsensitive !== false;
      }
      // need to transpose the column index when colReorder is enabled
      if (table.colReorder) i = table.colReorder.transpose(i);
      return table.column(i).search(value, regex, !regex, ci);
    };

    if (data.filter !== 'none') {
      if (!data.hasOwnProperty('filterSettings')) data.filterSettings = {};

      filterRow.each(function(i, td) {

        var $td = $(td), type = $td.data('type'), filter;
        var $input = $td.children('div').first().children('input');
        var disabled = $input.prop('disabled');
        var searchable = table.settings()[0].aoColumns[i].bSearchable;
        $input.prop('disabled', !searchable || disabled);
        $input.data('searchable', searchable); // for updating later
        $input.on('input blur', function() {
          $input.next('span').toggle(Boolean($input.val()));
        });
        // Bootstrap sets pointer-events to none and we won't be able to click
        // the clear button
        $input.next('span').css('pointer-events', 'auto').hide().click(function() {
          $(this).hide().prev('input').val('').trigger('input').focus();
        });
        var searchCol;  // search string for this column
        if (searchCols && searchCols[i]) {
          searchCol = searchCols[i];
          $input.val(searchCol).trigger('input');
        }
        var $x = $td.children('div').last();

        // remove the overflow: hidden attribute of the scrollHead
        // (otherwise the scrolling table body obscures the filters)
        // The workaround and the discussion from
        // https://github.com/rstudio/DT/issues/554#issuecomment-518007347
        // Otherwise the filter selection will not be anchored to the values
        // when the columns number is many and scrollX is enabled.
        var scrollHead = $(el).find('.dataTables_scrollHead,.dataTables_scrollFoot');
        var cssOverflowHead = scrollHead.css('overflow');
        var scrollBody = $(el).find('.dataTables_scrollBody');
        var cssOverflowBody = scrollBody.css('overflow');
        var scrollTable = $(el).find('.dataTables_scroll');
        var cssOverflowTable = scrollTable.css('overflow');
        if (cssOverflowHead === 'hidden') {
          $x.on('show hide', function(e) {
            if (e.type === 'show') {
              scrollHead.css('overflow', 'visible');
              scrollBody.css('overflow', 'visible');
              scrollTable.css('overflow-x', 'scroll');
            } else {
              scrollHead.css('overflow', cssOverflowHead);
              scrollBody.css('overflow', cssOverflowBody);
              scrollTable.css('overflow-x', cssOverflowTable);
            }
          });
          $x.css('z-index', 25);
        }

        if (inArray(type, ['factor', 'logical'])) {
          $input.on({
            click: function() {
              $input.parent().hide(); $x.show().trigger('show'); filter[0].selectize.focus();
            },
            input: function() {
              var v1 = JSON.stringify(filter[0].selectize.getValue()), v2 = $input.val();
              if (v1 === '[]') v1 = '';
              if (v1 !== v2) filter[0].selectize.setValue(v2 === '' ? [] : JSON.parse(v2));
            }
          });
          var $input2 = $x.children('select');
          filter = $input2.selectize($.extend({
            options: $input2.data('options').map(function(v, i) {
              return ({text: v, value: v});
            }),
            plugins: ['remove_button'],
            hideSelected: true,
            onChange: function(value) {
              if (value === null) value = []; // compatibility with jQuery 3.0
              $input.val(value.length ? JSON.stringify(value) : '');
              if (value.length) $input.trigger('input');
              $input.attr('title', $input.val());
              if (server) {
                searchColumn(i, value.length ? JSON.stringify(value) : '').draw();
                return;
              }
              // turn off filter if nothing selected
              $td.data('filter', value.length > 0);
              table.draw();  // redraw table, and filters will be applied
            }
          }, data.filterSettings.select));
          filter[0].selectize.on('blur', function() {
            $x.hide().trigger('hide'); $input.parent().show(); $input.trigger('blur');
          });
          filter.next('div').css('margin-bottom', 'auto');
        } else if (type === 'character') {
          var fun = function() {
            searchColumn(i, $input.val()).draw();
          };
          // throttle searching for server-side processing
          var throttledFun = $.fn.dataTable.util.throttle(fun, options.searchDelay);
          $input.on('input', function(e, immediate) {
            // always bypass throttling when immediate = true (via the updateSearch method)
            (immediate || !server) ? fun() : throttledFun();
          });
        } else if (inArray(type, ['number', 'integer', 'date', 'time'])) {
          var $x0 = $x;
          $x = $x0.children('div').first();
          $x0.css({
            'background-color': '#fff',
            'border': '1px #ddd solid',
            'border-radius': '4px',
            'padding': data.vertical ? '35px 20px': '20px 20px 10px 20px'
          });
          var $spans = $x0.children('span').css({
            'margin-top': data.vertical ? '0' : '10px',
            'white-space': 'nowrap'
          });
          var $span1 = $spans.first(), $span2 = $spans.last();
          var r1 = +$x.data('min'), r2 = +$x.data('max');
          // when the numbers are too small or have many decimal places, the
          // slider may have numeric precision problems (#150)
          var scale = Math.pow(10, Math.max(0, +$x.data('scale') || 0));
          r1 = Math.round(r1 * scale); r2 = Math.round(r2 * scale);
          var scaleBack = function(x, scale) {
            if (scale === 1) return x;
            var d = Math.round(Math.log(scale) / Math.log(10));
            // to avoid problems like 3.423/100 -> 0.034230000000000003
            return (x / scale).toFixed(d);
          };
          var slider_min = function() {
            return filter.noUiSlider('options').range.min;
          };
          var slider_max = function() {
            return filter.noUiSlider('options').range.max;
          };
          $input.on({
            focus: function() {
              $x0.show().trigger('show');
              // first, make sure the slider div leaves at least 20px between
              // the two (slider value) span's
              $x0.width(Math.max(160, $span1.outerWidth() + $span2.outerWidth() + 20));
              // then, if the input is really wide or slider is vertical,
              // make the slider the same width as the input
              if ($x0.outerWidth() < $input.outerWidth() || data.vertical) {
                $x0.outerWidth($input.outerWidth());
              }
              // make sure the slider div does not reach beyond the right margin
              if ($(window).width() < $x0.offset().left + $x0.width()) {
                $x0.offset({
                  'left': $input.offset().left + $input.outerWidth() - $x0.outerWidth()
                });
              }
            },
            blur: function() {
              $x0.hide().trigger('hide');
            },
            input: function() {
              if ($input.val() === '') filter.val([slider_min(), slider_max()]);
            },
            change: function() {
              var v = $input.val().replace(/\s/g, '');
              if (v === '') return;
              v = v.split('...');
              if (v.length !== 2) {
                $input.parent().addClass('has-error');
                return;
              }
              if (v[0] === '') v[0] = slider_min();
              if (v[1] === '') v[1] = slider_max();
              $input.parent().removeClass('has-error');
              // treat date as UTC time at midnight
              var strTime = function(x) {
                var s = type === 'date' ? 'T00:00:00Z' : '';
                var t = new Date(x + s).getTime();
                // add 10 minutes to date since it does not hurt the date, and
                // it helps avoid the tricky floating point arithmetic problems,
                // e.g. sometimes the date may be a few milliseconds earlier
                // than the midnight due to precision problems in noUiSlider
                return type === 'date' ? t + 3600000 : t;
              };
              if (inArray(type, ['date', 'time'])) {
                v[0] = strTime(v[0]);
                v[1] = strTime(v[1]);
              }
              if (v[0] != slider_min()) v[0] *= scale;
              if (v[1] != slider_max()) v[1] *= scale;
              filter.val(v);
            }
          });
          var formatDate = function(d) {
            d = scaleBack(d, scale);
            if (type === 'number') return d;
            if (type === 'integer') return parseInt(d);
            var x = new Date(+d);
            if (type === 'date') {
              var pad0 = function(x) {
                return ('0' + x).substr(-2, 2);
              };
              return x.getUTCFullYear() + '-' + pad0(1 + x.getUTCMonth())
                      + '-' + pad0(x.getUTCDate());
            } else {
              return x.toISOString();
            }
          };
          var opts = type === 'date' ? { step: 60 * 60 * 1000 } :
                     type === 'integer' ? { step: 1 } : {};

          opts.orientation = data.vertical ? 'vertical': 'horizontal';
          opts.direction = data.vertical ? 'rtl': 'ltr';

          filter = $x.noUiSlider($.extend({
            start: [r1, r2],
            range: {min: r1, max: r2},
            connect: true
          }, opts, data.filterSettings.slider));
          if (scale > 1) (function() {
            var t1 = r1, t2 = r2;
            var val = filter.val();
            while (val[0] > r1 || val[1] < r2) {
              if (val[0] > r1) {
                t1 -= val[0] - r1;
              }
              if (val[1] < r2) {
                t2 += r2 - val[1];
              }
              filter = $x.noUiSlider($.extend({
                start: [t1, t2],
                range: {min: t1, max: t2},
                connect: true
              }, opts, data.filterSettings.slider), true);
              val = filter.val();
            }
            r1  = t1; r2 = t2;
          })();
          // format with active column renderer, if defined
          var colDef = data.options.columnDefs.find(function(def) {
            return (def.targets === i || inArray(i, def.targets)) && 'render' in def;
          });
          var updateSliderText = function(v1, v2) {
            // we only know how to use function renderers
            if (colDef && typeof colDef.render === 'function') {
              var restore = function(v) {
                v = scaleBack(v, scale);
                return inArray(type, ['date', 'time']) ? new Date(+v) : v;
              }
              $span1.text(colDef.render(restore(v1), 'display'));
              $span2.text(colDef.render(restore(v2), 'display'));
            } else {
              $span1.text(formatDate(v1));
              $span2.text(formatDate(v2));
            }
          };
          updateSliderText(r1, r2);
          var updateSlider = function(e) {
            var val = filter.val();
            // turn off filter if in full range
            $td.data('filter', val[0] > slider_min() || val[1] < slider_max());
            var v1 = formatDate(val[0]), v2 = formatDate(val[1]), ival;
            if ($td.data('filter')) {
              ival = v1 + ' ... ' + v2;
              $input.attr('title', ival).val(ival).trigger('input');
            } else {
              $input.attr('title', '').val('');
            }
            updateSliderText(val[0], val[1]);
            if (e.type === 'slide') return;  // no searching when sliding only
            if (server) {
              searchColumn(i, $td.data('filter') ? ival : '').draw();
              return;
            }
            table.draw();
          };
          filter.on({
            set: updateSlider,
            slide: updateSlider
          });
        }

        // server-side processing will be handled by R (or whatever server
        // language you use); the following code is only needed for client-side
        // processing
        if (server) {
          // if a search string has been pre-set, search now
          if (searchCol) $input.trigger('input').trigger('change');
          return;
        }

        var customFilter = function(settings, data, dataIndex) {
          // there is no way to attach a search function to a specific table,
          // and we need to make sure a global search function is not applied to
          // all tables (i.e. a range filter in a previous table should not be
          // applied to the current table); we use the settings object to
          // determine if we want to perform searching on the current table,
          // since settings.sTableId will be different to different tables
          if (table.settings()[0] !== settings) return true;
          // no filter on this column or no need to filter this column
          if (typeof filter === 'undefined' || !$td.data('filter')) return true;

          var r = filter.val(), v, r0, r1;
          var i_data = function(i) {
            if (!colReorderEnabled()) return i;
            var order = table.colReorder.order(), k;
            for (k = 0; k < order.length; ++k) if (order[k] === i) return k;
            return i; // in theory it will never be here...
          }
          v = data[i_data(i)];
          if (type === 'number' || type === 'integer') {
            v = parseFloat(v);
            // how to handle NaN? currently exclude these rows
            if (isNaN(v)) return(false);
            r0 = parseFloat(scaleBack(r[0], scale))
            r1 = parseFloat(scaleBack(r[1], scale));
            if (v >= r0 && v <= r1) return true;
          } else if (type === 'date' || type === 'time') {
            v = new Date(v);
            r0 = new Date(r[0] / scale); r1 = new Date(r[1] / scale);
            if (v >= r0 && v <= r1) return true;
          } else if (type === 'factor') {
            if (r.length === 0 || inArray(v, r)) return true;
          } else if (type === 'logical') {
            if (r.length === 0) return true;
            if (inArray(v === '' ? 'na' : v, r)) return true;
          }
          return false;
        };

        $.fn.dataTable.ext.search.push(customFilter);

        // search for the preset search strings if it is non-empty
        if (searchCol) $input.trigger('input').trigger('change');

      });

    }

    // highlight search keywords
    var highlight = function() {
      var body = $(table.table().body());
      // removing the old highlighting first
      body.unhighlight();

      // don't highlight the "not found" row, so we get the rows using the api
      if (table.rows({ filter: 'applied' }).data().length === 0) return;
      // highlight global search keywords
      body.highlight($.trim(table.search()).split(/\s+/));
      // then highlight keywords from individual column filters
      if (filterRow) filterRow.each(function(i, td) {
        var $td = $(td), type = $td.data('type');
        if (type !== 'character') return;
        var $input = $td.children('div').first().children('input');
        var column = table.column(i).nodes().to$(),
            val = $.trim($input.val());
        if (type !== 'character' || val === '') return;
        column.highlight(val.split(/\s+/));
      });
    };

    if (options.searchHighlight) {
      table
      .on('draw.dt.dth column-visibility.dt.dth column-reorder.dt.dth', highlight)
      .on('destroy', function() {
        // remove event handler
        table.off('draw.dt.dth column-visibility.dt.dth column-reorder.dt.dth');
      });

      // Set the option for escaping regex characters in our search string.  This will be used
      // for all future matching.
      jQuery.fn.highlight.options.escapeRegex = (!options.search || !options.search.regex);

      // initial highlight for state saved conditions and initial states
      highlight();
    }

    // run the callback function on the table instance
    if (typeof data.callback === 'function') data.callback(table);

    // double click to edit the cell, row, column, or all cells
    if (data.editable) table.on('dblclick.dt', 'tbody td', function(e) {
      // only bring up the editor when the cell itself is dbclicked, and ignore
      // other dbclick events bubbled up (e.g. from the <input>)
      if (e.target !== this) return;
      var target = [], immediate = false;
      switch (data.editable.target) {
        case 'cell':
          target = [this];
          immediate = true;  // edit will take effect immediately
          break;
        case 'row':
          target = table.cells(table.cell(this).index().row, '*').nodes();
          break;
        case 'column':
          target = table.cells('*', table.cell(this).index().column).nodes();
          break;
        case 'all':
          target = table.cells().nodes();
          break;
        default:
          throw 'The editable parameter must be "cell", "row", "column", or "all"';
      }
      var disableCols = data.editable.disable ? data.editable.disable.columns : null;
      var numericCols = data.editable.numeric;
      var areaCols = data.editable.area;
      var dateCols = data.editable.date;
      for (var i = 0; i < target.length; i++) {
        (function(cell, current) {
          var $cell = $(cell), html = $cell.html();
          var _cell = table.cell(cell), value = _cell.data(), index = _cell.index().column;
          var $input;
          if (inArray(index, numericCols)) {
            $input = $('<input type="number">');
          } else if (inArray(index, areaCols)) {
            $input = $('<textarea></textarea>');
          } else if (inArray(index, dateCols)) {
            $input = $('<input type="date">');
          } else {
            $input = $('<input type="text">');
          }
          if (!immediate) {
            $cell.data('input', $input).data('html', html);
            $input.attr('title', 'Hit Ctrl+Enter to finish editing, or Esc to cancel');
          }
          $input.val(value);
          if (inArray(index, disableCols)) {
            $input.attr('readonly', '').css('filter', 'invert(25%)');
          }
          $cell.empty().append($input);
          if (cell === current) $input.focus();
          $input.css('width', '100%');

          if (immediate) $input.on('blur', function(e) {
            var valueNew = $input.val();
            if (valueNew !== value) {
              _cell.data(valueNew);
              if (HTMLWidgets.shinyMode) {
                changeInput('cell_edit', [cellInfo(cell)], 'DT.cellInfo', null, {priority: 'event'});
              }
              // for server-side processing, users have to call replaceData() to update the table
              if (!server) table.draw(false);
            } else {
              $cell.html(html);
            }
          }).on('keyup', function(e) {
            // hit Escape to cancel editing
            if (e.keyCode === 27) $input.trigger('blur');
          });

          // bulk edit (row, column, or all)
          if (!immediate) $input.on('keyup', function(e) {
            var removeInput = function($cell, restore) {
              $cell.data('input').remove();
              if (restore) $cell.html($cell.data('html'));
            }
            if (e.keyCode === 27) {
              for (var i = 0; i < target.length; i++) {
                removeInput($(target[i]), true);
              }
            } else if (e.keyCode === 13 && e.ctrlKey) {
              // Ctrl + Enter
              var cell, $cell, _cell, cellData = [];
              for (var i = 0; i < target.length; i++) {
                cell = target[i]; $cell = $(cell); _cell = table.cell(cell);
                _cell.data($cell.data('input').val());
                HTMLWidgets.shinyMode && cellData.push(cellInfo(cell));
                removeInput($cell, false);
              }
              if (HTMLWidgets.shinyMode) {
                changeInput('cell_edit', cellData, 'DT.cellInfo', null, {priority: "event"});
              }
              if (!server) table.draw(false);
            }
          });
        })(target[i], this);
      }
    });

    // interaction with shiny
    if (!HTMLWidgets.shinyMode && !crosstalkOptions.group) return;

    var methods = {};
    var shinyData = {};

    methods.updateCaption = function(caption) {
      if (!caption) return;
      $table.children('caption').replaceWith(caption);
    }

    // register clear functions to remove input values when the table is removed
    instance.clearInputs = {};

    var changeInput = function(id, value, type, noCrosstalk, opts) {
      var event = id;
      id = el.id + '_' + id;
      if (type) id = id + ':' + type;
      // do not update if the new value is the same as old value
      if (event !== 'cell_edit' && !/_clicked$/.test(event) && shinyData.hasOwnProperty(id) && shinyData[id] === JSON.stringify(value))
        return;
      shinyData[id] = JSON.stringify(value);
      if (HTMLWidgets.shinyMode && Shiny.setInputValue) {
        Shiny.setInputValue(id, value, opts);
        if (!instance.clearInputs[id]) instance.clearInputs[id] = function() {
          Shiny.setInputValue(id, null);
        }
      }

      // HACK
      if (event === "rows_selected" && !noCrosstalk) {
        if (crosstalkOptions.group) {
          var keys = crosstalkOptions.key;
          var selectedKeys = null;
          if (value) {
            selectedKeys = [];
            for (var i = 0; i < value.length; i++) {
              // The value array's contents use 1-based row numbers, so we must
              // convert to 0-based before indexing into the keys array.
              selectedKeys.push(keys[value[i] - 1]);
            }
          }
          instance.ctselectHandle.set(selectedKeys);
        }
      }
    };

    var addOne = function(x) {
      return x.map(function(i) { return 1 + i; });
    };

    var unique = function(x) {
      var ux = [];
      $.each(x, function(i, el){
        if ($.inArray(el, ux) === -1) ux.push(el);
      });
      return ux;
    }

    // change the row index of a cell
    var tweakCellIndex = function(cell) {
      var info = cell.index();
      // some cell may not be valid. e.g, #759
      // when using the RowGroup extension, datatables will
      // generate the row label and the cells are not part of
      // the data thus contain no row/col info
      if (info === undefined)
        return {row: null, col: null};
      if (server) {
        info.row = DT_rows_current[info.row];
      } else {
        info.row += 1;
      }
      return {row: info.row, col: info.column};
    }

    var cleanSelectedValues = function() {
      changeInput('rows_selected', []);
      changeInput('columns_selected', []);
      changeInput('cells_selected', transposeArray2D([]), 'shiny.matrix');
    }
    // #828 we should clean the selection on the server-side when the table reloads
    cleanSelectedValues();

    // a flag to indicates if select extension is initialized or not
    var flagSelectExt = table.settings()[0]._select !== undefined;
    // the Select extension should only be used in the client mode and
    // when the selection.mode is set to none
    if (data.selection.mode === 'none' && !server && flagSelectExt) {
      var updateRowsSelected = function() {
        var rows = table.rows({selected: true});
        var selected = [];
        $.each(rows.indexes().toArray(), function(i, v) {
          selected.push(v + 1);
        });
        changeInput('rows_selected', selected);
      }
      var updateColsSelected = function() {
        var columns = table.columns({selected: true});
        changeInput('columns_selected', columns.indexes().toArray());
      }
      var updateCellsSelected = function() {
        var cells = table.cells({selected: true});
        var selected = [];
        cells.every(function() {
          var row = this.index().row;
          var col = this.index().column;
          selected = selected.concat([[row + 1, col]]);
        });
        changeInput('cells_selected', transposeArray2D(selected), 'shiny.matrix');
      }
      table.on('select deselect', function(e, dt, type, indexes) {
        updateRowsSelected();
        updateColsSelected();
        updateCellsSelected();
      })
      updateRowsSelected();
      updateColsSelected();
      updateCellsSelected();
    }

    var selMode = data.selection.mode, selTarget = data.selection.target;
    var selDisable = data.selection.selectable === false;
    if (inArray(selMode, ['single', 'multiple'])) {
      var selClass = inArray(data.style, ['bootstrap', 'bootstrap4']) ? 'active' : 'selected';
      // selected1: row indices; selected2: column indices
      var initSel = function(x) {
        if (x === null || typeof x === 'boolean' || selTarget === 'cell') {
          return {rows: [], cols: []};
        } else if (selTarget === 'row') {
          return {rows: $.makeArray(x), cols: []};
        } else if (selTarget === 'column') {
          return {rows: [], cols: $.makeArray(x)};
        } else if (selTarget === 'row+column') {
          return {rows: $.makeArray(x.rows), cols: $.makeArray(x.cols)};
        }
      }
      var selected = data.selection.selected;
      var selected1 = initSel(selected).rows, selected2 = initSel(selected).cols;
      // selectable should contain either all positive or all non-positive values, not both
      // positive values indicate "selectable" while non-positive values means "nonselectable"
      // the assertion is performed on R side. (only column indicides could be zero which indicates
      // the row name)
      var selectable = data.selection.selectable;
      var selectable1 = initSel(selectable).rows, selectable2 = initSel(selectable).cols;

      // After users reorder the rows or filter the table, we cannot use the table index
      // directly. Instead, we need this function to find out the rows between the two clicks.
      // If user filter the table again between the start click and the end click, the behavior
      // would be undefined, but it should not be a problem.
      var shiftSelRowsIndex = function(start, end) {
        var indexes = server ? DT_rows_all : table.rows({ search: 'applied' }).indexes().toArray();
        start = indexes.indexOf(start); end = indexes.indexOf(end);
        // if start is larger than end, we need to swap
        if (start > end) {
          var tmp = end; end = start; start = tmp;
        }
        return indexes.slice(start, end + 1);
      }

      var serverRowIndex = function(clientRowIndex) {
        return server ? DT_rows_current[clientRowIndex] : clientRowIndex + 1;
      }

      // row, column, or cell selection
      var lastClickedRow;
      if (inArray(selTarget, ['row', 'row+column'])) {
        // Get the current selected rows. It will also
        // update the selected1's value based on the current row selection state
        // Note we can't put this function inside selectRows() directly,
        // the reason is method.selectRows() will override selected1's value but this
        // function will add rows to selected1 (keep the existing selection), which is
        // inconsistent with column and cell selection.
        var selectedRows = function() {
          var rows = table.rows('.' + selClass);
          var idx = rows.indexes().toArray();
          if (!server) {
            selected1 = addOne(idx);
            return selected1;
          }
          idx = idx.map(function(i) {
            return DT_rows_current[i];
          });
          selected1 = selMode === 'multiple' ? unique(selected1.concat(idx)) : idx;
          return selected1;
        }
        // Change selected1's value based on selectable1, then refresh the row state
        var onlyKeepSelectableRows = function() {
          if (selDisable) { // users can't select; useful when only want backend select
            selected1 = [];
            return;
          }
          if (selectable1.length === 0) return;
          var nonselectable = selectable1[0] <= 0;
          if (nonselectable) {
            // should make selectable1 positive
            selected1 = $(selected1).not(selectable1.map(function(i) { return -i; })).get();
          } else {
            selected1 = $(selected1).filter(selectable1).get();
          }
        }
        // Change selected1's value based on selectable1, then
        // refresh the row selection state according to values in selected1
        var selectRows = function(ignoreSelectable) {
          if (!ignoreSelectable) onlyKeepSelectableRows();
          table.$('tr.' + selClass).removeClass(selClass);
          if (selected1.length === 0) return;
          if (server) {
            table.rows({page: 'current'}).every(function() {
              if (inArray(DT_rows_current[this.index()], selected1)) {
                $(this.node()).addClass(selClass);
              }
            });
          } else {
            var selected0 = selected1.map(function(i) { return i - 1; });
            $(table.rows(selected0).nodes()).addClass(selClass);
          }
        }
        table.on('mousedown.dt', 'tbody tr', function(e) {
          var $this = $(this), thisRow = table.row(this);
          if (selMode === 'multiple') {
            if (e.shiftKey && lastClickedRow !== undefined) {
              // select or de-select depends on the last clicked row's status
              var flagSel = !$this.hasClass(selClass);
              var crtClickedRow = serverRowIndex(thisRow.index());
              if (server) {
                var rowsIndex = shiftSelRowsIndex(lastClickedRow, crtClickedRow);
                // update current page's selClass
                rowsIndex.map(function(i) {
                  var rowIndex = DT_rows_current.indexOf(i);
                  if (rowIndex >= 0) {
                    var row = table.row(rowIndex).nodes().to$();
                    var flagRowSel = !row.hasClass(selClass);
                    if (flagSel === flagRowSel) row.toggleClass(selClass);
                  }
                });
                // update selected1
                if (flagSel) {
                  selected1 = unique(selected1.concat(rowsIndex));
                } else {
                  selected1 = selected1.filter(function(index) {
                    return !inArray(index, rowsIndex);
                  });
                }
              } else {
                // js starts from 0
                shiftSelRowsIndex(lastClickedRow - 1, crtClickedRow - 1).map(function(value) {
                  var row = table.row(value).nodes().to$();
                  var flagRowSel = !row.hasClass(selClass);
                  if (flagSel === flagRowSel) row.toggleClass(selClass);
                });
              }
              e.preventDefault();
            } else {
              $this.toggleClass(selClass);
            }
          } else {
            if ($this.hasClass(selClass)) {
              $this.removeClass(selClass);
            } else {
              table.$('tr.' + selClass).removeClass(selClass);
              $this.addClass(selClass);
            }
          }
          if (server && !$this.hasClass(selClass)) {
            var id = DT_rows_current[thisRow.index()];
            // remove id from selected1 since its class .selected has been removed
            if (inArray(id, selected1)) selected1.splice($.inArray(id, selected1), 1);
          }
          selectedRows(); // update selected1's value based on selClass
          selectRows(false); // only keep the selectable rows
          changeInput('rows_selected', selected1);
          changeInput('row_last_clicked', serverRowIndex(thisRow.index()), null, null, {priority: 'event'});
          lastClickedRow = serverRowIndex(thisRow.index());
        });
        selectRows(false);  // in case users have specified pre-selected rows
        // restore selected rows after the table is redrawn (e.g. sort/search/page);
        // client-side tables will preserve the selections automatically; for
        // server-side tables, we have to *real* row indices are in `selected1`
        changeInput('rows_selected', selected1);
        if (server) table.on('draw.dt', function(e) { selectRows(false); });
        methods.selectRows = function(selected, ignoreSelectable) {
          selected1 = $.makeArray(selected);
          selectRows(ignoreSelectable);
          changeInput('rows_selected', selected1);
        }
      }

      if (inArray(selTarget, ['column', 'row+column'])) {
        if (selTarget === 'row+column') {
          $(table.columns().footer()).css('cursor', 'pointer');
        }
        // update selected2's value based on selectable2
        var onlyKeepSelectableCols = function() {
          if (selDisable) { // users can't select; useful when only want backend select
            selected2 = [];
            return;
          }
          if (selectable2.length === 0) return;
          var nonselectable = selectable2[0] <= 0;
          if (nonselectable) {
            // need to make selectable2 positive
            selected2 = $(selected2).not(selectable2.map(function(i) { return -i; })).get();
          } else {
            selected2 = $(selected2).filter(selectable2).get();
          }
        }
        // update selected2 and then
        // refresh the col selection state according to values in selected2
        var selectCols = function(ignoreSelectable) {
          if (!ignoreSelectable) onlyKeepSelectableCols();
          // if selected2 is not a valide index (e.g., larger than the column number)
          // table.columns(selected2) will fail and result in a blank table
          // this is different from the table.rows(), where the out-of-range indexes
          // doesn't affect at all
          selected2 = $(selected2).filter(table.columns().indexes()).get();
          table.columns().nodes().flatten().to$().removeClass(selClass);
          if (selected2.length > 0)
            table.columns(selected2).nodes().flatten().to$().addClass(selClass);
        }
        var callback = function() {
          var colIdx = selTarget === 'column' ? table.cell(this).index().column :
              $.inArray(this, table.columns().footer()),
              thisCol = $(table.column(colIdx).nodes());
          if (colIdx === -1) return;
          if (thisCol.hasClass(selClass)) {
            thisCol.removeClass(selClass);
            selected2.splice($.inArray(colIdx, selected2), 1);
          } else {
            if (selMode === 'single') $(table.cells().nodes()).removeClass(selClass);
            thisCol.addClass(selClass);
            selected2 = selMode === 'single' ? [colIdx] : unique(selected2.concat([colIdx]));
          }
          selectCols(false); // update selected2 based on selectable
          changeInput('columns_selected', selected2);
        }
        if (selTarget === 'column') {
          $(table.table().body()).on('click.dt', 'td', callback);
        } else {
          $(table.table().footer()).on('click.dt', 'tr th', callback);
        }
        selectCols(false);  // in case users have specified pre-selected columns
        changeInput('columns_selected', selected2);
        if (server) table.on('draw.dt', function(e) { selectCols(false); });
        methods.selectColumns = function(selected, ignoreSelectable) {
          selected2 = $.makeArray(selected);
          selectCols(ignoreSelectable);
          changeInput('columns_selected', selected2);
        }
      }

      if (selTarget === 'cell') {
        var selected3 = [], selectable3 = [];
        if (selected !== null) selected3 = selected;
        if (selectable !== null && typeof selectable !== 'boolean') selectable3 = selectable;
        var findIndex = function(ij, sel) {
          for (var i = 0; i < sel.length; i++) {
            if (ij[0] === sel[i][0] && ij[1] === sel[i][1]) return i;
          }
          return -1;
        }
         // Change selected3's value based on selectable3, then refresh the cell state
        var onlyKeepSelectableCells = function() {
          if (selDisable) { // users can't select; useful when only want backend select
            selected3 = [];
            return;
          }
          if (selectable3.length === 0) return;
          var nonselectable = selectable3[0][0] <= 0;
          var out = [];
          if (nonselectable) {
            selected3.map(function(ij) {
              // should make selectable3 positive
              if (findIndex([-ij[0], -ij[1]], selectable3) === -1) { out.push(ij); }
            });
          } else {
            selected3.map(function(ij) {
              if (findIndex(ij, selectable3) > -1) { out.push(ij); }
            });
          }
          selected3 = out;
        }
        // Change selected3's value based on selectable3, then
        // refresh the cell selection state according to values in selected3
        var selectCells = function(ignoreSelectable) {
          if (!ignoreSelectable) onlyKeepSelectableCells();
          table.$('td.' + selClass).removeClass(selClass);
          if (selected3.length === 0) return;
          if (server) {
            table.cells({page: 'current'}).every(function() {
              var info = tweakCellIndex(this);
              if (findIndex([info.row, info.col], selected3) > -1)
                $(this.node()).addClass(selClass);
            });
          } else {
            selected3.map(function(ij) {
              $(table.cell(ij[0] - 1, ij[1]).node()).addClass(selClass);
            });
          }
        };
        table.on('click.dt', 'tbody td', function() {
          var $this = $(this), info = tweakCellIndex(table.cell(this));
          if ($this.hasClass(selClass)) {
            $this.removeClass(selClass);
            selected3.splice(findIndex([info.row, info.col], selected3), 1);
          } else {
            if (selMode === 'single') $(table.cells().nodes()).removeClass(selClass);
            $this.addClass(selClass);
            selected3 = selMode === 'single' ? [[info.row, info.col]] :
              unique(selected3.concat([[info.row, info.col]]));
          }
          selectCells(false); // must call this to update selected3 based on selectable3
          changeInput('cells_selected', transposeArray2D(selected3), 'shiny.matrix');
        });
        selectCells(false);  // in case users have specified pre-selected columns
        changeInput('cells_selected', transposeArray2D(selected3), 'shiny.matrix');

        if (server) table.on('draw.dt', function(e) { selectCells(false); });
        methods.selectCells = function(selected, ignoreSelectable) {
          selected3 = selected ? selected : [];
          selectCells(ignoreSelectable);
          changeInput('cells_selected', transposeArray2D(selected3), 'shiny.matrix');
        }
      }
    }

    // expose some table info to Shiny
    var updateTableInfo = function(e, settings) {
      // TODO: is anyone interested in the page info?
      // changeInput('page_info', table.page.info());
      var updateRowInfo = function(id, modifier) {
        var idx;
        if (server) {
          idx = modifier.page === 'current' ? DT_rows_current : DT_rows_all;
        } else {
          var rows = table.rows($.extend({
            search: 'applied',
            page: 'all'
          }, modifier));
          idx = addOne(rows.indexes().toArray());
        }
        changeInput('rows' + '_' + id, idx);
      };
      updateRowInfo('current', {page: 'current'});
      updateRowInfo('all', {});
    }
    table.on('draw.dt', updateTableInfo);
    updateTableInfo();

    // state info
    table.on('draw.dt column-visibility.dt', function() {
      changeInput('state', table.state());
    });
    changeInput('state', table.state());

    // search info
    var updateSearchInfo = function() {
      changeInput('search', table.search());
      if (filterRow) changeInput('search_columns', filterRow.toArray().map(function(td) {
        return $(td).find('input').first().val();
      }));
    }
    table.on('draw.dt', updateSearchInfo);
    updateSearchInfo();

    var cellInfo = function(thiz) {
      var info = tweakCellIndex(table.cell(thiz));
      info.value = table.cell(thiz).data();
      return info;
    }
    // the current cell clicked on
    table.on('click.dt', 'tbody td', function() {
      changeInput('cell_clicked', cellInfo(this), null, null, {priority: 'event'});
    })
    changeInput('cell_clicked', {});

    // do not trigger table selection when clicking on links unless they have classes
    table.on('mousedown.dt', 'tbody td a', function(e) {
      if (this.className === '') e.stopPropagation();
    });

    methods.addRow = function(data, rowname, resetPaging) {
      var n = table.columns().indexes().length, d = n - data.length;
      if (d === 1) {
        data = rowname.concat(data)
      } else if (d !== 0) {
        console.log(data);
        console.log(table.columns().indexes());
        throw 'New data must be of the same length as current data (' + n + ')';
      };
      table.row.add(data).draw(resetPaging);
    }

    methods.updateSearch = function(keywords) {
      if (keywords.global !== null)
        $(table.table().container()).find('input[type=search]').first()
             .val(keywords.global).trigger('input');
      var columns = keywords.columns;
      if (!filterRow || columns === null) return;
      filterRow.toArray().map(function(td, i) {
        var v = typeof columns === 'string' ? columns : columns[i];
        if (typeof v === 'undefined') {
          console.log('The search keyword for column ' + i + ' is undefined')
          return;
        }
        // Update column search string and values on linked filter widgets.
        // 'input' for factor and char filters, 'change' for numeric filters.
        $(td).find('input').first().val(v).trigger('input', [true]).trigger('change');
      });
      table.draw();
    }

    methods.hideCols = function(hide, reset) {
      if (reset) table.columns().visible(true, false);
      table.columns(hide).visible(false);
    }

    methods.showCols = function(show, reset) {
      if (reset) table.columns().visible(false, false);
      table.columns(show).visible(true);
    }

    methods.colReorder = function(order, origOrder) {
      table.colReorder.order(order, origOrder);
    }

    methods.selectPage = function(page) {
      if (table.page.info().pages < page || page < 1) {
        throw 'Selected page is out of range';
      };
      table.page(page - 1).draw(false);
    }

    methods.reloadData = function(resetPaging, clearSelection) {
      // empty selections first if necessary
      if (methods.selectRows && inArray('row', clearSelection)) methods.selectRows([]);
      if (methods.selectColumns && inArray('column', clearSelection)) methods.selectColumns([]);
      if (methods.selectCells && inArray('cell', clearSelection)) methods.selectCells([]);
      table.ajax.reload(null, resetPaging);
    }

    // update table filters (set new limits of sliders)
    methods.updateFilters = function(newProps) {
      // loop through each filter in the filter row
      filterRow.each(function(i, td) {
        var k = i;
        if (filterRow.length > newProps.length) {
          if (i === 0) return;  // first column is row names
          k = i - 1;
        }
        // Update the filters to reflect the updated data.
        // Allow "falsy" (e.g. NULL) to signify a no-op.
        if (newProps[k]) {
          setFilterProps(td, newProps[k]);
        }
      });
    };

    table.shinyMethods = methods;
  },
  resize: function(el, width, height, instance) {
    if (instance.data) this.renderValue(el, instance.data, instance);

    // dynamically adjust height if fillContainer = TRUE
    if (instance.fillContainer)
      this.fillAvailableHeight(el, height);

    this.adjustWidth(el);
  },

  // dynamically set the scroll body to fill available height
  // (used with fillContainer = TRUE)
  fillAvailableHeight: function(el, availableHeight) {

    // see how much of the table is occupied by header/footer elements
    // and use that to compute a target scroll body height
    var dtWrapper = $(el).find('div.dataTables_wrapper');
    var dtScrollBody = $(el).find($('div.dataTables_scrollBody'));
    var framingHeight = dtWrapper.innerHeight() - dtScrollBody.innerHeight();
    var scrollBodyHeight = availableHeight - framingHeight;

    // we need to set `max-height` to none as datatables library now sets this
    // to a fixed height, disabling the ability to resize to fill the window,
    // as it will be set to a fixed 100px under such circumstances, e.g., RStudio IDE,
    // or FlexDashboard
    // see https://github.com/rstudio/DT/issues/951#issuecomment-1026464509
    dtScrollBody.css('max-height', 'none');
    // set the height
    dtScrollBody.height(scrollBodyHeight + 'px');
  },

  // adjust the width of columns; remove the hard-coded widths on table and the
  // scroll header when scrollX/Y are enabled
  adjustWidth: function(el) {
    var $el = $(el), table = $el.data('datatable');
    if (table) table.columns.adjust();
    $el.find('.dataTables_scrollHeadInner').css('width', '')
        .children('table').css('margin-left', '');
  }
});

  if (!HTMLWidgets.shinyMode) return;

  Shiny.addCustomMessageHandler('datatable-calls', function(data) {
    var id = data.id;
    var el = document.getElementById(id);
    var table = el ? $(el).data('datatable') : null;
    if (!table) {
      console.log("Couldn't find table with id " + id);
      return;
    }

    var methods = table.shinyMethods, call = data.call;
    if (methods[call.method]) {
      methods[call.method].apply(table, call.args);
    } else {
      console.log("Unknown method " + call.method);
    }
  });

})();
\"></script>\n",
       "<script title=\"jquery\" src=\"data:application/javascript;base64,/*! jQuery v3.6.0 | (c) OpenJS Foundation and other contributors | jquery.org/license */
!function(e,t){"use strict";"object"==typeof module&&"object"==typeof module.exports?module.exports=e.document?t(e,!0):function(e){if(!e.document)throw new Error("jQuery requires a window with a document");return t(e)}:t(e)}("undefined"!=typeof window?window:this,function(C,e){"use strict";var t=[],r=Object.getPrototypeOf,s=t.slice,g=t.flat?function(e){return t.flat.call(e)}:function(e){return t.concat.apply([],e)},u=t.push,i=t.indexOf,n={},o=n.toString,v=n.hasOwnProperty,a=v.toString,l=a.call(Object),y={},m=function(e){return"function"==typeof e&&"number"!=typeof e.nodeType&&"function"!=typeof e.item},x=function(e){return null!=e&&e===e.window},E=C.document,c={type:!0,src:!0,nonce:!0,noModule:!0};function b(e,t,n){var r,i,o=(n=n||E).createElement("script");if(o.text=e,t)for(r in c)(i=t[r]||t.getAttribute&&t.getAttribute(r))&&o.setAttribute(r,i);n.head.appendChild(o).parentNode.removeChild(o)}function w(e){return null==e?e+"":"object"==typeof e||"function"==typeof e?n[o.call(e)]||"object":typeof e}var f="3.6.0",S=function(e,t){return new S.fn.init(e,t)};function p(e){var t=!!e&&"length"in e&&e.length,n=w(e);return!m(e)&&!x(e)&&("array"===n||0===t||"number"==typeof t&&0<t&&t-1 in e)}S.fn=S.prototype={jquery:f,constructor:S,length:0,toArray:function(){return s.call(this)},get:function(e){return null==e?s.call(this):e<0?this[e+this.length]:this[e]},pushStack:function(e){var t=S.merge(this.constructor(),e);return t.prevObject=this,t},each:function(e){return S.each(this,e)},map:function(n){return this.pushStack(S.map(this,function(e,t){return n.call(e,t,e)}))},slice:function(){return this.pushStack(s.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},even:function(){return this.pushStack(S.grep(this,function(e,t){return(t+1)%2}))},odd:function(){return this.pushStack(S.grep(this,function(e,t){return t%2}))},eq:function(e){var t=this.length,n=+e+(e<0?t:0);return this.pushStack(0<=n&&n<t?[this[n]]:[])},end:function(){return this.prevObject||this.constructor()},push:u,sort:t.sort,splice:t.splice},S.extend=S.fn.extend=function(){var e,t,n,r,i,o,a=arguments[0]||{},s=1,u=arguments.length,l=!1;for("boolean"==typeof a&&(l=a,a=arguments[s]||{},s++),"object"==typeof a||m(a)||(a={}),s===u&&(a=this,s--);s<u;s++)if(null!=(e=arguments[s]))for(t in e)r=e[t],"__proto__"!==t&&a!==r&&(l&&r&&(S.isPlainObject(r)||(i=Array.isArray(r)))?(n=a[t],o=i&&!Array.isArray(n)?[]:i||S.isPlainObject(n)?n:{},i=!1,a[t]=S.extend(l,o,r)):void 0!==r&&(a[t]=r));return a},S.extend({expando:"jQuery"+(f+Math.random()).replace(/\D/g,""),isReady:!0,error:function(e){throw new Error(e)},noop:function(){},isPlainObject:function(e){var t,n;return!(!e||"[object Object]"!==o.call(e))&&(!(t=r(e))||"function"==typeof(n=v.call(t,"constructor")&&t.constructor)&&a.call(n)===l)},isEmptyObject:function(e){var t;for(t in e)return!1;return!0},globalEval:function(e,t,n){b(e,{nonce:t&&t.nonce},n)},each:function(e,t){var n,r=0;if(p(e)){for(n=e.length;r<n;r++)if(!1===t.call(e[r],r,e[r]))break}else for(r in e)if(!1===t.call(e[r],r,e[r]))break;return e},makeArray:function(e,t){var n=t||[];return null!=e&&(p(Object(e))?S.merge(n,"string"==typeof e?[e]:e):u.call(n,e)),n},inArray:function(e,t,n){return null==t?-1:i.call(t,e,n)},merge:function(e,t){for(var n=+t.length,r=0,i=e.length;r<n;r++)e[i++]=t[r];return e.length=i,e},grep:function(e,t,n){for(var r=[],i=0,o=e.length,a=!n;i<o;i++)!t(e[i],i)!==a&&r.push(e[i]);return r},map:function(e,t,n){var r,i,o=0,a=[];if(p(e))for(r=e.length;o<r;o++)null!=(i=t(e[o],o,n))&&a.push(i);else for(o in e)null!=(i=t(e[o],o,n))&&a.push(i);return g(a)},guid:1,support:y}),"function"==typeof Symbol&&(S.fn[Symbol.iterator]=t[Symbol.iterator]),S.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(e,t){n["[object "+t+"]"]=t.toLowerCase()});var d=function(n){var e,d,b,o,i,h,f,g,w,u,l,T,C,a,E,v,s,c,y,S="sizzle"+1*new Date,p=n.document,k=0,r=0,m=ue(),x=ue(),A=ue(),N=ue(),j=function(e,t){return e===t&&(l=!0),0},D={}.hasOwnProperty,t=[],q=t.pop,L=t.push,H=t.push,O=t.slice,P=function(e,t){for(var n=0,r=e.length;n<r;n++)if(e[n]===t)return n;return-1},R="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",M="[\\x20\\t\\r\\n\\f]",I="(?:\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\[^\\r\\n\\f]|[\\w-]|[^\0-\\x7f])+",W="\\["+M+"*("+I+")(?:"+M+"*([*^$|!~]?=)"+M+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+I+"))|)"+M+"*\\]",F=":("+I+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+W+")*)|.*)\\)|)",B=new RegExp(M+"+","g"),$=new RegExp("^"+M+"+|((?:^|[^\\\\])(?:\\\\.)*)"+M+"+$","g"),_=new RegExp("^"+M+"*,"+M+"*"),z=new RegExp("^"+M+"*([>+~]|"+M+")"+M+"*"),U=new RegExp(M+"|>"),X=new RegExp(F),V=new RegExp("^"+I+"$"),G={ID:new RegExp("^#("+I+")"),CLASS:new RegExp("^\\.("+I+")"),TAG:new RegExp("^("+I+"|[*])"),ATTR:new RegExp("^"+W),PSEUDO:new RegExp("^"+F),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+M+"*(even|odd|(([+-]|)(\\d*)n|)"+M+"*(?:([+-]|)"+M+"*(\\d+)|))"+M+"*\\)|)","i"),bool:new RegExp("^(?:"+R+")$","i"),needsContext:new RegExp("^"+M+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+M+"*((?:-\\d)?\\d*)"+M+"*\\)|)(?=[^-]|$)","i")},Y=/HTML$/i,Q=/^(?:input|select|textarea|button)$/i,J=/^h\d$/i,K=/^[^{]+\{\s*\[native \w/,Z=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,ee=/[+~]/,te=new RegExp("\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\([^\\r\\n\\f])","g"),ne=function(e,t){var n="0x"+e.slice(1)-65536;return t||(n<0?String.fromCharCode(n+65536):String.fromCharCode(n>>10|55296,1023&n|56320))},re=/([\0-\x1f\x7f]|^-?\d)|^-$|[^\0-\x1f\x7f-\uFFFF\w-]/g,ie=function(e,t){return t?"\0"===e?"\ufffd":e.slice(0,-1)+"\\"+e.charCodeAt(e.length-1).toString(16)+" ":"\\"+e},oe=function(){T()},ae=be(function(e){return!0===e.disabled&&"fieldset"===e.nodeName.toLowerCase()},{dir:"parentNode",next:"legend"});try{H.apply(t=O.call(p.childNodes),p.childNodes),t[p.childNodes.length].nodeType}catch(e){H={apply:t.length?function(e,t){L.apply(e,O.call(t))}:function(e,t){var n=e.length,r=0;while(e[n++]=t[r++]);e.length=n-1}}}function se(t,e,n,r){var i,o,a,s,u,l,c,f=e&&e.ownerDocument,p=e?e.nodeType:9;if(n=n||[],"string"!=typeof t||!t||1!==p&&9!==p&&11!==p)return n;if(!r&&(T(e),e=e||C,E)){if(11!==p&&(u=Z.exec(t)))if(i=u[1]){if(9===p){if(!(a=e.getElementById(i)))return n;if(a.id===i)return n.push(a),n}else if(f&&(a=f.getElementById(i))&&y(e,a)&&a.id===i)return n.push(a),n}else{if(u[2])return H.apply(n,e.getElementsByTagName(t)),n;if((i=u[3])&&d.getElementsByClassName&&e.getElementsByClassName)return H.apply(n,e.getElementsByClassName(i)),n}if(d.qsa&&!N[t+" "]&&(!v||!v.test(t))&&(1!==p||"object"!==e.nodeName.toLowerCase())){if(c=t,f=e,1===p&&(U.test(t)||z.test(t))){(f=ee.test(t)&&ye(e.parentNode)||e)===e&&d.scope||((s=e.getAttribute("id"))?s=s.replace(re,ie):e.setAttribute("id",s=S)),o=(l=h(t)).length;while(o--)l[o]=(s?"#"+s:":scope")+" "+xe(l[o]);c=l.join(",")}try{return H.apply(n,f.querySelectorAll(c)),n}catch(e){N(t,!0)}finally{s===S&&e.removeAttribute("id")}}}return g(t.replace($,"$1"),e,n,r)}function ue(){var r=[];return function e(t,n){return r.push(t+" ")>b.cacheLength&&delete e[r.shift()],e[t+" "]=n}}function le(e){return e[S]=!0,e}function ce(e){var t=C.createElement("fieldset");try{return!!e(t)}catch(e){return!1}finally{t.parentNode&&t.parentNode.removeChild(t),t=null}}function fe(e,t){var n=e.split("|"),r=n.length;while(r--)b.attrHandle[n[r]]=t}function pe(e,t){var n=t&&e,r=n&&1===e.nodeType&&1===t.nodeType&&e.sourceIndex-t.sourceIndex;if(r)return r;if(n)while(n=n.nextSibling)if(n===t)return-1;return e?1:-1}function de(t){return function(e){return"input"===e.nodeName.toLowerCase()&&e.type===t}}function he(n){return function(e){var t=e.nodeName.toLowerCase();return("input"===t||"button"===t)&&e.type===n}}function ge(t){return function(e){return"form"in e?e.parentNode&&!1===e.disabled?"label"in e?"label"in e.parentNode?e.parentNode.disabled===t:e.disabled===t:e.isDisabled===t||e.isDisabled!==!t&&ae(e)===t:e.disabled===t:"label"in e&&e.disabled===t}}function ve(a){return le(function(o){return o=+o,le(function(e,t){var n,r=a([],e.length,o),i=r.length;while(i--)e[n=r[i]]&&(e[n]=!(t[n]=e[n]))})})}function ye(e){return e&&"undefined"!=typeof e.getElementsByTagName&&e}for(e in d=se.support={},i=se.isXML=function(e){var t=e&&e.namespaceURI,n=e&&(e.ownerDocument||e).documentElement;return!Y.test(t||n&&n.nodeName||"HTML")},T=se.setDocument=function(e){var t,n,r=e?e.ownerDocument||e:p;return r!=C&&9===r.nodeType&&r.documentElement&&(a=(C=r).documentElement,E=!i(C),p!=C&&(n=C.defaultView)&&n.top!==n&&(n.addEventListener?n.addEventListener("unload",oe,!1):n.attachEvent&&n.attachEvent("onunload",oe)),d.scope=ce(function(e){return a.appendChild(e).appendChild(C.createElement("div")),"undefined"!=typeof e.querySelectorAll&&!e.querySelectorAll(":scope fieldset div").length}),d.attributes=ce(function(e){return e.className="i",!e.getAttribute("className")}),d.getElementsByTagName=ce(function(e){return e.appendChild(C.createComment("")),!e.getElementsByTagName("*").length}),d.getElementsByClassName=K.test(C.getElementsByClassName),d.getById=ce(function(e){return a.appendChild(e).id=S,!C.getElementsByName||!C.getElementsByName(S).length}),d.getById?(b.filter.ID=function(e){var t=e.replace(te,ne);return function(e){return e.getAttribute("id")===t}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n=t.getElementById(e);return n?[n]:[]}}):(b.filter.ID=function(e){var n=e.replace(te,ne);return function(e){var t="undefined"!=typeof e.getAttributeNode&&e.getAttributeNode("id");return t&&t.value===n}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n,r,i,o=t.getElementById(e);if(o){if((n=o.getAttributeNode("id"))&&n.value===e)return[o];i=t.getElementsByName(e),r=0;while(o=i[r++])if((n=o.getAttributeNode("id"))&&n.value===e)return[o]}return[]}}),b.find.TAG=d.getElementsByTagName?function(e,t){return"undefined"!=typeof t.getElementsByTagName?t.getElementsByTagName(e):d.qsa?t.querySelectorAll(e):void 0}:function(e,t){var n,r=[],i=0,o=t.getElementsByTagName(e);if("*"===e){while(n=o[i++])1===n.nodeType&&r.push(n);return r}return o},b.find.CLASS=d.getElementsByClassName&&function(e,t){if("undefined"!=typeof t.getElementsByClassName&&E)return t.getElementsByClassName(e)},s=[],v=[],(d.qsa=K.test(C.querySelectorAll))&&(ce(function(e){var t;a.appendChild(e).innerHTML="<a id='"+S+"'></a><select id='"+S+"-\r\\' msallowcapture=''><option selected=''></option></select>",e.querySelectorAll("[msallowcapture^='']").length&&v.push("[*^$]="+M+"*(?:''|\"\")"),e.querySelectorAll("[selected]").length||v.push("\\["+M+"*(?:value|"+R+")"),e.querySelectorAll("[id~="+S+"-]").length||v.push("~="),(t=C.createElement("input")).setAttribute("name",""),e.appendChild(t),e.querySelectorAll("[name='']").length||v.push("\\["+M+"*name"+M+"*="+M+"*(?:''|\"\")"),e.querySelectorAll(":checked").length||v.push(":checked"),e.querySelectorAll("a#"+S+"+*").length||v.push(".#.+[+~]"),e.querySelectorAll("\\\f"),v.push("[\\r\\n\\f]")}),ce(function(e){e.innerHTML="<a href='' disabled='disabled'></a><select disabled='disabled'><option/></select>";var t=C.createElement("input");t.setAttribute("type","hidden"),e.appendChild(t).setAttribute("name","D"),e.querySelectorAll("[name=d]").length&&v.push("name"+M+"*[*^$|!~]?="),2!==e.querySelectorAll(":enabled").length&&v.push(":enabled",":disabled"),a.appendChild(e).disabled=!0,2!==e.querySelectorAll(":disabled").length&&v.push(":enabled",":disabled"),e.querySelectorAll("*,:x"),v.push(",.*:")})),(d.matchesSelector=K.test(c=a.matches||a.webkitMatchesSelector||a.mozMatchesSelector||a.oMatchesSelector||a.msMatchesSelector))&&ce(function(e){d.disconnectedMatch=c.call(e,"*"),c.call(e,"[s!='']:x"),s.push("!=",F)}),v=v.length&&new RegExp(v.join("|")),s=s.length&&new RegExp(s.join("|")),t=K.test(a.compareDocumentPosition),y=t||K.test(a.contains)?function(e,t){var n=9===e.nodeType?e.documentElement:e,r=t&&t.parentNode;return e===r||!(!r||1!==r.nodeType||!(n.contains?n.contains(r):e.compareDocumentPosition&&16&e.compareDocumentPosition(r)))}:function(e,t){if(t)while(t=t.parentNode)if(t===e)return!0;return!1},j=t?function(e,t){if(e===t)return l=!0,0;var n=!e.compareDocumentPosition-!t.compareDocumentPosition;return n||(1&(n=(e.ownerDocument||e)==(t.ownerDocument||t)?e.compareDocumentPosition(t):1)||!d.sortDetached&&t.compareDocumentPosition(e)===n?e==C||e.ownerDocument==p&&y(p,e)?-1:t==C||t.ownerDocument==p&&y(p,t)?1:u?P(u,e)-P(u,t):0:4&n?-1:1)}:function(e,t){if(e===t)return l=!0,0;var n,r=0,i=e.parentNode,o=t.parentNode,a=[e],s=[t];if(!i||!o)return e==C?-1:t==C?1:i?-1:o?1:u?P(u,e)-P(u,t):0;if(i===o)return pe(e,t);n=e;while(n=n.parentNode)a.unshift(n);n=t;while(n=n.parentNode)s.unshift(n);while(a[r]===s[r])r++;return r?pe(a[r],s[r]):a[r]==p?-1:s[r]==p?1:0}),C},se.matches=function(e,t){return se(e,null,null,t)},se.matchesSelector=function(e,t){if(T(e),d.matchesSelector&&E&&!N[t+" "]&&(!s||!s.test(t))&&(!v||!v.test(t)))try{var n=c.call(e,t);if(n||d.disconnectedMatch||e.document&&11!==e.document.nodeType)return n}catch(e){N(t,!0)}return 0<se(t,C,null,[e]).length},se.contains=function(e,t){return(e.ownerDocument||e)!=C&&T(e),y(e,t)},se.attr=function(e,t){(e.ownerDocument||e)!=C&&T(e);var n=b.attrHandle[t.toLowerCase()],r=n&&D.call(b.attrHandle,t.toLowerCase())?n(e,t,!E):void 0;return void 0!==r?r:d.attributes||!E?e.getAttribute(t):(r=e.getAttributeNode(t))&&r.specified?r.value:null},se.escape=function(e){return(e+"").replace(re,ie)},se.error=function(e){throw new Error("Syntax error, unrecognized expression: "+e)},se.uniqueSort=function(e){var t,n=[],r=0,i=0;if(l=!d.detectDuplicates,u=!d.sortStable&&e.slice(0),e.sort(j),l){while(t=e[i++])t===e[i]&&(r=n.push(i));while(r--)e.splice(n[r],1)}return u=null,e},o=se.getText=function(e){var t,n="",r=0,i=e.nodeType;if(i){if(1===i||9===i||11===i){if("string"==typeof e.textContent)return e.textContent;for(e=e.firstChild;e;e=e.nextSibling)n+=o(e)}else if(3===i||4===i)return e.nodeValue}else while(t=e[r++])n+=o(t);return n},(b=se.selectors={cacheLength:50,createPseudo:le,match:G,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(e){return e[1]=e[1].replace(te,ne),e[3]=(e[3]||e[4]||e[5]||"").replace(te,ne),"~="===e[2]&&(e[3]=" "+e[3]+" "),e.slice(0,4)},CHILD:function(e){return e[1]=e[1].toLowerCase(),"nth"===e[1].slice(0,3)?(e[3]||se.error(e[0]),e[4]=+(e[4]?e[5]+(e[6]||1):2*("even"===e[3]||"odd"===e[3])),e[5]=+(e[7]+e[8]||"odd"===e[3])):e[3]&&se.error(e[0]),e},PSEUDO:function(e){var t,n=!e[6]&&e[2];return G.CHILD.test(e[0])?null:(e[3]?e[2]=e[4]||e[5]||"":n&&X.test(n)&&(t=h(n,!0))&&(t=n.indexOf(")",n.length-t)-n.length)&&(e[0]=e[0].slice(0,t),e[2]=n.slice(0,t)),e.slice(0,3))}},filter:{TAG:function(e){var t=e.replace(te,ne).toLowerCase();return"*"===e?function(){return!0}:function(e){return e.nodeName&&e.nodeName.toLowerCase()===t}},CLASS:function(e){var t=m[e+" "];return t||(t=new RegExp("(^|"+M+")"+e+"("+M+"|$)"))&&m(e,function(e){return t.test("string"==typeof e.className&&e.className||"undefined"!=typeof e.getAttribute&&e.getAttribute("class")||"")})},ATTR:function(n,r,i){return function(e){var t=se.attr(e,n);return null==t?"!="===r:!r||(t+="","="===r?t===i:"!="===r?t!==i:"^="===r?i&&0===t.indexOf(i):"*="===r?i&&-1<t.indexOf(i):"$="===r?i&&t.slice(-i.length)===i:"~="===r?-1<(" "+t.replace(B," ")+" ").indexOf(i):"|="===r&&(t===i||t.slice(0,i.length+1)===i+"-"))}},CHILD:function(h,e,t,g,v){var y="nth"!==h.slice(0,3),m="last"!==h.slice(-4),x="of-type"===e;return 1===g&&0===v?function(e){return!!e.parentNode}:function(e,t,n){var r,i,o,a,s,u,l=y!==m?"nextSibling":"previousSibling",c=e.parentNode,f=x&&e.nodeName.toLowerCase(),p=!n&&!x,d=!1;if(c){if(y){while(l){a=e;while(a=a[l])if(x?a.nodeName.toLowerCase()===f:1===a.nodeType)return!1;u=l="only"===h&&!u&&"nextSibling"}return!0}if(u=[m?c.firstChild:c.lastChild],m&&p){d=(s=(r=(i=(o=(a=c)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1])&&r[2],a=s&&c.childNodes[s];while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if(1===a.nodeType&&++d&&a===e){i[h]=[k,s,d];break}}else if(p&&(d=s=(r=(i=(o=(a=e)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1]),!1===d)while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if((x?a.nodeName.toLowerCase()===f:1===a.nodeType)&&++d&&(p&&((i=(o=a[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]=[k,d]),a===e))break;return(d-=v)===g||d%g==0&&0<=d/g}}},PSEUDO:function(e,o){var t,a=b.pseudos[e]||b.setFilters[e.toLowerCase()]||se.error("unsupported pseudo: "+e);return a[S]?a(o):1<a.length?(t=[e,e,"",o],b.setFilters.hasOwnProperty(e.toLowerCase())?le(function(e,t){var n,r=a(e,o),i=r.length;while(i--)e[n=P(e,r[i])]=!(t[n]=r[i])}):function(e){return a(e,0,t)}):a}},pseudos:{not:le(function(e){var r=[],i=[],s=f(e.replace($,"$1"));return s[S]?le(function(e,t,n,r){var i,o=s(e,null,r,[]),a=e.length;while(a--)(i=o[a])&&(e[a]=!(t[a]=i))}):function(e,t,n){return r[0]=e,s(r,null,n,i),r[0]=null,!i.pop()}}),has:le(function(t){return function(e){return 0<se(t,e).length}}),contains:le(function(t){return t=t.replace(te,ne),function(e){return-1<(e.textContent||o(e)).indexOf(t)}}),lang:le(function(n){return V.test(n||"")||se.error("unsupported lang: "+n),n=n.replace(te,ne).toLowerCase(),function(e){var t;do{if(t=E?e.lang:e.getAttribute("xml:lang")||e.getAttribute("lang"))return(t=t.toLowerCase())===n||0===t.indexOf(n+"-")}while((e=e.parentNode)&&1===e.nodeType);return!1}}),target:function(e){var t=n.location&&n.location.hash;return t&&t.slice(1)===e.id},root:function(e){return e===a},focus:function(e){return e===C.activeElement&&(!C.hasFocus||C.hasFocus())&&!!(e.type||e.href||~e.tabIndex)},enabled:ge(!1),disabled:ge(!0),checked:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&!!e.checked||"option"===t&&!!e.selected},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,!0===e.selected},empty:function(e){for(e=e.firstChild;e;e=e.nextSibling)if(e.nodeType<6)return!1;return!0},parent:function(e){return!b.pseudos.empty(e)},header:function(e){return J.test(e.nodeName)},input:function(e){return Q.test(e.nodeName)},button:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&"button"===e.type||"button"===t},text:function(e){var t;return"input"===e.nodeName.toLowerCase()&&"text"===e.type&&(null==(t=e.getAttribute("type"))||"text"===t.toLowerCase())},first:ve(function(){return[0]}),last:ve(function(e,t){return[t-1]}),eq:ve(function(e,t,n){return[n<0?n+t:n]}),even:ve(function(e,t){for(var n=0;n<t;n+=2)e.push(n);return e}),odd:ve(function(e,t){for(var n=1;n<t;n+=2)e.push(n);return e}),lt:ve(function(e,t,n){for(var r=n<0?n+t:t<n?t:n;0<=--r;)e.push(r);return e}),gt:ve(function(e,t,n){for(var r=n<0?n+t:n;++r<t;)e.push(r);return e})}}).pseudos.nth=b.pseudos.eq,{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})b.pseudos[e]=de(e);for(e in{submit:!0,reset:!0})b.pseudos[e]=he(e);function me(){}function xe(e){for(var t=0,n=e.length,r="";t<n;t++)r+=e[t].value;return r}function be(s,e,t){var u=e.dir,l=e.next,c=l||u,f=t&&"parentNode"===c,p=r++;return e.first?function(e,t,n){while(e=e[u])if(1===e.nodeType||f)return s(e,t,n);return!1}:function(e,t,n){var r,i,o,a=[k,p];if(n){while(e=e[u])if((1===e.nodeType||f)&&s(e,t,n))return!0}else while(e=e[u])if(1===e.nodeType||f)if(i=(o=e[S]||(e[S]={}))[e.uniqueID]||(o[e.uniqueID]={}),l&&l===e.nodeName.toLowerCase())e=e[u]||e;else{if((r=i[c])&&r[0]===k&&r[1]===p)return a[2]=r[2];if((i[c]=a)[2]=s(e,t,n))return!0}return!1}}function we(i){return 1<i.length?function(e,t,n){var r=i.length;while(r--)if(!i[r](e,t,n))return!1;return!0}:i[0]}function Te(e,t,n,r,i){for(var o,a=[],s=0,u=e.length,l=null!=t;s<u;s++)(o=e[s])&&(n&&!n(o,r,i)||(a.push(o),l&&t.push(s)));return a}function Ce(d,h,g,v,y,e){return v&&!v[S]&&(v=Ce(v)),y&&!y[S]&&(y=Ce(y,e)),le(function(e,t,n,r){var i,o,a,s=[],u=[],l=t.length,c=e||function(e,t,n){for(var r=0,i=t.length;r<i;r++)se(e,t[r],n);return n}(h||"*",n.nodeType?[n]:n,[]),f=!d||!e&&h?c:Te(c,s,d,n,r),p=g?y||(e?d:l||v)?[]:t:f;if(g&&g(f,p,n,r),v){i=Te(p,u),v(i,[],n,r),o=i.length;while(o--)(a=i[o])&&(p[u[o]]=!(f[u[o]]=a))}if(e){if(y||d){if(y){i=[],o=p.length;while(o--)(a=p[o])&&i.push(f[o]=a);y(null,p=[],i,r)}o=p.length;while(o--)(a=p[o])&&-1<(i=y?P(e,a):s[o])&&(e[i]=!(t[i]=a))}}else p=Te(p===t?p.splice(l,p.length):p),y?y(null,t,p,r):H.apply(t,p)})}function Ee(e){for(var i,t,n,r=e.length,o=b.relative[e[0].type],a=o||b.relative[" "],s=o?1:0,u=be(function(e){return e===i},a,!0),l=be(function(e){return-1<P(i,e)},a,!0),c=[function(e,t,n){var r=!o&&(n||t!==w)||((i=t).nodeType?u(e,t,n):l(e,t,n));return i=null,r}];s<r;s++)if(t=b.relative[e[s].type])c=[be(we(c),t)];else{if((t=b.filter[e[s].type].apply(null,e[s].matches))[S]){for(n=++s;n<r;n++)if(b.relative[e[n].type])break;return Ce(1<s&&we(c),1<s&&xe(e.slice(0,s-1).concat({value:" "===e[s-2].type?"*":""})).replace($,"$1"),t,s<n&&Ee(e.slice(s,n)),n<r&&Ee(e=e.slice(n)),n<r&&xe(e))}c.push(t)}return we(c)}return me.prototype=b.filters=b.pseudos,b.setFilters=new me,h=se.tokenize=function(e,t){var n,r,i,o,a,s,u,l=x[e+" "];if(l)return t?0:l.slice(0);a=e,s=[],u=b.preFilter;while(a){for(o in n&&!(r=_.exec(a))||(r&&(a=a.slice(r[0].length)||a),s.push(i=[])),n=!1,(r=z.exec(a))&&(n=r.shift(),i.push({value:n,type:r[0].replace($," ")}),a=a.slice(n.length)),b.filter)!(r=G[o].exec(a))||u[o]&&!(r=u[o](r))||(n=r.shift(),i.push({value:n,type:o,matches:r}),a=a.slice(n.length));if(!n)break}return t?a.length:a?se.error(e):x(e,s).slice(0)},f=se.compile=function(e,t){var n,v,y,m,x,r,i=[],o=[],a=A[e+" "];if(!a){t||(t=h(e)),n=t.length;while(n--)(a=Ee(t[n]))[S]?i.push(a):o.push(a);(a=A(e,(v=o,m=0<(y=i).length,x=0<v.length,r=function(e,t,n,r,i){var o,a,s,u=0,l="0",c=e&&[],f=[],p=w,d=e||x&&b.find.TAG("*",i),h=k+=null==p?1:Math.random()||.1,g=d.length;for(i&&(w=t==C||t||i);l!==g&&null!=(o=d[l]);l++){if(x&&o){a=0,t||o.ownerDocument==C||(T(o),n=!E);while(s=v[a++])if(s(o,t||C,n)){r.push(o);break}i&&(k=h)}m&&((o=!s&&o)&&u--,e&&c.push(o))}if(u+=l,m&&l!==u){a=0;while(s=y[a++])s(c,f,t,n);if(e){if(0<u)while(l--)c[l]||f[l]||(f[l]=q.call(r));f=Te(f)}H.apply(r,f),i&&!e&&0<f.length&&1<u+y.length&&se.uniqueSort(r)}return i&&(k=h,w=p),c},m?le(r):r))).selector=e}return a},g=se.select=function(e,t,n,r){var i,o,a,s,u,l="function"==typeof e&&e,c=!r&&h(e=l.selector||e);if(n=n||[],1===c.length){if(2<(o=c[0]=c[0].slice(0)).length&&"ID"===(a=o[0]).type&&9===t.nodeType&&E&&b.relative[o[1].type]){if(!(t=(b.find.ID(a.matches[0].replace(te,ne),t)||[])[0]))return n;l&&(t=t.parentNode),e=e.slice(o.shift().value.length)}i=G.needsContext.test(e)?0:o.length;while(i--){if(a=o[i],b.relative[s=a.type])break;if((u=b.find[s])&&(r=u(a.matches[0].replace(te,ne),ee.test(o[0].type)&&ye(t.parentNode)||t))){if(o.splice(i,1),!(e=r.length&&xe(o)))return H.apply(n,r),n;break}}}return(l||f(e,c))(r,t,!E,n,!t||ee.test(e)&&ye(t.parentNode)||t),n},d.sortStable=S.split("").sort(j).join("")===S,d.detectDuplicates=!!l,T(),d.sortDetached=ce(function(e){return 1&e.compareDocumentPosition(C.createElement("fieldset"))}),ce(function(e){return e.innerHTML="<a href='#'></a>","#"===e.firstChild.getAttribute("href")})||fe("type|href|height|width",function(e,t,n){if(!n)return e.getAttribute(t,"type"===t.toLowerCase()?1:2)}),d.attributes&&ce(function(e){return e.innerHTML="<input/>",e.firstChild.setAttribute("value",""),""===e.firstChild.getAttribute("value")})||fe("value",function(e,t,n){if(!n&&"input"===e.nodeName.toLowerCase())return e.defaultValue}),ce(function(e){return null==e.getAttribute("disabled")})||fe(R,function(e,t,n){var r;if(!n)return!0===e[t]?t.toLowerCase():(r=e.getAttributeNode(t))&&r.specified?r.value:null}),se}(C);S.find=d,S.expr=d.selectors,S.expr[":"]=S.expr.pseudos,S.uniqueSort=S.unique=d.uniqueSort,S.text=d.getText,S.isXMLDoc=d.isXML,S.contains=d.contains,S.escapeSelector=d.escape;var h=function(e,t,n){var r=[],i=void 0!==n;while((e=e[t])&&9!==e.nodeType)if(1===e.nodeType){if(i&&S(e).is(n))break;r.push(e)}return r},T=function(e,t){for(var n=[];e;e=e.nextSibling)1===e.nodeType&&e!==t&&n.push(e);return n},k=S.expr.match.needsContext;function A(e,t){return e.nodeName&&e.nodeName.toLowerCase()===t.toLowerCase()}var N=/^<([a-z][^\/\0>:\x20\t\r\n\f]*)[\x20\t\r\n\f]*\/?>(?:<\/\1>|)$/i;function j(e,n,r){return m(n)?S.grep(e,function(e,t){return!!n.call(e,t,e)!==r}):n.nodeType?S.grep(e,function(e){return e===n!==r}):"string"!=typeof n?S.grep(e,function(e){return-1<i.call(n,e)!==r}):S.filter(n,e,r)}S.filter=function(e,t,n){var r=t[0];return n&&(e=":not("+e+")"),1===t.length&&1===r.nodeType?S.find.matchesSelector(r,e)?[r]:[]:S.find.matches(e,S.grep(t,function(e){return 1===e.nodeType}))},S.fn.extend({find:function(e){var t,n,r=this.length,i=this;if("string"!=typeof e)return this.pushStack(S(e).filter(function(){for(t=0;t<r;t++)if(S.contains(i[t],this))return!0}));for(n=this.pushStack([]),t=0;t<r;t++)S.find(e,i[t],n);return 1<r?S.uniqueSort(n):n},filter:function(e){return this.pushStack(j(this,e||[],!1))},not:function(e){return this.pushStack(j(this,e||[],!0))},is:function(e){return!!j(this,"string"==typeof e&&k.test(e)?S(e):e||[],!1).length}});var D,q=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]+))$/;(S.fn.init=function(e,t,n){var r,i;if(!e)return this;if(n=n||D,"string"==typeof e){if(!(r="<"===e[0]&&">"===e[e.length-1]&&3<=e.length?[null,e,null]:q.exec(e))||!r[1]&&t)return!t||t.jquery?(t||n).find(e):this.constructor(t).find(e);if(r[1]){if(t=t instanceof S?t[0]:t,S.merge(this,S.parseHTML(r[1],t&&t.nodeType?t.ownerDocument||t:E,!0)),N.test(r[1])&&S.isPlainObject(t))for(r in t)m(this[r])?this[r](t[r]):this.attr(r,t[r]);return this}return(i=E.getElementById(r[2]))&&(this[0]=i,this.length=1),this}return e.nodeType?(this[0]=e,this.length=1,this):m(e)?void 0!==n.ready?n.ready(e):e(S):S.makeArray(e,this)}).prototype=S.fn,D=S(E);var L=/^(?:parents|prev(?:Until|All))/,H={children:!0,contents:!0,next:!0,prev:!0};function O(e,t){while((e=e[t])&&1!==e.nodeType);return e}S.fn.extend({has:function(e){var t=S(e,this),n=t.length;return this.filter(function(){for(var e=0;e<n;e++)if(S.contains(this,t[e]))return!0})},closest:function(e,t){var n,r=0,i=this.length,o=[],a="string"!=typeof e&&S(e);if(!k.test(e))for(;r<i;r++)for(n=this[r];n&&n!==t;n=n.parentNode)if(n.nodeType<11&&(a?-1<a.index(n):1===n.nodeType&&S.find.matchesSelector(n,e))){o.push(n);break}return this.pushStack(1<o.length?S.uniqueSort(o):o)},index:function(e){return e?"string"==typeof e?i.call(S(e),this[0]):i.call(this,e.jquery?e[0]:e):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(e,t){return this.pushStack(S.uniqueSort(S.merge(this.get(),S(e,t))))},addBack:function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}}),S.each({parent:function(e){var t=e.parentNode;return t&&11!==t.nodeType?t:null},parents:function(e){return h(e,"parentNode")},parentsUntil:function(e,t,n){return h(e,"parentNode",n)},next:function(e){return O(e,"nextSibling")},prev:function(e){return O(e,"previousSibling")},nextAll:function(e){return h(e,"nextSibling")},prevAll:function(e){return h(e,"previousSibling")},nextUntil:function(e,t,n){return h(e,"nextSibling",n)},prevUntil:function(e,t,n){return h(e,"previousSibling",n)},siblings:function(e){return T((e.parentNode||{}).firstChild,e)},children:function(e){return T(e.firstChild)},contents:function(e){return null!=e.contentDocument&&r(e.contentDocument)?e.contentDocument:(A(e,"template")&&(e=e.content||e),S.merge([],e.childNodes))}},function(r,i){S.fn[r]=function(e,t){var n=S.map(this,i,e);return"Until"!==r.slice(-5)&&(t=e),t&&"string"==typeof t&&(n=S.filter(t,n)),1<this.length&&(H[r]||S.uniqueSort(n),L.test(r)&&n.reverse()),this.pushStack(n)}});var P=/[^\x20\t\r\n\f]+/g;function R(e){return e}function M(e){throw e}function I(e,t,n,r){var i;try{e&&m(i=e.promise)?i.call(e).done(t).fail(n):e&&m(i=e.then)?i.call(e,t,n):t.apply(void 0,[e].slice(r))}catch(e){n.apply(void 0,[e])}}S.Callbacks=function(r){var e,n;r="string"==typeof r?(e=r,n={},S.each(e.match(P)||[],function(e,t){n[t]=!0}),n):S.extend({},r);var i,t,o,a,s=[],u=[],l=-1,c=function(){for(a=a||r.once,o=i=!0;u.length;l=-1){t=u.shift();while(++l<s.length)!1===s[l].apply(t[0],t[1])&&r.stopOnFalse&&(l=s.length,t=!1)}r.memory||(t=!1),i=!1,a&&(s=t?[]:"")},f={add:function(){return s&&(t&&!i&&(l=s.length-1,u.push(t)),function n(e){S.each(e,function(e,t){m(t)?r.unique&&f.has(t)||s.push(t):t&&t.length&&"string"!==w(t)&&n(t)})}(arguments),t&&!i&&c()),this},remove:function(){return S.each(arguments,function(e,t){var n;while(-1<(n=S.inArray(t,s,n)))s.splice(n,1),n<=l&&l--}),this},has:function(e){return e?-1<S.inArray(e,s):0<s.length},empty:function(){return s&&(s=[]),this},disable:function(){return a=u=[],s=t="",this},disabled:function(){return!s},lock:function(){return a=u=[],t||i||(s=t=""),this},locked:function(){return!!a},fireWith:function(e,t){return a||(t=[e,(t=t||[]).slice?t.slice():t],u.push(t),i||c()),this},fire:function(){return f.fireWith(this,arguments),this},fired:function(){return!!o}};return f},S.extend({Deferred:function(e){var o=[["notify","progress",S.Callbacks("memory"),S.Callbacks("memory"),2],["resolve","done",S.Callbacks("once memory"),S.Callbacks("once memory"),0,"resolved"],["reject","fail",S.Callbacks("once memory"),S.Callbacks("once memory"),1,"rejected"]],i="pending",a={state:function(){return i},always:function(){return s.done(arguments).fail(arguments),this},"catch":function(e){return a.then(null,e)},pipe:function(){var i=arguments;return S.Deferred(function(r){S.each(o,function(e,t){var n=m(i[t[4]])&&i[t[4]];s[t[1]](function(){var e=n&&n.apply(this,arguments);e&&m(e.promise)?e.promise().progress(r.notify).done(r.resolve).fail(r.reject):r[t[0]+"With"](this,n?[e]:arguments)})}),i=null}).promise()},then:function(t,n,r){var u=0;function l(i,o,a,s){return function(){var n=this,r=arguments,e=function(){var e,t;if(!(i<u)){if((e=a.apply(n,r))===o.promise())throw new TypeError("Thenable self-resolution");t=e&&("object"==typeof e||"function"==typeof e)&&e.then,m(t)?s?t.call(e,l(u,o,R,s),l(u,o,M,s)):(u++,t.call(e,l(u,o,R,s),l(u,o,M,s),l(u,o,R,o.notifyWith))):(a!==R&&(n=void 0,r=[e]),(s||o.resolveWith)(n,r))}},t=s?e:function(){try{e()}catch(e){S.Deferred.exceptionHook&&S.Deferred.exceptionHook(e,t.stackTrace),u<=i+1&&(a!==M&&(n=void 0,r=[e]),o.rejectWith(n,r))}};i?t():(S.Deferred.getStackHook&&(t.stackTrace=S.Deferred.getStackHook()),C.setTimeout(t))}}return S.Deferred(function(e){o[0][3].add(l(0,e,m(r)?r:R,e.notifyWith)),o[1][3].add(l(0,e,m(t)?t:R)),o[2][3].add(l(0,e,m(n)?n:M))}).promise()},promise:function(e){return null!=e?S.extend(e,a):a}},s={};return S.each(o,function(e,t){var n=t[2],r=t[5];a[t[1]]=n.add,r&&n.add(function(){i=r},o[3-e][2].disable,o[3-e][3].disable,o[0][2].lock,o[0][3].lock),n.add(t[3].fire),s[t[0]]=function(){return s[t[0]+"With"](this===s?void 0:this,arguments),this},s[t[0]+"With"]=n.fireWith}),a.promise(s),e&&e.call(s,s),s},when:function(e){var n=arguments.length,t=n,r=Array(t),i=s.call(arguments),o=S.Deferred(),a=function(t){return function(e){r[t]=this,i[t]=1<arguments.length?s.call(arguments):e,--n||o.resolveWith(r,i)}};if(n<=1&&(I(e,o.done(a(t)).resolve,o.reject,!n),"pending"===o.state()||m(i[t]&&i[t].then)))return o.then();while(t--)I(i[t],a(t),o.reject);return o.promise()}});var W=/^(Eval|Internal|Range|Reference|Syntax|Type|URI)Error$/;S.Deferred.exceptionHook=function(e,t){C.console&&C.console.warn&&e&&W.test(e.name)&&C.console.warn("jQuery.Deferred exception: "+e.message,e.stack,t)},S.readyException=function(e){C.setTimeout(function(){throw e})};var F=S.Deferred();function B(){E.removeEventListener("DOMContentLoaded",B),C.removeEventListener("load",B),S.ready()}S.fn.ready=function(e){return F.then(e)["catch"](function(e){S.readyException(e)}),this},S.extend({isReady:!1,readyWait:1,ready:function(e){(!0===e?--S.readyWait:S.isReady)||(S.isReady=!0)!==e&&0<--S.readyWait||F.resolveWith(E,[S])}}),S.ready.then=F.then,"complete"===E.readyState||"loading"!==E.readyState&&!E.documentElement.doScroll?C.setTimeout(S.ready):(E.addEventListener("DOMContentLoaded",B),C.addEventListener("load",B));var $=function(e,t,n,r,i,o,a){var s=0,u=e.length,l=null==n;if("object"===w(n))for(s in i=!0,n)$(e,t,s,n[s],!0,o,a);else if(void 0!==r&&(i=!0,m(r)||(a=!0),l&&(a?(t.call(e,r),t=null):(l=t,t=function(e,t,n){return l.call(S(e),n)})),t))for(;s<u;s++)t(e[s],n,a?r:r.call(e[s],s,t(e[s],n)));return i?e:l?t.call(e):u?t(e[0],n):o},_=/^-ms-/,z=/-([a-z])/g;function U(e,t){return t.toUpperCase()}function X(e){return e.replace(_,"ms-").replace(z,U)}var V=function(e){return 1===e.nodeType||9===e.nodeType||!+e.nodeType};function G(){this.expando=S.expando+G.uid++}G.uid=1,G.prototype={cache:function(e){var t=e[this.expando];return t||(t={},V(e)&&(e.nodeType?e[this.expando]=t:Object.defineProperty(e,this.expando,{value:t,configurable:!0}))),t},set:function(e,t,n){var r,i=this.cache(e);if("string"==typeof t)i[X(t)]=n;else for(r in t)i[X(r)]=t[r];return i},get:function(e,t){return void 0===t?this.cache(e):e[this.expando]&&e[this.expando][X(t)]},access:function(e,t,n){return void 0===t||t&&"string"==typeof t&&void 0===n?this.get(e,t):(this.set(e,t,n),void 0!==n?n:t)},remove:function(e,t){var n,r=e[this.expando];if(void 0!==r){if(void 0!==t){n=(t=Array.isArray(t)?t.map(X):(t=X(t))in r?[t]:t.match(P)||[]).length;while(n--)delete r[t[n]]}(void 0===t||S.isEmptyObject(r))&&(e.nodeType?e[this.expando]=void 0:delete e[this.expando])}},hasData:function(e){var t=e[this.expando];return void 0!==t&&!S.isEmptyObject(t)}};var Y=new G,Q=new G,J=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,K=/[A-Z]/g;function Z(e,t,n){var r,i;if(void 0===n&&1===e.nodeType)if(r="data-"+t.replace(K,"-$&").toLowerCase(),"string"==typeof(n=e.getAttribute(r))){try{n="true"===(i=n)||"false"!==i&&("null"===i?null:i===+i+""?+i:J.test(i)?JSON.parse(i):i)}catch(e){}Q.set(e,t,n)}else n=void 0;return n}S.extend({hasData:function(e){return Q.hasData(e)||Y.hasData(e)},data:function(e,t,n){return Q.access(e,t,n)},removeData:function(e,t){Q.remove(e,t)},_data:function(e,t,n){return Y.access(e,t,n)},_removeData:function(e,t){Y.remove(e,t)}}),S.fn.extend({data:function(n,e){var t,r,i,o=this[0],a=o&&o.attributes;if(void 0===n){if(this.length&&(i=Q.get(o),1===o.nodeType&&!Y.get(o,"hasDataAttrs"))){t=a.length;while(t--)a[t]&&0===(r=a[t].name).indexOf("data-")&&(r=X(r.slice(5)),Z(o,r,i[r]));Y.set(o,"hasDataAttrs",!0)}return i}return"object"==typeof n?this.each(function(){Q.set(this,n)}):$(this,function(e){var t;if(o&&void 0===e)return void 0!==(t=Q.get(o,n))?t:void 0!==(t=Z(o,n))?t:void 0;this.each(function(){Q.set(this,n,e)})},null,e,1<arguments.length,null,!0)},removeData:function(e){return this.each(function(){Q.remove(this,e)})}}),S.extend({queue:function(e,t,n){var r;if(e)return t=(t||"fx")+"queue",r=Y.get(e,t),n&&(!r||Array.isArray(n)?r=Y.access(e,t,S.makeArray(n)):r.push(n)),r||[]},dequeue:function(e,t){t=t||"fx";var n=S.queue(e,t),r=n.length,i=n.shift(),o=S._queueHooks(e,t);"inprogress"===i&&(i=n.shift(),r--),i&&("fx"===t&&n.unshift("inprogress"),delete o.stop,i.call(e,function(){S.dequeue(e,t)},o)),!r&&o&&o.empty.fire()},_queueHooks:function(e,t){var n=t+"queueHooks";return Y.get(e,n)||Y.access(e,n,{empty:S.Callbacks("once memory").add(function(){Y.remove(e,[t+"queue",n])})})}}),S.fn.extend({queue:function(t,n){var e=2;return"string"!=typeof t&&(n=t,t="fx",e--),arguments.length<e?S.queue(this[0],t):void 0===n?this:this.each(function(){var e=S.queue(this,t,n);S._queueHooks(this,t),"fx"===t&&"inprogress"!==e[0]&&S.dequeue(this,t)})},dequeue:function(e){return this.each(function(){S.dequeue(this,e)})},clearQueue:function(e){return this.queue(e||"fx",[])},promise:function(e,t){var n,r=1,i=S.Deferred(),o=this,a=this.length,s=function(){--r||i.resolveWith(o,[o])};"string"!=typeof e&&(t=e,e=void 0),e=e||"fx";while(a--)(n=Y.get(o[a],e+"queueHooks"))&&n.empty&&(r++,n.empty.add(s));return s(),i.promise(t)}});var ee=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,te=new RegExp("^(?:([+-])=|)("+ee+")([a-z%]*)$","i"),ne=["Top","Right","Bottom","Left"],re=E.documentElement,ie=function(e){return S.contains(e.ownerDocument,e)},oe={composed:!0};re.getRootNode&&(ie=function(e){return S.contains(e.ownerDocument,e)||e.getRootNode(oe)===e.ownerDocument});var ae=function(e,t){return"none"===(e=t||e).style.display||""===e.style.display&&ie(e)&&"none"===S.css(e,"display")};function se(e,t,n,r){var i,o,a=20,s=r?function(){return r.cur()}:function(){return S.css(e,t,"")},u=s(),l=n&&n[3]||(S.cssNumber[t]?"":"px"),c=e.nodeType&&(S.cssNumber[t]||"px"!==l&&+u)&&te.exec(S.css(e,t));if(c&&c[3]!==l){u/=2,l=l||c[3],c=+u||1;while(a--)S.style(e,t,c+l),(1-o)*(1-(o=s()/u||.5))<=0&&(a=0),c/=o;c*=2,S.style(e,t,c+l),n=n||[]}return n&&(c=+c||+u||0,i=n[1]?c+(n[1]+1)*n[2]:+n[2],r&&(r.unit=l,r.start=c,r.end=i)),i}var ue={};function le(e,t){for(var n,r,i,o,a,s,u,l=[],c=0,f=e.length;c<f;c++)(r=e[c]).style&&(n=r.style.display,t?("none"===n&&(l[c]=Y.get(r,"display")||null,l[c]||(r.style.display="")),""===r.style.display&&ae(r)&&(l[c]=(u=a=o=void 0,a=(i=r).ownerDocument,s=i.nodeName,(u=ue[s])||(o=a.body.appendChild(a.createElement(s)),u=S.css(o,"display"),o.parentNode.removeChild(o),"none"===u&&(u="block"),ue[s]=u)))):"none"!==n&&(l[c]="none",Y.set(r,"display",n)));for(c=0;c<f;c++)null!=l[c]&&(e[c].style.display=l[c]);return e}S.fn.extend({show:function(){return le(this,!0)},hide:function(){return le(this)},toggle:function(e){return"boolean"==typeof e?e?this.show():this.hide():this.each(function(){ae(this)?S(this).show():S(this).hide()})}});var ce,fe,pe=/^(?:checkbox|radio)$/i,de=/<([a-z][^\/\0>\x20\t\r\n\f]*)/i,he=/^$|^module$|\/(?:java|ecma)script/i;ce=E.createDocumentFragment().appendChild(E.createElement("div")),(fe=E.createElement("input")).setAttribute("type","radio"),fe.setAttribute("checked","checked"),fe.setAttribute("name","t"),ce.appendChild(fe),y.checkClone=ce.cloneNode(!0).cloneNode(!0).lastChild.checked,ce.innerHTML="<textarea>x</textarea>",y.noCloneChecked=!!ce.cloneNode(!0).lastChild.defaultValue,ce.innerHTML="<option></option>",y.option=!!ce.lastChild;var ge={thead:[1,"<table>","</table>"],col:[2,"<table><colgroup>","</colgroup></table>"],tr:[2,"<table><tbody>","</tbody></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:[0,"",""]};function ve(e,t){var n;return n="undefined"!=typeof e.getElementsByTagName?e.getElementsByTagName(t||"*"):"undefined"!=typeof e.querySelectorAll?e.querySelectorAll(t||"*"):[],void 0===t||t&&A(e,t)?S.merge([e],n):n}function ye(e,t){for(var n=0,r=e.length;n<r;n++)Y.set(e[n],"globalEval",!t||Y.get(t[n],"globalEval"))}ge.tbody=ge.tfoot=ge.colgroup=ge.caption=ge.thead,ge.th=ge.td,y.option||(ge.optgroup=ge.option=[1,"<select multiple='multiple'>","</select>"]);var me=/<|&#?\w+;/;function xe(e,t,n,r,i){for(var o,a,s,u,l,c,f=t.createDocumentFragment(),p=[],d=0,h=e.length;d<h;d++)if((o=e[d])||0===o)if("object"===w(o))S.merge(p,o.nodeType?[o]:o);else if(me.test(o)){a=a||f.appendChild(t.createElement("div")),s=(de.exec(o)||["",""])[1].toLowerCase(),u=ge[s]||ge._default,a.innerHTML=u[1]+S.htmlPrefilter(o)+u[2],c=u[0];while(c--)a=a.lastChild;S.merge(p,a.childNodes),(a=f.firstChild).textContent=""}else p.push(t.createTextNode(o));f.textContent="",d=0;while(o=p[d++])if(r&&-1<S.inArray(o,r))i&&i.push(o);else if(l=ie(o),a=ve(f.appendChild(o),"script"),l&&ye(a),n){c=0;while(o=a[c++])he.test(o.type||"")&&n.push(o)}return f}var be=/^([^.]*)(?:\.(.+)|)/;function we(){return!0}function Te(){return!1}function Ce(e,t){return e===function(){try{return E.activeElement}catch(e){}}()==("focus"===t)}function Ee(e,t,n,r,i,o){var a,s;if("object"==typeof t){for(s in"string"!=typeof n&&(r=r||n,n=void 0),t)Ee(e,s,n,r,t[s],o);return e}if(null==r&&null==i?(i=n,r=n=void 0):null==i&&("string"==typeof n?(i=r,r=void 0):(i=r,r=n,n=void 0)),!1===i)i=Te;else if(!i)return e;return 1===o&&(a=i,(i=function(e){return S().off(e),a.apply(this,arguments)}).guid=a.guid||(a.guid=S.guid++)),e.each(function(){S.event.add(this,t,i,r,n)})}function Se(e,i,o){o?(Y.set(e,i,!1),S.event.add(e,i,{namespace:!1,handler:function(e){var t,n,r=Y.get(this,i);if(1&e.isTrigger&&this[i]){if(r.length)(S.event.special[i]||{}).delegateType&&e.stopPropagation();else if(r=s.call(arguments),Y.set(this,i,r),t=o(this,i),this[i](),r!==(n=Y.get(this,i))||t?Y.set(this,i,!1):n={},r!==n)return e.stopImmediatePropagation(),e.preventDefault(),n&&n.value}else r.length&&(Y.set(this,i,{value:S.event.trigger(S.extend(r[0],S.Event.prototype),r.slice(1),this)}),e.stopImmediatePropagation())}})):void 0===Y.get(e,i)&&S.event.add(e,i,we)}S.event={global:{},add:function(t,e,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.get(t);if(V(t)){n.handler&&(n=(o=n).handler,i=o.selector),i&&S.find.matchesSelector(re,i),n.guid||(n.guid=S.guid++),(u=v.events)||(u=v.events=Object.create(null)),(a=v.handle)||(a=v.handle=function(e){return"undefined"!=typeof S&&S.event.triggered!==e.type?S.event.dispatch.apply(t,arguments):void 0}),l=(e=(e||"").match(P)||[""]).length;while(l--)d=g=(s=be.exec(e[l])||[])[1],h=(s[2]||"").split(".").sort(),d&&(f=S.event.special[d]||{},d=(i?f.delegateType:f.bindType)||d,f=S.event.special[d]||{},c=S.extend({type:d,origType:g,data:r,handler:n,guid:n.guid,selector:i,needsContext:i&&S.expr.match.needsContext.test(i),namespace:h.join(".")},o),(p=u[d])||((p=u[d]=[]).delegateCount=0,f.setup&&!1!==f.setup.call(t,r,h,a)||t.addEventListener&&t.addEventListener(d,a)),f.add&&(f.add.call(t,c),c.handler.guid||(c.handler.guid=n.guid)),i?p.splice(p.delegateCount++,0,c):p.push(c),S.event.global[d]=!0)}},remove:function(e,t,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.hasData(e)&&Y.get(e);if(v&&(u=v.events)){l=(t=(t||"").match(P)||[""]).length;while(l--)if(d=g=(s=be.exec(t[l])||[])[1],h=(s[2]||"").split(".").sort(),d){f=S.event.special[d]||{},p=u[d=(r?f.delegateType:f.bindType)||d]||[],s=s[2]&&new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"),a=o=p.length;while(o--)c=p[o],!i&&g!==c.origType||n&&n.guid!==c.guid||s&&!s.test(c.namespace)||r&&r!==c.selector&&("**"!==r||!c.selector)||(p.splice(o,1),c.selector&&p.delegateCount--,f.remove&&f.remove.call(e,c));a&&!p.length&&(f.teardown&&!1!==f.teardown.call(e,h,v.handle)||S.removeEvent(e,d,v.handle),delete u[d])}else for(d in u)S.event.remove(e,d+t[l],n,r,!0);S.isEmptyObject(u)&&Y.remove(e,"handle events")}},dispatch:function(e){var t,n,r,i,o,a,s=new Array(arguments.length),u=S.event.fix(e),l=(Y.get(this,"events")||Object.create(null))[u.type]||[],c=S.event.special[u.type]||{};for(s[0]=u,t=1;t<arguments.length;t++)s[t]=arguments[t];if(u.delegateTarget=this,!c.preDispatch||!1!==c.preDispatch.call(this,u)){a=S.event.handlers.call(this,u,l),t=0;while((i=a[t++])&&!u.isPropagationStopped()){u.currentTarget=i.elem,n=0;while((o=i.handlers[n++])&&!u.isImmediatePropagationStopped())u.rnamespace&&!1!==o.namespace&&!u.rnamespace.test(o.namespace)||(u.handleObj=o,u.data=o.data,void 0!==(r=((S.event.special[o.origType]||{}).handle||o.handler).apply(i.elem,s))&&!1===(u.result=r)&&(u.preventDefault(),u.stopPropagation()))}return c.postDispatch&&c.postDispatch.call(this,u),u.result}},handlers:function(e,t){var n,r,i,o,a,s=[],u=t.delegateCount,l=e.target;if(u&&l.nodeType&&!("click"===e.type&&1<=e.button))for(;l!==this;l=l.parentNode||this)if(1===l.nodeType&&("click"!==e.type||!0!==l.disabled)){for(o=[],a={},n=0;n<u;n++)void 0===a[i=(r=t[n]).selector+" "]&&(a[i]=r.needsContext?-1<S(i,this).index(l):S.find(i,this,null,[l]).length),a[i]&&o.push(r);o.length&&s.push({elem:l,handlers:o})}return l=this,u<t.length&&s.push({elem:l,handlers:t.slice(u)}),s},addProp:function(t,e){Object.defineProperty(S.Event.prototype,t,{enumerable:!0,configurable:!0,get:m(e)?function(){if(this.originalEvent)return e(this.originalEvent)}:function(){if(this.originalEvent)return this.originalEvent[t]},set:function(e){Object.defineProperty(this,t,{enumerable:!0,configurable:!0,writable:!0,value:e})}})},fix:function(e){return e[S.expando]?e:new S.Event(e)},special:{load:{noBubble:!0},click:{setup:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click",we),!1},trigger:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click"),!0},_default:function(e){var t=e.target;return pe.test(t.type)&&t.click&&A(t,"input")&&Y.get(t,"click")||A(t,"a")}},beforeunload:{postDispatch:function(e){void 0!==e.result&&e.originalEvent&&(e.originalEvent.returnValue=e.result)}}}},S.removeEvent=function(e,t,n){e.removeEventListener&&e.removeEventListener(t,n)},S.Event=function(e,t){if(!(this instanceof S.Event))return new S.Event(e,t);e&&e.type?(this.originalEvent=e,this.type=e.type,this.isDefaultPrevented=e.defaultPrevented||void 0===e.defaultPrevented&&!1===e.returnValue?we:Te,this.target=e.target&&3===e.target.nodeType?e.target.parentNode:e.target,this.currentTarget=e.currentTarget,this.relatedTarget=e.relatedTarget):this.type=e,t&&S.extend(this,t),this.timeStamp=e&&e.timeStamp||Date.now(),this[S.expando]=!0},S.Event.prototype={constructor:S.Event,isDefaultPrevented:Te,isPropagationStopped:Te,isImmediatePropagationStopped:Te,isSimulated:!1,preventDefault:function(){var e=this.originalEvent;this.isDefaultPrevented=we,e&&!this.isSimulated&&e.preventDefault()},stopPropagation:function(){var e=this.originalEvent;this.isPropagationStopped=we,e&&!this.isSimulated&&e.stopPropagation()},stopImmediatePropagation:function(){var e=this.originalEvent;this.isImmediatePropagationStopped=we,e&&!this.isSimulated&&e.stopImmediatePropagation(),this.stopPropagation()}},S.each({altKey:!0,bubbles:!0,cancelable:!0,changedTouches:!0,ctrlKey:!0,detail:!0,eventPhase:!0,metaKey:!0,pageX:!0,pageY:!0,shiftKey:!0,view:!0,"char":!0,code:!0,charCode:!0,key:!0,keyCode:!0,button:!0,buttons:!0,clientX:!0,clientY:!0,offsetX:!0,offsetY:!0,pointerId:!0,pointerType:!0,screenX:!0,screenY:!0,targetTouches:!0,toElement:!0,touches:!0,which:!0},S.event.addProp),S.each({focus:"focusin",blur:"focusout"},function(e,t){S.event.special[e]={setup:function(){return Se(this,e,Ce),!1},trigger:function(){return Se(this,e),!0},_default:function(){return!0},delegateType:t}}),S.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(e,i){S.event.special[e]={delegateType:i,bindType:i,handle:function(e){var t,n=e.relatedTarget,r=e.handleObj;return n&&(n===this||S.contains(this,n))||(e.type=r.origType,t=r.handler.apply(this,arguments),e.type=i),t}}}),S.fn.extend({on:function(e,t,n,r){return Ee(this,e,t,n,r)},one:function(e,t,n,r){return Ee(this,e,t,n,r,1)},off:function(e,t,n){var r,i;if(e&&e.preventDefault&&e.handleObj)return r=e.handleObj,S(e.delegateTarget).off(r.namespace?r.origType+"."+r.namespace:r.origType,r.selector,r.handler),this;if("object"==typeof e){for(i in e)this.off(i,t,e[i]);return this}return!1!==t&&"function"!=typeof t||(n=t,t=void 0),!1===n&&(n=Te),this.each(function(){S.event.remove(this,e,n,t)})}});var ke=/<script|<style|<link/i,Ae=/checked\s*(?:[^=]|=\s*.checked.)/i,Ne=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g;function je(e,t){return A(e,"table")&&A(11!==t.nodeType?t:t.firstChild,"tr")&&S(e).children("tbody")[0]||e}function De(e){return e.type=(null!==e.getAttribute("type"))+"/"+e.type,e}function qe(e){return"true/"===(e.type||"").slice(0,5)?e.type=e.type.slice(5):e.removeAttribute("type"),e}function Le(e,t){var n,r,i,o,a,s;if(1===t.nodeType){if(Y.hasData(e)&&(s=Y.get(e).events))for(i in Y.remove(t,"handle events"),s)for(n=0,r=s[i].length;n<r;n++)S.event.add(t,i,s[i][n]);Q.hasData(e)&&(o=Q.access(e),a=S.extend({},o),Q.set(t,a))}}function He(n,r,i,o){r=g(r);var e,t,a,s,u,l,c=0,f=n.length,p=f-1,d=r[0],h=m(d);if(h||1<f&&"string"==typeof d&&!y.checkClone&&Ae.test(d))return n.each(function(e){var t=n.eq(e);h&&(r[0]=d.call(this,e,t.html())),He(t,r,i,o)});if(f&&(t=(e=xe(r,n[0].ownerDocument,!1,n,o)).firstChild,1===e.childNodes.length&&(e=t),t||o)){for(s=(a=S.map(ve(e,"script"),De)).length;c<f;c++)u=e,c!==p&&(u=S.clone(u,!0,!0),s&&S.merge(a,ve(u,"script"))),i.call(n[c],u,c);if(s)for(l=a[a.length-1].ownerDocument,S.map(a,qe),c=0;c<s;c++)u=a[c],he.test(u.type||"")&&!Y.access(u,"globalEval")&&S.contains(l,u)&&(u.src&&"module"!==(u.type||"").toLowerCase()?S._evalUrl&&!u.noModule&&S._evalUrl(u.src,{nonce:u.nonce||u.getAttribute("nonce")},l):b(u.textContent.replace(Ne,""),u,l))}return n}function Oe(e,t,n){for(var r,i=t?S.filter(t,e):e,o=0;null!=(r=i[o]);o++)n||1!==r.nodeType||S.cleanData(ve(r)),r.parentNode&&(n&&ie(r)&&ye(ve(r,"script")),r.parentNode.removeChild(r));return e}S.extend({htmlPrefilter:function(e){return e},clone:function(e,t,n){var r,i,o,a,s,u,l,c=e.cloneNode(!0),f=ie(e);if(!(y.noCloneChecked||1!==e.nodeType&&11!==e.nodeType||S.isXMLDoc(e)))for(a=ve(c),r=0,i=(o=ve(e)).length;r<i;r++)s=o[r],u=a[r],void 0,"input"===(l=u.nodeName.toLowerCase())&&pe.test(s.type)?u.checked=s.checked:"input"!==l&&"textarea"!==l||(u.defaultValue=s.defaultValue);if(t)if(n)for(o=o||ve(e),a=a||ve(c),r=0,i=o.length;r<i;r++)Le(o[r],a[r]);else Le(e,c);return 0<(a=ve(c,"script")).length&&ye(a,!f&&ve(e,"script")),c},cleanData:function(e){for(var t,n,r,i=S.event.special,o=0;void 0!==(n=e[o]);o++)if(V(n)){if(t=n[Y.expando]){if(t.events)for(r in t.events)i[r]?S.event.remove(n,r):S.removeEvent(n,r,t.handle);n[Y.expando]=void 0}n[Q.expando]&&(n[Q.expando]=void 0)}}}),S.fn.extend({detach:function(e){return Oe(this,e,!0)},remove:function(e){return Oe(this,e)},text:function(e){return $(this,function(e){return void 0===e?S.text(this):this.empty().each(function(){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||(this.textContent=e)})},null,e,arguments.length)},append:function(){return He(this,arguments,function(e){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||je(this,e).appendChild(e)})},prepend:function(){return He(this,arguments,function(e){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var t=je(this,e);t.insertBefore(e,t.firstChild)}})},before:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this)})},after:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this.nextSibling)})},empty:function(){for(var e,t=0;null!=(e=this[t]);t++)1===e.nodeType&&(S.cleanData(ve(e,!1)),e.textContent="");return this},clone:function(e,t){return e=null!=e&&e,t=null==t?e:t,this.map(function(){return S.clone(this,e,t)})},html:function(e){return $(this,function(e){var t=this[0]||{},n=0,r=this.length;if(void 0===e&&1===t.nodeType)return t.innerHTML;if("string"==typeof e&&!ke.test(e)&&!ge[(de.exec(e)||["",""])[1].toLowerCase()]){e=S.htmlPrefilter(e);try{for(;n<r;n++)1===(t=this[n]||{}).nodeType&&(S.cleanData(ve(t,!1)),t.innerHTML=e);t=0}catch(e){}}t&&this.empty().append(e)},null,e,arguments.length)},replaceWith:function(){var n=[];return He(this,arguments,function(e){var t=this.parentNode;S.inArray(this,n)<0&&(S.cleanData(ve(this)),t&&t.replaceChild(e,this))},n)}}),S.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(e,a){S.fn[e]=function(e){for(var t,n=[],r=S(e),i=r.length-1,o=0;o<=i;o++)t=o===i?this:this.clone(!0),S(r[o])[a](t),u.apply(n,t.get());return this.pushStack(n)}});var Pe=new RegExp("^("+ee+")(?!px)[a-z%]+$","i"),Re=function(e){var t=e.ownerDocument.defaultView;return t&&t.opener||(t=C),t.getComputedStyle(e)},Me=function(e,t,n){var r,i,o={};for(i in t)o[i]=e.style[i],e.style[i]=t[i];for(i in r=n.call(e),t)e.style[i]=o[i];return r},Ie=new RegExp(ne.join("|"),"i");function We(e,t,n){var r,i,o,a,s=e.style;return(n=n||Re(e))&&(""!==(a=n.getPropertyValue(t)||n[t])||ie(e)||(a=S.style(e,t)),!y.pixelBoxStyles()&&Pe.test(a)&&Ie.test(t)&&(r=s.width,i=s.minWidth,o=s.maxWidth,s.minWidth=s.maxWidth=s.width=a,a=n.width,s.width=r,s.minWidth=i,s.maxWidth=o)),void 0!==a?a+"":a}function Fe(e,t){return{get:function(){if(!e())return(this.get=t).apply(this,arguments);delete this.get}}}!function(){function e(){if(l){u.style.cssText="position:absolute;left:-11111px;width:60px;margin-top:1px;padding:0;border:0",l.style.cssText="position:relative;display:block;box-sizing:border-box;overflow:scroll;margin:auto;border:1px;padding:1px;width:60%;top:1%",re.appendChild(u).appendChild(l);var e=C.getComputedStyle(l);n="1%"!==e.top,s=12===t(e.marginLeft),l.style.right="60%",o=36===t(e.right),r=36===t(e.width),l.style.position="absolute",i=12===t(l.offsetWidth/3),re.removeChild(u),l=null}}function t(e){return Math.round(parseFloat(e))}var n,r,i,o,a,s,u=E.createElement("div"),l=E.createElement("div");l.style&&(l.style.backgroundClip="content-box",l.cloneNode(!0).style.backgroundClip="",y.clearCloneStyle="content-box"===l.style.backgroundClip,S.extend(y,{boxSizingReliable:function(){return e(),r},pixelBoxStyles:function(){return e(),o},pixelPosition:function(){return e(),n},reliableMarginLeft:function(){return e(),s},scrollboxSize:function(){return e(),i},reliableTrDimensions:function(){var e,t,n,r;return null==a&&(e=E.createElement("table"),t=E.createElement("tr"),n=E.createElement("div"),e.style.cssText="position:absolute;left:-11111px;border-collapse:separate",t.style.cssText="border:1px solid",t.style.height="1px",n.style.height="9px",n.style.display="block",re.appendChild(e).appendChild(t).appendChild(n),r=C.getComputedStyle(t),a=parseInt(r.height,10)+parseInt(r.borderTopWidth,10)+parseInt(r.borderBottomWidth,10)===t.offsetHeight,re.removeChild(e)),a}}))}();var Be=["Webkit","Moz","ms"],$e=E.createElement("div").style,_e={};function ze(e){var t=S.cssProps[e]||_e[e];return t||(e in $e?e:_e[e]=function(e){var t=e[0].toUpperCase()+e.slice(1),n=Be.length;while(n--)if((e=Be[n]+t)in $e)return e}(e)||e)}var Ue=/^(none|table(?!-c[ea]).+)/,Xe=/^--/,Ve={position:"absolute",visibility:"hidden",display:"block"},Ge={letterSpacing:"0",fontWeight:"400"};function Ye(e,t,n){var r=te.exec(t);return r?Math.max(0,r[2]-(n||0))+(r[3]||"px"):t}function Qe(e,t,n,r,i,o){var a="width"===t?1:0,s=0,u=0;if(n===(r?"border":"content"))return 0;for(;a<4;a+=2)"margin"===n&&(u+=S.css(e,n+ne[a],!0,i)),r?("content"===n&&(u-=S.css(e,"padding"+ne[a],!0,i)),"margin"!==n&&(u-=S.css(e,"border"+ne[a]+"Width",!0,i))):(u+=S.css(e,"padding"+ne[a],!0,i),"padding"!==n?u+=S.css(e,"border"+ne[a]+"Width",!0,i):s+=S.css(e,"border"+ne[a]+"Width",!0,i));return!r&&0<=o&&(u+=Math.max(0,Math.ceil(e["offset"+t[0].toUpperCase()+t.slice(1)]-o-u-s-.5))||0),u}function Je(e,t,n){var r=Re(e),i=(!y.boxSizingReliable()||n)&&"border-box"===S.css(e,"boxSizing",!1,r),o=i,a=We(e,t,r),s="offset"+t[0].toUpperCase()+t.slice(1);if(Pe.test(a)){if(!n)return a;a="auto"}return(!y.boxSizingReliable()&&i||!y.reliableTrDimensions()&&A(e,"tr")||"auto"===a||!parseFloat(a)&&"inline"===S.css(e,"display",!1,r))&&e.getClientRects().length&&(i="border-box"===S.css(e,"boxSizing",!1,r),(o=s in e)&&(a=e[s])),(a=parseFloat(a)||0)+Qe(e,t,n||(i?"border":"content"),o,r,a)+"px"}function Ke(e,t,n,r,i){return new Ke.prototype.init(e,t,n,r,i)}S.extend({cssHooks:{opacity:{get:function(e,t){if(t){var n=We(e,"opacity");return""===n?"1":n}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,gridArea:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnStart:!0,gridRow:!0,gridRowEnd:!0,gridRowStart:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{},style:function(e,t,n,r){if(e&&3!==e.nodeType&&8!==e.nodeType&&e.style){var i,o,a,s=X(t),u=Xe.test(t),l=e.style;if(u||(t=ze(s)),a=S.cssHooks[t]||S.cssHooks[s],void 0===n)return a&&"get"in a&&void 0!==(i=a.get(e,!1,r))?i:l[t];"string"===(o=typeof n)&&(i=te.exec(n))&&i[1]&&(n=se(e,t,i),o="number"),null!=n&&n==n&&("number"!==o||u||(n+=i&&i[3]||(S.cssNumber[s]?"":"px")),y.clearCloneStyle||""!==n||0!==t.indexOf("background")||(l[t]="inherit"),a&&"set"in a&&void 0===(n=a.set(e,n,r))||(u?l.setProperty(t,n):l[t]=n))}},css:function(e,t,n,r){var i,o,a,s=X(t);return Xe.test(t)||(t=ze(s)),(a=S.cssHooks[t]||S.cssHooks[s])&&"get"in a&&(i=a.get(e,!0,n)),void 0===i&&(i=We(e,t,r)),"normal"===i&&t in Ge&&(i=Ge[t]),""===n||n?(o=parseFloat(i),!0===n||isFinite(o)?o||0:i):i}}),S.each(["height","width"],function(e,u){S.cssHooks[u]={get:function(e,t,n){if(t)return!Ue.test(S.css(e,"display"))||e.getClientRects().length&&e.getBoundingClientRect().width?Je(e,u,n):Me(e,Ve,function(){return Je(e,u,n)})},set:function(e,t,n){var r,i=Re(e),o=!y.scrollboxSize()&&"absolute"===i.position,a=(o||n)&&"border-box"===S.css(e,"boxSizing",!1,i),s=n?Qe(e,u,n,a,i):0;return a&&o&&(s-=Math.ceil(e["offset"+u[0].toUpperCase()+u.slice(1)]-parseFloat(i[u])-Qe(e,u,"border",!1,i)-.5)),s&&(r=te.exec(t))&&"px"!==(r[3]||"px")&&(e.style[u]=t,t=S.css(e,u)),Ye(0,t,s)}}}),S.cssHooks.marginLeft=Fe(y.reliableMarginLeft,function(e,t){if(t)return(parseFloat(We(e,"marginLeft"))||e.getBoundingClientRect().left-Me(e,{marginLeft:0},function(){return e.getBoundingClientRect().left}))+"px"}),S.each({margin:"",padding:"",border:"Width"},function(i,o){S.cssHooks[i+o]={expand:function(e){for(var t=0,n={},r="string"==typeof e?e.split(" "):[e];t<4;t++)n[i+ne[t]+o]=r[t]||r[t-2]||r[0];return n}},"margin"!==i&&(S.cssHooks[i+o].set=Ye)}),S.fn.extend({css:function(e,t){return $(this,function(e,t,n){var r,i,o={},a=0;if(Array.isArray(t)){for(r=Re(e),i=t.length;a<i;a++)o[t[a]]=S.css(e,t[a],!1,r);return o}return void 0!==n?S.style(e,t,n):S.css(e,t)},e,t,1<arguments.length)}}),((S.Tween=Ke).prototype={constructor:Ke,init:function(e,t,n,r,i,o){this.elem=e,this.prop=n,this.easing=i||S.easing._default,this.options=t,this.start=this.now=this.cur(),this.end=r,this.unit=o||(S.cssNumber[n]?"":"px")},cur:function(){var e=Ke.propHooks[this.prop];return e&&e.get?e.get(this):Ke.propHooks._default.get(this)},run:function(e){var t,n=Ke.propHooks[this.prop];return this.options.duration?this.pos=t=S.easing[this.easing](e,this.options.duration*e,0,1,this.options.duration):this.pos=t=e,this.now=(this.end-this.start)*t+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),n&&n.set?n.set(this):Ke.propHooks._default.set(this),this}}).init.prototype=Ke.prototype,(Ke.propHooks={_default:{get:function(e){var t;return 1!==e.elem.nodeType||null!=e.elem[e.prop]&&null==e.elem.style[e.prop]?e.elem[e.prop]:(t=S.css(e.elem,e.prop,""))&&"auto"!==t?t:0},set:function(e){S.fx.step[e.prop]?S.fx.step[e.prop](e):1!==e.elem.nodeType||!S.cssHooks[e.prop]&&null==e.elem.style[ze(e.prop)]?e.elem[e.prop]=e.now:S.style(e.elem,e.prop,e.now+e.unit)}}}).scrollTop=Ke.propHooks.scrollLeft={set:function(e){e.elem.nodeType&&e.elem.parentNode&&(e.elem[e.prop]=e.now)}},S.easing={linear:function(e){return e},swing:function(e){return.5-Math.cos(e*Math.PI)/2},_default:"swing"},S.fx=Ke.prototype.init,S.fx.step={};var Ze,et,tt,nt,rt=/^(?:toggle|show|hide)$/,it=/queueHooks$/;function ot(){et&&(!1===E.hidden&&C.requestAnimationFrame?C.requestAnimationFrame(ot):C.setTimeout(ot,S.fx.interval),S.fx.tick())}function at(){return C.setTimeout(function(){Ze=void 0}),Ze=Date.now()}function st(e,t){var n,r=0,i={height:e};for(t=t?1:0;r<4;r+=2-t)i["margin"+(n=ne[r])]=i["padding"+n]=e;return t&&(i.opacity=i.width=e),i}function ut(e,t,n){for(var r,i=(lt.tweeners[t]||[]).concat(lt.tweeners["*"]),o=0,a=i.length;o<a;o++)if(r=i[o].call(n,t,e))return r}function lt(o,e,t){var n,a,r=0,i=lt.prefilters.length,s=S.Deferred().always(function(){delete u.elem}),u=function(){if(a)return!1;for(var e=Ze||at(),t=Math.max(0,l.startTime+l.duration-e),n=1-(t/l.duration||0),r=0,i=l.tweens.length;r<i;r++)l.tweens[r].run(n);return s.notifyWith(o,[l,n,t]),n<1&&i?t:(i||s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l]),!1)},l=s.promise({elem:o,props:S.extend({},e),opts:S.extend(!0,{specialEasing:{},easing:S.easing._default},t),originalProperties:e,originalOptions:t,startTime:Ze||at(),duration:t.duration,tweens:[],createTween:function(e,t){var n=S.Tween(o,l.opts,e,t,l.opts.specialEasing[e]||l.opts.easing);return l.tweens.push(n),n},stop:function(e){var t=0,n=e?l.tweens.length:0;if(a)return this;for(a=!0;t<n;t++)l.tweens[t].run(1);return e?(s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l,e])):s.rejectWith(o,[l,e]),this}}),c=l.props;for(!function(e,t){var n,r,i,o,a;for(n in e)if(i=t[r=X(n)],o=e[n],Array.isArray(o)&&(i=o[1],o=e[n]=o[0]),n!==r&&(e[r]=o,delete e[n]),(a=S.cssHooks[r])&&"expand"in a)for(n in o=a.expand(o),delete e[r],o)n in e||(e[n]=o[n],t[n]=i);else t[r]=i}(c,l.opts.specialEasing);r<i;r++)if(n=lt.prefilters[r].call(l,o,c,l.opts))return m(n.stop)&&(S._queueHooks(l.elem,l.opts.queue).stop=n.stop.bind(n)),n;return S.map(c,ut,l),m(l.opts.start)&&l.opts.start.call(o,l),l.progress(l.opts.progress).done(l.opts.done,l.opts.complete).fail(l.opts.fail).always(l.opts.always),S.fx.timer(S.extend(u,{elem:o,anim:l,queue:l.opts.queue})),l}S.Animation=S.extend(lt,{tweeners:{"*":[function(e,t){var n=this.createTween(e,t);return se(n.elem,e,te.exec(t),n),n}]},tweener:function(e,t){m(e)?(t=e,e=["*"]):e=e.match(P);for(var n,r=0,i=e.length;r<i;r++)n=e[r],lt.tweeners[n]=lt.tweeners[n]||[],lt.tweeners[n].unshift(t)},prefilters:[function(e,t,n){var r,i,o,a,s,u,l,c,f="width"in t||"height"in t,p=this,d={},h=e.style,g=e.nodeType&&ae(e),v=Y.get(e,"fxshow");for(r in n.queue||(null==(a=S._queueHooks(e,"fx")).unqueued&&(a.unqueued=0,s=a.empty.fire,a.empty.fire=function(){a.unqueued||s()}),a.unqueued++,p.always(function(){p.always(function(){a.unqueued--,S.queue(e,"fx").length||a.empty.fire()})})),t)if(i=t[r],rt.test(i)){if(delete t[r],o=o||"toggle"===i,i===(g?"hide":"show")){if("show"!==i||!v||void 0===v[r])continue;g=!0}d[r]=v&&v[r]||S.style(e,r)}if((u=!S.isEmptyObject(t))||!S.isEmptyObject(d))for(r in f&&1===e.nodeType&&(n.overflow=[h.overflow,h.overflowX,h.overflowY],null==(l=v&&v.display)&&(l=Y.get(e,"display")),"none"===(c=S.css(e,"display"))&&(l?c=l:(le([e],!0),l=e.style.display||l,c=S.css(e,"display"),le([e]))),("inline"===c||"inline-block"===c&&null!=l)&&"none"===S.css(e,"float")&&(u||(p.done(function(){h.display=l}),null==l&&(c=h.display,l="none"===c?"":c)),h.display="inline-block")),n.overflow&&(h.overflow="hidden",p.always(function(){h.overflow=n.overflow[0],h.overflowX=n.overflow[1],h.overflowY=n.overflow[2]})),u=!1,d)u||(v?"hidden"in v&&(g=v.hidden):v=Y.access(e,"fxshow",{display:l}),o&&(v.hidden=!g),g&&le([e],!0),p.done(function(){for(r in g||le([e]),Y.remove(e,"fxshow"),d)S.style(e,r,d[r])})),u=ut(g?v[r]:0,r,p),r in v||(v[r]=u.start,g&&(u.end=u.start,u.start=0))}],prefilter:function(e,t){t?lt.prefilters.unshift(e):lt.prefilters.push(e)}}),S.speed=function(e,t,n){var r=e&&"object"==typeof e?S.extend({},e):{complete:n||!n&&t||m(e)&&e,duration:e,easing:n&&t||t&&!m(t)&&t};return S.fx.off?r.duration=0:"number"!=typeof r.duration&&(r.duration in S.fx.speeds?r.duration=S.fx.speeds[r.duration]:r.duration=S.fx.speeds._default),null!=r.queue&&!0!==r.queue||(r.queue="fx"),r.old=r.complete,r.complete=function(){m(r.old)&&r.old.call(this),r.queue&&S.dequeue(this,r.queue)},r},S.fn.extend({fadeTo:function(e,t,n,r){return this.filter(ae).css("opacity",0).show().end().animate({opacity:t},e,n,r)},animate:function(t,e,n,r){var i=S.isEmptyObject(t),o=S.speed(e,n,r),a=function(){var e=lt(this,S.extend({},t),o);(i||Y.get(this,"finish"))&&e.stop(!0)};return a.finish=a,i||!1===o.queue?this.each(a):this.queue(o.queue,a)},stop:function(i,e,o){var a=function(e){var t=e.stop;delete e.stop,t(o)};return"string"!=typeof i&&(o=e,e=i,i=void 0),e&&this.queue(i||"fx",[]),this.each(function(){var e=!0,t=null!=i&&i+"queueHooks",n=S.timers,r=Y.get(this);if(t)r[t]&&r[t].stop&&a(r[t]);else for(t in r)r[t]&&r[t].stop&&it.test(t)&&a(r[t]);for(t=n.length;t--;)n[t].elem!==this||null!=i&&n[t].queue!==i||(n[t].anim.stop(o),e=!1,n.splice(t,1));!e&&o||S.dequeue(this,i)})},finish:function(a){return!1!==a&&(a=a||"fx"),this.each(function(){var e,t=Y.get(this),n=t[a+"queue"],r=t[a+"queueHooks"],i=S.timers,o=n?n.length:0;for(t.finish=!0,S.queue(this,a,[]),r&&r.stop&&r.stop.call(this,!0),e=i.length;e--;)i[e].elem===this&&i[e].queue===a&&(i[e].anim.stop(!0),i.splice(e,1));for(e=0;e<o;e++)n[e]&&n[e].finish&&n[e].finish.call(this);delete t.finish})}}),S.each(["toggle","show","hide"],function(e,r){var i=S.fn[r];S.fn[r]=function(e,t,n){return null==e||"boolean"==typeof e?i.apply(this,arguments):this.animate(st(r,!0),e,t,n)}}),S.each({slideDown:st("show"),slideUp:st("hide"),slideToggle:st("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(e,r){S.fn[e]=function(e,t,n){return this.animate(r,e,t,n)}}),S.timers=[],S.fx.tick=function(){var e,t=0,n=S.timers;for(Ze=Date.now();t<n.length;t++)(e=n[t])()||n[t]!==e||n.splice(t--,1);n.length||S.fx.stop(),Ze=void 0},S.fx.timer=function(e){S.timers.push(e),S.fx.start()},S.fx.interval=13,S.fx.start=function(){et||(et=!0,ot())},S.fx.stop=function(){et=null},S.fx.speeds={slow:600,fast:200,_default:400},S.fn.delay=function(r,e){return r=S.fx&&S.fx.speeds[r]||r,e=e||"fx",this.queue(e,function(e,t){var n=C.setTimeout(e,r);t.stop=function(){C.clearTimeout(n)}})},tt=E.createElement("input"),nt=E.createElement("select").appendChild(E.createElement("option")),tt.type="checkbox",y.checkOn=""!==tt.value,y.optSelected=nt.selected,(tt=E.createElement("input")).value="t",tt.type="radio",y.radioValue="t"===tt.value;var ct,ft=S.expr.attrHandle;S.fn.extend({attr:function(e,t){return $(this,S.attr,e,t,1<arguments.length)},removeAttr:function(e){return this.each(function(){S.removeAttr(this,e)})}}),S.extend({attr:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return"undefined"==typeof e.getAttribute?S.prop(e,t,n):(1===o&&S.isXMLDoc(e)||(i=S.attrHooks[t.toLowerCase()]||(S.expr.match.bool.test(t)?ct:void 0)),void 0!==n?null===n?void S.removeAttr(e,t):i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:(e.setAttribute(t,n+""),n):i&&"get"in i&&null!==(r=i.get(e,t))?r:null==(r=S.find.attr(e,t))?void 0:r)},attrHooks:{type:{set:function(e,t){if(!y.radioValue&&"radio"===t&&A(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}}},removeAttr:function(e,t){var n,r=0,i=t&&t.match(P);if(i&&1===e.nodeType)while(n=i[r++])e.removeAttribute(n)}}),ct={set:function(e,t,n){return!1===t?S.removeAttr(e,n):e.setAttribute(n,n),n}},S.each(S.expr.match.bool.source.match(/\w+/g),function(e,t){var a=ft[t]||S.find.attr;ft[t]=function(e,t,n){var r,i,o=t.toLowerCase();return n||(i=ft[o],ft[o]=r,r=null!=a(e,t,n)?o:null,ft[o]=i),r}});var pt=/^(?:input|select|textarea|button)$/i,dt=/^(?:a|area)$/i;function ht(e){return(e.match(P)||[]).join(" ")}function gt(e){return e.getAttribute&&e.getAttribute("class")||""}function vt(e){return Array.isArray(e)?e:"string"==typeof e&&e.match(P)||[]}S.fn.extend({prop:function(e,t){return $(this,S.prop,e,t,1<arguments.length)},removeProp:function(e){return this.each(function(){delete this[S.propFix[e]||e]})}}),S.extend({prop:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return 1===o&&S.isXMLDoc(e)||(t=S.propFix[t]||t,i=S.propHooks[t]),void 0!==n?i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:e[t]=n:i&&"get"in i&&null!==(r=i.get(e,t))?r:e[t]},propHooks:{tabIndex:{get:function(e){var t=S.find.attr(e,"tabindex");return t?parseInt(t,10):pt.test(e.nodeName)||dt.test(e.nodeName)&&e.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),y.optSelected||(S.propHooks.selected={get:function(e){var t=e.parentNode;return t&&t.parentNode&&t.parentNode.selectedIndex,null},set:function(e){var t=e.parentNode;t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex)}}),S.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){S.propFix[this.toLowerCase()]=this}),S.fn.extend({addClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).addClass(t.call(this,e,gt(this)))});if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])r.indexOf(" "+o+" ")<0&&(r+=o+" ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},removeClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).removeClass(t.call(this,e,gt(this)))});if(!arguments.length)return this.attr("class","");if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])while(-1<r.indexOf(" "+o+" "))r=r.replace(" "+o+" "," ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},toggleClass:function(i,t){var o=typeof i,a="string"===o||Array.isArray(i);return"boolean"==typeof t&&a?t?this.addClass(i):this.removeClass(i):m(i)?this.each(function(e){S(this).toggleClass(i.call(this,e,gt(this),t),t)}):this.each(function(){var e,t,n,r;if(a){t=0,n=S(this),r=vt(i);while(e=r[t++])n.hasClass(e)?n.removeClass(e):n.addClass(e)}else void 0!==i&&"boolean"!==o||((e=gt(this))&&Y.set(this,"__className__",e),this.setAttribute&&this.setAttribute("class",e||!1===i?"":Y.get(this,"__className__")||""))})},hasClass:function(e){var t,n,r=0;t=" "+e+" ";while(n=this[r++])if(1===n.nodeType&&-1<(" "+ht(gt(n))+" ").indexOf(t))return!0;return!1}});var yt=/\r/g;S.fn.extend({val:function(n){var r,e,i,t=this[0];return arguments.length?(i=m(n),this.each(function(e){var t;1===this.nodeType&&(null==(t=i?n.call(this,e,S(this).val()):n)?t="":"number"==typeof t?t+="":Array.isArray(t)&&(t=S.map(t,function(e){return null==e?"":e+""})),(r=S.valHooks[this.type]||S.valHooks[this.nodeName.toLowerCase()])&&"set"in r&&void 0!==r.set(this,t,"value")||(this.value=t))})):t?(r=S.valHooks[t.type]||S.valHooks[t.nodeName.toLowerCase()])&&"get"in r&&void 0!==(e=r.get(t,"value"))?e:"string"==typeof(e=t.value)?e.replace(yt,""):null==e?"":e:void 0}}),S.extend({valHooks:{option:{get:function(e){var t=S.find.attr(e,"value");return null!=t?t:ht(S.text(e))}},select:{get:function(e){var t,n,r,i=e.options,o=e.selectedIndex,a="select-one"===e.type,s=a?null:[],u=a?o+1:i.length;for(r=o<0?u:a?o:0;r<u;r++)if(((n=i[r]).selected||r===o)&&!n.disabled&&(!n.parentNode.disabled||!A(n.parentNode,"optgroup"))){if(t=S(n).val(),a)return t;s.push(t)}return s},set:function(e,t){var n,r,i=e.options,o=S.makeArray(t),a=i.length;while(a--)((r=i[a]).selected=-1<S.inArray(S.valHooks.option.get(r),o))&&(n=!0);return n||(e.selectedIndex=-1),o}}}}),S.each(["radio","checkbox"],function(){S.valHooks[this]={set:function(e,t){if(Array.isArray(t))return e.checked=-1<S.inArray(S(e).val(),t)}},y.checkOn||(S.valHooks[this].get=function(e){return null===e.getAttribute("value")?"on":e.value})}),y.focusin="onfocusin"in C;var mt=/^(?:focusinfocus|focusoutblur)$/,xt=function(e){e.stopPropagation()};S.extend(S.event,{trigger:function(e,t,n,r){var i,o,a,s,u,l,c,f,p=[n||E],d=v.call(e,"type")?e.type:e,h=v.call(e,"namespace")?e.namespace.split("."):[];if(o=f=a=n=n||E,3!==n.nodeType&&8!==n.nodeType&&!mt.test(d+S.event.triggered)&&(-1<d.indexOf(".")&&(d=(h=d.split(".")).shift(),h.sort()),u=d.indexOf(":")<0&&"on"+d,(e=e[S.expando]?e:new S.Event(d,"object"==typeof e&&e)).isTrigger=r?2:3,e.namespace=h.join("."),e.rnamespace=e.namespace?new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,e.result=void 0,e.target||(e.target=n),t=null==t?[e]:S.makeArray(t,[e]),c=S.event.special[d]||{},r||!c.trigger||!1!==c.trigger.apply(n,t))){if(!r&&!c.noBubble&&!x(n)){for(s=c.delegateType||d,mt.test(s+d)||(o=o.parentNode);o;o=o.parentNode)p.push(o),a=o;a===(n.ownerDocument||E)&&p.push(a.defaultView||a.parentWindow||C)}i=0;while((o=p[i++])&&!e.isPropagationStopped())f=o,e.type=1<i?s:c.bindType||d,(l=(Y.get(o,"events")||Object.create(null))[e.type]&&Y.get(o,"handle"))&&l.apply(o,t),(l=u&&o[u])&&l.apply&&V(o)&&(e.result=l.apply(o,t),!1===e.result&&e.preventDefault());return e.type=d,r||e.isDefaultPrevented()||c._default&&!1!==c._default.apply(p.pop(),t)||!V(n)||u&&m(n[d])&&!x(n)&&((a=n[u])&&(n[u]=null),S.event.triggered=d,e.isPropagationStopped()&&f.addEventListener(d,xt),n[d](),e.isPropagationStopped()&&f.removeEventListener(d,xt),S.event.triggered=void 0,a&&(n[u]=a)),e.result}},simulate:function(e,t,n){var r=S.extend(new S.Event,n,{type:e,isSimulated:!0});S.event.trigger(r,null,t)}}),S.fn.extend({trigger:function(e,t){return this.each(function(){S.event.trigger(e,t,this)})},triggerHandler:function(e,t){var n=this[0];if(n)return S.event.trigger(e,t,n,!0)}}),y.focusin||S.each({focus:"focusin",blur:"focusout"},function(n,r){var i=function(e){S.event.simulate(r,e.target,S.event.fix(e))};S.event.special[r]={setup:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r);t||e.addEventListener(n,i,!0),Y.access(e,r,(t||0)+1)},teardown:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r)-1;t?Y.access(e,r,t):(e.removeEventListener(n,i,!0),Y.remove(e,r))}}});var bt=C.location,wt={guid:Date.now()},Tt=/\?/;S.parseXML=function(e){var t,n;if(!e||"string"!=typeof e)return null;try{t=(new C.DOMParser).parseFromString(e,"text/xml")}catch(e){}return n=t&&t.getElementsByTagName("parsererror")[0],t&&!n||S.error("Invalid XML: "+(n?S.map(n.childNodes,function(e){return e.textContent}).join("\n"):e)),t};var Ct=/\[\]$/,Et=/\r?\n/g,St=/^(?:submit|button|image|reset|file)$/i,kt=/^(?:input|select|textarea|keygen)/i;function At(n,e,r,i){var t;if(Array.isArray(e))S.each(e,function(e,t){r||Ct.test(n)?i(n,t):At(n+"["+("object"==typeof t&&null!=t?e:"")+"]",t,r,i)});else if(r||"object"!==w(e))i(n,e);else for(t in e)At(n+"["+t+"]",e[t],r,i)}S.param=function(e,t){var n,r=[],i=function(e,t){var n=m(t)?t():t;r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(null==n?"":n)};if(null==e)return"";if(Array.isArray(e)||e.jquery&&!S.isPlainObject(e))S.each(e,function(){i(this.name,this.value)});else for(n in e)At(n,e[n],t,i);return r.join("&")},S.fn.extend({serialize:function(){return S.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var e=S.prop(this,"elements");return e?S.makeArray(e):this}).filter(function(){var e=this.type;return this.name&&!S(this).is(":disabled")&&kt.test(this.nodeName)&&!St.test(e)&&(this.checked||!pe.test(e))}).map(function(e,t){var n=S(this).val();return null==n?null:Array.isArray(n)?S.map(n,function(e){return{name:t.name,value:e.replace(Et,"\r\n")}}):{name:t.name,value:n.replace(Et,"\r\n")}}).get()}});var Nt=/%20/g,jt=/#.*$/,Dt=/([?&])_=[^&]*/,qt=/^(.*?):[ \t]*([^\r\n]*)$/gm,Lt=/^(?:GET|HEAD)$/,Ht=/^\/\//,Ot={},Pt={},Rt="*/".concat("*"),Mt=E.createElement("a");function It(o){return function(e,t){"string"!=typeof e&&(t=e,e="*");var n,r=0,i=e.toLowerCase().match(P)||[];if(m(t))while(n=i[r++])"+"===n[0]?(n=n.slice(1)||"*",(o[n]=o[n]||[]).unshift(t)):(o[n]=o[n]||[]).push(t)}}function Wt(t,i,o,a){var s={},u=t===Pt;function l(e){var r;return s[e]=!0,S.each(t[e]||[],function(e,t){var n=t(i,o,a);return"string"!=typeof n||u||s[n]?u?!(r=n):void 0:(i.dataTypes.unshift(n),l(n),!1)}),r}return l(i.dataTypes[0])||!s["*"]&&l("*")}function Ft(e,t){var n,r,i=S.ajaxSettings.flatOptions||{};for(n in t)void 0!==t[n]&&((i[n]?e:r||(r={}))[n]=t[n]);return r&&S.extend(!0,e,r),e}Mt.href=bt.href,S.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:bt.href,type:"GET",isLocal:/^(?:about|app|app-storage|.+-extension|file|res|widget):$/.test(bt.protocol),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Rt,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":JSON.parse,"text xml":S.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(e,t){return t?Ft(Ft(e,S.ajaxSettings),t):Ft(S.ajaxSettings,e)},ajaxPrefilter:It(Ot),ajaxTransport:It(Pt),ajax:function(e,t){"object"==typeof e&&(t=e,e=void 0),t=t||{};var c,f,p,n,d,r,h,g,i,o,v=S.ajaxSetup({},t),y=v.context||v,m=v.context&&(y.nodeType||y.jquery)?S(y):S.event,x=S.Deferred(),b=S.Callbacks("once memory"),w=v.statusCode||{},a={},s={},u="canceled",T={readyState:0,getResponseHeader:function(e){var t;if(h){if(!n){n={};while(t=qt.exec(p))n[t[1].toLowerCase()+" "]=(n[t[1].toLowerCase()+" "]||[]).concat(t[2])}t=n[e.toLowerCase()+" "]}return null==t?null:t.join(", ")},getAllResponseHeaders:function(){return h?p:null},setRequestHeader:function(e,t){return null==h&&(e=s[e.toLowerCase()]=s[e.toLowerCase()]||e,a[e]=t),this},overrideMimeType:function(e){return null==h&&(v.mimeType=e),this},statusCode:function(e){var t;if(e)if(h)T.always(e[T.status]);else for(t in e)w[t]=[w[t],e[t]];return this},abort:function(e){var t=e||u;return c&&c.abort(t),l(0,t),this}};if(x.promise(T),v.url=((e||v.url||bt.href)+"").replace(Ht,bt.protocol+"//"),v.type=t.method||t.type||v.method||v.type,v.dataTypes=(v.dataType||"*").toLowerCase().match(P)||[""],null==v.crossDomain){r=E.createElement("a");try{r.href=v.url,r.href=r.href,v.crossDomain=Mt.protocol+"//"+Mt.host!=r.protocol+"//"+r.host}catch(e){v.crossDomain=!0}}if(v.data&&v.processData&&"string"!=typeof v.data&&(v.data=S.param(v.data,v.traditional)),Wt(Ot,v,t,T),h)return T;for(i in(g=S.event&&v.global)&&0==S.active++&&S.event.trigger("ajaxStart"),v.type=v.type.toUpperCase(),v.hasContent=!Lt.test(v.type),f=v.url.replace(jt,""),v.hasContent?v.data&&v.processData&&0===(v.contentType||"").indexOf("application/x-www-form-urlencoded")&&(v.data=v.data.replace(Nt,"+")):(o=v.url.slice(f.length),v.data&&(v.processData||"string"==typeof v.data)&&(f+=(Tt.test(f)?"&":"?")+v.data,delete v.data),!1===v.cache&&(f=f.replace(Dt,"$1"),o=(Tt.test(f)?"&":"?")+"_="+wt.guid+++o),v.url=f+o),v.ifModified&&(S.lastModified[f]&&T.setRequestHeader("If-Modified-Since",S.lastModified[f]),S.etag[f]&&T.setRequestHeader("If-None-Match",S.etag[f])),(v.data&&v.hasContent&&!1!==v.contentType||t.contentType)&&T.setRequestHeader("Content-Type",v.contentType),T.setRequestHeader("Accept",v.dataTypes[0]&&v.accepts[v.dataTypes[0]]?v.accepts[v.dataTypes[0]]+("*"!==v.dataTypes[0]?", "+Rt+"; q=0.01":""):v.accepts["*"]),v.headers)T.setRequestHeader(i,v.headers[i]);if(v.beforeSend&&(!1===v.beforeSend.call(y,T,v)||h))return T.abort();if(u="abort",b.add(v.complete),T.done(v.success),T.fail(v.error),c=Wt(Pt,v,t,T)){if(T.readyState=1,g&&m.trigger("ajaxSend",[T,v]),h)return T;v.async&&0<v.timeout&&(d=C.setTimeout(function(){T.abort("timeout")},v.timeout));try{h=!1,c.send(a,l)}catch(e){if(h)throw e;l(-1,e)}}else l(-1,"No Transport");function l(e,t,n,r){var i,o,a,s,u,l=t;h||(h=!0,d&&C.clearTimeout(d),c=void 0,p=r||"",T.readyState=0<e?4:0,i=200<=e&&e<300||304===e,n&&(s=function(e,t,n){var r,i,o,a,s=e.contents,u=e.dataTypes;while("*"===u[0])u.shift(),void 0===r&&(r=e.mimeType||t.getResponseHeader("Content-Type"));if(r)for(i in s)if(s[i]&&s[i].test(r)){u.unshift(i);break}if(u[0]in n)o=u[0];else{for(i in n){if(!u[0]||e.converters[i+" "+u[0]]){o=i;break}a||(a=i)}o=o||a}if(o)return o!==u[0]&&u.unshift(o),n[o]}(v,T,n)),!i&&-1<S.inArray("script",v.dataTypes)&&S.inArray("json",v.dataTypes)<0&&(v.converters["text script"]=function(){}),s=function(e,t,n,r){var i,o,a,s,u,l={},c=e.dataTypes.slice();if(c[1])for(a in e.converters)l[a.toLowerCase()]=e.converters[a];o=c.shift();while(o)if(e.responseFields[o]&&(n[e.responseFields[o]]=t),!u&&r&&e.dataFilter&&(t=e.dataFilter(t,e.dataType)),u=o,o=c.shift())if("*"===o)o=u;else if("*"!==u&&u!==o){if(!(a=l[u+" "+o]||l["* "+o]))for(i in l)if((s=i.split(" "))[1]===o&&(a=l[u+" "+s[0]]||l["* "+s[0]])){!0===a?a=l[i]:!0!==l[i]&&(o=s[0],c.unshift(s[1]));break}if(!0!==a)if(a&&e["throws"])t=a(t);else try{t=a(t)}catch(e){return{state:"parsererror",error:a?e:"No conversion from "+u+" to "+o}}}return{state:"success",data:t}}(v,s,T,i),i?(v.ifModified&&((u=T.getResponseHeader("Last-Modified"))&&(S.lastModified[f]=u),(u=T.getResponseHeader("etag"))&&(S.etag[f]=u)),204===e||"HEAD"===v.type?l="nocontent":304===e?l="notmodified":(l=s.state,o=s.data,i=!(a=s.error))):(a=l,!e&&l||(l="error",e<0&&(e=0))),T.status=e,T.statusText=(t||l)+"",i?x.resolveWith(y,[o,l,T]):x.rejectWith(y,[T,l,a]),T.statusCode(w),w=void 0,g&&m.trigger(i?"ajaxSuccess":"ajaxError",[T,v,i?o:a]),b.fireWith(y,[T,l]),g&&(m.trigger("ajaxComplete",[T,v]),--S.active||S.event.trigger("ajaxStop")))}return T},getJSON:function(e,t,n){return S.get(e,t,n,"json")},getScript:function(e,t){return S.get(e,void 0,t,"script")}}),S.each(["get","post"],function(e,i){S[i]=function(e,t,n,r){return m(t)&&(r=r||n,n=t,t=void 0),S.ajax(S.extend({url:e,type:i,dataType:r,data:t,success:n},S.isPlainObject(e)&&e))}}),S.ajaxPrefilter(function(e){var t;for(t in e.headers)"content-type"===t.toLowerCase()&&(e.contentType=e.headers[t]||"")}),S._evalUrl=function(e,t,n){return S.ajax({url:e,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,converters:{"text script":function(){}},dataFilter:function(e){S.globalEval(e,t,n)}})},S.fn.extend({wrapAll:function(e){var t;return this[0]&&(m(e)&&(e=e.call(this[0])),t=S(e,this[0].ownerDocument).eq(0).clone(!0),this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstElementChild)e=e.firstElementChild;return e}).append(this)),this},wrapInner:function(n){return m(n)?this.each(function(e){S(this).wrapInner(n.call(this,e))}):this.each(function(){var e=S(this),t=e.contents();t.length?t.wrapAll(n):e.append(n)})},wrap:function(t){var n=m(t);return this.each(function(e){S(this).wrapAll(n?t.call(this,e):t)})},unwrap:function(e){return this.parent(e).not("body").each(function(){S(this).replaceWith(this.childNodes)}),this}}),S.expr.pseudos.hidden=function(e){return!S.expr.pseudos.visible(e)},S.expr.pseudos.visible=function(e){return!!(e.offsetWidth||e.offsetHeight||e.getClientRects().length)},S.ajaxSettings.xhr=function(){try{return new C.XMLHttpRequest}catch(e){}};var Bt={0:200,1223:204},$t=S.ajaxSettings.xhr();y.cors=!!$t&&"withCredentials"in $t,y.ajax=$t=!!$t,S.ajaxTransport(function(i){var o,a;if(y.cors||$t&&!i.crossDomain)return{send:function(e,t){var n,r=i.xhr();if(r.open(i.type,i.url,i.async,i.username,i.password),i.xhrFields)for(n in i.xhrFields)r[n]=i.xhrFields[n];for(n in i.mimeType&&r.overrideMimeType&&r.overrideMimeType(i.mimeType),i.crossDomain||e["X-Requested-With"]||(e["X-Requested-With"]="XMLHttpRequest"),e)r.setRequestHeader(n,e[n]);o=function(e){return function(){o&&(o=a=r.onload=r.onerror=r.onabort=r.ontimeout=r.onreadystatechange=null,"abort"===e?r.abort():"error"===e?"number"!=typeof r.status?t(0,"error"):t(r.status,r.statusText):t(Bt[r.status]||r.status,r.statusText,"text"!==(r.responseType||"text")||"string"!=typeof r.responseText?{binary:r.response}:{text:r.responseText},r.getAllResponseHeaders()))}},r.onload=o(),a=r.onerror=r.ontimeout=o("error"),void 0!==r.onabort?r.onabort=a:r.onreadystatechange=function(){4===r.readyState&&C.setTimeout(function(){o&&a()})},o=o("abort");try{r.send(i.hasContent&&i.data||null)}catch(e){if(o)throw e}},abort:function(){o&&o()}}}),S.ajaxPrefilter(function(e){e.crossDomain&&(e.contents.script=!1)}),S.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(e){return S.globalEval(e),e}}}),S.ajaxPrefilter("script",function(e){void 0===e.cache&&(e.cache=!1),e.crossDomain&&(e.type="GET")}),S.ajaxTransport("script",function(n){var r,i;if(n.crossDomain||n.scriptAttrs)return{send:function(e,t){r=S("<script>").attr(n.scriptAttrs||{}).prop({charset:n.scriptCharset,src:n.url}).on("load error",i=function(e){r.remove(),i=null,e&&t("error"===e.type?404:200,e.type)}),E.head.appendChild(r[0])},abort:function(){i&&i()}}});var _t,zt=[],Ut=/(=)\?(?=&|$)|\?\?/;S.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var e=zt.pop()||S.expando+"_"+wt.guid++;return this[e]=!0,e}}),S.ajaxPrefilter("json jsonp",function(e,t,n){var r,i,o,a=!1!==e.jsonp&&(Ut.test(e.url)?"url":"string"==typeof e.data&&0===(e.contentType||"").indexOf("application/x-www-form-urlencoded")&&Ut.test(e.data)&&"data");if(a||"jsonp"===e.dataTypes[0])return r=e.jsonpCallback=m(e.jsonpCallback)?e.jsonpCallback():e.jsonpCallback,a?e[a]=e[a].replace(Ut,"$1"+r):!1!==e.jsonp&&(e.url+=(Tt.test(e.url)?"&":"?")+e.jsonp+"="+r),e.converters["script json"]=function(){return o||S.error(r+" was not called"),o[0]},e.dataTypes[0]="json",i=C[r],C[r]=function(){o=arguments},n.always(function(){void 0===i?S(C).removeProp(r):C[r]=i,e[r]&&(e.jsonpCallback=t.jsonpCallback,zt.push(r)),o&&m(i)&&i(o[0]),o=i=void 0}),"script"}),y.createHTMLDocument=((_t=E.implementation.createHTMLDocument("").body).innerHTML="<form></form><form></form>",2===_t.childNodes.length),S.parseHTML=function(e,t,n){return"string"!=typeof e?[]:("boolean"==typeof t&&(n=t,t=!1),t||(y.createHTMLDocument?((r=(t=E.implementation.createHTMLDocument("")).createElement("base")).href=E.location.href,t.head.appendChild(r)):t=E),o=!n&&[],(i=N.exec(e))?[t.createElement(i[1])]:(i=xe([e],t,o),o&&o.length&&S(o).remove(),S.merge([],i.childNodes)));var r,i,o},S.fn.load=function(e,t,n){var r,i,o,a=this,s=e.indexOf(" ");return-1<s&&(r=ht(e.slice(s)),e=e.slice(0,s)),m(t)?(n=t,t=void 0):t&&"object"==typeof t&&(i="POST"),0<a.length&&S.ajax({url:e,type:i||"GET",dataType:"html",data:t}).done(function(e){o=arguments,a.html(r?S("<div>").append(S.parseHTML(e)).find(r):e)}).always(n&&function(e,t){a.each(function(){n.apply(this,o||[e.responseText,t,e])})}),this},S.expr.pseudos.animated=function(t){return S.grep(S.timers,function(e){return t===e.elem}).length},S.offset={setOffset:function(e,t,n){var r,i,o,a,s,u,l=S.css(e,"position"),c=S(e),f={};"static"===l&&(e.style.position="relative"),s=c.offset(),o=S.css(e,"top"),u=S.css(e,"left"),("absolute"===l||"fixed"===l)&&-1<(o+u).indexOf("auto")?(a=(r=c.position()).top,i=r.left):(a=parseFloat(o)||0,i=parseFloat(u)||0),m(t)&&(t=t.call(e,n,S.extend({},s))),null!=t.top&&(f.top=t.top-s.top+a),null!=t.left&&(f.left=t.left-s.left+i),"using"in t?t.using.call(e,f):c.css(f)}},S.fn.extend({offset:function(t){if(arguments.length)return void 0===t?this:this.each(function(e){S.offset.setOffset(this,t,e)});var e,n,r=this[0];return r?r.getClientRects().length?(e=r.getBoundingClientRect(),n=r.ownerDocument.defaultView,{top:e.top+n.pageYOffset,left:e.left+n.pageXOffset}):{top:0,left:0}:void 0},position:function(){if(this[0]){var e,t,n,r=this[0],i={top:0,left:0};if("fixed"===S.css(r,"position"))t=r.getBoundingClientRect();else{t=this.offset(),n=r.ownerDocument,e=r.offsetParent||n.documentElement;while(e&&(e===n.body||e===n.documentElement)&&"static"===S.css(e,"position"))e=e.parentNode;e&&e!==r&&1===e.nodeType&&((i=S(e).offset()).top+=S.css(e,"borderTopWidth",!0),i.left+=S.css(e,"borderLeftWidth",!0))}return{top:t.top-i.top-S.css(r,"marginTop",!0),left:t.left-i.left-S.css(r,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var e=this.offsetParent;while(e&&"static"===S.css(e,"position"))e=e.offsetParent;return e||re})}}),S.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(t,i){var o="pageYOffset"===i;S.fn[t]=function(e){return $(this,function(e,t,n){var r;if(x(e)?r=e:9===e.nodeType&&(r=e.defaultView),void 0===n)return r?r[i]:e[t];r?r.scrollTo(o?r.pageXOffset:n,o?n:r.pageYOffset):e[t]=n},t,e,arguments.length)}}),S.each(["top","left"],function(e,n){S.cssHooks[n]=Fe(y.pixelPosition,function(e,t){if(t)return t=We(e,n),Pe.test(t)?S(e).position()[n]+"px":t})}),S.each({Height:"height",Width:"width"},function(a,s){S.each({padding:"inner"+a,content:s,"":"outer"+a},function(r,o){S.fn[o]=function(e,t){var n=arguments.length&&(r||"boolean"!=typeof e),i=r||(!0===e||!0===t?"margin":"border");return $(this,function(e,t,n){var r;return x(e)?0===o.indexOf("outer")?e["inner"+a]:e.document.documentElement["client"+a]:9===e.nodeType?(r=e.documentElement,Math.max(e.body["scroll"+a],r["scroll"+a],e.body["offset"+a],r["offset"+a],r["client"+a])):void 0===n?S.css(e,t,i):S.style(e,t,n,i)},s,n?e:void 0,n)}})}),S.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(e,t){S.fn[t]=function(e){return this.on(t,e)}}),S.fn.extend({bind:function(e,t,n){return this.on(e,null,t,n)},unbind:function(e,t){return this.off(e,null,t)},delegate:function(e,t,n,r){return this.on(t,e,n,r)},undelegate:function(e,t,n){return 1===arguments.length?this.off(e,"**"):this.off(t,e||"**",n)},hover:function(e,t){return this.mouseenter(e).mouseleave(t||e)}}),S.each("blur focus focusin focusout resize scroll click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup contextmenu".split(" "),function(e,n){S.fn[n]=function(e,t){return 0<arguments.length?this.on(n,null,e,t):this.trigger(n)}});var Xt=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g;S.proxy=function(e,t){var n,r,i;if("string"==typeof t&&(n=e[t],t=e,e=n),m(e))return r=s.call(arguments,2),(i=function(){return e.apply(t||this,r.concat(s.call(arguments)))}).guid=e.guid=e.guid||S.guid++,i},S.holdReady=function(e){e?S.readyWait++:S.ready(!0)},S.isArray=Array.isArray,S.parseJSON=JSON.parse,S.nodeName=A,S.isFunction=m,S.isWindow=x,S.camelCase=X,S.type=w,S.now=Date.now,S.isNumeric=function(e){var t=S.type(e);return("number"===t||"string"===t)&&!isNaN(e-parseFloat(e))},S.trim=function(e){return null==e?"":(e+"").replace(Xt,"")},"function"==typeof define&&define.amd&&define("jquery",[],function(){return S});var Vt=C.jQuery,Gt=C.$;return S.noConflict=function(e){return C.$===S&&(C.$=Gt),e&&C.jQuery===S&&(C.jQuery=Vt),S},"undefined"==typeof e&&(C.jQuery=C.$=S),S});
\"></script>\n",
       "<script title=\"dt-core\" src=\"data:application/javascript;base64,/*! DataTables 1.13.6
 * ©2008-2023 SpryMedia Ltd - datatables.net/license
 */
!function(n){"use strict";var a;"function"==typeof define&&define.amd?define(["jquery"],function(t){return n(t,window,document)}):"object"==typeof exports?(a=require("jquery"),"undefined"==typeof window?module.exports=function(t,e){return t=t||window,e=e||a(t),n(e,t,t.document)}:n(a,window,window.document)):window.DataTable=n(jQuery,window,document)}(function(P,j,v,H){"use strict";function d(t){var e=parseInt(t,10);return!isNaN(e)&&isFinite(t)?e:null}function l(t,e,n){var a=typeof t,r="string"==a;return"number"==a||"bigint"==a||!!h(t)||(e&&r&&(t=$(t,e)),n&&r&&(t=t.replace(q,"")),!isNaN(parseFloat(t))&&isFinite(t))}function a(t,e,n){var a;return!!h(t)||(h(a=t)||"string"==typeof a)&&!!l(t.replace(V,"").replace(/<script/i,""),e,n)||null}function m(t,e,n,a){var r=[],o=0,i=e.length;if(a!==H)for(;o<i;o++)t[e[o]][n]&&r.push(t[e[o]][n][a]);else for(;o<i;o++)r.push(t[e[o]][n]);return r}function f(t,e){var n,a=[];e===H?(e=0,n=t):(n=e,e=t);for(var r=e;r<n;r++)a.push(r);return a}function _(t){for(var e=[],n=0,a=t.length;n<a;n++)t[n]&&e.push(t[n]);return e}function s(t,e){return-1!==this.indexOf(t,e=e===H?0:e)}var p,e,t,w=function(t,v){if(w.factory(t,v))return w;if(this instanceof w)return P(t).DataTable(v);v=t,this.$=function(t,e){return this.api(!0).$(t,e)},this._=function(t,e){return this.api(!0).rows(t,e).data()},this.api=function(t){return new B(t?ge(this[p.iApiIndex]):this)},this.fnAddData=function(t,e){var n=this.api(!0),t=(Array.isArray(t)&&(Array.isArray(t[0])||P.isPlainObject(t[0]))?n.rows:n.row).add(t);return e!==H&&!e||n.draw(),t.flatten().toArray()},this.fnAdjustColumnSizing=function(t){var e=this.api(!0).columns.adjust(),n=e.settings()[0],a=n.oScroll;t===H||t?e.draw(!1):""===a.sX&&""===a.sY||Qt(n)},this.fnClearTable=function(t){var e=this.api(!0).clear();t!==H&&!t||e.draw()},this.fnClose=function(t){this.api(!0).row(t).child.hide()},this.fnDeleteRow=function(t,e,n){var a=this.api(!0),t=a.rows(t),r=t.settings()[0],o=r.aoData[t[0][0]];return t.remove(),e&&e.call(this,r,o),n!==H&&!n||a.draw(),o},this.fnDestroy=function(t){this.api(!0).destroy(t)},this.fnDraw=function(t){this.api(!0).draw(t)},this.fnFilter=function(t,e,n,a,r,o){var i=this.api(!0);(null===e||e===H?i:i.column(e)).search(t,n,a,o),i.draw()},this.fnGetData=function(t,e){var n,a=this.api(!0);return t!==H?(n=t.nodeName?t.nodeName.toLowerCase():"",e!==H||"td"==n||"th"==n?a.cell(t,e).data():a.row(t).data()||null):a.data().toArray()},this.fnGetNodes=function(t){var e=this.api(!0);return t!==H?e.row(t).node():e.rows().nodes().flatten().toArray()},this.fnGetPosition=function(t){var e=this.api(!0),n=t.nodeName.toUpperCase();return"TR"==n?e.row(t).index():"TD"==n||"TH"==n?[(n=e.cell(t).index()).row,n.columnVisible,n.column]:null},this.fnIsOpen=function(t){return this.api(!0).row(t).child.isShown()},this.fnOpen=function(t,e,n){return this.api(!0).row(t).child(e,n).show().child()[0]},this.fnPageChange=function(t,e){t=this.api(!0).page(t);e!==H&&!e||t.draw(!1)},this.fnSetColumnVis=function(t,e,n){t=this.api(!0).column(t).visible(e);n!==H&&!n||t.columns.adjust().draw()},this.fnSettings=function(){return ge(this[p.iApiIndex])},this.fnSort=function(t){this.api(!0).order(t).draw()},this.fnSortListener=function(t,e,n){this.api(!0).order.listener(t,e,n)},this.fnUpdate=function(t,e,n,a,r){var o=this.api(!0);return(n===H||null===n?o.row(e):o.cell(e,n)).data(t),r!==H&&!r||o.columns.adjust(),a!==H&&!a||o.draw(),0},this.fnVersionCheck=p.fnVersionCheck;var e,y=this,D=v===H,_=this.length;for(e in D&&(v={}),this.oApi=this.internal=p.internal,w.ext.internal)e&&(this[e]=$e(e));return this.each(function(){var r=1<_?be({},v,!0):v,o=0,t=this.getAttribute("id"),i=!1,e=w.defaults,l=P(this);if("table"!=this.nodeName.toLowerCase())W(null,0,"Non-table node initialisation ("+this.nodeName+")",2);else{K(e),Q(e.column),C(e,e,!0),C(e.column,e.column,!0),C(e,P.extend(r,l.data()),!0);for(var n=w.settings,o=0,s=n.length;o<s;o++){var a=n[o];if(a.nTable==this||a.nTHead&&a.nTHead.parentNode==this||a.nTFoot&&a.nTFoot.parentNode==this){var u=(r.bRetrieve!==H?r:e).bRetrieve,c=(r.bDestroy!==H?r:e).bDestroy;if(D||u)return a.oInstance;if(c){a.oInstance.fnDestroy();break}return void W(a,0,"Cannot reinitialise DataTable",3)}if(a.sTableId==this.id){n.splice(o,1);break}}null!==t&&""!==t||(t="DataTables_Table_"+w.ext._unique++,this.id=t);var f,d,h=P.extend(!0,{},w.models.oSettings,{sDestroyWidth:l[0].style.width,sInstance:t,sTableId:t}),p=(h.nTable=this,h.oApi=y.internal,h.oInit=r,n.push(h),h.oInstance=1===y.length?y:l.dataTable(),K(r),Z(r.oLanguage),r.aLengthMenu&&!r.iDisplayLength&&(r.iDisplayLength=(Array.isArray(r.aLengthMenu[0])?r.aLengthMenu[0]:r.aLengthMenu)[0]),r=be(P.extend(!0,{},e),r),F(h.oFeatures,r,["bPaginate","bLengthChange","bFilter","bSort","bSortMulti","bInfo","bProcessing","bAutoWidth","bSortClasses","bServerSide","bDeferRender"]),F(h,r,["asStripeClasses","ajax","fnServerData","fnFormatNumber","sServerMethod","aaSorting","aaSortingFixed","aLengthMenu","sPaginationType","sAjaxSource","sAjaxDataProp","iStateDuration","sDom","bSortCellsTop","iTabIndex","fnStateLoadCallback","fnStateSaveCallback","renderer","searchDelay","rowId",["iCookieDuration","iStateDuration"],["oSearch","oPreviousSearch"],["aoSearchCols","aoPreSearchCols"],["iDisplayLength","_iDisplayLength"]]),F(h.oScroll,r,[["sScrollX","sX"],["sScrollXInner","sXInner"],["sScrollY","sY"],["bScrollCollapse","bCollapse"]]),F(h.oLanguage,r,"fnInfoCallback"),L(h,"aoDrawCallback",r.fnDrawCallback,"user"),L(h,"aoServerParams",r.fnServerParams,"user"),L(h,"aoStateSaveParams",r.fnStateSaveParams,"user"),L(h,"aoStateLoadParams",r.fnStateLoadParams,"user"),L(h,"aoStateLoaded",r.fnStateLoaded,"user"),L(h,"aoRowCallback",r.fnRowCallback,"user"),L(h,"aoRowCreatedCallback",r.fnCreatedRow,"user"),L(h,"aoHeaderCallback",r.fnHeaderCallback,"user"),L(h,"aoFooterCallback",r.fnFooterCallback,"user"),L(h,"aoInitComplete",r.fnInitComplete,"user"),L(h,"aoPreDrawCallback",r.fnPreDrawCallback,"user"),h.rowIdFn=A(r.rowId),tt(h),h.oClasses),g=(P.extend(p,w.ext.classes,r.oClasses),l.addClass(p.sTable),h.iInitDisplayStart===H&&(h.iInitDisplayStart=r.iDisplayStart,h._iDisplayStart=r.iDisplayStart),null!==r.iDeferLoading&&(h.bDeferLoading=!0,t=Array.isArray(r.iDeferLoading),h._iRecordsDisplay=t?r.iDeferLoading[0]:r.iDeferLoading,h._iRecordsTotal=t?r.iDeferLoading[1]:r.iDeferLoading),h.oLanguage),t=(P.extend(!0,g,r.oLanguage),g.sUrl?(P.ajax({dataType:"json",url:g.sUrl,success:function(t){C(e.oLanguage,t),Z(t),P.extend(!0,g,t,h.oInit.oLanguage),R(h,null,"i18n",[h]),Jt(h)},error:function(){Jt(h)}}),i=!0):R(h,null,"i18n",[h]),null===r.asStripeClasses&&(h.asStripeClasses=[p.sStripeOdd,p.sStripeEven]),h.asStripeClasses),b=l.children("tbody").find("tr").eq(0),m=(-1!==P.inArray(!0,P.map(t,function(t,e){return b.hasClass(t)}))&&(P("tbody tr",this).removeClass(t.join(" ")),h.asDestroyStripes=t.slice()),[]),t=this.getElementsByTagName("thead");if(0!==t.length&&(wt(h.aoHeader,t[0]),m=Ct(h)),null===r.aoColumns)for(f=[],o=0,s=m.length;o<s;o++)f.push(null);else f=r.aoColumns;for(o=0,s=f.length;o<s;o++)nt(h,m?m[o]:null);st(h,r.aoColumnDefs,f,function(t,e){at(h,t,e)}),b.length&&(d=function(t,e){return null!==t.getAttribute("data-"+e)?e:null},P(b[0]).children("th, td").each(function(t,e){var n,a=h.aoColumns[t];a||W(h,0,"Incorrect column count",18),a.mData===t&&(n=d(e,"sort")||d(e,"order"),e=d(e,"filter")||d(e,"search"),null===n&&null===e||(a.mData={_:t+".display",sort:null!==n?t+".@data-"+n:H,type:null!==n?t+".@data-"+n:H,filter:null!==e?t+".@data-"+e:H},a._isArrayHost=!0,at(h,t)))}));var S=h.oFeatures,t=function(){if(r.aaSorting===H){var t=h.aaSorting;for(o=0,s=t.length;o<s;o++)t[o][1]=h.aoColumns[o].asSorting[0]}ce(h),S.bSort&&L(h,"aoDrawCallback",function(){var t,n;h.bSorted&&(t=I(h),n={},P.each(t,function(t,e){n[e.src]=e.dir}),R(h,null,"order",[h,t,n]),le(h))}),L(h,"aoDrawCallback",function(){(h.bSorted||"ssp"===E(h)||S.bDeferRender)&&ce(h)},"sc");var e=l.children("caption").each(function(){this._captionSide=P(this).css("caption-side")}),n=l.children("thead"),a=(0===n.length&&(n=P("<thead/>").appendTo(l)),h.nTHead=n[0],l.children("tbody")),n=(0===a.length&&(a=P("<tbody/>").insertAfter(n)),h.nTBody=a[0],l.children("tfoot"));if(0===(n=0===n.length&&0<e.length&&(""!==h.oScroll.sX||""!==h.oScroll.sY)?P("<tfoot/>").appendTo(l):n).length||0===n.children().length?l.addClass(p.sNoFooter):0<n.length&&(h.nTFoot=n[0],wt(h.aoFooter,h.nTFoot)),r.aaData)for(o=0;o<r.aaData.length;o++)x(h,r.aaData[o]);else!h.bDeferLoading&&"dom"!=E(h)||ut(h,P(h.nTBody).children("tr"));h.aiDisplay=h.aiDisplayMaster.slice(),!(h.bInitialised=!0)===i&&Jt(h)};L(h,"aoDrawCallback",de,"state_save"),r.bStateSave?(S.bStateSave=!0,he(h,0,t)):t()}}),y=null,this},c={},U=/[\r\n\u2028]/g,V=/<.*?>/g,X=/^\d{2,4}[\.\/\-]\d{1,2}[\.\/\-]\d{1,2}([T ]{1}\d{1,2}[:\.]\d{2}([\.:]\d{2})?)?$/,J=new RegExp("(\\"+["/",".","*","+","?","|","(",")","[","]","{","}","\\","$","^","-"].join("|\\")+")","g"),q=/['\u00A0,$£€¥%\u2009\u202F\u20BD\u20a9\u20BArfkɃΞ]/gi,h=function(t){return!t||!0===t||"-"===t},$=function(t,e){return c[e]||(c[e]=new RegExp(Ot(e),"g")),"string"==typeof t&&"."!==e?t.replace(/\./g,"").replace(c[e],"."):t},N=function(t,e,n){var a=[],r=0,o=t.length;if(n!==H)for(;r<o;r++)t[r]&&t[r][e]&&a.push(t[r][e][n]);else for(;r<o;r++)t[r]&&a.push(t[r][e]);return a},G=function(t){if(!(t.length<2))for(var e=t.slice().sort(),n=e[0],a=1,r=e.length;a<r;a++){if(e[a]===n)return!1;n=e[a]}return!0},z=function(t){if(G(t))return t.slice();var e,n,a,r=[],o=t.length,i=0;t:for(n=0;n<o;n++){for(e=t[n],a=0;a<i;a++)if(r[a]===e)continue t;r.push(e),i++}return r},Y=function(t,e){if(Array.isArray(e))for(var n=0;n<e.length;n++)Y(t,e[n]);else t.push(e);return t};function i(n){var a,r,o={};P.each(n,function(t,e){(a=t.match(/^([^A-Z]+?)([A-Z])/))&&-1!=="a aa ai ao as b fn i m o s ".indexOf(a[1]+" ")&&(r=t.replace(a[0],a[2].toLowerCase()),o[r]=t,"o"===a[1])&&i(n[t])}),n._hungarianMap=o}function C(n,a,r){var o;n._hungarianMap||i(n),P.each(a,function(t,e){(o=n._hungarianMap[t])===H||!r&&a[o]!==H||("o"===o.charAt(0)?(a[o]||(a[o]={}),P.extend(!0,a[o],a[t]),C(n[o],a[o],r)):a[o]=a[t])})}function Z(t){var e,n=w.defaults.oLanguage,a=n.sDecimal;a&&Me(a),t&&(e=t.sZeroRecords,!t.sEmptyTable&&e&&"No data available in table"===n.sEmptyTable&&F(t,t,"sZeroRecords","sEmptyTable"),!t.sLoadingRecords&&e&&"Loading..."===n.sLoadingRecords&&F(t,t,"sZeroRecords","sLoadingRecords"),t.sInfoThousands&&(t.sThousands=t.sInfoThousands),e=t.sDecimal)&&a!==e&&Me(e)}Array.isArray||(Array.isArray=function(t){return"[object Array]"===Object.prototype.toString.call(t)}),Array.prototype.includes||(Array.prototype.includes=s),String.prototype.trim||(String.prototype.trim=function(){return this.replace(/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g,"")}),String.prototype.includes||(String.prototype.includes=s),w.util={throttle:function(a,t){var r,o,i=t!==H?t:200;return function(){var t=this,e=+new Date,n=arguments;r&&e<r+i?(clearTimeout(o),o=setTimeout(function(){r=H,a.apply(t,n)},i)):(r=e,a.apply(t,n))}},escapeRegex:function(t){return t.replace(J,"\\$1")},set:function(a){var d;return P.isPlainObject(a)?w.util.set(a._):null===a?function(){}:"function"==typeof a?function(t,e,n){a(t,"set",e,n)}:"string"!=typeof a||-1===a.indexOf(".")&&-1===a.indexOf("[")&&-1===a.indexOf("(")?function(t,e){t[a]=e}:(d=function(t,e,n){for(var a,r,o,i,l=dt(n),n=l[l.length-1],s=0,u=l.length-1;s<u;s++){if("__proto__"===l[s]||"constructor"===l[s])throw new Error("Cannot set prototype values");if(a=l[s].match(ft),r=l[s].match(g),a){if(l[s]=l[s].replace(ft,""),t[l[s]]=[],(a=l.slice()).splice(0,s+1),i=a.join("."),Array.isArray(e))for(var c=0,f=e.length;c<f;c++)d(o={},e[c],i),t[l[s]].push(o);else t[l[s]]=e;return}r&&(l[s]=l[s].replace(g,""),t=t[l[s]](e)),null!==t[l[s]]&&t[l[s]]!==H||(t[l[s]]={}),t=t[l[s]]}n.match(g)?t[n.replace(g,"")](e):t[n.replace(ft,"")]=e},function(t,e){return d(t,e,a)})},get:function(r){var o,d;return P.isPlainObject(r)?(o={},P.each(r,function(t,e){e&&(o[t]=w.util.get(e))}),function(t,e,n,a){var r=o[e]||o._;return r!==H?r(t,e,n,a):t}):null===r?function(t){return t}:"function"==typeof r?function(t,e,n,a){return r(t,e,n,a)}:"string"!=typeof r||-1===r.indexOf(".")&&-1===r.indexOf("[")&&-1===r.indexOf("(")?function(t,e){return t[r]}:(d=function(t,e,n){var a,r,o;if(""!==n)for(var i=dt(n),l=0,s=i.length;l<s;l++){if(f=i[l].match(ft),a=i[l].match(g),f){if(i[l]=i[l].replace(ft,""),""!==i[l]&&(t=t[i[l]]),r=[],i.splice(0,l+1),o=i.join("."),Array.isArray(t))for(var u=0,c=t.length;u<c;u++)r.push(d(t[u],e,o));var f=f[0].substring(1,f[0].length-1);t=""===f?r:r.join(f);break}if(a)i[l]=i[l].replace(g,""),t=t[i[l]]();else{if(null===t||null===t[i[l]])return null;if(t===H||t[i[l]]===H)return H;t=t[i[l]]}}return t},function(t,e){return d(t,e,r)})}};var r=function(t,e,n){t[e]!==H&&(t[n]=t[e])};function K(t){r(t,"ordering","bSort"),r(t,"orderMulti","bSortMulti"),r(t,"orderClasses","bSortClasses"),r(t,"orderCellsTop","bSortCellsTop"),r(t,"order","aaSorting"),r(t,"orderFixed","aaSortingFixed"),r(t,"paging","bPaginate"),r(t,"pagingType","sPaginationType"),r(t,"pageLength","iDisplayLength"),r(t,"searching","bFilter"),"boolean"==typeof t.sScrollX&&(t.sScrollX=t.sScrollX?"100%":""),"boolean"==typeof t.scrollX&&(t.scrollX=t.scrollX?"100%":"");var e=t.aoSearchCols;if(e)for(var n=0,a=e.length;n<a;n++)e[n]&&C(w.models.oSearch,e[n])}function Q(t){r(t,"orderable","bSortable"),r(t,"orderData","aDataSort"),r(t,"orderSequence","asSorting"),r(t,"orderDataType","sortDataType");var e=t.aDataSort;"number"!=typeof e||Array.isArray(e)||(t.aDataSort=[e])}function tt(t){var e,n,a,r;w.__browser||(w.__browser=e={},r=(a=(n=P("<div/>").css({position:"fixed",top:0,left:-1*P(j).scrollLeft(),height:1,width:1,overflow:"hidden"}).append(P("<div/>").css({position:"absolute",top:1,left:1,width:100,overflow:"scroll"}).append(P("<div/>").css({width:"100%",height:10}))).appendTo("body")).children()).children(),e.barWidth=a[0].offsetWidth-a[0].clientWidth,e.bScrollOversize=100===r[0].offsetWidth&&100!==a[0].clientWidth,e.bScrollbarLeft=1!==Math.round(r.offset().left),e.bBounding=!!n[0].getBoundingClientRect().width,n.remove()),P.extend(t.oBrowser,w.__browser),t.oScroll.iBarWidth=w.__browser.barWidth}function et(t,e,n,a,r,o){var i,l=a,s=!1;for(n!==H&&(i=n,s=!0);l!==r;)t.hasOwnProperty(l)&&(i=s?e(i,t[l],l,t):t[l],s=!0,l+=o);return i}function nt(t,e){var n=w.defaults.column,a=t.aoColumns.length,n=P.extend({},w.models.oColumn,n,{nTh:e||v.createElement("th"),sTitle:n.sTitle||(e?e.innerHTML:""),aDataSort:n.aDataSort||[a],mData:n.mData||a,idx:a}),n=(t.aoColumns.push(n),t.aoPreSearchCols);n[a]=P.extend({},w.models.oSearch,n[a]),at(t,a,P(e).data())}function at(t,e,n){function a(t){return"string"==typeof t&&-1!==t.indexOf("@")}var e=t.aoColumns[e],r=t.oClasses,o=P(e.nTh),i=(!e.sWidthOrig&&(e.sWidthOrig=o.attr("width")||null,u=(o.attr("style")||"").match(/width:\s*(\d+[pxem%]+)/))&&(e.sWidthOrig=u[1]),n!==H&&null!==n&&(Q(n),C(w.defaults.column,n,!0),n.mDataProp===H||n.mData||(n.mData=n.mDataProp),n.sType&&(e._sManualType=n.sType),n.className&&!n.sClass&&(n.sClass=n.className),n.sClass&&o.addClass(n.sClass),u=e.sClass,P.extend(e,n),F(e,n,"sWidth","sWidthOrig"),u!==e.sClass&&(e.sClass=u+" "+e.sClass),n.iDataSort!==H&&(e.aDataSort=[n.iDataSort]),F(e,n,"aDataSort"),e.ariaTitle||(e.ariaTitle=o.attr("aria-label"))),e.mData),l=A(i),s=e.mRender?A(e.mRender):null,u=(e._bAttrSrc=P.isPlainObject(i)&&(a(i.sort)||a(i.type)||a(i.filter)),e._setter=null,e.fnGetData=function(t,e,n){var a=l(t,e,H,n);return s&&e?s(a,e,t,n):a},e.fnSetData=function(t,e,n){return b(i)(t,e,n)},"number"==typeof i||e._isArrayHost||(t._rowReadObject=!0),t.oFeatures.bSort||(e.bSortable=!1,o.addClass(r.sSortableNone)),-1!==P.inArray("asc",e.asSorting)),n=-1!==P.inArray("desc",e.asSorting);e.bSortable&&(u||n)?u&&!n?(e.sSortingClass=r.sSortableAsc,e.sSortingClassJUI=r.sSortJUIAscAllowed):!u&&n?(e.sSortingClass=r.sSortableDesc,e.sSortingClassJUI=r.sSortJUIDescAllowed):(e.sSortingClass=r.sSortable,e.sSortingClassJUI=r.sSortJUI):(e.sSortingClass=r.sSortableNone,e.sSortingClassJUI="")}function O(t){if(!1!==t.oFeatures.bAutoWidth){var e=t.aoColumns;ee(t);for(var n=0,a=e.length;n<a;n++)e[n].nTh.style.width=e[n].sWidth}var r=t.oScroll;""===r.sY&&""===r.sX||Qt(t),R(t,null,"column-sizing",[t])}function rt(t,e){t=it(t,"bVisible");return"number"==typeof t[e]?t[e]:null}function ot(t,e){t=it(t,"bVisible"),e=P.inArray(e,t);return-1!==e?e:null}function T(t){var n=0;return P.each(t.aoColumns,function(t,e){e.bVisible&&"none"!==P(e.nTh).css("display")&&n++}),n}function it(t,n){var a=[];return P.map(t.aoColumns,function(t,e){t[n]&&a.push(e)}),a}function lt(t){for(var e,n,a,r,o,i,l,s=t.aoColumns,u=t.aoData,c=w.ext.type.detect,f=0,d=s.length;f<d;f++)if(l=[],!(o=s[f]).sType&&o._sManualType)o.sType=o._sManualType;else if(!o.sType){for(e=0,n=c.length;e<n;e++){for(a=0,r=u.length;a<r&&(l[a]===H&&(l[a]=S(t,a,f,"type")),(i=c[e](l[a],t))||e===c.length-1)&&("html"!==i||h(l[a]));a++);if(i){o.sType=i;break}}o.sType||(o.sType="string")}}function st(t,e,n,a){var r,o,i,l,s=t.aoColumns;if(e)for(r=e.length-1;0<=r;r--)for(var u,c=(u=e[r]).target!==H?u.target:u.targets!==H?u.targets:u.aTargets,f=0,d=(c=Array.isArray(c)?c:[c]).length;f<d;f++)if("number"==typeof c[f]&&0<=c[f]){for(;s.length<=c[f];)nt(t);a(c[f],u)}else if("number"==typeof c[f]&&c[f]<0)a(s.length+c[f],u);else if("string"==typeof c[f])for(i=0,l=s.length;i<l;i++)"_all"!=c[f]&&!P(s[i].nTh).hasClass(c[f])||a(i,u);if(n)for(r=0,o=n.length;r<o;r++)a(r,n[r])}function x(t,e,n,a){for(var r=t.aoData.length,o=P.extend(!0,{},w.models.oRow,{src:n?"dom":"data",idx:r}),i=(o._aData=e,t.aoData.push(o),t.aoColumns),l=0,s=i.length;l<s;l++)i[l].sType=null;t.aiDisplayMaster.push(r);e=t.rowIdFn(e);return e!==H&&(t.aIds[e]=o),!n&&t.oFeatures.bDeferRender||St(t,r,n,a),r}function ut(n,t){var a;return(t=t instanceof P?t:P(t)).map(function(t,e){return a=mt(n,e),x(n,a.data,e,a.cells)})}function S(t,e,n,a){"search"===a?a="filter":"order"===a&&(a="sort");var r=t.iDraw,o=t.aoColumns[n],i=t.aoData[e]._aData,l=o.sDefaultContent,s=o.fnGetData(i,a,{settings:t,row:e,col:n});if(s===H)return t.iDrawError!=r&&null===l&&(W(t,0,"Requested unknown parameter "+("function"==typeof o.mData?"{function}":"'"+o.mData+"'")+" for row "+e+", column "+n,4),t.iDrawError=r),l;if(s!==i&&null!==s||null===l||a===H){if("function"==typeof s)return s.call(i)}else s=l;return null===s&&"display"===a?"":"filter"===a&&(e=w.ext.type.search)[o.sType]?e[o.sType](s):s}function ct(t,e,n,a){var r=t.aoColumns[n],o=t.aoData[e]._aData;r.fnSetData(o,a,{settings:t,row:e,col:n})}var ft=/\[.*?\]$/,g=/\(\)$/;function dt(t){return P.map(t.match(/(\\.|[^\.])+/g)||[""],function(t){return t.replace(/\\\./g,".")})}var A=w.util.get,b=w.util.set;function ht(t){return N(t.aoData,"_aData")}function pt(t){t.aoData.length=0,t.aiDisplayMaster.length=0,t.aiDisplay.length=0,t.aIds={}}function gt(t,e,n){for(var a=-1,r=0,o=t.length;r<o;r++)t[r]==e?a=r:t[r]>e&&t[r]--;-1!=a&&n===H&&t.splice(a,1)}function bt(n,a,t,e){function r(t,e){for(;t.childNodes.length;)t.removeChild(t.firstChild);t.innerHTML=S(n,a,e,"display")}var o,i,l=n.aoData[a];if("dom"!==t&&(t&&"auto"!==t||"dom"!==l.src)){var s=l.anCells;if(s)if(e!==H)r(s[e],e);else for(o=0,i=s.length;o<i;o++)r(s[o],o)}else l._aData=mt(n,l,e,e===H?H:l._aData).data;l._aSortData=null,l._aFilterData=null;var u=n.aoColumns;if(e!==H)u[e].sType=null;else{for(o=0,i=u.length;o<i;o++)u[o].sType=null;vt(n,l)}}function mt(t,e,n,a){function r(t,e){var n;"string"==typeof t&&-1!==(n=t.indexOf("@"))&&(n=t.substring(n+1),b(t)(a,e.getAttribute(n)))}function o(t){n!==H&&n!==f||(l=d[f],s=t.innerHTML.trim(),l&&l._bAttrSrc?(b(l.mData._)(a,s),r(l.mData.sort,t),r(l.mData.type,t),r(l.mData.filter,t)):h?(l._setter||(l._setter=b(l.mData)),l._setter(a,s)):a[f]=s),f++}var i,l,s,u=[],c=e.firstChild,f=0,d=t.aoColumns,h=t._rowReadObject;a=a!==H?a:h?{}:[];if(c)for(;c;)"TD"!=(i=c.nodeName.toUpperCase())&&"TH"!=i||(o(c),u.push(c)),c=c.nextSibling;else for(var p=0,g=(u=e.anCells).length;p<g;p++)o(u[p]);var e=e.firstChild?e:e.nTr;return e&&(e=e.getAttribute("id"))&&b(t.rowId)(a,e),{data:a,cells:u}}function St(t,e,n,a){var r,o,i,l,s,u,c=t.aoData[e],f=c._aData,d=[];if(null===c.nTr){for(r=n||v.createElement("tr"),c.nTr=r,c.anCells=d,r._DT_RowIndex=e,vt(t,c),l=0,s=t.aoColumns.length;l<s;l++)i=t.aoColumns[l],(o=(u=!n)?v.createElement(i.sCellType):a[l])||W(t,0,"Incorrect column count",18),o._DT_CellIndex={row:e,column:l},d.push(o),!u&&(!i.mRender&&i.mData===l||P.isPlainObject(i.mData)&&i.mData._===l+".display")||(o.innerHTML=S(t,e,l,"display")),i.sClass&&(o.className+=" "+i.sClass),i.bVisible&&!n?r.appendChild(o):!i.bVisible&&n&&o.parentNode.removeChild(o),i.fnCreatedCell&&i.fnCreatedCell.call(t.oInstance,o,S(t,e,l),f,e,l);R(t,"aoRowCreatedCallback",null,[r,f,e,d])}}function vt(t,e){var n=e.nTr,a=e._aData;n&&((t=t.rowIdFn(a))&&(n.id=t),a.DT_RowClass&&(t=a.DT_RowClass.split(" "),e.__rowc=e.__rowc?z(e.__rowc.concat(t)):t,P(n).removeClass(e.__rowc.join(" ")).addClass(a.DT_RowClass)),a.DT_RowAttr&&P(n).attr(a.DT_RowAttr),a.DT_RowData)&&P(n).data(a.DT_RowData)}function yt(t){var e,n,a,r=t.nTHead,o=t.nTFoot,i=0===P("th, td",r).length,l=t.oClasses,s=t.aoColumns;for(i&&(n=P("<tr/>").appendTo(r)),c=0,f=s.length;c<f;c++)a=s[c],e=P(a.nTh).addClass(a.sClass),i&&e.appendTo(n),t.oFeatures.bSort&&(e.addClass(a.sSortingClass),!1!==a.bSortable)&&(e.attr("tabindex",t.iTabIndex).attr("aria-controls",t.sTableId),ue(t,a.nTh,c)),a.sTitle!=e[0].innerHTML&&e.html(a.sTitle),ve(t,"header")(t,e,a,l);if(i&&wt(t.aoHeader,r),P(r).children("tr").children("th, td").addClass(l.sHeaderTH),P(o).children("tr").children("th, td").addClass(l.sFooterTH),null!==o)for(var u=t.aoFooter[0],c=0,f=u.length;c<f;c++)(a=s[c])?(a.nTf=u[c].cell,a.sClass&&P(a.nTf).addClass(a.sClass)):W(t,0,"Incorrect column count",18)}function Dt(t,e,n){var a,r,o,i,l,s,u,c,f,d=[],h=[],p=t.aoColumns.length;if(e){for(n===H&&(n=!1),a=0,r=e.length;a<r;a++){for(d[a]=e[a].slice(),d[a].nTr=e[a].nTr,o=p-1;0<=o;o--)t.aoColumns[o].bVisible||n||d[a].splice(o,1);h.push([])}for(a=0,r=d.length;a<r;a++){if(u=d[a].nTr)for(;s=u.firstChild;)u.removeChild(s);for(o=0,i=d[a].length;o<i;o++)if(f=c=1,h[a][o]===H){for(u.appendChild(d[a][o].cell),h[a][o]=1;d[a+c]!==H&&d[a][o].cell==d[a+c][o].cell;)h[a+c][o]=1,c++;for(;d[a][o+f]!==H&&d[a][o].cell==d[a][o+f].cell;){for(l=0;l<c;l++)h[a+l][o+f]=1;f++}P(d[a][o].cell).attr("rowspan",c).attr("colspan",f)}}}}function y(t,e){n="ssp"==E(s=t),(l=s.iInitDisplayStart)!==H&&-1!==l&&(s._iDisplayStart=!n&&l>=s.fnRecordsDisplay()?0:l,s.iInitDisplayStart=-1);var n=R(t,"aoPreDrawCallback","preDraw",[t]);if(-1!==P.inArray(!1,n))D(t,!1);else{var a=[],r=0,o=t.asStripeClasses,i=o.length,l=t.oLanguage,s="ssp"==E(t),u=t.aiDisplay,n=t._iDisplayStart,c=t.fnDisplayEnd();if(t.bDrawing=!0,t.bDeferLoading)t.bDeferLoading=!1,t.iDraw++,D(t,!1);else if(s){if(!t.bDestroying&&!e)return void xt(t)}else t.iDraw++;if(0!==u.length)for(var f=s?t.aoData.length:c,d=s?0:n;d<f;d++){var h,p=u[d],g=t.aoData[p],b=(null===g.nTr&&St(t,p),g.nTr);0!==i&&(h=o[r%i],g._sRowStripe!=h)&&(P(b).removeClass(g._sRowStripe).addClass(h),g._sRowStripe=h),R(t,"aoRowCallback",null,[b,g._aData,r,d,p]),a.push(b),r++}else{e=l.sZeroRecords;1==t.iDraw&&"ajax"==E(t)?e=l.sLoadingRecords:l.sEmptyTable&&0===t.fnRecordsTotal()&&(e=l.sEmptyTable),a[0]=P("<tr/>",{class:i?o[0]:""}).append(P("<td />",{valign:"top",colSpan:T(t),class:t.oClasses.sRowEmpty}).html(e))[0]}R(t,"aoHeaderCallback","header",[P(t.nTHead).children("tr")[0],ht(t),n,c,u]),R(t,"aoFooterCallback","footer",[P(t.nTFoot).children("tr")[0],ht(t),n,c,u]);s=P(t.nTBody);s.children().detach(),s.append(P(a)),R(t,"aoDrawCallback","draw",[t]),t.bSorted=!1,t.bFiltered=!1,t.bDrawing=!1}}function u(t,e){var n=t.oFeatures,a=n.bSort,n=n.bFilter;a&&ie(t),n?Rt(t,t.oPreviousSearch):t.aiDisplay=t.aiDisplayMaster.slice(),!0!==e&&(t._iDisplayStart=0),t._drawHold=e,y(t),t._drawHold=!1}function _t(t){for(var e,n,a,r,o,i,l,s=t.oClasses,u=P(t.nTable),u=P("<div/>").insertBefore(u),c=t.oFeatures,f=P("<div/>",{id:t.sTableId+"_wrapper",class:s.sWrapper+(t.nTFoot?"":" "+s.sNoFooter)}),d=(t.nHolding=u[0],t.nTableWrapper=f[0],t.nTableReinsertBefore=t.nTable.nextSibling,t.sDom.split("")),h=0;h<d.length;h++){if(e=null,"<"==(n=d[h])){if(a=P("<div/>")[0],"'"==(r=d[h+1])||'"'==r){for(o="",i=2;d[h+i]!=r;)o+=d[h+i],i++;"H"==o?o=s.sJUIHeader:"F"==o&&(o=s.sJUIFooter),-1!=o.indexOf(".")?(l=o.split("."),a.id=l[0].substr(1,l[0].length-1),a.className=l[1]):"#"==o.charAt(0)?a.id=o.substr(1,o.length-1):a.className=o,h+=i}f.append(a),f=P(a)}else if(">"==n)f=f.parent();else if("l"==n&&c.bPaginate&&c.bLengthChange)e=Gt(t);else if("f"==n&&c.bFilter)e=Lt(t);else if("r"==n&&c.bProcessing)e=Zt(t);else if("t"==n)e=Kt(t);else if("i"==n&&c.bInfo)e=Ut(t);else if("p"==n&&c.bPaginate)e=zt(t);else if(0!==w.ext.feature.length)for(var p=w.ext.feature,g=0,b=p.length;g<b;g++)if(n==p[g].cFeature){e=p[g].fnInit(t);break}e&&((l=t.aanFeatures)[n]||(l[n]=[]),l[n].push(e),f.append(e))}u.replaceWith(f),t.nHolding=null}function wt(t,e){var n,a,r,o,i,l,s,u,c,f,d=P(e).children("tr");for(t.splice(0,t.length),r=0,l=d.length;r<l;r++)t.push([]);for(r=0,l=d.length;r<l;r++)for(a=(n=d[r]).firstChild;a;){if("TD"==a.nodeName.toUpperCase()||"TH"==a.nodeName.toUpperCase())for(u=(u=+a.getAttribute("colspan"))&&0!=u&&1!=u?u:1,c=(c=+a.getAttribute("rowspan"))&&0!=c&&1!=c?c:1,s=function(t,e,n){for(var a=t[e];a[n];)n++;return n}(t,r,0),f=1==u,i=0;i<u;i++)for(o=0;o<c;o++)t[r+o][s+i]={cell:a,unique:f},t[r+o].nTr=n;a=a.nextSibling}}function Ct(t,e,n){var a=[];n||(n=t.aoHeader,e&&wt(n=[],e));for(var r=0,o=n.length;r<o;r++)for(var i=0,l=n[r].length;i<l;i++)!n[r][i].unique||a[i]&&t.bSortCellsTop||(a[i]=n[r][i].cell);return a}function Tt(r,t,n){function e(t){var e=r.jqXHR?r.jqXHR.status:null;(null===t||"number"==typeof e&&204==e)&&Ft(r,t={},[]),(e=t.error||t.sError)&&W(r,0,e),r.json=t,R(r,null,"xhr",[r,t,r.jqXHR]),n(t)}R(r,"aoServerParams","serverParams",[t]),t&&Array.isArray(t)&&(a={},o=/(.*?)\[\]$/,P.each(t,function(t,e){var n=e.name.match(o);n?(n=n[0],a[n]||(a[n]=[]),a[n].push(e.value)):a[e.name]=e.value}),t=a);var a,o,i,l=r.ajax,s=r.oInstance,u=(P.isPlainObject(l)&&l.data&&(u="function"==typeof(i=l.data)?i(t,r):i,t="function"==typeof i&&u?u:P.extend(!0,t,u),delete l.data),{data:t,success:e,dataType:"json",cache:!1,type:r.sServerMethod,error:function(t,e,n){var a=R(r,null,"xhr",[r,null,r.jqXHR]);-1===P.inArray(!0,a)&&("parsererror"==e?W(r,0,"Invalid JSON response",1):4===t.readyState&&W(r,0,"Ajax error",7)),D(r,!1)}});r.oAjaxData=t,R(r,null,"preXhr",[r,t]),r.fnServerData?r.fnServerData.call(s,r.sAjaxSource,P.map(t,function(t,e){return{name:e,value:t}}),e,r):r.sAjaxSource||"string"==typeof l?r.jqXHR=P.ajax(P.extend(u,{url:l||r.sAjaxSource})):"function"==typeof l?r.jqXHR=l.call(s,t,e,r):(r.jqXHR=P.ajax(P.extend(u,l)),l.data=i)}function xt(e){e.iDraw++,D(e,!0);var n=e._drawHold;Tt(e,At(e),function(t){e._drawHold=n,It(e,t),e._drawHold=!1})}function At(t){for(var e,n,a,r=t.aoColumns,o=r.length,i=t.oFeatures,l=t.oPreviousSearch,s=t.aoPreSearchCols,u=[],c=I(t),f=t._iDisplayStart,d=!1!==i.bPaginate?t._iDisplayLength:-1,h=function(t,e){u.push({name:t,value:e})},p=(h("sEcho",t.iDraw),h("iColumns",o),h("sColumns",N(r,"sName").join(",")),h("iDisplayStart",f),h("iDisplayLength",d),{draw:t.iDraw,columns:[],order:[],start:f,length:d,search:{value:l.sSearch,regex:l.bRegex}}),g=0;g<o;g++)n=r[g],a=s[g],e="function"==typeof n.mData?"function":n.mData,p.columns.push({data:e,name:n.sName,searchable:n.bSearchable,orderable:n.bSortable,search:{value:a.sSearch,regex:a.bRegex}}),h("mDataProp_"+g,e),i.bFilter&&(h("sSearch_"+g,a.sSearch),h("bRegex_"+g,a.bRegex),h("bSearchable_"+g,n.bSearchable)),i.bSort&&h("bSortable_"+g,n.bSortable);i.bFilter&&(h("sSearch",l.sSearch),h("bRegex",l.bRegex)),i.bSort&&(P.each(c,function(t,e){p.order.push({column:e.col,dir:e.dir}),h("iSortCol_"+t,e.col),h("sSortDir_"+t,e.dir)}),h("iSortingCols",c.length));f=w.ext.legacy.ajax;return null===f?t.sAjaxSource?u:p:f?u:p}function It(t,n){function e(t,e){return n[t]!==H?n[t]:n[e]}var a=Ft(t,n),r=e("sEcho","draw"),o=e("iTotalRecords","recordsTotal"),i=e("iTotalDisplayRecords","recordsFiltered");if(r!==H){if(+r<t.iDraw)return;t.iDraw=+r}a=a||[],pt(t),t._iRecordsTotal=parseInt(o,10),t._iRecordsDisplay=parseInt(i,10);for(var l=0,s=a.length;l<s;l++)x(t,a[l]);t.aiDisplay=t.aiDisplayMaster.slice(),y(t,!0),t._bInitComplete||qt(t,n),D(t,!1)}function Ft(t,e,n){t=P.isPlainObject(t.ajax)&&t.ajax.dataSrc!==H?t.ajax.dataSrc:t.sAjaxDataProp;if(!n)return"data"===t?e.aaData||e[t]:""!==t?A(t)(e):e;b(t)(e,n)}function Lt(n){function e(t){i.f;var e=this.value||"";o.return&&"Enter"!==t.key||e!=o.sSearch&&(Rt(n,{sSearch:e,bRegex:o.bRegex,bSmart:o.bSmart,bCaseInsensitive:o.bCaseInsensitive,return:o.return}),n._iDisplayStart=0,y(n))}var t=n.oClasses,a=n.sTableId,r=n.oLanguage,o=n.oPreviousSearch,i=n.aanFeatures,l='<input type="search" class="'+t.sFilterInput+'"/>',s=(s=r.sSearch).match(/_INPUT_/)?s.replace("_INPUT_",l):s+l,l=P("<div/>",{id:i.f?null:a+"_filter",class:t.sFilter}).append(P("<label/>").append(s)),t=null!==n.searchDelay?n.searchDelay:"ssp"===E(n)?400:0,u=P("input",l).val(o.sSearch).attr("placeholder",r.sSearchPlaceholder).on("keyup.DT search.DT input.DT paste.DT cut.DT",t?ne(e,t):e).on("mouseup.DT",function(t){setTimeout(function(){e.call(u[0],t)},10)}).on("keypress.DT",function(t){if(13==t.keyCode)return!1}).attr("aria-controls",a);return P(n.nTable).on("search.dt.DT",function(t,e){if(n===e)try{u[0]!==v.activeElement&&u.val(o.sSearch)}catch(t){}}),l[0]}function Rt(t,e,n){function a(t){o.sSearch=t.sSearch,o.bRegex=t.bRegex,o.bSmart=t.bSmart,o.bCaseInsensitive=t.bCaseInsensitive,o.return=t.return}function r(t){return t.bEscapeRegex!==H?!t.bEscapeRegex:t.bRegex}var o=t.oPreviousSearch,i=t.aoPreSearchCols;if(lt(t),"ssp"!=E(t)){Ht(t,e.sSearch,n,r(e),e.bSmart,e.bCaseInsensitive),a(e);for(var l=0;l<i.length;l++)jt(t,i[l].sSearch,l,r(i[l]),i[l].bSmart,i[l].bCaseInsensitive);Pt(t)}else a(e);t.bFiltered=!0,R(t,null,"search",[t])}function Pt(t){for(var e,n,a=w.ext.search,r=t.aiDisplay,o=0,i=a.length;o<i;o++){for(var l=[],s=0,u=r.length;s<u;s++)n=r[s],e=t.aoData[n],a[o](t,e._aFilterData,n,e._aData,s)&&l.push(n);r.length=0,P.merge(r,l)}}function jt(t,e,n,a,r,o){if(""!==e){for(var i,l=[],s=t.aiDisplay,u=Nt(e,a,r,o),c=0;c<s.length;c++)i=t.aoData[s[c]]._aFilterData[n],u.test(i)&&l.push(s[c]);t.aiDisplay=l}}function Ht(t,e,n,a,r,o){var i,l,s,u=Nt(e,a,r,o),r=t.oPreviousSearch.sSearch,o=t.aiDisplayMaster,c=[];if(0!==w.ext.search.length&&(n=!0),l=Wt(t),e.length<=0)t.aiDisplay=o.slice();else{for((l||n||a||r.length>e.length||0!==e.indexOf(r)||t.bSorted)&&(t.aiDisplay=o.slice()),i=t.aiDisplay,s=0;s<i.length;s++)u.test(t.aoData[i[s]]._sFilterRow)&&c.push(i[s]);t.aiDisplay=c}}function Nt(t,e,n,a){return t=e?t:Ot(t),n&&(t="^(?=.*?"+P.map(t.match(/["\u201C][^"\u201D]+["\u201D]|[^ ]+/g)||[""],function(t){var e;return'"'===t.charAt(0)?t=(e=t.match(/^"(.*)"$/))?e[1]:t:"“"===t.charAt(0)&&(t=(e=t.match(/^\u201C(.*)\u201D$/))?e[1]:t),t.replace('"',"")}).join(")(?=.*?")+").*$"),new RegExp(t,a?"i":"")}var Ot=w.util.escapeRegex,kt=P("<div>")[0],Mt=kt.textContent!==H;function Wt(t){for(var e,n,a,r,o,i=t.aoColumns,l=!1,s=0,u=t.aoData.length;s<u;s++)if(!(o=t.aoData[s])._aFilterData){for(a=[],e=0,n=i.length;e<n;e++)i[e].bSearchable?"string"!=typeof(r=null===(r=S(t,s,e,"filter"))?"":r)&&r.toString&&(r=r.toString()):r="",r.indexOf&&-1!==r.indexOf("&")&&(kt.innerHTML=r,r=Mt?kt.textContent:kt.innerText),r.replace&&(r=r.replace(/[\r\n\u2028]/g,"")),a.push(r);o._aFilterData=a,o._sFilterRow=a.join("  "),l=!0}return l}function Et(t){return{search:t.sSearch,smart:t.bSmart,regex:t.bRegex,caseInsensitive:t.bCaseInsensitive}}function Bt(t){return{sSearch:t.search,bSmart:t.smart,bRegex:t.regex,bCaseInsensitive:t.caseInsensitive}}function Ut(t){var e=t.sTableId,n=t.aanFeatures.i,a=P("<div/>",{class:t.oClasses.sInfo,id:n?null:e+"_info"});return n||(t.aoDrawCallback.push({fn:Vt,sName:"information"}),a.attr("role","status").attr("aria-live","polite"),P(t.nTable).attr("aria-describedby",e+"_info")),a[0]}function Vt(t){var e,n,a,r,o,i,l=t.aanFeatures.i;0!==l.length&&(i=t.oLanguage,e=t._iDisplayStart+1,n=t.fnDisplayEnd(),a=t.fnRecordsTotal(),o=(r=t.fnRecordsDisplay())?i.sInfo:i.sInfoEmpty,r!==a&&(o+=" "+i.sInfoFiltered),o=Xt(t,o+=i.sInfoPostFix),null!==(i=i.fnInfoCallback)&&(o=i.call(t.oInstance,t,e,n,a,r,o)),P(l).html(o))}function Xt(t,e){var n=t.fnFormatNumber,a=t._iDisplayStart+1,r=t._iDisplayLength,o=t.fnRecordsDisplay(),i=-1===r;return e.replace(/_START_/g,n.call(t,a)).replace(/_END_/g,n.call(t,t.fnDisplayEnd())).replace(/_MAX_/g,n.call(t,t.fnRecordsTotal())).replace(/_TOTAL_/g,n.call(t,o)).replace(/_PAGE_/g,n.call(t,i?1:Math.ceil(a/r))).replace(/_PAGES_/g,n.call(t,i?1:Math.ceil(o/r)))}function Jt(n){var a,t,e,r=n.iInitDisplayStart,o=n.aoColumns,i=n.oFeatures,l=n.bDeferLoading;if(n.bInitialised){for(_t(n),yt(n),Dt(n,n.aoHeader),Dt(n,n.aoFooter),D(n,!0),i.bAutoWidth&&ee(n),a=0,t=o.length;a<t;a++)(e=o[a]).sWidth&&(e.nTh.style.width=M(e.sWidth));R(n,null,"preInit",[n]),u(n);i=E(n);"ssp"==i&&!l||("ajax"==i?Tt(n,[],function(t){var e=Ft(n,t);for(a=0;a<e.length;a++)x(n,e[a]);n.iInitDisplayStart=r,u(n),D(n,!1),qt(n,t)}):(D(n,!1),qt(n)))}else setTimeout(function(){Jt(n)},200)}function qt(t,e){t._bInitComplete=!0,(e||t.oInit.aaData)&&O(t),R(t,null,"plugin-init",[t,e]),R(t,"aoInitComplete","init",[t,e])}function $t(t,e){e=parseInt(e,10);t._iDisplayLength=e,Se(t),R(t,null,"length",[t,e])}function Gt(a){for(var t=a.oClasses,e=a.sTableId,n=a.aLengthMenu,r=Array.isArray(n[0]),o=r?n[0]:n,i=r?n[1]:n,l=P("<select/>",{name:e+"_length","aria-controls":e,class:t.sLengthSelect}),s=0,u=o.length;s<u;s++)l[0][s]=new Option("number"==typeof i[s]?a.fnFormatNumber(i[s]):i[s],o[s]);var c=P("<div><label/></div>").addClass(t.sLength);return a.aanFeatures.l||(c[0].id=e+"_length"),c.children().append(a.oLanguage.sLengthMenu.replace("_MENU_",l[0].outerHTML)),P("select",c).val(a._iDisplayLength).on("change.DT",function(t){$t(a,P(this).val()),y(a)}),P(a.nTable).on("length.dt.DT",function(t,e,n){a===e&&P("select",c).val(n)}),c[0]}function zt(t){function c(t){y(t)}var e=t.sPaginationType,f=w.ext.pager[e],d="function"==typeof f,e=P("<div/>").addClass(t.oClasses.sPaging+e)[0],h=t.aanFeatures;return d||f.fnInit(t,e,c),h.p||(e.id=t.sTableId+"_paginate",t.aoDrawCallback.push({fn:function(t){if(d)for(var e=t._iDisplayStart,n=t._iDisplayLength,a=t.fnRecordsDisplay(),r=-1===n,o=r?0:Math.ceil(e/n),i=r?1:Math.ceil(a/n),l=f(o,i),s=0,u=h.p.length;s<u;s++)ve(t,"pageButton")(t,h.p[s],s,l,o,i);else f.fnUpdate(t,c)},sName:"pagination"})),e}function Yt(t,e,n){var a=t._iDisplayStart,r=t._iDisplayLength,o=t.fnRecordsDisplay(),o=(0===o||-1===r?a=0:"number"==typeof e?o<(a=e*r)&&(a=0):"first"==e?a=0:"previous"==e?(a=0<=r?a-r:0)<0&&(a=0):"next"==e?a+r<o&&(a+=r):"last"==e?a=Math.floor((o-1)/r)*r:W(t,0,"Unknown paging action: "+e,5),t._iDisplayStart!==a);return t._iDisplayStart=a,o?(R(t,null,"page",[t]),n&&y(t)):R(t,null,"page-nc",[t]),o}function Zt(t){return P("<div/>",{id:t.aanFeatures.r?null:t.sTableId+"_processing",class:t.oClasses.sProcessing,role:"status"}).html(t.oLanguage.sProcessing).append("<div><div></div><div></div><div></div><div></div></div>").insertBefore(t.nTable)[0]}function D(t,e){t.oFeatures.bProcessing&&P(t.aanFeatures.r).css("display",e?"block":"none"),R(t,null,"processing",[t,e])}function Kt(t){var e,n,a,r,o,i,l,s,u,c,f,d,h=P(t.nTable),p=t.oScroll;return""===p.sX&&""===p.sY?t.nTable:(e=p.sX,n=p.sY,a=t.oClasses,o=(r=h.children("caption")).length?r[0]._captionSide:null,s=P(h[0].cloneNode(!1)),i=P(h[0].cloneNode(!1)),u=function(t){return t?M(t):null},(l=h.children("tfoot")).length||(l=null),s=P(f="<div/>",{class:a.sScrollWrapper}).append(P(f,{class:a.sScrollHead}).css({overflow:"hidden",position:"relative",border:0,width:e?u(e):"100%"}).append(P(f,{class:a.sScrollHeadInner}).css({"box-sizing":"content-box",width:p.sXInner||"100%"}).append(s.removeAttr("id").css("margin-left",0).append("top"===o?r:null).append(h.children("thead"))))).append(P(f,{class:a.sScrollBody}).css({position:"relative",overflow:"auto",width:u(e)}).append(h)),l&&s.append(P(f,{class:a.sScrollFoot}).css({overflow:"hidden",border:0,width:e?u(e):"100%"}).append(P(f,{class:a.sScrollFootInner}).append(i.removeAttr("id").css("margin-left",0).append("bottom"===o?r:null).append(h.children("tfoot"))))),u=s.children(),c=u[0],f=u[1],d=l?u[2]:null,e&&P(f).on("scroll.DT",function(t){var e=this.scrollLeft;c.scrollLeft=e,l&&(d.scrollLeft=e)}),P(f).css("max-height",n),p.bCollapse||P(f).css("height",n),t.nScrollHead=c,t.nScrollBody=f,t.nScrollFoot=d,t.aoDrawCallback.push({fn:Qt,sName:"scrolling"}),s[0])}function Qt(n){function t(t){(t=t.style).paddingTop="0",t.paddingBottom="0",t.borderTopWidth="0",t.borderBottomWidth="0",t.height=0}var e,a,r,o,i,l=n.oScroll,s=l.sX,u=l.sXInner,c=l.sY,l=l.iBarWidth,f=P(n.nScrollHead),d=f[0].style,h=f.children("div"),p=h[0].style,h=h.children("table"),g=n.nScrollBody,b=P(g),m=g.style,S=P(n.nScrollFoot).children("div"),v=S.children("table"),y=P(n.nTHead),D=P(n.nTable),_=D[0],w=_.style,C=n.nTFoot?P(n.nTFoot):null,T=n.oBrowser,x=T.bScrollOversize,A=(N(n.aoColumns,"nTh"),[]),I=[],F=[],L=[],R=g.scrollHeight>g.clientHeight;n.scrollBarVis!==R&&n.scrollBarVis!==H?(n.scrollBarVis=R,O(n)):(n.scrollBarVis=R,D.children("thead, tfoot").remove(),C&&(R=C.clone().prependTo(D),i=C.find("tr"),a=R.find("tr"),R.find("[id]").removeAttr("id")),R=y.clone().prependTo(D),y=y.find("tr"),e=R.find("tr"),R.find("th, td").removeAttr("tabindex"),R.find("[id]").removeAttr("id"),s||(m.width="100%",f[0].style.width="100%"),P.each(Ct(n,R),function(t,e){r=rt(n,t),e.style.width=n.aoColumns[r].sWidth}),C&&k(function(t){t.style.width=""},a),f=D.outerWidth(),""===s?(w.width="100%",x&&(D.find("tbody").height()>g.offsetHeight||"scroll"==b.css("overflow-y"))&&(w.width=M(D.outerWidth()-l)),f=D.outerWidth()):""!==u&&(w.width=M(u),f=D.outerWidth()),k(t,e),k(function(t){var e=j.getComputedStyle?j.getComputedStyle(t).width:M(P(t).width());F.push(t.innerHTML),A.push(e)},e),k(function(t,e){t.style.width=A[e]},y),P(e).css("height",0),C&&(k(t,a),k(function(t){L.push(t.innerHTML),I.push(M(P(t).css("width")))},a),k(function(t,e){t.style.width=I[e]},i),P(a).height(0)),k(function(t,e){t.innerHTML='<div class="dataTables_sizing">'+F[e]+"</div>",t.childNodes[0].style.height="0",t.childNodes[0].style.overflow="hidden",t.style.width=A[e]},e),C&&k(function(t,e){t.innerHTML='<div class="dataTables_sizing">'+L[e]+"</div>",t.childNodes[0].style.height="0",t.childNodes[0].style.overflow="hidden",t.style.width=I[e]},a),Math.round(D.outerWidth())<Math.round(f)?(o=g.scrollHeight>g.offsetHeight||"scroll"==b.css("overflow-y")?f+l:f,x&&(g.scrollHeight>g.offsetHeight||"scroll"==b.css("overflow-y"))&&(w.width=M(o-l)),""!==s&&""===u||W(n,1,"Possible column misalignment",6)):o="100%",m.width=M(o),d.width=M(o),C&&(n.nScrollFoot.style.width=M(o)),c||x&&(m.height=M(_.offsetHeight+l)),R=D.outerWidth(),h[0].style.width=M(R),p.width=M(R),y=D.height()>g.clientHeight||"scroll"==b.css("overflow-y"),p[i="padding"+(T.bScrollbarLeft?"Left":"Right")]=y?l+"px":"0px",C&&(v[0].style.width=M(R),S[0].style.width=M(R),S[0].style[i]=y?l+"px":"0px"),D.children("colgroup").insertBefore(D.children("thead")),b.trigger("scroll"),!n.bSorted&&!n.bFiltered||n._drawHold||(g.scrollTop=0))}function k(t,e,n){for(var a,r,o=0,i=0,l=e.length;i<l;){for(a=e[i].firstChild,r=n?n[i].firstChild:null;a;)1===a.nodeType&&(n?t(a,r,o):t(a,o),o++),a=a.nextSibling,r=n?r.nextSibling:null;i++}}var te=/<.*?>/g;function ee(t){var e,n,a=t.nTable,r=t.aoColumns,o=t.oScroll,i=o.sY,l=o.sX,o=o.sXInner,s=r.length,u=it(t,"bVisible"),c=P("th",t.nTHead),f=a.getAttribute("width"),d=a.parentNode,h=!1,p=t.oBrowser,g=p.bScrollOversize,b=a.style.width;for(b&&-1!==b.indexOf("%")&&(f=b),D=0;D<u.length;D++)null!==(e=r[u[D]]).sWidth&&(e.sWidth=ae(e.sWidthOrig,d),h=!0);if(g||!h&&!l&&!i&&s==T(t)&&s==c.length)for(D=0;D<s;D++){var m=rt(t,D);null!==m&&(r[m].sWidth=M(c.eq(D).width()))}else{var b=P(a).clone().css("visibility","hidden").removeAttr("id"),S=(b.find("tbody tr").remove(),P("<tr/>").appendTo(b.find("tbody")));for(b.find("thead, tfoot").remove(),b.append(P(t.nTHead).clone()).append(P(t.nTFoot).clone()),b.find("tfoot th, tfoot td").css("width",""),c=Ct(t,b.find("thead")[0]),D=0;D<u.length;D++)e=r[u[D]],c[D].style.width=null!==e.sWidthOrig&&""!==e.sWidthOrig?M(e.sWidthOrig):"",e.sWidthOrig&&l&&P(c[D]).append(P("<div/>").css({width:e.sWidthOrig,margin:0,padding:0,border:0,height:1}));if(t.aoData.length)for(D=0;D<u.length;D++)e=r[n=u[D]],P(re(t,n)).clone(!1).append(e.sContentPadding).appendTo(S);P("[name]",b).removeAttr("name");for(var v=P("<div/>").css(l||i?{position:"absolute",top:0,left:0,height:1,right:0,overflow:"hidden"}:{}).append(b).appendTo(d),y=(l&&o?b.width(o):l?(b.css("width","auto"),b.removeAttr("width"),b.width()<d.clientWidth&&f&&b.width(d.clientWidth)):i?b.width(d.clientWidth):f&&b.width(f),0),D=0;D<u.length;D++){var _=P(c[D]),w=_.outerWidth()-_.width(),_=p.bBounding?Math.ceil(c[D].getBoundingClientRect().width):_.outerWidth();y+=_,r[u[D]].sWidth=M(_-w)}a.style.width=M(y),v.remove()}f&&(a.style.width=M(f)),!f&&!l||t._reszEvt||(o=function(){P(j).on("resize.DT-"+t.sInstance,ne(function(){O(t)}))},g?setTimeout(o,1e3):o(),t._reszEvt=!0)}var ne=w.util.throttle;function ae(t,e){return t?(e=(t=P("<div/>").css("width",M(t)).appendTo(e||v.body))[0].offsetWidth,t.remove(),e):0}function re(t,e){var n,a=oe(t,e);return a<0?null:(n=t.aoData[a]).nTr?n.anCells[e]:P("<td/>").html(S(t,a,e,"display"))[0]}function oe(t,e){for(var n,a=-1,r=-1,o=0,i=t.aoData.length;o<i;o++)(n=(n=(n=S(t,o,e,"display")+"").replace(te,"")).replace(/&nbsp;/g," ")).length>a&&(a=n.length,r=o);return r}function M(t){return null===t?"0px":"number"==typeof t?t<0?"0px":t+"px":t.match(/\d$/)?t+"px":t}function I(t){function e(t){t.length&&!Array.isArray(t[0])?h.push(t):P.merge(h,t)}var n,a,r,o,i,l,s,u=[],c=t.aoColumns,f=t.aaSortingFixed,d=P.isPlainObject(f),h=[];for(Array.isArray(f)&&e(f),d&&f.pre&&e(f.pre),e(t.aaSorting),d&&f.post&&e(f.post),n=0;n<h.length;n++)for(r=(o=c[s=h[n][a=0]].aDataSort).length;a<r;a++)l=c[i=o[a]].sType||"string",h[n]._idx===H&&(h[n]._idx=P.inArray(h[n][1],c[i].asSorting)),u.push({src:s,col:i,dir:h[n][1],index:h[n]._idx,type:l,formatter:w.ext.type.order[l+"-pre"]});return u}function ie(t){var e,n,a,r,c,f=[],u=w.ext.type.order,d=t.aoData,o=(t.aoColumns,0),i=t.aiDisplayMaster;for(lt(t),e=0,n=(c=I(t)).length;e<n;e++)(r=c[e]).formatter&&o++,fe(t,r.col);if("ssp"!=E(t)&&0!==c.length){for(e=0,a=i.length;e<a;e++)f[i[e]]=e;o===c.length?i.sort(function(t,e){for(var n,a,r,o,i=c.length,l=d[t]._aSortData,s=d[e]._aSortData,u=0;u<i;u++)if(0!=(r=(n=l[(o=c[u]).col])<(a=s[o.col])?-1:a<n?1:0))return"asc"===o.dir?r:-r;return(n=f[t])<(a=f[e])?-1:a<n?1:0}):i.sort(function(t,e){for(var n,a,r,o=c.length,i=d[t]._aSortData,l=d[e]._aSortData,s=0;s<o;s++)if(n=i[(r=c[s]).col],a=l[r.col],0!==(r=(u[r.type+"-"+r.dir]||u["string-"+r.dir])(n,a)))return r;return(n=f[t])<(a=f[e])?-1:a<n?1:0})}t.bSorted=!0}function le(t){for(var e=t.aoColumns,n=I(t),a=t.oLanguage.oAria,r=0,o=e.length;r<o;r++){var i=e[r],l=i.asSorting,s=i.ariaTitle||i.sTitle.replace(/<.*?>/g,""),u=i.nTh;u.removeAttribute("aria-sort"),i=i.bSortable?s+("asc"===(0<n.length&&n[0].col==r&&(u.setAttribute("aria-sort","asc"==n[0].dir?"ascending":"descending"),l[n[0].index+1])||l[0])?a.sSortAscending:a.sSortDescending):s,u.setAttribute("aria-label",i)}}function se(t,e,n,a){function r(t,e){var n=t._idx;return(n=n===H?P.inArray(t[1],s):n)+1<s.length?n+1:e?null:0}var o,i=t.aoColumns[e],l=t.aaSorting,s=i.asSorting;"number"==typeof l[0]&&(l=t.aaSorting=[l]),n&&t.oFeatures.bSortMulti?-1!==(i=P.inArray(e,N(l,"0")))?null===(o=null===(o=r(l[i],!0))&&1===l.length?0:o)?l.splice(i,1):(l[i][1]=s[o],l[i]._idx=o):(l.push([e,s[0],0]),l[l.length-1]._idx=0):l.length&&l[0][0]==e?(o=r(l[0]),l.length=1,l[0][1]=s[o],l[0]._idx=o):(l.length=0,l.push([e,s[0]]),l[0]._idx=0),u(t),"function"==typeof a&&a(t)}function ue(e,t,n,a){var r=e.aoColumns[n];me(t,{},function(t){!1!==r.bSortable&&(e.oFeatures.bProcessing?(D(e,!0),setTimeout(function(){se(e,n,t.shiftKey,a),"ssp"!==E(e)&&D(e,!1)},0)):se(e,n,t.shiftKey,a))})}function ce(t){var e,n,a,r=t.aLastSort,o=t.oClasses.sSortColumn,i=I(t),l=t.oFeatures;if(l.bSort&&l.bSortClasses){for(e=0,n=r.length;e<n;e++)a=r[e].src,P(N(t.aoData,"anCells",a)).removeClass(o+(e<2?e+1:3));for(e=0,n=i.length;e<n;e++)a=i[e].src,P(N(t.aoData,"anCells",a)).addClass(o+(e<2?e+1:3))}t.aLastSort=i}function fe(t,e){for(var n,a,r,o=t.aoColumns[e],i=w.ext.order[o.sSortDataType],l=(i&&(n=i.call(t.oInstance,t,e,ot(t,e))),w.ext.type.order[o.sType+"-pre"]),s=0,u=t.aoData.length;s<u;s++)(a=t.aoData[s])._aSortData||(a._aSortData=[]),a._aSortData[e]&&!i||(r=i?n[s]:S(t,s,e,"sort"),a._aSortData[e]=l?l(r):r)}function de(n){var t;n._bLoadingState||(t={time:+new Date,start:n._iDisplayStart,length:n._iDisplayLength,order:P.extend(!0,[],n.aaSorting),search:Et(n.oPreviousSearch),columns:P.map(n.aoColumns,function(t,e){return{visible:t.bVisible,search:Et(n.aoPreSearchCols[e])}})},n.oSavedState=t,R(n,"aoStateSaveParams","stateSaveParams",[n,t]),n.oFeatures.bStateSave&&!n.bDestroying&&n.fnStateSaveCallback.call(n.oInstance,n,t))}function he(e,t,n){var a;if(e.oFeatures.bStateSave)return(a=e.fnStateLoadCallback.call(e.oInstance,e,function(t){pe(e,t,n)}))!==H&&pe(e,a,n),!0;n()}function pe(n,t,e){var a,r,o=n.aoColumns,i=(n._bLoadingState=!0,n._bInitComplete?new w.Api(n):null);if(t&&t.time){var l=R(n,"aoStateLoadParams","stateLoadParams",[n,t]);if(-1!==P.inArray(!1,l))n._bLoadingState=!1;else{l=n.iStateDuration;if(0<l&&t.time<+new Date-1e3*l)n._bLoadingState=!1;else if(t.columns&&o.length!==t.columns.length)n._bLoadingState=!1;else{if(n.oLoadedState=P.extend(!0,{},t),t.length!==H&&(i?i.page.len(t.length):n._iDisplayLength=t.length),t.start!==H&&(null===i?(n._iDisplayStart=t.start,n.iInitDisplayStart=t.start):Yt(n,t.start/n._iDisplayLength)),t.order!==H&&(n.aaSorting=[],P.each(t.order,function(t,e){n.aaSorting.push(e[0]>=o.length?[0,e[1]]:e)})),t.search!==H&&P.extend(n.oPreviousSearch,Bt(t.search)),t.columns){for(a=0,r=t.columns.length;a<r;a++){var s=t.columns[a];s.visible!==H&&(i?i.column(a).visible(s.visible,!1):o[a].bVisible=s.visible),s.search!==H&&P.extend(n.aoPreSearchCols[a],Bt(s.search))}i&&i.columns.adjust()}n._bLoadingState=!1,R(n,"aoStateLoaded","stateLoaded",[n,t])}}}else n._bLoadingState=!1;e()}function ge(t){var e=w.settings,t=P.inArray(t,N(e,"nTable"));return-1!==t?e[t]:null}function W(t,e,n,a){if(n="DataTables warning: "+(t?"table id="+t.sTableId+" - ":"")+n,a&&(n+=". For more information about this error, please see http://datatables.net/tn/"+a),e)j.console&&console.log&&console.log(n);else{e=w.ext,e=e.sErrMode||e.errMode;if(t&&R(t,null,"error",[t,a,n]),"alert"==e)alert(n);else{if("throw"==e)throw new Error(n);"function"==typeof e&&e(t,a,n)}}}function F(n,a,t,e){Array.isArray(t)?P.each(t,function(t,e){Array.isArray(e)?F(n,a,e[0],e[1]):F(n,a,e)}):(e===H&&(e=t),a[t]!==H&&(n[e]=a[t]))}function be(t,e,n){var a,r;for(r in e)e.hasOwnProperty(r)&&(a=e[r],P.isPlainObject(a)?(P.isPlainObject(t[r])||(t[r]={}),P.extend(!0,t[r],a)):n&&"data"!==r&&"aaData"!==r&&Array.isArray(a)?t[r]=a.slice():t[r]=a);return t}function me(e,t,n){P(e).on("click.DT",t,function(t){P(e).trigger("blur"),n(t)}).on("keypress.DT",t,function(t){13===t.which&&(t.preventDefault(),n(t))}).on("selectstart.DT",function(){return!1})}function L(t,e,n,a){n&&t[e].push({fn:n,sName:a})}function R(n,t,e,a){var r=[];return t&&(r=P.map(n[t].slice().reverse(),function(t,e){return t.fn.apply(n.oInstance,a)})),null!==e&&(t=P.Event(e+".dt"),(e=P(n.nTable)).trigger(t,a),0===e.parents("body").length&&P("body").trigger(t,a),r.push(t.result)),r}function Se(t){var e=t._iDisplayStart,n=t.fnDisplayEnd(),a=t._iDisplayLength;n<=e&&(e=n-a),e-=e%a,t._iDisplayStart=e=-1===a||e<0?0:e}function ve(t,e){var t=t.renderer,n=w.ext.renderer[e];return P.isPlainObject(t)&&t[e]?n[t[e]]||n._:"string"==typeof t&&n[t]||n._}function E(t){return t.oFeatures.bServerSide?"ssp":t.ajax||t.sAjaxSource?"ajax":"dom"}function ye(t,n){var a;return Array.isArray(t)?P.map(t,function(t){return ye(t,n)}):"number"==typeof t?[n[t]]:(a=P.map(n,function(t,e){return t.nTable}),P(a).filter(t).map(function(t){var e=P.inArray(this,a);return n[e]}).toArray())}function De(r,o,t){var e,n;t&&(e=new B(r)).one("draw",function(){t(e.ajax.json())}),"ssp"==E(r)?u(r,o):(D(r,!0),(n=r.jqXHR)&&4!==n.readyState&&n.abort(),Tt(r,[],function(t){pt(r);for(var e=Ft(r,t),n=0,a=e.length;n<a;n++)x(r,e[n]);u(r,o),D(r,!1)}))}function _e(t,e,n,a,r){for(var o,i,l,s,u=[],c=typeof e,f=0,d=(e=e&&"string"!=c&&"function"!=c&&e.length!==H?e:[e]).length;f<d;f++)for(l=0,s=(i=e[f]&&e[f].split&&!e[f].match(/[\[\(:]/)?e[f].split(","):[e[f]]).length;l<s;l++)(o=n("string"==typeof i[l]?i[l].trim():i[l]))&&o.length&&(u=u.concat(o));var h=p.selector[t];if(h.length)for(f=0,d=h.length;f<d;f++)u=h[f](a,r,u);return z(u)}function we(t){return(t=t||{}).filter&&t.search===H&&(t.search=t.filter),P.extend({search:"none",order:"current",page:"all"},t)}function Ce(t){for(var e=0,n=t.length;e<n;e++)if(0<t[e].length)return t[0]=t[e],t[0].length=1,t.length=1,t.context=[t.context[e]],t;return t.length=0,t}function Te(o,t,e,n){function i(t,e){var n;if(Array.isArray(t)||t instanceof P)for(var a=0,r=t.length;a<r;a++)i(t[a],e);else t.nodeName&&"tr"===t.nodeName.toLowerCase()?l.push(t):(n=P("<tr><td></td></tr>").addClass(e),P("td",n).addClass(e).html(t)[0].colSpan=T(o),l.push(n[0]))}var l=[];i(e,n),t._details&&t._details.detach(),t._details=P(l),t._detailsShow&&t._details.insertAfter(t.nTr)}function xe(t,e){var n=t.context;if(n.length&&t.length){var a=n[0].aoData[t[0]];if(a._details){(a._detailsShow=e)?(a._details.insertAfter(a.nTr),P(a.nTr).addClass("dt-hasChild")):(a._details.detach(),P(a.nTr).removeClass("dt-hasChild")),R(n[0],null,"childRow",[e,t.row(t[0])]);var s=n[0],r=new B(s),a=".dt.DT_details",e="draw"+a,t="column-sizing"+a,a="destroy"+a,u=s.aoData;if(r.off(e+" "+t+" "+a),N(u,"_details").length>0){r.on(e,function(t,e){if(s!==e)return;r.rows({page:"current"}).eq(0).each(function(t){var e=u[t];if(e._detailsShow)e._details.insertAfter(e.nTr)})});r.on(t,function(t,e,n,a){if(s!==e)return;var r,o=T(e);for(var i=0,l=u.length;i<l;i++){r=u[i];if(r._details)r._details.children("td[colspan]").attr("colspan",o)}});r.on(a,function(t,e){if(s!==e)return;for(var n=0,a=u.length;n<a;n++)if(u[n]._details)Re(r,n)})}Le(n)}}}function Ae(t,e,n,a,r){for(var o=[],i=0,l=r.length;i<l;i++)o.push(S(t,r[i],e));return o}var Ie=[],o=Array.prototype,B=function(t,e){if(!(this instanceof B))return new B(t,e);function n(t){var e,n,a,r;t=t,a=w.settings,r=P.map(a,function(t,e){return t.nTable}),(t=t?t.nTable&&t.oApi?[t]:t.nodeName&&"table"===t.nodeName.toLowerCase()?-1!==(e=P.inArray(t,r))?[a[e]]:null:t&&"function"==typeof t.settings?t.settings().toArray():("string"==typeof t?n=P(t):t instanceof P&&(n=t),n?n.map(function(t){return-1!==(e=P.inArray(this,r))?a[e]:null}).toArray():void 0):[])&&o.push.apply(o,t)}var o=[];if(Array.isArray(t))for(var a=0,r=t.length;a<r;a++)n(t[a]);else n(t);this.context=z(o),e&&P.merge(this,e),this.selector={rows:null,cols:null,opts:null},B.extend(this,this,Ie)},Fe=(w.Api=B,P.extend(B.prototype,{any:function(){return 0!==this.count()},concat:o.concat,context:[],count:function(){return this.flatten().length},each:function(t){for(var e=0,n=this.length;e<n;e++)t.call(this,this[e],e,this);return this},eq:function(t){var e=this.context;return e.length>t?new B(e[t],this[t]):null},filter:function(t){var e=[];if(o.filter)e=o.filter.call(this,t,this);else for(var n=0,a=this.length;n<a;n++)t.call(this,this[n],n,this)&&e.push(this[n]);return new B(this.context,e)},flatten:function(){var t=[];return new B(this.context,t.concat.apply(t,this.toArray()))},join:o.join,indexOf:o.indexOf||function(t,e){for(var n=e||0,a=this.length;n<a;n++)if(this[n]===t)return n;return-1},iterator:function(t,e,n,a){var r,o,i,l,s,u,c,f,d=[],h=this.context,p=this.selector;for("string"==typeof t&&(a=n,n=e,e=t,t=!1),o=0,i=h.length;o<i;o++){var g=new B(h[o]);if("table"===e)(r=n.call(g,h[o],o))!==H&&d.push(r);else if("columns"===e||"rows"===e)(r=n.call(g,h[o],this[o],o))!==H&&d.push(r);else if("column"===e||"column-rows"===e||"row"===e||"cell"===e)for(c=this[o],"column-rows"===e&&(u=Fe(h[o],p.opts)),l=0,s=c.length;l<s;l++)f=c[l],(r="cell"===e?n.call(g,h[o],f.row,f.column,o,l):n.call(g,h[o],f,o,l,u))!==H&&d.push(r)}return d.length||a?((t=(a=new B(h,t?d.concat.apply([],d):d)).selector).rows=p.rows,t.cols=p.cols,t.opts=p.opts,a):this},lastIndexOf:o.lastIndexOf||function(t,e){return this.indexOf.apply(this.toArray.reverse(),arguments)},length:0,map:function(t){var e=[];if(o.map)e=o.map.call(this,t,this);else for(var n=0,a=this.length;n<a;n++)e.push(t.call(this,this[n],n));return new B(this.context,e)},pluck:function(t){var e=w.util.get(t);return this.map(function(t){return e(t)})},pop:o.pop,push:o.push,reduce:o.reduce||function(t,e){return et(this,t,e,0,this.length,1)},reduceRight:o.reduceRight||function(t,e){return et(this,t,e,this.length-1,-1,-1)},reverse:o.reverse,selector:null,shift:o.shift,slice:function(){return new B(this.context,this)},sort:o.sort,splice:o.splice,toArray:function(){return o.slice.call(this)},to$:function(){return P(this)},toJQuery:function(){return P(this)},unique:function(){return new B(this.context,z(this))},unshift:o.unshift}),B.extend=function(t,e,n){if(n.length&&e&&(e instanceof B||e.__dt_wrapper))for(var a,r=0,o=n.length;r<o;r++)e[(a=n[r]).name]="function"===a.type?function(e,n,a){return function(){var t=n.apply(e,arguments);return B.extend(t,t,a.methodExt),t}}(t,a.val,a):"object"===a.type?{}:a.val,e[a.name].__dt_wrapper=!0,B.extend(t,e[a.name],a.propExt)},B.register=e=function(t,e){if(Array.isArray(t))for(var n=0,a=t.length;n<a;n++)B.register(t[n],e);else for(var r=t.split("."),o=Ie,i=0,l=r.length;i<l;i++){var s,u,c=function(t,e){for(var n=0,a=t.length;n<a;n++)if(t[n].name===e)return t[n];return null}(o,u=(s=-1!==r[i].indexOf("()"))?r[i].replace("()",""):r[i]);c||o.push(c={name:u,val:{},methodExt:[],propExt:[],type:"object"}),i===l-1?(c.val=e,c.type="function"==typeof e?"function":P.isPlainObject(e)?"object":"other"):o=s?c.methodExt:c.propExt}},B.registerPlural=t=function(t,e,n){B.register(t,n),B.register(e,function(){var t=n.apply(this,arguments);return t===this?this:t instanceof B?t.length?Array.isArray(t[0])?new B(t.context,t[0]):t[0]:H:t})},e("tables()",function(t){return t!==H&&null!==t?new B(ye(t,this.context)):this}),e("table()",function(t){var t=this.tables(t),e=t.context;return e.length?new B(e[0]):t}),t("tables().nodes()","table().node()",function(){return this.iterator("table",function(t){return t.nTable},1)}),t("tables().body()","table().body()",function(){return this.iterator("table",function(t){return t.nTBody},1)}),t("tables().header()","table().header()",function(){return this.iterator("table",function(t){return t.nTHead},1)}),t("tables().footer()","table().footer()",function(){return this.iterator("table",function(t){return t.nTFoot},1)}),t("tables().containers()","table().container()",function(){return this.iterator("table",function(t){return t.nTableWrapper},1)}),e("draw()",function(e){return this.iterator("table",function(t){"page"===e?y(t):u(t,!1===(e="string"==typeof e?"full-hold"!==e:e))})}),e("page()",function(e){return e===H?this.page.info().page:this.iterator("table",function(t){Yt(t,e)})}),e("page.info()",function(t){var e,n,a,r,o;return 0===this.context.length?H:(n=(e=this.context[0])._iDisplayStart,a=e.oFeatures.bPaginate?e._iDisplayLength:-1,r=e.fnRecordsDisplay(),{page:(o=-1===a)?0:Math.floor(n/a),pages:o?1:Math.ceil(r/a),start:n,end:e.fnDisplayEnd(),length:a,recordsTotal:e.fnRecordsTotal(),recordsDisplay:r,serverSide:"ssp"===E(e)})}),e("page.len()",function(e){return e===H?0!==this.context.length?this.context[0]._iDisplayLength:H:this.iterator("table",function(t){$t(t,e)})}),e("ajax.json()",function(){var t=this.context;if(0<t.length)return t[0].json}),e("ajax.params()",function(){var t=this.context;if(0<t.length)return t[0].oAjaxData}),e("ajax.reload()",function(e,n){return this.iterator("table",function(t){De(t,!1===n,e)})}),e("ajax.url()",function(e){var t=this.context;return e===H?0===t.length?H:(t=t[0]).ajax?P.isPlainObject(t.ajax)?t.ajax.url:t.ajax:t.sAjaxSource:this.iterator("table",function(t){P.isPlainObject(t.ajax)?t.ajax.url=e:t.ajax=e})}),e("ajax.url().load()",function(e,n){return this.iterator("table",function(t){De(t,!1===n,e)})}),function(t,e){var n,a=[],r=t.aiDisplay,o=t.aiDisplayMaster,i=e.search,l=e.order,e=e.page;if("ssp"==E(t))return"removed"===i?[]:f(0,o.length);if("current"==e)for(u=t._iDisplayStart,c=t.fnDisplayEnd();u<c;u++)a.push(r[u]);else if("current"==l||"applied"==l){if("none"==i)a=o.slice();else if("applied"==i)a=r.slice();else if("removed"==i){for(var s={},u=0,c=r.length;u<c;u++)s[r[u]]=null;a=P.map(o,function(t){return s.hasOwnProperty(t)?null:t})}}else if("index"==l||"original"==l)for(u=0,c=t.aoData.length;u<c;u++)("none"==i||-1===(n=P.inArray(u,r))&&"removed"==i||0<=n&&"applied"==i)&&a.push(u);return a}),Le=(e("rows()",function(e,n){e===H?e="":P.isPlainObject(e)&&(n=e,e=""),n=we(n);var t=this.iterator("table",function(t){return _e("row",e,function(n){var t=d(n),a=r.aoData;if(null!==t&&!o)return[t];if(i=i||Fe(r,o),null!==t&&-1!==P.inArray(t,i))return[t];if(null===n||n===H||""===n)return i;if("function"==typeof n)return P.map(i,function(t){var e=a[t];return n(t,e._aData,e.nTr)?t:null});if(n.nodeName)return t=n._DT_RowIndex,e=n._DT_CellIndex,t!==H?a[t]&&a[t].nTr===n?[t]:[]:e?a[e.row]&&a[e.row].nTr===n.parentNode?[e.row]:[]:(t=P(n).closest("*[data-dt-row]")).length?[t.data("dt-row")]:[];if("string"==typeof n&&"#"===n.charAt(0)){var e=r.aIds[n.replace(/^#/,"")];if(e!==H)return[e.idx]}t=_(m(r.aoData,i,"nTr"));return P(t).filter(n).map(function(){return this._DT_RowIndex}).toArray()},r=t,o=n);var r,o,i},1);return t.selector.rows=e,t.selector.opts=n,t}),e("rows().nodes()",function(){return this.iterator("row",function(t,e){return t.aoData[e].nTr||H},1)}),e("rows().data()",function(){return this.iterator(!0,"rows",function(t,e){return m(t.aoData,e,"_aData")},1)}),t("rows().cache()","row().cache()",function(n){return this.iterator("row",function(t,e){t=t.aoData[e];return"search"===n?t._aFilterData:t._aSortData},1)}),t("rows().invalidate()","row().invalidate()",function(n){return this.iterator("row",function(t,e){bt(t,e,n)})}),t("rows().indexes()","row().index()",function(){return this.iterator("row",function(t,e){return e},1)}),t("rows().ids()","row().id()",function(t){for(var e=[],n=this.context,a=0,r=n.length;a<r;a++)for(var o=0,i=this[a].length;o<i;o++){var l=n[a].rowIdFn(n[a].aoData[this[a][o]]._aData);e.push((!0===t?"#":"")+l)}return new B(n,e)}),t("rows().remove()","row().remove()",function(){var f=this;return this.iterator("row",function(t,e,n){var a,r,o,i,l,s,u=t.aoData,c=u[e];for(u.splice(e,1),a=0,r=u.length;a<r;a++)if(s=(l=u[a]).anCells,null!==l.nTr&&(l.nTr._DT_RowIndex=a),null!==s)for(o=0,i=s.length;o<i;o++)s[o]._DT_CellIndex.row=a;gt(t.aiDisplayMaster,e),gt(t.aiDisplay,e),gt(f[n],e,!1),0<t._iRecordsDisplay&&t._iRecordsDisplay--,Se(t);n=t.rowIdFn(c._aData);n!==H&&delete t.aIds[n]}),this.iterator("table",function(t){for(var e=0,n=t.aoData.length;e<n;e++)t.aoData[e].idx=e}),this}),e("rows.add()",function(o){var t=this.iterator("table",function(t){for(var e,n=[],a=0,r=o.length;a<r;a++)(e=o[a]).nodeName&&"TR"===e.nodeName.toUpperCase()?n.push(ut(t,e)[0]):n.push(x(t,e));return n},1),e=this.rows(-1);return e.pop(),P.merge(e,t),e}),e("row()",function(t,e){return Ce(this.rows(t,e))}),e("row().data()",function(t){var e,n=this.context;return t===H?n.length&&this.length?n[0].aoData[this[0]]._aData:H:((e=n[0].aoData[this[0]])._aData=t,Array.isArray(t)&&e.nTr&&e.nTr.id&&b(n[0].rowId)(t,e.nTr.id),bt(n[0],this[0],"data"),this)}),e("row().node()",function(){var t=this.context;return t.length&&this.length&&t[0].aoData[this[0]].nTr||null}),e("row.add()",function(e){e instanceof P&&e.length&&(e=e[0]);var t=this.iterator("table",function(t){return e.nodeName&&"TR"===e.nodeName.toUpperCase()?ut(t,e)[0]:x(t,e)});return this.row(t[0])}),P(v).on("plugin-init.dt",function(t,e){var n=new B(e),a="on-plugin-init",r="stateSaveParams."+a,o="destroy. "+a,a=(n.on(r,function(t,e,n){for(var a=e.rowIdFn,r=e.aoData,o=[],i=0;i<r.length;i++)r[i]._detailsShow&&o.push("#"+a(r[i]._aData));n.childRows=o}),n.on(o,function(){n.off(r+" "+o)}),n.state.loaded());a&&a.childRows&&n.rows(P.map(a.childRows,function(t){return t.replace(/:/g,"\\:")})).every(function(){R(e,null,"requestChild",[this])})}),w.util.throttle(function(t){de(t[0])},500)),Re=function(t,e){var n=t.context;n.length&&(e=n[0].aoData[e!==H?e:t[0]])&&e._details&&(e._details.remove(),e._detailsShow=H,e._details=H,P(e.nTr).removeClass("dt-hasChild"),Le(n))},Pe="row().child",je=Pe+"()",He=(e(je,function(t,e){var n=this.context;return t===H?n.length&&this.length?n[0].aoData[this[0]]._details:H:(!0===t?this.child.show():!1===t?Re(this):n.length&&this.length&&Te(n[0],n[0].aoData[this[0]],t,e),this)}),e([Pe+".show()",je+".show()"],function(t){return xe(this,!0),this}),e([Pe+".hide()",je+".hide()"],function(){return xe(this,!1),this}),e([Pe+".remove()",je+".remove()"],function(){return Re(this),this}),e(Pe+".isShown()",function(){var t=this.context;return t.length&&this.length&&t[0].aoData[this[0]]._detailsShow||!1}),/^([^:]+):(name|visIdx|visible)$/),Ne=(e("columns()",function(n,a){n===H?n="":P.isPlainObject(n)&&(a=n,n=""),a=we(a);var t=this.iterator("table",function(t){return e=n,l=a,s=(i=t).aoColumns,u=N(s,"sName"),c=N(s,"nTh"),_e("column",e,function(n){var a,t=d(n);if(""===n)return f(s.length);if(null!==t)return[0<=t?t:s.length+t];if("function"==typeof n)return a=Fe(i,l),P.map(s,function(t,e){return n(e,Ae(i,e,0,0,a),c[e])?e:null});var r="string"==typeof n?n.match(He):"";if(r)switch(r[2]){case"visIdx":case"visible":var e,o=parseInt(r[1],10);return o<0?[(e=P.map(s,function(t,e){return t.bVisible?e:null}))[e.length+o]]:[rt(i,o)];case"name":return P.map(u,function(t,e){return t===r[1]?e:null});default:return[]}return n.nodeName&&n._DT_CellIndex?[n._DT_CellIndex.column]:(t=P(c).filter(n).map(function(){return P.inArray(this,c)}).toArray()).length||!n.nodeName?t:(t=P(n).closest("*[data-dt-column]")).length?[t.data("dt-column")]:[]},i,l);var i,e,l,s,u,c},1);return t.selector.cols=n,t.selector.opts=a,t}),t("columns().header()","column().header()",function(t,e){return this.iterator("column",function(t,e){return t.aoColumns[e].nTh},1)}),t("columns().footer()","column().footer()",function(t,e){return this.iterator("column",function(t,e){return t.aoColumns[e].nTf},1)}),t("columns().data()","column().data()",function(){return this.iterator("column-rows",Ae,1)}),t("columns().dataSrc()","column().dataSrc()",function(){return this.iterator("column",function(t,e){return t.aoColumns[e].mData},1)}),t("columns().cache()","column().cache()",function(o){return this.iterator("column-rows",function(t,e,n,a,r){return m(t.aoData,r,"search"===o?"_aFilterData":"_aSortData",e)},1)}),t("columns().nodes()","column().nodes()",function(){return this.iterator("column-rows",function(t,e,n,a,r){return m(t.aoData,r,"anCells",e)},1)}),t("columns().visible()","column().visible()",function(f,n){var e=this,t=this.iterator("column",function(t,e){if(f===H)return t.aoColumns[e].bVisible;var n,a,r=e,e=f,o=t.aoColumns,i=o[r],l=t.aoData;if(e===H)i.bVisible;else if(i.bVisible!==e){if(e)for(var s=P.inArray(!0,N(o,"bVisible"),r+1),u=0,c=l.length;u<c;u++)a=l[u].nTr,n=l[u].anCells,a&&a.insertBefore(n[r],n[s]||null);else P(N(t.aoData,"anCells",r)).detach();i.bVisible=e}});return f!==H&&this.iterator("table",function(t){Dt(t,t.aoHeader),Dt(t,t.aoFooter),t.aiDisplay.length||P(t.nTBody).find("td[colspan]").attr("colspan",T(t)),de(t),e.iterator("column",function(t,e){R(t,null,"column-visibility",[t,e,f,n])}),n!==H&&!n||e.columns.adjust()}),t}),t("columns().indexes()","column().index()",function(n){return this.iterator("column",function(t,e){return"visible"===n?ot(t,e):e},1)}),e("columns.adjust()",function(){return this.iterator("table",function(t){O(t)},1)}),e("column.index()",function(t,e){var n;if(0!==this.context.length)return n=this.context[0],"fromVisible"===t||"toData"===t?rt(n,e):"fromData"===t||"toVisible"===t?ot(n,e):void 0}),e("column()",function(t,e){return Ce(this.columns(t,e))}),e("cells()",function(g,t,b){var a,r,o,i,l,s,e;return P.isPlainObject(g)&&(g.row===H?(b=g,g=null):(b=t,t=null)),P.isPlainObject(t)&&(b=t,t=null),null===t||t===H?this.iterator("table",function(t){return a=t,t=g,e=we(b),f=a.aoData,d=Fe(a,e),n=_(m(f,d,"anCells")),h=P(Y([],n)),p=a.aoColumns.length,_e("cell",t,function(t){var e,n="function"==typeof t;if(null===t||t===H||n){for(o=[],i=0,l=d.length;i<l;i++)for(r=d[i],s=0;s<p;s++)u={row:r,column:s},(!n||(c=f[r],t(u,S(a,r,s),c.anCells?c.anCells[s]:null)))&&o.push(u);return o}return P.isPlainObject(t)?t.column!==H&&t.row!==H&&-1!==P.inArray(t.row,d)?[t]:[]:(e=h.filter(t).map(function(t,e){return{row:e._DT_CellIndex.row,column:e._DT_CellIndex.column}}).toArray()).length||!t.nodeName?e:(c=P(t).closest("*[data-dt-row]")).length?[{row:c.data("dt-row"),column:c.data("dt-column")}]:[]},a,e);var a,e,r,o,i,l,s,u,c,f,d,n,h,p}):(e=b?{page:b.page,order:b.order,search:b.search}:{},a=this.columns(t,e),r=this.rows(g,e),e=this.iterator("table",function(t,e){var n=[];for(o=0,i=r[e].length;o<i;o++)for(l=0,s=a[e].length;l<s;l++)n.push({row:r[e][o],column:a[e][l]});return n},1),e=b&&b.selected?this.cells(e,b):e,P.extend(e.selector,{cols:t,rows:g,opts:b}),e)}),t("cells().nodes()","cell().node()",function(){return this.iterator("cell",function(t,e,n){t=t.aoData[e];return t&&t.anCells?t.anCells[n]:H},1)}),e("cells().data()",function(){return this.iterator("cell",function(t,e,n){return S(t,e,n)},1)}),t("cells().cache()","cell().cache()",function(a){return a="search"===a?"_aFilterData":"_aSortData",this.iterator("cell",function(t,e,n){return t.aoData[e][a][n]},1)}),t("cells().render()","cell().render()",function(a){return this.iterator("cell",function(t,e,n){return S(t,e,n,a)},1)}),t("cells().indexes()","cell().index()",function(){return this.iterator("cell",function(t,e,n){return{row:e,column:n,columnVisible:ot(t,n)}},1)}),t("cells().invalidate()","cell().invalidate()",function(a){return this.iterator("cell",function(t,e,n){bt(t,e,a,n)})}),e("cell()",function(t,e,n){return Ce(this.cells(t,e,n))}),e("cell().data()",function(t){var e=this.context,n=this[0];return t===H?e.length&&n.length?S(e[0],n[0].row,n[0].column):H:(ct(e[0],n[0].row,n[0].column,t),bt(e[0],n[0].row,"data",n[0].column),this)}),e("order()",function(e,t){var n=this.context;return e===H?0!==n.length?n[0].aaSorting:H:("number"==typeof e?e=[[e,t]]:e.length&&!Array.isArray(e[0])&&(e=Array.prototype.slice.call(arguments)),this.iterator("table",function(t){t.aaSorting=e.slice()}))}),e("order.listener()",function(e,n,a){return this.iterator("table",function(t){ue(t,e,n,a)})}),e("order.fixed()",function(e){var t;return e?this.iterator("table",function(t){t.aaSortingFixed=P.extend(!0,{},e)}):(t=(t=this.context).length?t[0].aaSortingFixed:H,Array.isArray(t)?{pre:t}:t)}),e(["columns().order()","column().order()"],function(a){var r=this;return this.iterator("table",function(t,e){var n=[];P.each(r[e],function(t,e){n.push([e,a])}),t.aaSorting=n})}),e("search()",function(e,n,a,r){var t=this.context;return e===H?0!==t.length?t[0].oPreviousSearch.sSearch:H:this.iterator("table",function(t){t.oFeatures.bFilter&&Rt(t,P.extend({},t.oPreviousSearch,{sSearch:e+"",bRegex:null!==n&&n,bSmart:null===a||a,bCaseInsensitive:null===r||r}),1)})}),t("columns().search()","column().search()",function(a,r,o,i){return this.iterator("column",function(t,e){var n=t.aoPreSearchCols;if(a===H)return n[e].sSearch;t.oFeatures.bFilter&&(P.extend(n[e],{sSearch:a+"",bRegex:null!==r&&r,bSmart:null===o||o,bCaseInsensitive:null===i||i}),Rt(t,t.oPreviousSearch,1))})}),e("state()",function(){return this.context.length?this.context[0].oSavedState:null}),e("state.clear()",function(){return this.iterator("table",function(t){t.fnStateSaveCallback.call(t.oInstance,t,{})})}),e("state.loaded()",function(){return this.context.length?this.context[0].oLoadedState:null}),e("state.save()",function(){return this.iterator("table",function(t){de(t)})}),w.use=function(t,e){"lib"===e||t.fn?P=t:"win"==e||t.document?v=(j=t).document:"datetime"!==e&&"DateTime"!==t.type||(w.DateTime=t)},w.factory=function(t,e){var n=!1;return t&&t.document&&(v=(j=t).document),e&&e.fn&&e.fn.jquery&&(P=e,n=!0),n},w.versionCheck=w.fnVersionCheck=function(t){for(var e,n,a=w.version.split("."),r=t.split("."),o=0,i=r.length;o<i;o++)if((e=parseInt(a[o],10)||0)!==(n=parseInt(r[o],10)||0))return n<e;return!0},w.isDataTable=w.fnIsDataTable=function(t){var r=P(t).get(0),o=!1;return t instanceof w.Api||(P.each(w.settings,function(t,e){var n=e.nScrollHead?P("table",e.nScrollHead)[0]:null,a=e.nScrollFoot?P("table",e.nScrollFoot)[0]:null;e.nTable!==r&&n!==r&&a!==r||(o=!0)}),o)},w.tables=w.fnTables=function(e){var t=!1,n=(P.isPlainObject(e)&&(t=e.api,e=e.visible),P.map(w.settings,function(t){if(!e||P(t.nTable).is(":visible"))return t.nTable}));return t?new B(n):n},w.camelToHungarian=C,e("$()",function(t,e){e=this.rows(e).nodes(),e=P(e);return P([].concat(e.filter(t).toArray(),e.find(t).toArray()))}),P.each(["on","one","off"],function(t,n){e(n+"()",function(){var t=Array.prototype.slice.call(arguments),e=(t[0]=P.map(t[0].split(/\s/),function(t){return t.match(/\.dt\b/)?t:t+".dt"}).join(" "),P(this.tables().nodes()));return e[n].apply(e,t),this})}),e("clear()",function(){return this.iterator("table",function(t){pt(t)})}),e("settings()",function(){return new B(this.context,this.context)}),e("init()",function(){var t=this.context;return t.length?t[0].oInit:null}),e("data()",function(){return this.iterator("table",function(t){return N(t.aoData,"_aData")}).flatten()}),e("destroy()",function(c){return c=c||!1,this.iterator("table",function(e){var n,t=e.oClasses,a=e.nTable,r=e.nTBody,o=e.nTHead,i=e.nTFoot,l=P(a),r=P(r),s=P(e.nTableWrapper),u=P.map(e.aoData,function(t){return t.nTr}),i=(e.bDestroying=!0,R(e,"aoDestroyCallback","destroy",[e]),c||new B(e).columns().visible(!0),s.off(".DT").find(":not(tbody *)").off(".DT"),P(j).off(".DT-"+e.sInstance),a!=o.parentNode&&(l.children("thead").detach(),l.append(o)),i&&a!=i.parentNode&&(l.children("tfoot").detach(),l.append(i)),e.aaSorting=[],e.aaSortingFixed=[],ce(e),P(u).removeClass(e.asStripeClasses.join(" ")),P("th, td",o).removeClass(t.sSortable+" "+t.sSortableAsc+" "+t.sSortableDesc+" "+t.sSortableNone),r.children().detach(),r.append(u),e.nTableWrapper.parentNode),o=c?"remove":"detach",u=(l[o](),s[o](),!c&&i&&(i.insertBefore(a,e.nTableReinsertBefore),l.css("width",e.sDestroyWidth).removeClass(t.sTable),n=e.asDestroyStripes.length)&&r.children().each(function(t){P(this).addClass(e.asDestroyStripes[t%n])}),P.inArray(e,w.settings));-1!==u&&w.settings.splice(u,1)})}),P.each(["column","row","cell"],function(t,s){e(s+"s().every()",function(o){var i=this.selector.opts,l=this;return this.iterator(s,function(t,e,n,a,r){o.call(l[s](e,"cell"===s?n:i,"cell"===s?i:H),e,n,a,r)})})}),e("i18n()",function(t,e,n){var a=this.context[0],t=A(t)(a.oLanguage);return t===H&&(t=e),"string"==typeof(t=n!==H&&P.isPlainObject(t)?t[n]!==H?t[n]:t._:t)?t.replace("%d",n):t}),w.version="1.13.6",w.settings=[],w.models={},w.models.oSearch={bCaseInsensitive:!0,sSearch:"",bRegex:!1,bSmart:!0,return:!1},w.models.oRow={nTr:null,anCells:null,_aData:[],_aSortData:null,_aFilterData:null,_sFilterRow:null,_sRowStripe:"",src:null,idx:-1},w.models.oColumn={idx:null,aDataSort:null,asSorting:null,bSearchable:null,bSortable:null,bVisible:null,_sManualType:null,_bAttrSrc:!1,fnCreatedCell:null,fnGetData:null,fnSetData:null,mData:null,mRender:null,nTh:null,nTf:null,sClass:null,sContentPadding:null,sDefaultContent:null,sName:null,sSortDataType:"std",sSortingClass:null,sSortingClassJUI:null,sTitle:null,sType:null,sWidth:null,sWidthOrig:null},w.defaults={aaData:null,aaSorting:[[0,"asc"]],aaSortingFixed:[],ajax:null,aLengthMenu:[10,25,50,100],aoColumns:null,aoColumnDefs:null,aoSearchCols:[],asStripeClasses:null,bAutoWidth:!0,bDeferRender:!1,bDestroy:!1,bFilter:!0,bInfo:!0,bLengthChange:!0,bPaginate:!0,bProcessing:!1,bRetrieve:!1,bScrollCollapse:!1,bServerSide:!1,bSort:!0,bSortMulti:!0,bSortCellsTop:!1,bSortClasses:!0,bStateSave:!1,fnCreatedRow:null,fnDrawCallback:null,fnFooterCallback:null,fnFormatNumber:function(t){return t.toString().replace(/\B(?=(\d{3})+(?!\d))/g,this.oLanguage.sThousands)},fnHeaderCallback:null,fnInfoCallback:null,fnInitComplete:null,fnPreDrawCallback:null,fnRowCallback:null,fnServerData:null,fnServerParams:null,fnStateLoadCallback:function(t){try{return JSON.parse((-1===t.iStateDuration?sessionStorage:localStorage).getItem("DataTables_"+t.sInstance+"_"+location.pathname))}catch(t){return{}}},fnStateLoadParams:null,fnStateLoaded:null,fnStateSaveCallback:function(t,e){try{(-1===t.iStateDuration?sessionStorage:localStorage).setItem("DataTables_"+t.sInstance+"_"+location.pathname,JSON.stringify(e))}catch(t){}},fnStateSaveParams:null,iStateDuration:7200,iDeferLoading:null,iDisplayLength:10,iDisplayStart:0,iTabIndex:0,oClasses:{},oLanguage:{oAria:{sSortAscending:": activate to sort column ascending",sSortDescending:": activate to sort column descending"},oPaginate:{sFirst:"First",sLast:"Last",sNext:"Next",sPrevious:"Previous"},sEmptyTable:"No data available in table",sInfo:"Showing _START_ to _END_ of _TOTAL_ entries",sInfoEmpty:"Showing 0 to 0 of 0 entries",sInfoFiltered:"(filtered from _MAX_ total entries)",sInfoPostFix:"",sDecimal:"",sThousands:",",sLengthMenu:"Show _MENU_ entries",sLoadingRecords:"Loading...",sProcessing:"",sSearch:"Search:",sSearchPlaceholder:"",sUrl:"",sZeroRecords:"No matching records found"},oSearch:P.extend({},w.models.oSearch),sAjaxDataProp:"data",sAjaxSource:null,sDom:"lfrtip",searchDelay:null,sPaginationType:"simple_numbers",sScrollX:"",sScrollXInner:"",sScrollY:"",sServerMethod:"GET",renderer:null,rowId:"DT_RowId"},i(w.defaults),w.defaults.column={aDataSort:null,iDataSort:-1,asSorting:["asc","desc"],bSearchable:!0,bSortable:!0,bVisible:!0,fnCreatedCell:null,mData:null,mRender:null,sCellType:"td",sClass:"",sContentPadding:"",sDefaultContent:null,sName:"",sSortDataType:"std",sTitle:null,sType:null,sWidth:null},i(w.defaults.column),w.models.oSettings={oFeatures:{bAutoWidth:null,bDeferRender:null,bFilter:null,bInfo:null,bLengthChange:null,bPaginate:null,bProcessing:null,bServerSide:null,bSort:null,bSortMulti:null,bSortClasses:null,bStateSave:null},oScroll:{bCollapse:null,iBarWidth:0,sX:null,sXInner:null,sY:null},oLanguage:{fnInfoCallback:null},oBrowser:{bScrollOversize:!1,bScrollbarLeft:!1,bBounding:!1,barWidth:0},ajax:null,aanFeatures:[],aoData:[],aiDisplay:[],aiDisplayMaster:[],aIds:{},aoColumns:[],aoHeader:[],aoFooter:[],oPreviousSearch:{},aoPreSearchCols:[],aaSorting:null,aaSortingFixed:[],asStripeClasses:null,asDestroyStripes:[],sDestroyWidth:0,aoRowCallback:[],aoHeaderCallback:[],aoFooterCallback:[],aoDrawCallback:[],aoRowCreatedCallback:[],aoPreDrawCallback:[],aoInitComplete:[],aoStateSaveParams:[],aoStateLoadParams:[],aoStateLoaded:[],sTableId:"",nTable:null,nTHead:null,nTFoot:null,nTBody:null,nTableWrapper:null,bDeferLoading:!1,bInitialised:!1,aoOpenRows:[],sDom:null,searchDelay:null,sPaginationType:"two_button",iStateDuration:0,aoStateSave:[],aoStateLoad:[],oSavedState:null,oLoadedState:null,sAjaxSource:null,sAjaxDataProp:null,jqXHR:null,json:H,oAjaxData:H,fnServerData:null,aoServerParams:[],sServerMethod:null,fnFormatNumber:null,aLengthMenu:null,iDraw:0,bDrawing:!1,iDrawError:-1,_iDisplayLength:10,_iDisplayStart:0,_iRecordsTotal:0,_iRecordsDisplay:0,oClasses:{},bFiltered:!1,bSorted:!1,bSortCellsTop:null,oInit:null,aoDestroyCallback:[],fnRecordsTotal:function(){return"ssp"==E(this)?+this._iRecordsTotal:this.aiDisplayMaster.length},fnRecordsDisplay:function(){return"ssp"==E(this)?+this._iRecordsDisplay:this.aiDisplay.length},fnDisplayEnd:function(){var t=this._iDisplayLength,e=this._iDisplayStart,n=e+t,a=this.aiDisplay.length,r=this.oFeatures,o=r.bPaginate;return r.bServerSide?!1===o||-1===t?e+a:Math.min(e+t,this._iRecordsDisplay):!o||a<n||-1===t?a:n},oInstance:null,sInstance:null,iTabIndex:0,nScrollHead:null,nScrollFoot:null,aLastSort:[],oPlugins:{},rowIdFn:null,rowId:null},w.ext=p={buttons:{},classes:{},builder:"-source-",errMode:"alert",feature:[],search:[],selector:{cell:[],column:[],row:[]},internal:{},legacy:{ajax:null},pager:{},renderer:{pageButton:{},header:{}},order:{},type:{detect:[],search:{},order:{}},_unique:0,fnVersionCheck:w.fnVersionCheck,iApiIndex:0,oJUIClasses:{},sVersion:w.version},P.extend(p,{afnFiltering:p.search,aTypes:p.type.detect,ofnSearch:p.type.search,oSort:p.type.order,afnSortData:p.order,aoFeatures:p.feature,oApi:p.internal,oStdClasses:p.classes,oPagination:p.pager}),P.extend(w.ext.classes,{sTable:"dataTable",sNoFooter:"no-footer",sPageButton:"paginate_button",sPageButtonActive:"current",sPageButtonDisabled:"disabled",sStripeOdd:"odd",sStripeEven:"even",sRowEmpty:"dataTables_empty",sWrapper:"dataTables_wrapper",sFilter:"dataTables_filter",sInfo:"dataTables_info",sPaging:"dataTables_paginate paging_",sLength:"dataTables_length",sProcessing:"dataTables_processing",sSortAsc:"sorting_asc",sSortDesc:"sorting_desc",sSortable:"sorting",sSortableAsc:"sorting_desc_disabled",sSortableDesc:"sorting_asc_disabled",sSortableNone:"sorting_disabled",sSortColumn:"sorting_",sFilterInput:"",sLengthSelect:"",sScrollWrapper:"dataTables_scroll",sScrollHead:"dataTables_scrollHead",sScrollHeadInner:"dataTables_scrollHeadInner",sScrollBody:"dataTables_scrollBody",sScrollFoot:"dataTables_scrollFoot",sScrollFootInner:"dataTables_scrollFootInner",sHeaderTH:"",sFooterTH:"",sSortJUIAsc:"",sSortJUIDesc:"",sSortJUI:"",sSortJUIAscAllowed:"",sSortJUIDescAllowed:"",sSortJUIWrapper:"",sSortIcon:"",sJUIHeader:"",sJUIFooter:""}),w.ext.pager);function Oe(t,e){var n=[],a=Ne.numbers_length,r=Math.floor(a/2);return e<=a?n=f(0,e):t<=r?((n=f(0,a-2)).push("ellipsis"),n.push(e-1)):((e-1-r<=t?n=f(e-(a-2),e):((n=f(t-r+2,t+r-1)).push("ellipsis"),n.push(e-1),n)).splice(0,0,"ellipsis"),n.splice(0,0,0)),n.DT_el="span",n}P.extend(Ne,{simple:function(t,e){return["previous","next"]},full:function(t,e){return["first","previous","next","last"]},numbers:function(t,e){return[Oe(t,e)]},simple_numbers:function(t,e){return["previous",Oe(t,e),"next"]},full_numbers:function(t,e){return["first","previous",Oe(t,e),"next","last"]},first_last_numbers:function(t,e){return["first",Oe(t,e),"last"]},_numbers:Oe,numbers_length:7}),P.extend(!0,w.ext.renderer,{pageButton:{_:function(u,t,c,e,f,d){function h(t,e){for(var n,a=b.sPageButtonDisabled,r=function(t){Yt(u,t.data.action,!0)},o=0,i=e.length;o<i;o++)if(n=e[o],Array.isArray(n)){var l=P("<"+(n.DT_el||"div")+"/>").appendTo(t);h(l,n)}else{var s=!1;switch(p=null,g=n){case"ellipsis":t.append('<span class="ellipsis">&#x2026;</span>');break;case"first":p=m.sFirst,0===f&&(s=!0);break;case"previous":p=m.sPrevious,0===f&&(s=!0);break;case"next":p=m.sNext,0!==d&&f!==d-1||(s=!0);break;case"last":p=m.sLast,0!==d&&f!==d-1||(s=!0);break;default:p=u.fnFormatNumber(n+1),g=f===n?b.sPageButtonActive:""}null!==p&&(l=u.oInit.pagingTag||"a",s&&(g+=" "+a),me(P("<"+l+">",{class:b.sPageButton+" "+g,"aria-controls":u.sTableId,"aria-disabled":s?"true":null,"aria-label":S[n],role:"link","aria-current":g===b.sPageButtonActive?"page":null,"data-dt-idx":n,tabindex:s?-1:u.iTabIndex,id:0===c&&"string"==typeof n?u.sTableId+"_"+n:null}).html(p).appendTo(t),{action:n},r))}}var p,g,n,b=u.oClasses,m=u.oLanguage.oPaginate,S=u.oLanguage.oAria.paginate||{};try{n=P(t).find(v.activeElement).data("dt-idx")}catch(t){}h(P(t).empty(),e),n!==H&&P(t).find("[data-dt-idx="+n+"]").trigger("focus")}}}),P.extend(w.ext.type.detect,[function(t,e){e=e.oLanguage.sDecimal;return l(t,e)?"num"+e:null},function(t,e){var n;return(!t||t instanceof Date||X.test(t))&&(null!==(n=Date.parse(t))&&!isNaN(n)||h(t))?"date":null},function(t,e){e=e.oLanguage.sDecimal;return l(t,e,!0)?"num-fmt"+e:null},function(t,e){e=e.oLanguage.sDecimal;return a(t,e)?"html-num"+e:null},function(t,e){e=e.oLanguage.sDecimal;return a(t,e,!0)?"html-num-fmt"+e:null},function(t,e){return h(t)||"string"==typeof t&&-1!==t.indexOf("<")?"html":null}]),P.extend(w.ext.type.search,{html:function(t){return h(t)?t:"string"==typeof t?t.replace(U," ").replace(V,""):""},string:function(t){return!h(t)&&"string"==typeof t?t.replace(U," "):t}});function ke(t,e,n,a){var r;return 0===t||t&&"-"!==t?"number"==(r=typeof t)||"bigint"==r?t:+(t=(t=e?$(t,e):t).replace&&(n&&(t=t.replace(n,"")),a)?t.replace(a,""):t):-1/0}function Me(n){P.each({num:function(t){return ke(t,n)},"num-fmt":function(t){return ke(t,n,q)},"html-num":function(t){return ke(t,n,V)},"html-num-fmt":function(t){return ke(t,n,V,q)}},function(t,e){p.type.order[t+n+"-pre"]=e,t.match(/^html\-/)&&(p.type.search[t+n]=p.type.search.html)})}P.extend(p.type.order,{"date-pre":function(t){t=Date.parse(t);return isNaN(t)?-1/0:t},"html-pre":function(t){return h(t)?"":t.replace?t.replace(/<.*?>/g,"").toLowerCase():t+""},"string-pre":function(t){return h(t)?"":"string"==typeof t?t.toLowerCase():t.toString?t.toString():""},"string-asc":function(t,e){return t<e?-1:e<t?1:0},"string-desc":function(t,e){return t<e?1:e<t?-1:0}}),Me(""),P.extend(!0,w.ext.renderer,{header:{_:function(r,o,i,l){P(r.nTable).on("order.dt.DT",function(t,e,n,a){r===e&&(e=i.idx,o.removeClass(l.sSortAsc+" "+l.sSortDesc).addClass("asc"==a[e]?l.sSortAsc:"desc"==a[e]?l.sSortDesc:i.sSortingClass))})},jqueryui:function(r,o,i,l){P("<div/>").addClass(l.sSortJUIWrapper).append(o.contents()).append(P("<span/>").addClass(l.sSortIcon+" "+i.sSortingClassJUI)).appendTo(o),P(r.nTable).on("order.dt.DT",function(t,e,n,a){r===e&&(e=i.idx,o.removeClass(l.sSortAsc+" "+l.sSortDesc).addClass("asc"==a[e]?l.sSortAsc:"desc"==a[e]?l.sSortDesc:i.sSortingClass),o.find("span."+l.sSortIcon).removeClass(l.sSortJUIAsc+" "+l.sSortJUIDesc+" "+l.sSortJUI+" "+l.sSortJUIAscAllowed+" "+l.sSortJUIDescAllowed).addClass("asc"==a[e]?l.sSortJUIAsc:"desc"==a[e]?l.sSortJUIDesc:i.sSortingClassJUI))})}}});function We(t){return"string"==typeof(t=Array.isArray(t)?t.join(","):t)?t.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;").replace(/"/g,"&quot;"):t}function Ee(t,e,n,a,r){return j.moment?t[e](r):j.luxon?t[n](r):a?t[a](r):t}var Be=!1;function Ue(t,e,n){var a;if(j.moment){if(!(a=j.moment.utc(t,e,n,!0)).isValid())return null}else if(j.luxon){if(!(a=e&&"string"==typeof t?j.luxon.DateTime.fromFormat(t,e):j.luxon.DateTime.fromISO(t)).isValid)return null;a.setLocale(n)}else e?(Be||alert("DataTables warning: Formatted date without Moment.js or Luxon - https://datatables.net/tn/17"),Be=!0):a=new Date(t);return a}function Ve(s){return function(a,r,o,i){0===arguments.length?(o="en",a=r=null):1===arguments.length?(o="en",r=a,a=null):2===arguments.length&&(o=r,r=a,a=null);var l="datetime-"+r;return w.ext.type.order[l]||(w.ext.type.detect.unshift(function(t){return t===l&&l}),w.ext.type.order[l+"-asc"]=function(t,e){t=t.valueOf(),e=e.valueOf();return t===e?0:t<e?-1:1},w.ext.type.order[l+"-desc"]=function(t,e){t=t.valueOf(),e=e.valueOf();return t===e?0:e<t?-1:1}),function(t,e){var n;return null!==t&&t!==H||(t="--now"===i?(n=new Date,new Date(Date.UTC(n.getFullYear(),n.getMonth(),n.getDate(),n.getHours(),n.getMinutes(),n.getSeconds()))):""),"type"===e?l:""===t?"sort"!==e?"":Ue("0000-01-01 00:00:00",null,o):!(null===r||a!==r||"sort"===e||"type"===e||t instanceof Date)||null===(n=Ue(t,a,o))?t:"sort"===e?n:(t=null===r?Ee(n,"toDate","toJSDate","")[s]():Ee(n,"format","toFormat","toISOString",r),"display"===e?We(t):t)}}}var Xe=",",Je=".";if(j.Intl!==H)try{for(var qe=(new Intl.NumberFormat).formatToParts(100000.1),n=0;n<qe.length;n++)"group"===qe[n].type?Xe=qe[n].value:"decimal"===qe[n].type&&(Je=qe[n].value)}catch(t){}function $e(e){return function(){var t=[ge(this[w.ext.iApiIndex])].concat(Array.prototype.slice.call(arguments));return w.ext.internal[e].apply(this,t)}}return w.datetime=function(n,a){var r="datetime-detect-"+n;a=a||"en",w.ext.type.order[r]||(w.ext.type.detect.unshift(function(t){var e=Ue(t,n,a);return!(""!==t&&!e)&&r}),w.ext.type.order[r+"-pre"]=function(t){return Ue(t,n,a)||0})},w.render={date:Ve("toLocaleDateString"),datetime:Ve("toLocaleString"),time:Ve("toLocaleTimeString"),number:function(a,r,o,i,l){return null!==a&&a!==H||(a=Xe),null!==r&&r!==H||(r=Je),{display:function(t){if("number"!=typeof t&&"string"!=typeof t)return t;if(""===t||null===t)return t;var e=t<0?"-":"",n=parseFloat(t);if(isNaN(n))return We(t);n=n.toFixed(o),t=Math.abs(n);n=parseInt(t,10),t=o?r+(t-n).toFixed(o).substring(2):"";return(e=0===n&&0===parseFloat(t)?"":e)+(i||"")+n.toString().replace(/\B(?=(\d{3})+(?!\d))/g,a)+t+(l||"")}}},text:function(){return{display:We,filter:We}}},P.extend(w.ext.internal,{_fnExternApiFunc:$e,_fnBuildAjax:Tt,_fnAjaxUpdate:xt,_fnAjaxParameters:At,_fnAjaxUpdateDraw:It,_fnAjaxDataSrc:Ft,_fnAddColumn:nt,_fnColumnOptions:at,_fnAdjustColumnSizing:O,_fnVisibleToColumnIndex:rt,_fnColumnIndexToVisible:ot,_fnVisbleColumns:T,_fnGetColumns:it,_fnColumnTypes:lt,_fnApplyColumnDefs:st,_fnHungarianMap:i,_fnCamelToHungarian:C,_fnLanguageCompat:Z,_fnBrowserDetect:tt,_fnAddData:x,_fnAddTr:ut,_fnNodeToDataIndex:function(t,e){return e._DT_RowIndex!==H?e._DT_RowIndex:null},_fnNodeToColumnIndex:function(t,e,n){return P.inArray(n,t.aoData[e].anCells)},_fnGetCellData:S,_fnSetCellData:ct,_fnSplitObjNotation:dt,_fnGetObjectDataFn:A,_fnSetObjectDataFn:b,_fnGetDataMaster:ht,_fnClearTable:pt,_fnDeleteIndex:gt,_fnInvalidate:bt,_fnGetRowElements:mt,_fnCreateTr:St,_fnBuildHead:yt,_fnDrawHead:Dt,_fnDraw:y,_fnReDraw:u,_fnAddOptionsHtml:_t,_fnDetectHeader:wt,_fnGetUniqueThs:Ct,_fnFeatureHtmlFilter:Lt,_fnFilterComplete:Rt,_fnFilterCustom:Pt,_fnFilterColumn:jt,_fnFilter:Ht,_fnFilterCreateSearch:Nt,_fnEscapeRegex:Ot,_fnFilterData:Wt,_fnFeatureHtmlInfo:Ut,_fnUpdateInfo:Vt,_fnInfoMacros:Xt,_fnInitialise:Jt,_fnInitComplete:qt,_fnLengthChange:$t,_fnFeatureHtmlLength:Gt,_fnFeatureHtmlPaginate:zt,_fnPageChange:Yt,_fnFeatureHtmlProcessing:Zt,_fnProcessingDisplay:D,_fnFeatureHtmlTable:Kt,_fnScrollDraw:Qt,_fnApplyToChildren:k,_fnCalculateColumnWidths:ee,_fnThrottle:ne,_fnConvertToWidth:ae,_fnGetWidestNode:re,_fnGetMaxLenString:oe,_fnStringToCss:M,_fnSortFlatten:I,_fnSort:ie,_fnSortAria:le,_fnSortListener:se,_fnSortAttachListener:ue,_fnSortingClasses:ce,_fnSortData:fe,_fnSaveState:de,_fnLoadState:he,_fnImplementState:pe,_fnSettingsFromNode:ge,_fnLog:W,_fnMap:F,_fnBindAction:me,_fnCallbackReg:L,_fnCallbackFire:R,_fnLengthOverflow:Se,_fnRenderer:ve,_fnDataSource:E,_fnRowAttributes:vt,_fnExtend:be,_fnCalculateEnd:function(){}}),((P.fn.dataTable=w).$=P).fn.dataTableSettings=w.settings,P.fn.dataTableExt=w.ext,P.fn.DataTable=function(t){return P(this).dataTable(t).api()},P.each(w,function(t,e){P.fn.DataTable[t]=e}),w});\"></script>\n",
       "<link href=\"data:text/css;charset-utf-8;base64,:root{--dt-row-selected: 13, 110, 253;--dt-row-selected-text: 255, 255, 255;--dt-row-selected-link: 9, 10, 11;--dt-row-stripe: 0, 0, 0;--dt-row-hover: 0, 0, 0;--dt-column-ordering: 0, 0, 0;--dt-html-background: white}:root.dark{--dt-html-background: rgb(33, 37, 41)}table.dataTable td.dt-control{text-align:center;cursor:pointer}table.dataTable td.dt-control:before{display:inline-block;color:rgba(0, 0, 0, 0.5);content:"►"}table.dataTable tr.dt-hasChild td.dt-control:before{content:"▼"}html.dark table.dataTable td.dt-control:before{color:rgba(255, 255, 255, 0.5)}html.dark table.dataTable tr.dt-hasChild td.dt-control:before{color:rgba(255, 255, 255, 0.5)}table.dataTable thead>tr>th.sorting,table.dataTable thead>tr>th.sorting_asc,table.dataTable thead>tr>th.sorting_desc,table.dataTable thead>tr>th.sorting_asc_disabled,table.dataTable thead>tr>th.sorting_desc_disabled,table.dataTable thead>tr>td.sorting,table.dataTable thead>tr>td.sorting_asc,table.dataTable thead>tr>td.sorting_desc,table.dataTable thead>tr>td.sorting_asc_disabled,table.dataTable thead>tr>td.sorting_desc_disabled{cursor:pointer;position:relative;padding-right:26px}table.dataTable thead>tr>th.sorting:before,table.dataTable thead>tr>th.sorting:after,table.dataTable thead>tr>th.sorting_asc:before,table.dataTable thead>tr>th.sorting_asc:after,table.dataTable thead>tr>th.sorting_desc:before,table.dataTable thead>tr>th.sorting_desc:after,table.dataTable thead>tr>th.sorting_asc_disabled:before,table.dataTable thead>tr>th.sorting_asc_disabled:after,table.dataTable thead>tr>th.sorting_desc_disabled:before,table.dataTable thead>tr>th.sorting_desc_disabled:after,table.dataTable thead>tr>td.sorting:before,table.dataTable thead>tr>td.sorting:after,table.dataTable thead>tr>td.sorting_asc:before,table.dataTable thead>tr>td.sorting_asc:after,table.dataTable thead>tr>td.sorting_desc:before,table.dataTable thead>tr>td.sorting_desc:after,table.dataTable thead>tr>td.sorting_asc_disabled:before,table.dataTable thead>tr>td.sorting_asc_disabled:after,table.dataTable thead>tr>td.sorting_desc_disabled:before,table.dataTable thead>tr>td.sorting_desc_disabled:after{position:absolute;display:block;opacity:.125;right:10px;line-height:9px;font-size:.8em}table.dataTable thead>tr>th.sorting:before,table.dataTable thead>tr>th.sorting_asc:before,table.dataTable thead>tr>th.sorting_desc:before,table.dataTable thead>tr>th.sorting_asc_disabled:before,table.dataTable thead>tr>th.sorting_desc_disabled:before,table.dataTable thead>tr>td.sorting:before,table.dataTable thead>tr>td.sorting_asc:before,table.dataTable thead>tr>td.sorting_desc:before,table.dataTable thead>tr>td.sorting_asc_disabled:before,table.dataTable thead>tr>td.sorting_desc_disabled:before{bottom:50%;content:"▲";content:"▲"/""}table.dataTable thead>tr>th.sorting:after,table.dataTable thead>tr>th.sorting_asc:after,table.dataTable thead>tr>th.sorting_desc:after,table.dataTable thead>tr>th.sorting_asc_disabled:after,table.dataTable thead>tr>th.sorting_desc_disabled:after,table.dataTable thead>tr>td.sorting:after,table.dataTable thead>tr>td.sorting_asc:after,table.dataTable thead>tr>td.sorting_desc:after,table.dataTable thead>tr>td.sorting_asc_disabled:after,table.dataTable thead>tr>td.sorting_desc_disabled:after{top:50%;content:"▼";content:"▼"/""}table.dataTable thead>tr>th.sorting_asc:before,table.dataTable thead>tr>th.sorting_desc:after,table.dataTable thead>tr>td.sorting_asc:before,table.dataTable thead>tr>td.sorting_desc:after{opacity:.6}table.dataTable thead>tr>th.sorting_desc_disabled:after,table.dataTable thead>tr>th.sorting_asc_disabled:before,table.dataTable thead>tr>td.sorting_desc_disabled:after,table.dataTable thead>tr>td.sorting_asc_disabled:before{display:none}table.dataTable thead>tr>th:active,table.dataTable thead>tr>td:active{outline:none}div.dataTables_scrollBody>table.dataTable>thead>tr>th:before,div.dataTables_scrollBody>table.dataTable>thead>tr>th:after,div.dataTables_scrollBody>table.dataTable>thead>tr>td:before,div.dataTables_scrollBody>table.dataTable>thead>tr>td:after{display:none}div.dataTables_processing{position:absolute;top:50%;left:50%;width:200px;margin-left:-100px;margin-top:-26px;text-align:center;padding:2px}div.dataTables_processing>div:last-child{position:relative;width:80px;height:15px;margin:1em auto}div.dataTables_processing>div:last-child>div{position:absolute;top:0;width:13px;height:13px;border-radius:50%;background:rgb(13, 110, 253);background:rgb(var(--dt-row-selected));animation-timing-function:cubic-bezier(0, 1, 1, 0)}div.dataTables_processing>div:last-child>div:nth-child(1){left:8px;animation:datatables-loader-1 .6s infinite}div.dataTables_processing>div:last-child>div:nth-child(2){left:8px;animation:datatables-loader-2 .6s infinite}div.dataTables_processing>div:last-child>div:nth-child(3){left:32px;animation:datatables-loader-2 .6s infinite}div.dataTables_processing>div:last-child>div:nth-child(4){left:56px;animation:datatables-loader-3 .6s infinite}@keyframes datatables-loader-1{0%{transform:scale(0)}100%{transform:scale(1)}}@keyframes datatables-loader-3{0%{transform:scale(1)}100%{transform:scale(0)}}@keyframes datatables-loader-2{0%{transform:translate(0, 0)}100%{transform:translate(24px, 0)}}table.dataTable.nowrap th,table.dataTable.nowrap td{white-space:nowrap}table.dataTable th.dt-left,table.dataTable td.dt-left{text-align:left}table.dataTable th.dt-center,table.dataTable td.dt-center,table.dataTable td.dataTables_empty{text-align:center}table.dataTable th.dt-right,table.dataTable td.dt-right{text-align:right}table.dataTable th.dt-justify,table.dataTable td.dt-justify{text-align:justify}table.dataTable th.dt-nowrap,table.dataTable td.dt-nowrap{white-space:nowrap}table.dataTable thead th,table.dataTable thead td,table.dataTable tfoot th,table.dataTable tfoot td{text-align:left}table.dataTable thead th.dt-head-left,table.dataTable thead td.dt-head-left,table.dataTable tfoot th.dt-head-left,table.dataTable tfoot td.dt-head-left{text-align:left}table.dataTable thead th.dt-head-center,table.dataTable thead td.dt-head-center,table.dataTable tfoot th.dt-head-center,table.dataTable tfoot td.dt-head-center{text-align:center}table.dataTable thead th.dt-head-right,table.dataTable thead td.dt-head-right,table.dataTable tfoot th.dt-head-right,table.dataTable tfoot td.dt-head-right{text-align:right}table.dataTable thead th.dt-head-justify,table.dataTable thead td.dt-head-justify,table.dataTable tfoot th.dt-head-justify,table.dataTable tfoot td.dt-head-justify{text-align:justify}table.dataTable thead th.dt-head-nowrap,table.dataTable thead td.dt-head-nowrap,table.dataTable tfoot th.dt-head-nowrap,table.dataTable tfoot td.dt-head-nowrap{white-space:nowrap}table.dataTable tbody th.dt-body-left,table.dataTable tbody td.dt-body-left{text-align:left}table.dataTable tbody th.dt-body-center,table.dataTable tbody td.dt-body-center{text-align:center}table.dataTable tbody th.dt-body-right,table.dataTable tbody td.dt-body-right{text-align:right}table.dataTable tbody th.dt-body-justify,table.dataTable tbody td.dt-body-justify{text-align:justify}table.dataTable tbody th.dt-body-nowrap,table.dataTable tbody td.dt-body-nowrap{white-space:nowrap}table.dataTable{width:100%;margin:0 auto;clear:both;border-collapse:separate;border-spacing:0}table.dataTable thead th,table.dataTable tfoot th{font-weight:bold}table.dataTable>thead>tr>th,table.dataTable>thead>tr>td{padding:10px;border-bottom:1px solid rgba(0, 0, 0, 0.3)}table.dataTable>thead>tr>th:active,table.dataTable>thead>tr>td:active{outline:none}table.dataTable>tfoot>tr>th,table.dataTable>tfoot>tr>td{padding:10px 10px 6px 10px;border-top:1px solid rgba(0, 0, 0, 0.3)}table.dataTable tbody tr{background-color:transparent}table.dataTable tbody tr.selected>*{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.9);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.9);color:rgb(255, 255, 255);color:rgb(var(--dt-row-selected-text))}table.dataTable tbody tr.selected a{color:rgb(9, 10, 11);color:rgb(var(--dt-row-selected-link))}table.dataTable tbody th,table.dataTable tbody td{padding:8px 10px}table.dataTable.row-border>tbody>tr>th,table.dataTable.row-border>tbody>tr>td,table.dataTable.display>tbody>tr>th,table.dataTable.display>tbody>tr>td{border-top:1px solid rgba(0, 0, 0, 0.15)}table.dataTable.row-border>tbody>tr:first-child>th,table.dataTable.row-border>tbody>tr:first-child>td,table.dataTable.display>tbody>tr:first-child>th,table.dataTable.display>tbody>tr:first-child>td{border-top:none}table.dataTable.row-border>tbody>tr.selected+tr.selected>td,table.dataTable.display>tbody>tr.selected+tr.selected>td{border-top-color:#0262ef}table.dataTable.cell-border>tbody>tr>th,table.dataTable.cell-border>tbody>tr>td{border-top:1px solid rgba(0, 0, 0, 0.15);border-right:1px solid rgba(0, 0, 0, 0.15)}table.dataTable.cell-border>tbody>tr>th:first-child,table.dataTable.cell-border>tbody>tr>td:first-child{border-left:1px solid rgba(0, 0, 0, 0.15)}table.dataTable.cell-border>tbody>tr:first-child>th,table.dataTable.cell-border>tbody>tr:first-child>td{border-top:none}table.dataTable.stripe>tbody>tr.odd>*,table.dataTable.display>tbody>tr.odd>*{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.023);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-stripe), 0.023)}table.dataTable.stripe>tbody>tr.odd.selected>*,table.dataTable.display>tbody>tr.odd.selected>*{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.923);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.923)}table.dataTable.hover>tbody>tr:hover>*,table.dataTable.display>tbody>tr:hover>*{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.035);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-hover), 0.035)}table.dataTable.hover>tbody>tr.selected:hover>*,table.dataTable.display>tbody>tr.selected:hover>*{box-shadow:inset 0 0 0 9999px #0d6efd !important;box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 1) !important}table.dataTable.order-column>tbody tr>.sorting_1,table.dataTable.order-column>tbody tr>.sorting_2,table.dataTable.order-column>tbody tr>.sorting_3,table.dataTable.display>tbody tr>.sorting_1,table.dataTable.display>tbody tr>.sorting_2,table.dataTable.display>tbody tr>.sorting_3{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.019);box-shadow:inset 0 0 0 9999px rgba(var(--dt-column-ordering), 0.019)}table.dataTable.order-column>tbody tr.selected>.sorting_1,table.dataTable.order-column>tbody tr.selected>.sorting_2,table.dataTable.order-column>tbody tr.selected>.sorting_3,table.dataTable.display>tbody tr.selected>.sorting_1,table.dataTable.display>tbody tr.selected>.sorting_2,table.dataTable.display>tbody tr.selected>.sorting_3{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.919);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.919)}table.dataTable.display>tbody>tr.odd>.sorting_1,table.dataTable.order-column.stripe>tbody>tr.odd>.sorting_1{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.054);box-shadow:inset 0 0 0 9999px rgba(var(--dt-column-ordering), 0.054)}table.dataTable.display>tbody>tr.odd>.sorting_2,table.dataTable.order-column.stripe>tbody>tr.odd>.sorting_2{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.047);box-shadow:inset 0 0 0 9999px rgba(var(--dt-column-ordering), 0.047)}table.dataTable.display>tbody>tr.odd>.sorting_3,table.dataTable.order-column.stripe>tbody>tr.odd>.sorting_3{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.039);box-shadow:inset 0 0 0 9999px rgba(var(--dt-column-ordering), 0.039)}table.dataTable.display>tbody>tr.odd.selected>.sorting_1,table.dataTable.order-column.stripe>tbody>tr.odd.selected>.sorting_1{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.954);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.954)}table.dataTable.display>tbody>tr.odd.selected>.sorting_2,table.dataTable.order-column.stripe>tbody>tr.odd.selected>.sorting_2{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.947);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.947)}table.dataTable.display>tbody>tr.odd.selected>.sorting_3,table.dataTable.order-column.stripe>tbody>tr.odd.selected>.sorting_3{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.939);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.939)}table.dataTable.display>tbody>tr.even>.sorting_1,table.dataTable.order-column.stripe>tbody>tr.even>.sorting_1{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.019);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.019)}table.dataTable.display>tbody>tr.even>.sorting_2,table.dataTable.order-column.stripe>tbody>tr.even>.sorting_2{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.011);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.011)}table.dataTable.display>tbody>tr.even>.sorting_3,table.dataTable.order-column.stripe>tbody>tr.even>.sorting_3{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.003);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.003)}table.dataTable.display>tbody>tr.even.selected>.sorting_1,table.dataTable.order-column.stripe>tbody>tr.even.selected>.sorting_1{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.919);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.919)}table.dataTable.display>tbody>tr.even.selected>.sorting_2,table.dataTable.order-column.stripe>tbody>tr.even.selected>.sorting_2{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.911);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.911)}table.dataTable.display>tbody>tr.even.selected>.sorting_3,table.dataTable.order-column.stripe>tbody>tr.even.selected>.sorting_3{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.903);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.903)}table.dataTable.display tbody tr:hover>.sorting_1,table.dataTable.order-column.hover tbody tr:hover>.sorting_1{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.082);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-hover), 0.082)}table.dataTable.display tbody tr:hover>.sorting_2,table.dataTable.order-column.hover tbody tr:hover>.sorting_2{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.074);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-hover), 0.074)}table.dataTable.display tbody tr:hover>.sorting_3,table.dataTable.order-column.hover tbody tr:hover>.sorting_3{box-shadow:inset 0 0 0 9999px rgba(0, 0, 0, 0.062);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-hover), 0.062)}table.dataTable.display tbody tr:hover.selected>.sorting_1,table.dataTable.order-column.hover tbody tr:hover.selected>.sorting_1{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.982);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.982)}table.dataTable.display tbody tr:hover.selected>.sorting_2,table.dataTable.order-column.hover tbody tr:hover.selected>.sorting_2{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.974);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.974)}table.dataTable.display tbody tr:hover.selected>.sorting_3,table.dataTable.order-column.hover tbody tr:hover.selected>.sorting_3{box-shadow:inset 0 0 0 9999px rgba(13, 110, 253, 0.962);box-shadow:inset 0 0 0 9999px rgba(var(--dt-row-selected), 0.962)}table.dataTable.no-footer{border-bottom:1px solid rgba(0, 0, 0, 0.3)}table.dataTable.compact thead th,table.dataTable.compact thead td,table.dataTable.compact tfoot th,table.dataTable.compact tfoot td,table.dataTable.compact tbody th,table.dataTable.compact tbody td{padding:4px}table.dataTable th,table.dataTable td{box-sizing:content-box}.dataTables_wrapper{position:relative;clear:both}.dataTables_wrapper .dataTables_length{float:left}.dataTables_wrapper .dataTables_length select{border:1px solid #aaa;border-radius:3px;padding:5px;background-color:transparent;color:inherit;padding:4px}.dataTables_wrapper .dataTables_filter{float:right;text-align:right}.dataTables_wrapper .dataTables_filter input{border:1px solid #aaa;border-radius:3px;padding:5px;background-color:transparent;color:inherit;margin-left:3px}.dataTables_wrapper .dataTables_info{clear:both;float:left;padding-top:.755em}.dataTables_wrapper .dataTables_paginate{float:right;text-align:right;padding-top:.25em}.dataTables_wrapper .dataTables_paginate .paginate_button{box-sizing:border-box;display:inline-block;min-width:1.5em;padding:.5em 1em;margin-left:2px;text-align:center;text-decoration:none !important;cursor:pointer;color:inherit !important;border:1px solid transparent;border-radius:2px;background:transparent}.dataTables_wrapper .dataTables_paginate .paginate_button.current,.dataTables_wrapper .dataTables_paginate .paginate_button.current:hover{color:inherit !important;border:1px solid rgba(0, 0, 0, 0.3);background-color:rgba(0, 0, 0, 0.05);background:-webkit-gradient(linear, left top, left bottom, color-stop(0%, rgba(230, 230, 230, 0.05)), color-stop(100%, rgba(0, 0, 0, 0.05)));background:-webkit-linear-gradient(top, rgba(230, 230, 230, 0.05) 0%, rgba(0, 0, 0, 0.05) 100%);background:-moz-linear-gradient(top, rgba(230, 230, 230, 0.05) 0%, rgba(0, 0, 0, 0.05) 100%);background:-ms-linear-gradient(top, rgba(230, 230, 230, 0.05) 0%, rgba(0, 0, 0, 0.05) 100%);background:-o-linear-gradient(top, rgba(230, 230, 230, 0.05) 0%, rgba(0, 0, 0, 0.05) 100%);background:linear-gradient(to bottom, rgba(230, 230, 230, 0.05) 0%, rgba(0, 0, 0, 0.05) 100%)}.dataTables_wrapper .dataTables_paginate .paginate_button.disabled,.dataTables_wrapper .dataTables_paginate .paginate_button.disabled:hover,.dataTables_wrapper .dataTables_paginate .paginate_button.disabled:active{cursor:default;color:#666 !important;border:1px solid transparent;background:transparent;box-shadow:none}.dataTables_wrapper .dataTables_paginate .paginate_button:hover{color:white !important;border:1px solid #111;background-color:#111;background:-webkit-gradient(linear, left top, left bottom, color-stop(0%, #585858), color-stop(100%, #111));background:-webkit-linear-gradient(top, #585858 0%, #111 100%);background:-moz-linear-gradient(top, #585858 0%, #111 100%);background:-ms-linear-gradient(top, #585858 0%, #111 100%);background:-o-linear-gradient(top, #585858 0%, #111 100%);background:linear-gradient(to bottom, #585858 0%, #111 100%)}.dataTables_wrapper .dataTables_paginate .paginate_button:active{outline:none;background-color:#0c0c0c;background:-webkit-gradient(linear, left top, left bottom, color-stop(0%, #2b2b2b), color-stop(100%, #0c0c0c));background:-webkit-linear-gradient(top, #2b2b2b 0%, #0c0c0c 100%);background:-moz-linear-gradient(top, #2b2b2b 0%, #0c0c0c 100%);background:-ms-linear-gradient(top, #2b2b2b 0%, #0c0c0c 100%);background:-o-linear-gradient(top, #2b2b2b 0%, #0c0c0c 100%);background:linear-gradient(to bottom, #2b2b2b 0%, #0c0c0c 100%);box-shadow:inset 0 0 3px #111}.dataTables_wrapper .dataTables_paginate .ellipsis{padding:0 1em}.dataTables_wrapper .dataTables_length,.dataTables_wrapper .dataTables_filter,.dataTables_wrapper .dataTables_info,.dataTables_wrapper .dataTables_processing,.dataTables_wrapper .dataTables_paginate{color:inherit}.dataTables_wrapper .dataTables_scroll{clear:both}.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody{-webkit-overflow-scrolling:touch}.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody>table>thead>tr>th,.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody>table>thead>tr>td,.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody>table>tbody>tr>th,.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody>table>tbody>tr>td{vertical-align:middle}.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody>table>thead>tr>th>div.dataTables_sizing,.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody>table>thead>tr>td>div.dataTables_sizing,.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody>table>tbody>tr>th>div.dataTables_sizing,.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody>table>tbody>tr>td>div.dataTables_sizing{height:0;overflow:hidden;margin:0 !important;padding:0 !important}.dataTables_wrapper.no-footer .dataTables_scrollBody{border-bottom:1px solid rgba(0, 0, 0, 0.3)}.dataTables_wrapper.no-footer div.dataTables_scrollHead table.dataTable,.dataTables_wrapper.no-footer div.dataTables_scrollBody>table{border-bottom:none}.dataTables_wrapper:after{visibility:hidden;display:block;content:"";clear:both;height:0}@media screen and (max-width: 767px){.dataTables_wrapper .dataTables_info,.dataTables_wrapper .dataTables_paginate{float:none;text-align:center}.dataTables_wrapper .dataTables_paginate{margin-top:.5em}}@media screen and (max-width: 640px){.dataTables_wrapper .dataTables_length,.dataTables_wrapper .dataTables_filter{float:none;text-align:center}.dataTables_wrapper .dataTables_filter{margin-top:.5em}}html.dark{--dt-row-hover: 255, 255, 255;--dt-row-stripe: 255, 255, 255;--dt-column-ordering: 255, 255, 255}html.dark table.dataTable>thead>tr>th,html.dark table.dataTable>thead>tr>td{border-bottom:1px solid rgb(89, 91, 94)}html.dark table.dataTable>thead>tr>th:active,html.dark table.dataTable>thead>tr>td:active{outline:none}html.dark table.dataTable>tfoot>tr>th,html.dark table.dataTable>tfoot>tr>td{border-top:1px solid rgb(89, 91, 94)}html.dark table.dataTable.row-border>tbody>tr>th,html.dark table.dataTable.row-border>tbody>tr>td,html.dark table.dataTable.display>tbody>tr>th,html.dark table.dataTable.display>tbody>tr>td{border-top:1px solid rgb(64, 67, 70)}html.dark table.dataTable.row-border>tbody>tr.selected+tr.selected>td,html.dark table.dataTable.display>tbody>tr.selected+tr.selected>td{border-top-color:#0257d5}html.dark table.dataTable.cell-border>tbody>tr>th,html.dark table.dataTable.cell-border>tbody>tr>td{border-top:1px solid rgb(64, 67, 70);border-right:1px solid rgb(64, 67, 70)}html.dark table.dataTable.cell-border>tbody>tr>th:first-child,html.dark table.dataTable.cell-border>tbody>tr>td:first-child{border-left:1px solid rgb(64, 67, 70)}html.dark .dataTables_wrapper .dataTables_filter input,html.dark .dataTables_wrapper .dataTables_length select{border:1px solid rgba(255, 255, 255, 0.2);background-color:var(--dt-html-background)}html.dark .dataTables_wrapper .dataTables_paginate .paginate_button.current,html.dark .dataTables_wrapper .dataTables_paginate .paginate_button.current:hover{border:1px solid rgb(89, 91, 94);background:rgba(255, 255, 255, 0.15)}html.dark .dataTables_wrapper .dataTables_paginate .paginate_button.disabled,html.dark .dataTables_wrapper .dataTables_paginate .paginate_button.disabled:hover,html.dark .dataTables_wrapper .dataTables_paginate .paginate_button.disabled:active{color:#666 !important}html.dark .dataTables_wrapper .dataTables_paginate .paginate_button:hover{border:1px solid rgb(53, 53, 53);background:rgb(53, 53, 53)}html.dark .dataTables_wrapper .dataTables_paginate .paginate_button:active{background:#3a3a3a}
\" rel=\"stylesheet\" />\n",
       "<link href=\"data:text/css;charset-utf-8;base64,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\" rel=\"stylesheet\" />\n",
       "<script title=\"crosstalk\" src=\"data:application/javascript;base64,!function o(u,a,l){function s(n,e){if(!a[n]){if(!u[n]){var t="function"==typeof require&&require;if(!e&&t)return t(n,!0);if(f)return f(n,!0);var r=new Error("Cannot find module '"+n+"'");throw r.code="MODULE_NOT_FOUND",r}var i=a[n]={exports:{}};u[n][0].call(i.exports,function(e){var t=u[n][1][e];return s(t||e)},i,i.exports,o,u,a,l)}return a[n].exports}for(var f="function"==typeof require&&require,e=0;e<l.length;e++)s(l[e]);return s}({1:[function(e,t,n){"use strict";Object.defineProperty(n,"__esModule",{value:!0});var r=function(){function r(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(e,t,n){return t&&r(e.prototype,t),n&&r(e,n),e}}();var i=function(){function e(){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,e),this._types={},this._seq=0}return r(e,[{key:"on",value:function(e,t){var n=this._types[e];n||(n=this._types[e]={});var r="sub"+this._seq++;return n[r]=t,r}},{key:"off",value:function(e,t){var n=this._types[e];if("function"==typeof t){for(var r in n)if(n.hasOwnProperty(r)&&n[r]===t)return delete n[r],r;return!1}if("string"==typeof t)return!(!n||!n[t])&&(delete n[t],t);throw new Error("Unexpected type for listener")}},{key:"trigger",value:function(e,t,n){var r=this._types[e];for(var i in r)r.hasOwnProperty(i)&&r[i].call(n,t)}}]),e}();n.default=i},{}],2:[function(e,t,n){"use strict";Object.defineProperty(n,"__esModule",{value:!0}),n.FilterHandle=void 0;var r=function(){function r(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(e,t,n){return t&&r(e.prototype,t),n&&r(e,n),e}}(),i=l(e("./events")),o=l(e("./filterset")),u=l(e("./group")),a=function(e){{if(e&&e.__esModule)return e;var t={};if(null!=e)for(var n in e)Object.prototype.hasOwnProperty.call(e,n)&&(t[n]=e[n]);return t.default=e,t}}(e("./util"));function l(e){return e&&e.__esModule?e:{default:e}}var s=1;n.FilterHandle=function(){function n(e,t){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,n),this._eventRelay=new i.default,this._emitter=new a.SubscriptionTracker(this._eventRelay),this._group=null,this._filterSet=null,this._filterVar=null,this._varOnChangeSub=null,this._extraInfo=a.extend({sender:this},t),this._id="filter"+s++,this.setGroup(e)}return r(n,[{key:"setGroup",value:function(e){var t,n,r=this;if(this._group!==e&&((this._group||e)&&(this._filterVar&&(this._filterVar.off("change",this._varOnChangeSub),this.clear(),this._varOnChangeSub=null,this._filterVar=null,this._filterSet=null),this._group=e))){e=(0,u.default)(e),this._filterSet=(t=e.var("filterset"),(n=t.get())||(n=new o.default,t.set(n)),n),this._filterVar=(0,u.default)(e).var("filter");var i=this._filterVar.on("change",function(e){r._eventRelay.trigger("change",e,r)});this._varOnChangeSub=i}}},{key:"_mergeExtraInfo",value:function(e){return a.extend({},this._extraInfo?this._extraInfo:null,e||null)}},{key:"close",value:function(){this._emitter.removeAllListeners(),this.clear(),this.setGroup(null)}},{key:"clear",value:function(e){this._filterSet&&(this._filterSet.clear(this._id),this._onChange(e))}},{key:"set",value:function(e,t){this._filterSet&&(this._filterSet.update(this._id,e),this._onChange(t))}},{key:"on",value:function(e,t){return this._emitter.on(e,t)}},{key:"off",value:function(e,t){return this._emitter.off(e,t)}},{key:"_onChange",value:function(e){this._filterSet&&this._filterVar.set(this._filterSet.value,this._mergeExtraInfo(e))}},{key:"filteredKeys",get:function(){return this._filterSet?this._filterSet.value:null}}]),n}()},{"./events":1,"./filterset":3,"./group":4,"./util":11}],3:[function(e,t,n){"use strict";Object.defineProperty(n,"__esModule",{value:!0});var r=function(){function r(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(e,t,n){return t&&r(e.prototype,t),n&&r(e,n),e}}(),a=e("./util");function l(e,t){return e===t?0:e<t?-1:t<e?1:void 0}var i=function(){function e(){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,e),this.reset()}return r(e,[{key:"reset",value:function(){this._handles={},this._keys={},this._value=null,this._activeHandles=0}},{key:"update",value:function(e,t){null!==t&&(t=t.slice(0)).sort(l);var n=(0,a.diffSortedLists)(this._handles[e],t),r=n.added,i=n.removed;this._handles[e]=t;for(var o=0;o<r.length;o++)this._keys[r[o]]=(this._keys[r[o]]||0)+1;for(var u=0;u<i.length;u++)this._keys[i[u]]--;this._updateValue(t)}},{key:"_updateValue",value:function(){var e=0<arguments.length&&void 0!==arguments[0]?arguments[0]:this._allKeys,t=Object.keys(this._handles).length;if(0===t)this._value=null;else{this._value=[];for(var n=0;n<e.length;n++){this._keys[e[n]]===t&&this._value.push(e[n])}}}},{key:"clear",value:function(e){if(void 0!==this._handles[e]){var t=this._handles[e];t||(t=[]);for(var n=0;n<t.length;n++)this._keys[t[n]]--;delete this._handles[e],this._updateValue()}}},{key:"value",get:function(){return this._value}},{key:"_allKeys",get:function(){var e=Object.keys(this._keys);return e.sort(l),e}}]),e}();n.default=i},{"./util":11}],4:[function(l,e,s){(function(e){"use strict";Object.defineProperty(s,"__esModule",{value:!0});var n=function(){function r(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(e,t,n){return t&&r(e.prototype,t),n&&r(e,n),e}}(),r="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};s.default=function e(t){{if(t&&"string"==typeof t)return u.hasOwnProperty(t)||(u[t]=new a(t)),u[t];if("object"===(void 0===t?"undefined":r(t))&&t._vars&&t.var)return t;if(Array.isArray(t)&&1==t.length&&"string"==typeof t[0])return e(t[0]);throw new Error("Invalid groupName argument")}};var t,i=l("./var"),o=(t=i)&&t.__esModule?t:{default:t};e.__crosstalk_groups=e.__crosstalk_groups||{};var u=e.__crosstalk_groups;var a=function(){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t),this.name=e,this._vars={}}return n(t,[{key:"var",value:function(e){if(!e||"string"!=typeof e)throw new Error("Invalid var name");return this._vars.hasOwnProperty(e)||(this._vars[e]=new o.default(this,e)),this._vars[e]}},{key:"has",value:function(e){if(!e||"string"!=typeof e)throw new Error("Invalid var name");return this._vars.hasOwnProperty(e)}}]),t}()}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./var":12}],5:[function(f,e,c){(function(e){"use strict";Object.defineProperty(c,"__esModule",{value:!0});var t,n=f("./group"),r=(t=n)&&t.__esModule?t:{default:t},i=f("./selection"),o=f("./filter"),u=f("./input");f("./input_selectize"),f("./input_checkboxgroup"),f("./input_slider");var a=(0,r.default)("default");function l(e){return a.var(e)}e.Shiny&&e.Shiny.addCustomMessageHandler("update-client-value",function(e){"string"==typeof e.group?(0,r.default)(e.group).var(e.name).set(e.value):l(e.name).set(e.value)});var s={group:r.default,var:l,has:function(e){return a.has(e)},SelectionHandle:i.SelectionHandle,FilterHandle:o.FilterHandle,bind:u.bind};c.default=s,e.crosstalk=s}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./filter":2,"./group":4,"./input":6,"./input_checkboxgroup":7,"./input_selectize":8,"./input_slider":9,"./selection":10}],6:[function(e,t,a){(function(t){"use strict";Object.defineProperty(a,"__esModule",{value:!0}),a.register=function(e){r[e.className]=e,t.document&&"complete"!==t.document.readyState?o(function(){n()}):t.document&&setTimeout(n,100)},a.bind=n;var o=t.jQuery,r={};function n(){Object.keys(r).forEach(function(e){var n=r[e];o("."+n.className).not(".crosstalk-input-bound").each(function(e,t){i(n,t)})})}function i(e,t){var n=o(t).find("script[type='application/json'][data-for='"+t.id.replace(/([!"#$%&'()*+,./:;<=>?@[\\\]^`{|}~])/g,"\\$1")+"']"),r=JSON.parse(n[0].innerText),i=e.factory(t,r);o(t).data("crosstalk-instance",i),o(t).addClass("crosstalk-input-bound")}if(t.Shiny){var e=new t.Shiny.InputBinding,u=t.jQuery;u.extend(e,{find:function(e){return u(e).find(".crosstalk-input")},initialize:function(e){var t,n;u(e).hasClass("crosstalk-input-bound")||(n=o(t=e),Object.keys(r).forEach(function(e){n.hasClass(e)&&!n.hasClass("crosstalk-input-bound")&&i(r[e],t)}))},getId:function(e){return e.id},getValue:function(e){},setValue:function(e,t){},receiveMessage:function(e,t){},subscribe:function(e,t){u(e).data("crosstalk-instance").resume()},unsubscribe:function(e){u(e).data("crosstalk-instance").suspend()}}),t.Shiny.inputBindings.register(e,"crosstalk.inputBinding")}}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{}],7:[function(r,e,t){(function(e){"use strict";var t=function(e){{if(e&&e.__esModule)return e;var t={};if(null!=e)for(var n in e)Object.prototype.hasOwnProperty.call(e,n)&&(t[n]=e[n]);return t.default=e,t}}(r("./input")),n=r("./filter");var a=e.jQuery;t.register({className:"crosstalk-input-checkboxgroup",factory:function(e,r){var i=new n.FilterHandle(r.group),o=void 0,u=a(e);return u.on("change","input[type='checkbox']",function(){var e=u.find("input[type='checkbox']:checked");if(0===e.length)o=null,i.clear();else{var t={};e.each(function(){r.map[this.value].forEach(function(e){t[e]=!0})});var n=Object.keys(t);n.sort(),o=n,i.set(n)}}),{suspend:function(){i.clear()},resume:function(){o&&i.set(o)}}}})}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./filter":2,"./input":6}],8:[function(r,e,t){(function(e){"use strict";var t=n(r("./input")),l=n(r("./util")),s=r("./filter");function n(e){if(e&&e.__esModule)return e;var t={};if(null!=e)for(var n in e)Object.prototype.hasOwnProperty.call(e,n)&&(t[n]=e[n]);return t.default=e,t}var f=e.jQuery;t.register({className:"crosstalk-input-select",factory:function(e,n){var t=l.dataframeToD3(n.items),r={options:[{value:"",label:"(All)"}].concat(t),valueField:"value",labelField:"label",searchField:"label"},i=f(e).find("select")[0],o=f(i).selectize(r)[0].selectize,u=new s.FilterHandle(n.group),a=void 0;return o.on("change",function(){if(0===o.items.length)a=null,u.clear();else{var t={};o.items.forEach(function(e){n.map[e].forEach(function(e){t[e]=!0})});var e=Object.keys(t);e.sort(),a=e,u.set(e)}}),{suspend:function(){u.clear()},resume:function(){a&&u.set(a)}}}})}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./filter":2,"./input":6,"./util":11}],9:[function(n,e,t){(function(e){"use strict";var d=function(e,t){if(Array.isArray(e))return e;if(Symbol.iterator in Object(e))return function(e,t){var n=[],r=!0,i=!1,o=void 0;try{for(var u,a=e[Symbol.iterator]();!(r=(u=a.next()).done)&&(n.push(u.value),!t||n.length!==t);r=!0);}catch(e){i=!0,o=e}finally{try{!r&&a.return&&a.return()}finally{if(i)throw o}}return n}(e,t);throw new TypeError("Invalid attempt to destructure non-iterable instance")},t=function(e){{if(e&&e.__esModule)return e;var t={};if(null!=e)for(var n in e)Object.prototype.hasOwnProperty.call(e,n)&&(t[n]=e[n]);return t.default=e,t}}(n("./input")),a=n("./filter");var v=e.jQuery,p=e.strftime;function y(e,t){for(var n=e.toString();n.length<t;)n="0"+n;return n}t.register({className:"crosstalk-input-slider",factory:function(e,l){var s=new a.FilterHandle(l.group),t={},f=v(e).find("input"),n=f.data("data-type"),r=f.data("time-format"),i=f.data("round"),o=void 0;if("date"===n)o=p.utc(),t.prettify=function(e){return o(r,new Date(e))};else if("datetime"===n){var u=f.data("timezone");o=u?p.timezone(u):p,t.prettify=function(e){return o(r,new Date(e))}}else"number"===n&&void 0!==i&&(t.prettify=function(e){var t=Math.pow(10,i);return Math.round(e*t)/t});function c(){var e=f.data("ionRangeSlider").result,t=void 0,n=f.data("data-type");return t="date"===n?function(e){return(t=new Date(+e))instanceof Date?t.getUTCFullYear()+"-"+y(t.getUTCMonth()+1,2)+"-"+y(t.getUTCDate(),2):null;var t}:"datetime"===n?function(e){return+e/1e3}:function(e){return+e},"double"===f.data("ionRangeSlider").options.type?[t(e.from),t(e.to)]:t(e.from)}f.ionRangeSlider(t);var h=null;return f.on("change.crosstalkSliderInput",function(e){if(!f.data("updating")&&!f.data("animating")){for(var t=c(),n=d(t,2),r=n[0],i=n[1],o=[],u=0;u<l.values.length;u++){var a=l.values[u];r<=a&&a<=i&&o.push(l.keys[u])}o.sort(),s.set(o),h=o}}),{suspend:function(){s.clear()},resume:function(){h&&s.set(h)}}}})}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./filter":2,"./input":6}],10:[function(e,t,n){"use strict";Object.defineProperty(n,"__esModule",{value:!0}),n.SelectionHandle=void 0;var r=function(){function r(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(e,t,n){return t&&r(e.prototype,t),n&&r(e,n),e}}(),i=a(e("./events")),o=a(e("./group")),u=function(e){{if(e&&e.__esModule)return e;var t={};if(null!=e)for(var n in e)Object.prototype.hasOwnProperty.call(e,n)&&(t[n]=e[n]);return t.default=e,t}}(e("./util"));function a(e){return e&&e.__esModule?e:{default:e}}n.SelectionHandle=function(){function n(){var e=0<arguments.length&&void 0!==arguments[0]?arguments[0]:null,t=1<arguments.length&&void 0!==arguments[1]?arguments[1]:null;!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,n),this._eventRelay=new i.default,this._emitter=new u.SubscriptionTracker(this._eventRelay),this._group=null,this._var=null,this._varOnChangeSub=null,this._extraInfo=u.extend({sender:this},t),this.setGroup(e)}return r(n,[{key:"setGroup",value:function(e){var t=this;if(this._group!==e&&(this._group||e)&&(this._var&&(this._var.off("change",this._varOnChangeSub),this._var=null,this._varOnChangeSub=null),this._group=e)){this._var=(0,o.default)(e).var("selection");var n=this._var.on("change",function(e){t._eventRelay.trigger("change",e,t)});this._varOnChangeSub=n}}},{key:"_mergeExtraInfo",value:function(e){return u.extend({},this._extraInfo?this._extraInfo:null,e||null)}},{key:"set",value:function(e,t){this._var&&this._var.set(e,this._mergeExtraInfo(t))}},{key:"clear",value:function(e){this._var&&this.set(void 0,this._mergeExtraInfo(e))}},{key:"on",value:function(e,t){return this._emitter.on(e,t)}},{key:"off",value:function(e,t){return this._emitter.off(e,t)}},{key:"close",value:function(){this._emitter.removeAllListeners(),this.setGroup(null)}},{key:"value",get:function(){return this._var?this._var.get():null}}]),n}()},{"./events":1,"./group":4,"./util":11}],11:[function(e,t,n){"use strict";Object.defineProperty(n,"__esModule",{value:!0});var r=function(){function r(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(e,t,n){return t&&r(e.prototype,t),n&&r(e,n),e}}(),l="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};function u(e){for(var t=1;t<e.length;t++)if(e[t]<=e[t-1])throw new Error("List is not sorted or contains duplicate")}n.extend=function(e){for(var t=arguments.length,n=Array(1<t?t-1:0),r=1;r<t;r++)n[r-1]=arguments[r];for(var i=0;i<n.length;i++){var o=n[i];if(null!=o)for(var u in o)o.hasOwnProperty(u)&&(e[u]=o[u])}return e},n.checkSorted=u,n.diffSortedLists=function(e,t){var n=0,r=0;e||(e=[]);t||(t=[]);var i=[],o=[];u(e),u(t);for(;n<e.length&&r<t.length;)e[n]===t[r]?(n++,r++):e[n]<t[r]?i.push(e[n++]):o.push(t[r++]);n<e.length&&(i=i.concat(e.slice(n)));r<t.length&&(o=o.concat(t.slice(r)));return{removed:i,added:o}},n.dataframeToD3=function(e){var t=[],n=void 0;for(var r in e){if(e.hasOwnProperty(r)&&t.push(r),"object"!==l(e[r])||void 0===e[r].length)throw new Error("All fields must be arrays");if(void 0!==n&&n!==e[r].length)throw new Error("All fields must be arrays of the same length");n=e[r].length}for(var i=[],o=void 0,u=0;u<n;u++){o={};for(var a=0;a<t.length;a++)o[t[a]]=e[t[a]][u];i.push(o)}return i};n.SubscriptionTracker=function(){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t),this._emitter=e,this._subs={}}return r(t,[{key:"on",value:function(e,t){var n=this._emitter.on(e,t);return this._subs[n]=e,n}},{key:"off",value:function(e,t){var n=this._emitter.off(e,t);return n&&delete this._subs[n],n}},{key:"removeAllListeners",value:function(){var t=this,n=this._subs;this._subs={},Object.keys(n).forEach(function(e){t._emitter.off(n[e],e)})}}]),t}()},{}],12:[function(a,e,l){(function(o){"use strict";Object.defineProperty(l,"__esModule",{value:!0});var e,u="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},t=function(){function r(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(e,t,n){return t&&r(e.prototype,t),n&&r(e,n),e}}(),n=a("./events"),i=(e=n)&&e.__esModule?e:{default:e};var r=function(){function r(e,t,n){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,r),this._group=e,this._name=t,this._value=n,this._events=new i.default}return t(r,[{key:"get",value:function(){return this._value}},{key:"set",value:function(e,t){if(this._value!==e){var n=this._value;this._value=e;var r={};if(t&&"object"===(void 0===t?"undefined":u(t)))for(var i in t)t.hasOwnProperty(i)&&(r[i]=t[i]);r.oldValue=n,r.value=e,this._events.trigger("change",r,this),o.Shiny&&o.Shiny.onInputChange&&o.Shiny.onInputChange(".clientValue-"+(null!==this._group.name?this._group.name+"-":"")+this._name,void 0===e?null:e)}}},{key:"on",value:function(e,t){return this._events.on(e,t)}},{key:"off",value:function(e,t){return this._events.off(e,t)}}]),r}();l.default=r}).call(this,"undefined"!=typeof global?global:"undefined"!=typeof self?self:"undefined"!=typeof window?window:{})},{"./events":1}]},{},[5]);
//# sourceMappingURL=crosstalk.min.js.map\"></script>\n",
       "<link href=\"data:text/css;charset-utf-8;base64,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\" rel=\"stylesheet\" />\n",
       "\t</head>\n",
       "\t<body>\n",
       "\t\t<div class=\"datatables html-widget html-fill-item\" id=\"htmlwidget-08457ed5bd970183851c\" style=\"width:100%;height:auto;\"></div>\n",
       "<script type=\"application/json\" data-for=\"htmlwidget-08457ed5bd970183851c\">{\"x\":{\"filter\":\"none\",\"vertical\":false,\"data\":[[\"1\",\"2\",\"3\",\"4\",\"5\",\"6\",\"7\",\"8\",\"9\",\"10\"],[\"NCT05444894\",\"NCT07150091\",\"NCT05421598\",\"NCT05394350\",\"NCT04765514\",\"NCT05432934\",\"NCT05489211\",\"NCT05593445\",\"NCT05407675\",\"NCT05482971\"],[\"EM-301-BThal-001\",\"208887 Sub Study 6\",\"DRI17509\",\"1088-002\",\"IIT-0012\",\"BIO-2549\",\"D926UC00001\",\"INCB 18424-220\",\"CA099-003\",\"EXCEED ET / A22-301\"],[\"EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)\",\"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM\",\"Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma\",\"A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)\",\"Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients\",\"Transversus Abdominis Plane Blocks With and Without Dexamethasone\",\"Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)\",\"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus\",\"A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors\",\"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET\"],[\"A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)\",\"A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination\",\"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma\",\"A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors\",\"A Randomized Controlled Trial of Chemo-Radiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail Patients With Newly Diagnosed Glioblastoma\",\"Transversus Abdominis Plane Blocks With and Without Dexamethasone: A Randomized Clinical Trial in Minimally Invasive Colorectal Surgery\",\"A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours\",\"A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus\",\"A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors\",\"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential Thrombocythemia\"],[\"ACTIVE_NOT_RECRUITING\",\"ACTIVE_NOT_RECRUITING\",\"COMPLETED\",\"TERMINATED\",\"RECRUITING\",\"UNKNOWN\",\"RECRUITING\",\"COMPLETED\",\"COMPLETED\",\"ACTIVE_NOT_RECRUITING\"],[null,null,null,\"Business Reasons\",null,null,null,null,null,null],[\"2022-04-29\",\"2022-07-19\",\"2022-06-30\",\"2022-07-07\",\"2022-07-27\",\"2022-09-01\",\"2022-09-06\",\"2022-11-18\",\"2022-08-02\",\"2022-09-29\"],[\"2025-09\",\"2025-04-17\",\"2024-10-11\",\"2023-09-07\",\"2032-06\",\"2024-03-31\",\"2026-08-19\",\"2023-09-01\",\"2024-08-22\",\"2025-05-09\"],[\"2025-12\",\"2027-03-11\",\"2025-03-20\",\"2023-09-07\",\"2032-06\",\"2024-08-31\",\"2026-08-19\",\"2023-12-21\",\"2025-07-24\",\"2027-03-31\"],[\"2025-04-02\",\"2025-09-02\",\"2025-10-09\",\"2024-11-08\",\"2025-06-12\",\"2023-12-07\",\"2025-07-11\",\"2024-09-24\",\"2025-10-03\",\"2025-08-13\"],[\"Editas Medicine, Inc.\",\"GlaxoSmithKline\",\"Sanofi\",\"Merck Sharp &amp; Dohme LLC\",\"AHS Cancer Control Alberta\",\"University of Saskatchewan\",\"AstraZeneca\",\"Incyte Corporation\",\"Bristol-Myers Squibb\",\"PharmaEssentia\"],[\"INDUSTRY\",\"INDUSTRY\",\"INDUSTRY\",\"INDUSTRY\",\"OTHER\",\"OTHER\",\"INDUSTRY\",\"INDUSTRY\",\"INDUSTRY\",\"INDUSTRY\"],[\"INTERVENTIONAL\",\"INTERVENTIONAL\",\"INTERVENTIONAL\",\"INTERVENTIONAL\",\"INTERVENTIONAL\",\"INTERVENTIONAL\",\"INTERVENTIONAL\",\"INTERVENTIONAL\",\"INTERVENTIONAL\",\"INTERVENTIONAL\"],[\"PHASE1, PHASE2\",\"PHASE1, PHASE2\",\"PHASE2\",\"PHASE1, PHASE2\",\"PHASE2\",\"PHASE1, PHASE2\",\"PHASE2\",\"PHASE2\",\"PHASE1, PHASE2\",\"PHASE2\"],[\"NA\",\"NA\",\"RANDOMIZED\",\"NON_RANDOMIZED\",\"RANDOMIZED\",\"RANDOMIZED\",\"NON_RANDOMIZED\",\"RANDOMIZED\",\"NON_RANDOMIZED\",\"NA\"],[\"SINGLE_GROUP\",\"SINGLE_GROUP\",\"PARALLEL\",\"PARALLEL\",\"PARALLEL\",\"PARALLEL\",\"PARALLEL\",\"PARALLEL\",\"SEQUENTIAL\",\"SINGLE_GROUP\"],[\"TREATMENT\",\"TREATMENT\",\"TREATMENT\",\"TREATMENT\",\"TREATMENT\",\"TREATMENT\",\"TREATMENT\",\"TREATMENT\",\"TREATMENT\",\"TREATMENT\"],[\"NONE\",\"NONE\",\"QUADRUPLE\",\"NONE\",\"NONE\",\"DOUBLE\",\"NONE\",\"TRIPLE\",\"NONE\",\"NONE\"],[\"9\",\"20\",\"446\",\"27\",\"121\",\"60\",\"582\",\"61\",\"68\",\"91\"],[\"ESTIMATED\",\"ACTUAL\",\"ACTUAL\",\"ACTUAL\",\"ESTIMATED\",\"ESTIMATED\",\"ESTIMATED\",\"ACTUAL\",\"ACTUAL\",\"ACTUAL\"],[\"Transfusion Dependent Beta Thalassemia; Hemoglobinopathies; Thalassemia Major; Thalassemia Intermedia\",\"Multiple Myeloma\",\"Asthma\",\"Advanced Solid Tumors\",\"Glioblastoma Multiforme\",\"Colorectal Disorders; Regional Anesthesia Morbidity; Analgesia; Local Anesthetic Complication; Pain, Postoperative; Colorectal Cancer; Crohn Disease; Diverticular Diseases\",\"Endometrial Cancer; Gastric Cancer; Metastatic Castration-resistant Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Urothelial Cancer; Biliary Tract Cancer\",\"Lichen Sclerosus\",\"Advanced Solid Tumors\",\"Essential Thrombocythemia\"],[\"United States; Canada\",\"United States; Brazil; Canada; France; Germany; Greece; Mexico; South Korea\",\"United States; Argentina; Brazil; Canada; Chile; Hungary; Italy; Japan; Mexico; Poland; South Africa; South Korea; Turkey (Türkiye); United Kingdom\",\"United States; Canada; Denmark; Israel; Switzerland\",\"Canada\",\"Canada\",\"United States; Canada; China; France; Germany; Italy; Japan; Poland; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom\",\"United States; Canada\",\"United States; Canada; France; Spain; Switzerland\",\"United States; Canada\"],[8,12,113,13,2,1,95,14,18,34],[false,false,false,true,false,false,false,true,true,false]],\"container\":\"<table class=\\\"display\\\">\\n  <thead>\\n    <tr>\\n      <th> <\\/th>\\n      <th>nct_id<\\/th>\\n      <th>org_study_id<\\/th>\\n      <th>brief_title<\\/th>\\n      <th>official_title<\\/th>\\n      <th>overall_status<\\/th>\\n      <th>why_stopped<\\/th>\\n      <th>start_date<\\/th>\\n      <th>primary_completion_date<\\/th>\\n      <th>completion_date<\\/th>\\n      <th>last_update_posted<\\/th>\\n      <th>sponsor<\\/th>\\n      <th>sponsor_class<\\/th>\\n      <th>study_type<\\/th>\\n      <th>phase<\\/th>\\n      <th>allocation<\\/th>\\n      <th>intervention_model<\\/th>\\n      <th>primary_purpose<\\/th>\\n      <th>masking<\\/th>\\n      <th>enrollment<\\/th>\\n      <th>enrollment_type<\\/th>\\n      <th>conditions<\\/th>\\n      <th>countries<\\/th>\\n      <th>n_sites<\\/th>\\n      <th>has_results<\\/th>\\n    <\\/tr>\\n  <\\/thead>\\n<\\/table>\",\"options\":{\"pageLength\":10,\"columnDefs\":[{\"className\":\"dt-right\",\"targets\":23},{\"orderable\":false,\"targets\":0},{\"name\":\" \",\"targets\":0},{\"name\":\"nct_id\",\"targets\":1},{\"name\":\"org_study_id\",\"targets\":2},{\"name\":\"brief_title\",\"targets\":3},{\"name\":\"official_title\",\"targets\":4},{\"name\":\"overall_status\",\"targets\":5},{\"name\":\"why_stopped\",\"targets\":6},{\"name\":\"start_date\",\"targets\":7},{\"name\":\"primary_completion_date\",\"targets\":8},{\"name\":\"completion_date\",\"targets\":9},{\"name\":\"last_update_posted\",\"targets\":10},{\"name\":\"sponsor\",\"targets\":11},{\"name\":\"sponsor_class\",\"targets\":12},{\"name\":\"study_type\",\"targets\":13},{\"name\":\"phase\",\"targets\":14},{\"name\":\"allocation\",\"targets\":15},{\"name\":\"intervention_model\",\"targets\":16},{\"name\":\"primary_purpose\",\"targets\":17},{\"name\":\"masking\",\"targets\":18},{\"name\":\"enrollment\",\"targets\":19},{\"name\":\"enrollment_type\",\"targets\":20},{\"name\":\"conditions\",\"targets\":21},{\"name\":\"countries\",\"targets\":22},{\"name\":\"n_sites\",\"targets\":23},{\"name\":\"has_results\",\"targets\":24}],\"order\":[],\"autoWidth\":false,\"orderClasses\":false},\"selection\":{\"mode\":\"multiple\",\"selected\":null,\"target\":\"row\",\"selectable\":null}},\"evals\":[],\"jsHooks\":[]}</script>\n",
       "\t</body>\n",
       "</html>\n"
      ],
      "text/plain": [
       "HTML widgets cannot be represented in plain text (need html)"
      ]
     },
     "metadata": {
      "text/html": {
       "isolated": true
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "DT::datatable(tbl, options = list(pageLength = 10))\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b8a18eee-ee40-416c-81bc-00cad7c90877",
   "metadata": {},
   "source": [
    "Parameters I am keeping in the summary table:\n",
    "\n",
    "| Column name    | Description                                          |\n",
    "| -------------- | ---------------------------------------------------- |\n",
    "| `nct_id`       | ClinicalTrials.gov identifier (e.g. `\"NCT05444894\"`) |\n",
    "| `org_study_id` | Sponsor’s internal study ID                          |\n",
    "| `brief_title`    | Short public title of the study |\n",
    "| `official_title` | Full official study title       |\n",
    "| `overall_status` | Recruitment status (e.g. `RECRUITING`, `ACTIVE_NOT_RECRUITING`) |\n",
    "| `why_stopped`    | Reason study was stopped early (if applicable)                  |\n",
    "| `start_date`              | Study start date                                |\n",
    "| `primary_completion_date` | Primary outcome completion date                 |\n",
    "| `completion_date`         | Final study completion date                     |\n",
    "| `last_update_posted`      | Most recent update posted to ClinicalTrials.gov |\n",
    "| `sponsor`       | Lead sponsor organization name                      |\n",
    "| `sponsor_class` | Sponsor classification (`INDUSTRY`, `NIH`, `OTHER`) |\n",
    "| `study_type`         | Study type (e.g. `INTERVENTIONAL`, `OBSERVATIONAL`) |\n",
    "| `phase`              | Study phase(s), collapsed (e.g. `\"PHASE1, PHASE2\"`) |\n",
    "| `allocation`         | Allocation method (`RANDOMIZED`, `NA`, etc.)        |\n",
    "| `intervention_model` | Intervention model (e.g. `SINGLE_GROUP`)            |\n",
    "| `primary_purpose`    | Primary purpose (e.g. `TREATMENT`)                  |\n",
    "| `masking`            | Masking/blinding status                             |\n",
    "| `enrollment`      | Target or actual enrollment count         |\n",
    "| `enrollment_type` | Enrollment type (`ACTUAL` or `ESTIMATED`) |\n",
    "| `conditions` | All study conditions collapsed into a single semicolon-separated string |\n",
    "| `countries` | Unique list of countries with study sites (collapsed) |\n",
    "| `n_sites`   | Total number of study locations                       |\n",
    "| `has_results` | Logical indicating whether posted results are available |\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "341c49eb-2f81-4a45-a2dc-9c5e155de51b",
   "metadata": {},
   "source": [
    "### Why we are choosing these field names:\n",
    "\n",
    "- I chose these paramters as a good starting place to start research\n",
    "- these fields are important for policy creations."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "0030ddc8-8bae-4bd9-8c86-fb1d2c293ccc",
   "metadata": {},
   "source": [
    "created the function"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "5f69628f-9802-41e8-9b4f-79c46251090b",
   "metadata": {},
   "outputs": [],
   "source": [
    "library(tibble)\n",
    "library(purrr)\n",
    "library(dplyr)\n",
    "\n",
    "#' Build a study-level table from CT.gov v2 JSON with curated module columns\n",
    "#'\n",
    "#' @param studies List of study records (e.g., result$studies).\n",
    "#' @param modules Character vector of protocolSection module names to include.\n",
    "#'   Use \"all\" to include all supported modules.\n",
    "#'   Supported: identificationModule, statusModule, sponsorCollaboratorsModule,\n",
    "#'   designModule, eligibilityModule, contactsLocationsModule, referencesModule.\n",
    "#' @return Tibble with 1 row per study.\n",
    "studies_to_table <- function(\n",
    "  studies,\n",
    "  modules = c(\"identificationModule\", \"statusModule\", \"sponsorCollaboratorsModule\", \"designModule\")\n",
    ") {\n",
    "\n",
    "  extractors <- list(\n",
    "\n",
    "    identificationModule = function(st) tibble(\n",
    "      nct_id        = get_in(st, c(\"protocolSection\",\"identificationModule\",\"nctId\")),\n",
    "      org_study_id   = get_in(st, c(\"protocolSection\",\"identificationModule\",\"orgStudyIdInfo\",\"id\")),\n",
    "      brief_title    = get_in(st, c(\"protocolSection\",\"identificationModule\",\"briefTitle\")),\n",
    "      official_title = get_in(st, c(\"protocolSection\",\"identificationModule\",\"officialTitle\")),\n",
    "      acronym        = get_in(st, c(\"protocolSection\",\"identificationModule\",\"acronym\"))\n",
    "    ),\n",
    "\n",
    "    statusModule = function(st) tibble(\n",
    "      overall_status            = get_in(st, c(\"protocolSection\",\"statusModule\",\"overallStatus\")),\n",
    "      status_verified_ym        = get_in(st, c(\"protocolSection\",\"statusModule\",\"statusVerifiedDate\")),\n",
    "      start_date                = get_in(st, c(\"protocolSection\",\"statusModule\",\"startDateStruct\",\"date\")),\n",
    "      start_date_type           = get_in(st, c(\"protocolSection\",\"statusModule\",\"startDateStruct\",\"type\")),\n",
    "      primary_completion_date   = get_in(st, c(\"protocolSection\",\"statusModule\",\"primaryCompletionDateStruct\",\"date\")),\n",
    "      primary_completion_type   = get_in(st, c(\"protocolSection\",\"statusModule\",\"primaryCompletionDateStruct\",\"type\")),\n",
    "      completion_date           = get_in(st, c(\"protocolSection\",\"statusModule\",\"completionDateStruct\",\"date\")),\n",
    "      completion_date_type      = get_in(st, c(\"protocolSection\",\"statusModule\",\"completionDateStruct\",\"type\")),\n",
    "      last_update_posted        = get_in(st, c(\"protocolSection\",\"statusModule\",\"lastUpdatePostDateStruct\",\"date\")),\n",
    "      last_update_posted_type   = get_in(st, c(\"protocolSection\",\"statusModule\",\"lastUpdatePostDateStruct\",\"type\")),\n",
    "      why_stopped               = get_in(st, c(\"protocolSection\",\"statusModule\",\"whyStopped\"))\n",
    "    ),\n",
    "\n",
    "    sponsorCollaboratorsModule = function(st) {\n",
    "      collabs <- st$protocolSection$sponsorCollaboratorsModule$collaborators %||% list()\n",
    "      collab_names <- unique(vapply(collabs, function(z) z$name %||% NA_character_, character(1)))\n",
    "      collab_names <- collab_names[!is.na(collab_names)]\n",
    "      tibble(\n",
    "        lead_sponsor_name  = get_in(st, c(\"protocolSection\",\"sponsorCollaboratorsModule\",\"leadSponsor\",\"name\")),\n",
    "        lead_sponsor_class = get_in(st, c(\"protocolSection\",\"sponsorCollaboratorsModule\",\"leadSponsor\",\"class\")),\n",
    "        collaborators      = if (length(collab_names) == 0) NA_character_ else paste(collab_names, collapse = \"; \")\n",
    "      )\n",
    "    },\n",
    "\n",
    "    designModule = function(st) {\n",
    "      phases <- st$protocolSection$designModule$phases %||% character(0)\n",
    "      tibble(\n",
    "        study_type         = get_in(st, c(\"protocolSection\",\"designModule\",\"studyType\")),\n",
    "        phases             = if (length(phases) == 0) NA_character_ else paste(unlist(phases), collapse = \", \"),\n",
    "        allocation         = get_in(st, c(\"protocolSection\",\"designModule\",\"designInfo\",\"allocation\")),\n",
    "        intervention_model = get_in(st, c(\"protocolSection\",\"designModule\",\"designInfo\",\"interventionModel\")),\n",
    "        primary_purpose    = get_in(st, c(\"protocolSection\",\"designModule\",\"designInfo\",\"primaryPurpose\")),\n",
    "        masking            = get_in(st, c(\"protocolSection\",\"designModule\",\"designInfo\",\"maskingInfo\",\"masking\")),\n",
    "        enrollment_count   = get_in(st, c(\"protocolSection\",\"designModule\",\"enrollmentInfo\",\"count\")),\n",
    "        enrollment_type    = get_in(st, c(\"protocolSection\",\"designModule\",\"enrollmentInfo\",\"type\"))\n",
    "      )\n",
    "    },\n",
    "\n",
    "    eligibilityModule = function(st) tibble(\n",
    "      eligibility_criteria = get_in(st, c(\"protocolSection\",\"eligibilityModule\",\"eligibilityCriteria\")),\n",
    "      healthy_volunteers   = get_in(st, c(\"protocolSection\",\"eligibilityModule\",\"healthyVolunteers\")),\n",
    "      sex                  = get_in(st, c(\"protocolSection\",\"eligibilityModule\",\"sex\")),\n",
    "      minimum_age          = get_in(st, c(\"protocolSection\",\"eligibilityModule\",\"minimumAge\")),\n",
    "      maximum_age          = get_in(st, c(\"protocolSection\",\"eligibilityModule\",\"maximumAge\")),\n",
    "      std_ages             = {\n",
    "        ages <- st$protocolSection$eligibilityModule$stdAges %||% character(0)\n",
    "        if (length(ages) == 0) NA_character_ else paste(unlist(ages), collapse = \", \")\n",
    "      }\n",
    "    ),\n",
    "\n",
    "    contactsLocationsModule = function(st) {\n",
    "      locs <- st$protocolSection$contactsLocationsModule$locations %||% list()\n",
    "      countries <- unique(vapply(locs, function(z) z$country %||% NA_character_, character(1)))\n",
    "      countries <- countries[!is.na(countries)]\n",
    "      cities <- unique(vapply(locs, function(z) z$city %||% NA_character_, character(1)))\n",
    "      cities <- cities[!is.na(cities)]\n",
    "\n",
    "      tibble(\n",
    "        n_sites   = length(locs),\n",
    "        countries = if (length(countries) == 0) NA_character_ else paste(countries, collapse = \"; \"),\n",
    "        cities    = if (length(cities) == 0) NA_character_ else paste(cities, collapse = \"; \")\n",
    "      )\n",
    "    },\n",
    "\n",
    "    referencesModule = function(st) {\n",
    "      refs <- st$protocolSection$referencesModule$references %||% list()\n",
    "\n",
    "      pmids <- vapply(refs, function(r) r$pmid %||% NA_character_, character(1))\n",
    "      pmids <- pmids[!is.na(pmids) & nzchar(pmids)]\n",
    "\n",
    "      citations <- vapply(refs, function(r) r$citation %||% NA_character_, character(1))\n",
    "      citations <- citations[!is.na(citations) & nzchar(citations)]\n",
    "\n",
    "      tibble(\n",
    "        n_references = length(refs),\n",
    "        pmids        = if (length(pmids) == 0) NA_character_ else paste(unique(pmids), collapse = \"; \"),\n",
    "        citations    = if (length(citations) == 0) NA_character_ else paste(unique(citations), collapse = \" | \")\n",
    "      )\n",
    "    }\n",
    "  )\n",
    "\n",
    "  supported <- names(extractors)\n",
    "\n",
    "  if (length(modules) == 1 && identical(modules, \"all\")) {\n",
    "    modules <- supported\n",
    "  }\n",
    "\n",
    "  bad <- setdiff(modules, supported)\n",
    "  if (length(bad) > 0) {\n",
    "    stop(\n",
    "      \"Unknown module(s): \", paste(bad, collapse = \", \"),\n",
    "      \"\\nSupported modules: \", paste(supported, collapse = \", \")\n",
    "    )\n",
    "  }\n",
    "\n",
    "  out <- map_dfr(studies, function(st) {\n",
    "    cols <- lapply(modules, function(m) extractors[[m]](st))\n",
    "    bind_cols(cols)\n",
    "  })\n",
    "\n",
    "  # de-dup by nct_id when present\n",
    "  if (\"nct_id\" %in% names(out)) {\n",
    "    out <- distinct(out, nct_id, .keep_all = TRUE)\n",
    "  }\n",
    "\n",
    "  out\n",
    "}\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "283cdfca-f31a-4c40-a490-f00100be730f",
   "metadata": {},
   "source": [
    "- testing the function"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "eefb2458-f265-4d92-a1ff-f7df8e8eda71",
   "metadata": {},
   "outputs": [],
   "source": [
    "tbl_basic <- studies_to_table(result$studies)\n",
    "\n",
    "tbl_with_sites <- studies_to_table(\n",
    "  result$studies,\n",
    "  modules = c(\"identificationModule\", \"statusModule\", \"contactsLocationsModule\")\n",
    ")\n",
    "\n",
    "tbl_all <- studies_to_table(result$studies, modules = \"all\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "f9de8291-dd5c-42ce-afdd-90efc009b707",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A tibble: 10 × 39</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>nct_id</th><th scope=col>org_study_id</th><th scope=col>brief_title</th><th scope=col>official_title</th><th scope=col>acronym</th><th scope=col>overall_status</th><th scope=col>status_verified_ym</th><th scope=col>start_date</th><th scope=col>start_date_type</th><th scope=col>primary_completion_date</th><th scope=col>⋯</th><th scope=col>sex</th><th scope=col>minimum_age</th><th scope=col>maximum_age</th><th scope=col>std_ages</th><th scope=col>n_sites</th><th scope=col>countries</th><th scope=col>cities</th><th scope=col>n_references</th><th scope=col>pmids</th><th scope=col>citations</th></tr>\n",
       "\t<tr><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>⋯</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;int&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td>NCT05444894</td><td>EM-301-BThal-001   </td><td>EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)                                         </td><td>A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)                                   </td><td>NA         </td><td>ACTIVE_NOT_RECRUITING</td><td>2025-03</td><td>2022-04-29</td><td>ACTUAL</td><td>2025-09   </td><td>⋯</td><td>ALL   </td><td>18 Years</td><td>35 Years </td><td>ADULT             </td><td>  8</td><td>United States; Canada                                                                                                                              </td><td>Oakland; Minneapolis; New York; Cleveland; Philadelphia; Nashville; Toronto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </td><td>0</td><td>NA      </td><td>NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </td></tr>\n",
       "\t<tr><td>NCT07150091</td><td>208887 Sub Study 6 </td><td>Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM                                  </td><td>A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination</td><td>NA         </td><td>ACTIVE_NOT_RECRUITING</td><td>2025-08</td><td>2022-07-19</td><td>ACTUAL</td><td>2025-04-17</td><td>⋯</td><td>ALL   </td><td>18 Years</td><td>NA       </td><td>ADULT, OLDER_ADULT</td><td> 12</td><td>United States; Brazil; Canada; France; Germany; Greece; Mexico; South Korea                                                                        </td><td>Boston; Salvador; São Paulo; Halifax; Villejuif; Hamburg; Athens; Mexico City; Seoul; Ulsan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </td><td>0</td><td>NA      </td><td>NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </td></tr>\n",
       "\t<tr><td>NCT05421598</td><td>DRI17509           </td><td>Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                      </td><td>A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                                                                                </td><td>TIDE-asthma</td><td>COMPLETED            </td><td>2025-10</td><td>2022-06-30</td><td>ACTUAL</td><td>2024-10-11</td><td>⋯</td><td>ALL   </td><td>18 Years</td><td>75 Years </td><td>ADULT, OLDER_ADULT</td><td>113</td><td>United States; Argentina; Brazil; Canada; Chile; Hungary; Italy; Japan; Mexico; Poland; South Africa; South Korea; Turkey (Türkiye); United Kingdom</td><td>La Jolla; Los Angeles; San Jose; Stockton; Westminster; Boynton Beach; Cape Coral; Cutler Bay; Hialeah; Miami; Pembroke Pines; Boise; South Bend; Kansas City; Baltimore; Southfield; Henderson; Toledo; Edmond; Oklahoma City; Boerne; CABA; La Plata; Buenos Aires; Rosario; Ciudad Autonoma Buenos Aires; Vitória; Salvador; Natal; Passo Fundo; Porto Alegre; São Paulo; Sorocaba; Brampton; Ottawa; Toronto; Trois-Rivières; Québec; Talca; Santiago; Quillota; Budapest; Edelény; Gödöllö; Hajdunánás; Mosonmagyaróvár; Püspökladány; Százhalombatta; Szombathely; Cona (FE); Rome; Napoli; Verona; Narita-shi; Kamakura-shi; Yokohama; Nankoku-shi; Kumamoto; Sakai-shi; Chuo-ku; Kiyose-shi; Shinagawa-ku; Shinjuku-ku; Tachikawa-shi; Toshima-ku; Fukuoka; Hiroshima; Guadalajara; Chihuahua City; Durango, Durango; Tlalnepantla; Yucatán; Poznan; Krakow; Bialystok; Elblag; Gdansk; Tarnów; Benoni; Cape Town; Durban; George; Johannesburg; Middelburg; Daegu; Seoul; Seongnam-si, Gyeonggi-do; Istanbul; Izmir; Kayseri; Kocaeli; Mersin; Bradford</td><td>0</td><td>NA      </td><td>NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </td></tr>\n",
       "\t<tr><td>NCT05394350</td><td>1088-002           </td><td>A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)                                            </td><td>A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors                                                                                                                                                                                          </td><td>NA         </td><td>TERMINATED           </td><td>2024-11</td><td>2022-07-07</td><td>ACTUAL</td><td>2023-09-07</td><td>⋯</td><td>ALL   </td><td>18 Years</td><td>NA       </td><td>ADULT, OLDER_ADULT</td><td> 13</td><td>United States; Canada; Denmark; Israel; Switzerland                                                                                                </td><td>Miami; New York; San Antonio; Toronto; Québec; Copenhagen; Odense; Haifa; Jerusalem; Sankt Gallen; Bellinzona; Chur                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </td><td>0</td><td>NA      </td><td>NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </td></tr>\n",
       "\t<tr><td>NCT04765514</td><td>IIT-0012           </td><td>Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients                                                                                        </td><td>A Randomized Controlled Trial of Chemo-Radiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail Patients With Newly Diagnosed Glioblastoma                                                                                                                                                                                                                </td><td>NA         </td><td>RECRUITING           </td><td>2025-06</td><td>2022-07-27</td><td>ACTUAL</td><td>2032-06   </td><td>⋯</td><td>MALE  </td><td>65 Years</td><td>NA       </td><td>OLDER_ADULT       </td><td>  2</td><td>Canada                                                                                                                                             </td><td>Calgary; Edmonton                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </td><td>0</td><td>NA      </td><td>NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </td></tr>\n",
       "\t<tr><td>NCT05432934</td><td>BIO-2549           </td><td>Transversus Abdominis Plane Blocks With and Without Dexamethasone                                                                                                           </td><td>Transversus Abdominis Plane Blocks With and Without Dexamethasone: A Randomized Clinical Trial in Minimally Invasive Colorectal Surgery                                                                                                                                                                                                                             </td><td>TAP-DEX    </td><td>UNKNOWN              </td><td>2023-11</td><td>2022-09-01</td><td>ACTUAL</td><td>2024-03-31</td><td>⋯</td><td>ALL   </td><td>18 Years</td><td>NA       </td><td>ADULT, OLDER_ADULT</td><td>  1</td><td>Canada                                                                                                                                             </td><td>Saskatoon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </td><td>0</td><td>NA      </td><td>NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </td></tr>\n",
       "\t<tr><td>NCT05489211</td><td>D926UC00001        </td><td>Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)                                    </td><td>A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours                                                                                                                           </td><td>NA         </td><td>RECRUITING           </td><td>2025-07</td><td>2022-09-06</td><td>ACTUAL</td><td>2026-08-19</td><td>⋯</td><td>ALL   </td><td>18 Years</td><td>130 Years</td><td>ADULT, OLDER_ADULT</td><td> 95</td><td>United States; Canada; China; France; Germany; Italy; Japan; Poland; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom     </td><td>Los Angeles; San Diego; Santa Rosa; Muncie; Kansas City; Boston; Grand Rapids; East Brunswick; Albuquerque; Commack; Cincinnati; Columbus; Portland; Nashville; Houston; Madison; Toronto; Montreal; Québec; Changsha; Chongqing; Guangzhou; Hangzhou; Hefei; Shanghai; Shenyang; Wuhan; Xi'an; Zhengzhou; Bordeaux; Lyon; Marseille; Suresnes; Berlin; Essen; Hanover; München; Regensburg; Florence; Genova; Milan; Napoli; Rome; Chūōku; Kashiwa; Kōtoku; Nagoya; Shinagawa-ku; Suita-shi; Gliwice; Krakow; Lodz; Poznan; Warsaw; Seoul; Barcelona; Córdoba; Madrid; Málaga; Pamplona; Seville; Basel; Bellinzona; Sankt Gallen; Liou Ying Township; Taipei; Taoyuan District; Ankara; Edirne; Kadıkoy/Istanbul; Karşıyaka; Konya; Pamukkale; Samsun; Cambridge; Dundee; London; Manchester                                                                                                                                                                                                                                                                  </td><td>0</td><td>NA      </td><td>NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </td></tr>\n",
       "\t<tr><td>NCT05593445</td><td>INCB 18424-220     </td><td>A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus                                                                      </td><td>A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus                                                                                                                                                                                                                </td><td>NA         </td><td>COMPLETED            </td><td>2024-08</td><td>2022-11-18</td><td>ACTUAL</td><td>2023-09-01</td><td>⋯</td><td>FEMALE</td><td>18 Years</td><td>NA       </td><td>ADULT, OLDER_ADULT</td><td> 14</td><td>United States; Canada                                                                                                                              </td><td>Birmingham; Scottsdale; Irvine; Washington D.C.; Miami; West Seneca; Chapel Hill; Ashtabula; Bexley; Dallas; Murray; Seattle; Waterloo; Québec                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </td><td>0</td><td>NA      </td><td>NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </td></tr>\n",
       "\t<tr><td>NCT05407675</td><td>CA099-003          </td><td>A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors</td><td>A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors                                                                                                                                                                                                                 </td><td>NA         </td><td>COMPLETED            </td><td>2025-09</td><td>2022-08-02</td><td>ACTUAL</td><td>2024-08-22</td><td>⋯</td><td>ALL   </td><td>18 Years</td><td>NA       </td><td>ADULT, OLDER_ADULT</td><td> 18</td><td>United States; Canada; France; Spain; Switzerland                                                                                                  </td><td>Boston; Hackensack; Houston; Edmonton; Hamilton; Ottawa; Toronto; Bordeaux; Villejuif; Marseille; Toulouse; Málaga; Madrid; Sankt Gallen; Basel; Geneva                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </td><td>0</td><td>NA      </td><td>NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </td></tr>\n",
       "\t<tr><td>NCT05482971</td><td>EXCEED ET / A22-301</td><td>A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET                                                                 </td><td>A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential Thrombocythemia                                                                                                                                                                                           </td><td>NA         </td><td>ACTIVE_NOT_RECRUITING</td><td>2025-08</td><td>2022-09-29</td><td>ACTUAL</td><td>2025-05-09</td><td>⋯</td><td>ALL   </td><td>18 Years</td><td>NA       </td><td>ADULT, OLDER_ADULT</td><td> 34</td><td>United States; Canada                                                                                                                              </td><td>Birmingham; Duarte; Greenbrae; Los Angeles; New Haven; Washington D.C.; Atlanta; Fort Wayne; Paducah; New Orleans; Baltimore; Boston; St Louis; Reno; East Brunswick; Hackensack; New York; Stony Brook; The Bronx; Chapel Hill; Durham; Greenville; Wilson; Memphis; Houston; Salt Lake City; Charlottesville; Seattle; Calgary; Vancouver; Hamilton; Toronto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  </td><td>1</td><td>40330782</td><td>Masarova L, Reeves BN, El Chaer F, Foltz L, Tashi T, Abu-Zeinah G, Lucas J, Halpern AB, Maze D, Qin A, Safah H, Lan F, O'Connell CL, Goel S, Rein L, Fang B, How J, Babu S, Li Z, Cerquozzi S, Oh ST, Hunter AM, Podoltsev N, Vachhani P, Yacoub A, Cunningham JM, Hillis C, Otoukesh S, Zagrijtschuk O, Castro H, Bose P. A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. Front Med (Lausanne). 2025 Apr 17;12:1548590. doi: 10.3389/fmed.2025.1548590. eCollection 2025.</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A tibble: 10 × 39\n",
       "\\begin{tabular}{lllllllllllllllllllll}\n",
       " nct\\_id & org\\_study\\_id & brief\\_title & official\\_title & acronym & overall\\_status & status\\_verified\\_ym & start\\_date & start\\_date\\_type & primary\\_completion\\_date & ⋯ & sex & minimum\\_age & maximum\\_age & std\\_ages & n\\_sites & countries & cities & n\\_references & pmids & citations\\\\\n",
       " <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & ⋯ & <chr> & <chr> & <chr> & <chr> & <int> & <chr> & <chr> & <int> & <chr> & <chr>\\\\\n",
       "\\hline\n",
       "\t NCT05444894 & EM-301-BThal-001    & EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)                                          & A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)                                    & NA          & ACTIVE\\_NOT\\_RECRUITING & 2025-03 & 2022-04-29 & ACTUAL & 2025-09    & ⋯ & ALL    & 18 Years & 35 Years  & ADULT              &   8 & United States; Canada                                                                                                                               & Oakland; Minneapolis; New York; Cleveland; Philadelphia; Nashville; Toronto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      & 0 & NA       & NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \\\\\n",
       "\t NCT07150091 & 208887 Sub Study 6  & Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM                                   & A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination & NA          & ACTIVE\\_NOT\\_RECRUITING & 2025-08 & 2022-07-19 & ACTUAL & 2025-04-17 & ⋯ & ALL    & 18 Years & NA        & ADULT, OLDER\\_ADULT &  12 & United States; Brazil; Canada; France; Germany; Greece; Mexico; South Korea                                                                         & Boston; Salvador; São Paulo; Halifax; Villejuif; Hamburg; Athens; Mexico City; Seoul; Ulsan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      & 0 & NA       & NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \\\\\n",
       "\t NCT05421598 & DRI17509            & Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                       & A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                                                                                 & TIDE-asthma & COMPLETED             & 2025-10 & 2022-06-30 & ACTUAL & 2024-10-11 & ⋯ & ALL    & 18 Years & 75 Years  & ADULT, OLDER\\_ADULT & 113 & United States; Argentina; Brazil; Canada; Chile; Hungary; Italy; Japan; Mexico; Poland; South Africa; South Korea; Turkey (Türkiye); United Kingdom & La Jolla; Los Angeles; San Jose; Stockton; Westminster; Boynton Beach; Cape Coral; Cutler Bay; Hialeah; Miami; Pembroke Pines; Boise; South Bend; Kansas City; Baltimore; Southfield; Henderson; Toledo; Edmond; Oklahoma City; Boerne; CABA; La Plata; Buenos Aires; Rosario; Ciudad Autonoma Buenos Aires; Vitória; Salvador; Natal; Passo Fundo; Porto Alegre; São Paulo; Sorocaba; Brampton; Ottawa; Toronto; Trois-Rivières; Québec; Talca; Santiago; Quillota; Budapest; Edelény; Gödöllö; Hajdunánás; Mosonmagyaróvár; Püspökladány; Százhalombatta; Szombathely; Cona (FE); Rome; Napoli; Verona; Narita-shi; Kamakura-shi; Yokohama; Nankoku-shi; Kumamoto; Sakai-shi; Chuo-ku; Kiyose-shi; Shinagawa-ku; Shinjuku-ku; Tachikawa-shi; Toshima-ku; Fukuoka; Hiroshima; Guadalajara; Chihuahua City; Durango, Durango; Tlalnepantla; Yucatán; Poznan; Krakow; Bialystok; Elblag; Gdansk; Tarnów; Benoni; Cape Town; Durban; George; Johannesburg; Middelburg; Daegu; Seoul; Seongnam-si, Gyeonggi-do; Istanbul; Izmir; Kayseri; Kocaeli; Mersin; Bradford & 0 & NA       & NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \\\\\n",
       "\t NCT05394350 & 1088-002            & A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)                                             & A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors                                                                                                                                                                                           & NA          & TERMINATED            & 2024-11 & 2022-07-07 & ACTUAL & 2023-09-07 & ⋯ & ALL    & 18 Years & NA        & ADULT, OLDER\\_ADULT &  13 & United States; Canada; Denmark; Israel; Switzerland                                                                                                 & Miami; New York; San Antonio; Toronto; Québec; Copenhagen; Odense; Haifa; Jerusalem; Sankt Gallen; Bellinzona; Chur                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              & 0 & NA       & NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \\\\\n",
       "\t NCT04765514 & IIT-0012            & Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients                                                                                         & A Randomized Controlled Trial of Chemo-Radiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail Patients With Newly Diagnosed Glioblastoma                                                                                                                                                                                                                 & NA          & RECRUITING            & 2025-06 & 2022-07-27 & ACTUAL & 2032-06    & ⋯ & MALE   & 65 Years & NA        & OLDER\\_ADULT        &   2 & Canada                                                                                                                                              & Calgary; Edmonton                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                & 0 & NA       & NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \\\\\n",
       "\t NCT05432934 & BIO-2549            & Transversus Abdominis Plane Blocks With and Without Dexamethasone                                                                                                            & Transversus Abdominis Plane Blocks With and Without Dexamethasone: A Randomized Clinical Trial in Minimally Invasive Colorectal Surgery                                                                                                                                                                                                                              & TAP-DEX     & UNKNOWN               & 2023-11 & 2022-09-01 & ACTUAL & 2024-03-31 & ⋯ & ALL    & 18 Years & NA        & ADULT, OLDER\\_ADULT &   1 & Canada                                                                                                                                              & Saskatoon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        & 0 & NA       & NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \\\\\n",
       "\t NCT05489211 & D926UC00001         & Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)                                     & A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours                                                                                                                            & NA          & RECRUITING            & 2025-07 & 2022-09-06 & ACTUAL & 2026-08-19 & ⋯ & ALL    & 18 Years & 130 Years & ADULT, OLDER\\_ADULT &  95 & United States; Canada; China; France; Germany; Italy; Japan; Poland; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom      & Los Angeles; San Diego; Santa Rosa; Muncie; Kansas City; Boston; Grand Rapids; East Brunswick; Albuquerque; Commack; Cincinnati; Columbus; Portland; Nashville; Houston; Madison; Toronto; Montreal; Québec; Changsha; Chongqing; Guangzhou; Hangzhou; Hefei; Shanghai; Shenyang; Wuhan; Xi'an; Zhengzhou; Bordeaux; Lyon; Marseille; Suresnes; Berlin; Essen; Hanover; München; Regensburg; Florence; Genova; Milan; Napoli; Rome; Chūōku; Kashiwa; Kōtoku; Nagoya; Shinagawa-ku; Suita-shi; Gliwice; Krakow; Lodz; Poznan; Warsaw; Seoul; Barcelona; Córdoba; Madrid; Málaga; Pamplona; Seville; Basel; Bellinzona; Sankt Gallen; Liou Ying Township; Taipei; Taoyuan District; Ankara; Edirne; Kadıkoy/Istanbul; Karşıyaka; Konya; Pamukkale; Samsun; Cambridge; Dundee; London; Manchester                                                                                                                                                                                                                                                                   & 0 & NA       & NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \\\\\n",
       "\t NCT05593445 & INCB 18424-220      & A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus                                                                       & A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus                                                                                                                                                                                                                 & NA          & COMPLETED             & 2024-08 & 2022-11-18 & ACTUAL & 2023-09-01 & ⋯ & FEMALE & 18 Years & NA        & ADULT, OLDER\\_ADULT &  14 & United States; Canada                                                                                                                               & Birmingham; Scottsdale; Irvine; Washington D.C.; Miami; West Seneca; Chapel Hill; Ashtabula; Bexley; Dallas; Murray; Seattle; Waterloo; Québec                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   & 0 & NA       & NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \\\\\n",
       "\t NCT05407675 & CA099-003           & A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors & A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors                                                                                                                                                                                                                  & NA          & COMPLETED             & 2025-09 & 2022-08-02 & ACTUAL & 2024-08-22 & ⋯ & ALL    & 18 Years & NA        & ADULT, OLDER\\_ADULT &  18 & United States; Canada; France; Spain; Switzerland                                                                                                   & Boston; Hackensack; Houston; Edmonton; Hamilton; Ottawa; Toronto; Bordeaux; Villejuif; Marseille; Toulouse; Málaga; Madrid; Sankt Gallen; Basel; Geneva                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          & 0 & NA       & NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \\\\\n",
       "\t NCT05482971 & EXCEED ET / A22-301 & A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET                                                                  & A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential Thrombocythemia                                                                                                                                                                                            & NA          & ACTIVE\\_NOT\\_RECRUITING & 2025-08 & 2022-09-29 & ACTUAL & 2025-05-09 & ⋯ & ALL    & 18 Years & NA        & ADULT, OLDER\\_ADULT &  34 & United States; Canada                                                                                                                               & Birmingham; Duarte; Greenbrae; Los Angeles; New Haven; Washington D.C.; Atlanta; Fort Wayne; Paducah; New Orleans; Baltimore; Boston; St Louis; Reno; East Brunswick; Hackensack; New York; Stony Brook; The Bronx; Chapel Hill; Durham; Greenville; Wilson; Memphis; Houston; Salt Lake City; Charlottesville; Seattle; Calgary; Vancouver; Hamilton; Toronto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   & 1 & 40330782 & Masarova L, Reeves BN, El Chaer F, Foltz L, Tashi T, Abu-Zeinah G, Lucas J, Halpern AB, Maze D, Qin A, Safah H, Lan F, O'Connell CL, Goel S, Rein L, Fang B, How J, Babu S, Li Z, Cerquozzi S, Oh ST, Hunter AM, Podoltsev N, Vachhani P, Yacoub A, Cunningham JM, Hillis C, Otoukesh S, Zagrijtschuk O, Castro H, Bose P. A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. Front Med (Lausanne). 2025 Apr 17;12:1548590. doi: 10.3389/fmed.2025.1548590. eCollection 2025.\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A tibble: 10 × 39\n",
       "\n",
       "| nct_id &lt;chr&gt; | org_study_id &lt;chr&gt; | brief_title &lt;chr&gt; | official_title &lt;chr&gt; | acronym &lt;chr&gt; | overall_status &lt;chr&gt; | status_verified_ym &lt;chr&gt; | start_date &lt;chr&gt; | start_date_type &lt;chr&gt; | primary_completion_date &lt;chr&gt; | ⋯ ⋯ | sex &lt;chr&gt; | minimum_age &lt;chr&gt; | maximum_age &lt;chr&gt; | std_ages &lt;chr&gt; | n_sites &lt;int&gt; | countries &lt;chr&gt; | cities &lt;chr&gt; | n_references &lt;int&gt; | pmids &lt;chr&gt; | citations &lt;chr&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|\n",
       "| NCT05444894 | EM-301-BThal-001    | EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)                                          | A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)                                    | NA          | ACTIVE_NOT_RECRUITING | 2025-03 | 2022-04-29 | ACTUAL | 2025-09    | ⋯ | ALL    | 18 Years | 35 Years  | ADULT              |   8 | United States; Canada                                                                                                                               | Oakland; Minneapolis; New York; Cleveland; Philadelphia; Nashville; Toronto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0 | NA       | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
       "| NCT07150091 | 208887 Sub Study 6  | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM                                   | A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination | NA          | ACTIVE_NOT_RECRUITING | 2025-08 | 2022-07-19 | ACTUAL | 2025-04-17 | ⋯ | ALL    | 18 Years | NA        | ADULT, OLDER_ADULT |  12 | United States; Brazil; Canada; France; Germany; Greece; Mexico; South Korea                                                                         | Boston; Salvador; São Paulo; Halifax; Villejuif; Hamburg; Athens; Mexico City; Seoul; Ulsan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0 | NA       | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
       "| NCT05421598 | DRI17509            | Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                       | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                                                                                 | TIDE-asthma | COMPLETED             | 2025-10 | 2022-06-30 | ACTUAL | 2024-10-11 | ⋯ | ALL    | 18 Years | 75 Years  | ADULT, OLDER_ADULT | 113 | United States; Argentina; Brazil; Canada; Chile; Hungary; Italy; Japan; Mexico; Poland; South Africa; South Korea; Turkey (Türkiye); United Kingdom | La Jolla; Los Angeles; San Jose; Stockton; Westminster; Boynton Beach; Cape Coral; Cutler Bay; Hialeah; Miami; Pembroke Pines; Boise; South Bend; Kansas City; Baltimore; Southfield; Henderson; Toledo; Edmond; Oklahoma City; Boerne; CABA; La Plata; Buenos Aires; Rosario; Ciudad Autonoma Buenos Aires; Vitória; Salvador; Natal; Passo Fundo; Porto Alegre; São Paulo; Sorocaba; Brampton; Ottawa; Toronto; Trois-Rivières; Québec; Talca; Santiago; Quillota; Budapest; Edelény; Gödöllö; Hajdunánás; Mosonmagyaróvár; Püspökladány; Százhalombatta; Szombathely; Cona (FE); Rome; Napoli; Verona; Narita-shi; Kamakura-shi; Yokohama; Nankoku-shi; Kumamoto; Sakai-shi; Chuo-ku; Kiyose-shi; Shinagawa-ku; Shinjuku-ku; Tachikawa-shi; Toshima-ku; Fukuoka; Hiroshima; Guadalajara; Chihuahua City; Durango, Durango; Tlalnepantla; Yucatán; Poznan; Krakow; Bialystok; Elblag; Gdansk; Tarnów; Benoni; Cape Town; Durban; George; Johannesburg; Middelburg; Daegu; Seoul; Seongnam-si, Gyeonggi-do; Istanbul; Izmir; Kayseri; Kocaeli; Mersin; Bradford | 0 | NA       | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
       "| NCT05394350 | 1088-002            | A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)                                             | A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors                                                                                                                                                                                           | NA          | TERMINATED            | 2024-11 | 2022-07-07 | ACTUAL | 2023-09-07 | ⋯ | ALL    | 18 Years | NA        | ADULT, OLDER_ADULT |  13 | United States; Canada; Denmark; Israel; Switzerland                                                                                                 | Miami; New York; San Antonio; Toronto; Québec; Copenhagen; Odense; Haifa; Jerusalem; Sankt Gallen; Bellinzona; Chur                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0 | NA       | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
       "| NCT04765514 | IIT-0012            | Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients                                                                                         | A Randomized Controlled Trial of Chemo-Radiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail Patients With Newly Diagnosed Glioblastoma                                                                                                                                                                                                                 | NA          | RECRUITING            | 2025-06 | 2022-07-27 | ACTUAL | 2032-06    | ⋯ | MALE   | 65 Years | NA        | OLDER_ADULT        |   2 | Canada                                                                                                                                              | Calgary; Edmonton                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0 | NA       | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
       "| NCT05432934 | BIO-2549            | Transversus Abdominis Plane Blocks With and Without Dexamethasone                                                                                                            | Transversus Abdominis Plane Blocks With and Without Dexamethasone: A Randomized Clinical Trial in Minimally Invasive Colorectal Surgery                                                                                                                                                                                                                              | TAP-DEX     | UNKNOWN               | 2023-11 | 2022-09-01 | ACTUAL | 2024-03-31 | ⋯ | ALL    | 18 Years | NA        | ADULT, OLDER_ADULT |   1 | Canada                                                                                                                                              | Saskatoon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0 | NA       | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
       "| NCT05489211 | D926UC00001         | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)                                     | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours                                                                                                                            | NA          | RECRUITING            | 2025-07 | 2022-09-06 | ACTUAL | 2026-08-19 | ⋯ | ALL    | 18 Years | 130 Years | ADULT, OLDER_ADULT |  95 | United States; Canada; China; France; Germany; Italy; Japan; Poland; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom      | Los Angeles; San Diego; Santa Rosa; Muncie; Kansas City; Boston; Grand Rapids; East Brunswick; Albuquerque; Commack; Cincinnati; Columbus; Portland; Nashville; Houston; Madison; Toronto; Montreal; Québec; Changsha; Chongqing; Guangzhou; Hangzhou; Hefei; Shanghai; Shenyang; Wuhan; Xi'an; Zhengzhou; Bordeaux; Lyon; Marseille; Suresnes; Berlin; Essen; Hanover; München; Regensburg; Florence; Genova; Milan; Napoli; Rome; Chūōku; Kashiwa; Kōtoku; Nagoya; Shinagawa-ku; Suita-shi; Gliwice; Krakow; Lodz; Poznan; Warsaw; Seoul; Barcelona; Córdoba; Madrid; Málaga; Pamplona; Seville; Basel; Bellinzona; Sankt Gallen; Liou Ying Township; Taipei; Taoyuan District; Ankara; Edirne; Kadıkoy/Istanbul; Karşıyaka; Konya; Pamukkale; Samsun; Cambridge; Dundee; London; Manchester                                                                                                                                                                                                                                                                   | 0 | NA       | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
       "| NCT05593445 | INCB 18424-220      | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus                                                                       | A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus                                                                                                                                                                                                                 | NA          | COMPLETED             | 2024-08 | 2022-11-18 | ACTUAL | 2023-09-01 | ⋯ | FEMALE | 18 Years | NA        | ADULT, OLDER_ADULT |  14 | United States; Canada                                                                                                                               | Birmingham; Scottsdale; Irvine; Washington D.C.; Miami; West Seneca; Chapel Hill; Ashtabula; Bexley; Dallas; Murray; Seattle; Waterloo; Québec                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0 | NA       | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
       "| NCT05407675 | CA099-003           | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors                                                                                                                                                                                                                  | NA          | COMPLETED             | 2025-09 | 2022-08-02 | ACTUAL | 2024-08-22 | ⋯ | ALL    | 18 Years | NA        | ADULT, OLDER_ADULT |  18 | United States; Canada; France; Spain; Switzerland                                                                                                   | Boston; Hackensack; Houston; Edmonton; Hamilton; Ottawa; Toronto; Bordeaux; Villejuif; Marseille; Toulouse; Málaga; Madrid; Sankt Gallen; Basel; Geneva                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0 | NA       | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n",
       "| NCT05482971 | EXCEED ET / A22-301 | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET                                                                  | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential Thrombocythemia                                                                                                                                                                                            | NA          | ACTIVE_NOT_RECRUITING | 2025-08 | 2022-09-29 | ACTUAL | 2025-05-09 | ⋯ | ALL    | 18 Years | NA        | ADULT, OLDER_ADULT |  34 | United States; Canada                                                                                                                               | Birmingham; Duarte; Greenbrae; Los Angeles; New Haven; Washington D.C.; Atlanta; Fort Wayne; Paducah; New Orleans; Baltimore; Boston; St Louis; Reno; East Brunswick; Hackensack; New York; Stony Brook; The Bronx; Chapel Hill; Durham; Greenville; Wilson; Memphis; Houston; Salt Lake City; Charlottesville; Seattle; Calgary; Vancouver; Hamilton; Toronto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 1 | 40330782 | Masarova L, Reeves BN, El Chaer F, Foltz L, Tashi T, Abu-Zeinah G, Lucas J, Halpern AB, Maze D, Qin A, Safah H, Lan F, O'Connell CL, Goel S, Rein L, Fang B, How J, Babu S, Li Z, Cerquozzi S, Oh ST, Hunter AM, Podoltsev N, Vachhani P, Yacoub A, Cunningham JM, Hillis C, Otoukesh S, Zagrijtschuk O, Castro H, Bose P. A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. Front Med (Lausanne). 2025 Apr 17;12:1548590. doi: 10.3389/fmed.2025.1548590. eCollection 2025. |\n",
       "\n"
      ],
      "text/plain": [
       "   nct_id      org_study_id       \n",
       "1  NCT05444894 EM-301-BThal-001   \n",
       "2  NCT07150091 208887 Sub Study 6 \n",
       "3  NCT05421598 DRI17509           \n",
       "4  NCT05394350 1088-002           \n",
       "5  NCT04765514 IIT-0012           \n",
       "6  NCT05432934 BIO-2549           \n",
       "7  NCT05489211 D926UC00001        \n",
       "8  NCT05593445 INCB 18424-220     \n",
       "9  NCT05407675 CA099-003          \n",
       "10 NCT05482971 EXCEED ET / A22-301\n",
       "   brief_title                                                                                                                                                                 \n",
       "1  EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)                                         \n",
       "2  Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM                                  \n",
       "3  Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                      \n",
       "4  A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)                                            \n",
       "5  Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients                                                                                        \n",
       "6  Transversus Abdominis Plane Blocks With and Without Dexamethasone                                                                                                           \n",
       "7  Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)                                    \n",
       "8  A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus                                                                      \n",
       "9  A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors\n",
       "10 A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET                                                                 \n",
       "   official_title                                                                                                                                                                                                                                                                                                                                                      \n",
       "1  A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)                                   \n",
       "2  A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 6 - Belantamab Mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone in Combination\n",
       "3  A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma                                                                                                                                                \n",
       "4  A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors                                                                                                                                                                                          \n",
       "5  A Randomized Controlled Trial of Chemo-Radiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail Patients With Newly Diagnosed Glioblastoma                                                                                                                                                                                                                \n",
       "6  Transversus Abdominis Plane Blocks With and Without Dexamethasone: A Randomized Clinical Trial in Minimally Invasive Colorectal Surgery                                                                                                                                                                                                                             \n",
       "7  A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours                                                                                                                           \n",
       "8  A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus                                                                                                                                                                                                                \n",
       "9  A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors                                                                                                                                                                                                                 \n",
       "10 A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential Thrombocythemia                                                                                                                                                                                           \n",
       "   acronym     overall_status        status_verified_ym start_date\n",
       "1  NA          ACTIVE_NOT_RECRUITING 2025-03            2022-04-29\n",
       "2  NA          ACTIVE_NOT_RECRUITING 2025-08            2022-07-19\n",
       "3  TIDE-asthma COMPLETED             2025-10            2022-06-30\n",
       "4  NA          TERMINATED            2024-11            2022-07-07\n",
       "5  NA          RECRUITING            2025-06            2022-07-27\n",
       "6  TAP-DEX     UNKNOWN               2023-11            2022-09-01\n",
       "7  NA          RECRUITING            2025-07            2022-09-06\n",
       "8  NA          COMPLETED             2024-08            2022-11-18\n",
       "9  NA          COMPLETED             2025-09            2022-08-02\n",
       "10 NA          ACTIVE_NOT_RECRUITING 2025-08            2022-09-29\n",
       "   start_date_type primary_completion_date ⋯ sex    minimum_age maximum_age\n",
       "1  ACTUAL          2025-09                 ⋯ ALL    18 Years    35 Years   \n",
       "2  ACTUAL          2025-04-17              ⋯ ALL    18 Years    NA         \n",
       "3  ACTUAL          2024-10-11              ⋯ ALL    18 Years    75 Years   \n",
       "4  ACTUAL          2023-09-07              ⋯ ALL    18 Years    NA         \n",
       "5  ACTUAL          2032-06                 ⋯ MALE   65 Years    NA         \n",
       "6  ACTUAL          2024-03-31              ⋯ ALL    18 Years    NA         \n",
       "7  ACTUAL          2026-08-19              ⋯ ALL    18 Years    130 Years  \n",
       "8  ACTUAL          2023-09-01              ⋯ FEMALE 18 Years    NA         \n",
       "9  ACTUAL          2024-08-22              ⋯ ALL    18 Years    NA         \n",
       "10 ACTUAL          2025-05-09              ⋯ ALL    18 Years    NA         \n",
       "   std_ages           n_sites\n",
       "1  ADULT                8    \n",
       "2  ADULT, OLDER_ADULT  12    \n",
       "3  ADULT, OLDER_ADULT 113    \n",
       "4  ADULT, OLDER_ADULT  13    \n",
       "5  OLDER_ADULT          2    \n",
       "6  ADULT, OLDER_ADULT   1    \n",
       "7  ADULT, OLDER_ADULT  95    \n",
       "8  ADULT, OLDER_ADULT  14    \n",
       "9  ADULT, OLDER_ADULT  18    \n",
       "10 ADULT, OLDER_ADULT  34    \n",
       "   countries                                                                                                                                          \n",
       "1  United States; Canada                                                                                                                              \n",
       "2  United States; Brazil; Canada; France; Germany; Greece; Mexico; South Korea                                                                        \n",
       "3  United States; Argentina; Brazil; Canada; Chile; Hungary; Italy; Japan; Mexico; Poland; South Africa; South Korea; Turkey (Türkiye); United Kingdom\n",
       "4  United States; Canada; Denmark; Israel; Switzerland                                                                                                \n",
       "5  Canada                                                                                                                                             \n",
       "6  Canada                                                                                                                                             \n",
       "7  United States; Canada; China; France; Germany; Italy; Japan; Poland; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom     \n",
       "8  United States; Canada                                                                                                                              \n",
       "9  United States; Canada; France; Spain; Switzerland                                                                                                  \n",
       "10 United States; Canada                                                                                                                              \n",
       "   cities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n",
       "1  Oakland; Minneapolis; New York; Cleveland; Philadelphia; Nashville; Toronto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \n",
       "2  Boston; Salvador; São Paulo; Halifax; Villejuif; Hamburg; Athens; Mexico City; Seoul; Ulsan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     \n",
       "3  La Jolla; Los Angeles; San Jose; Stockton; Westminster; Boynton Beach; Cape Coral; Cutler Bay; Hialeah; Miami; Pembroke Pines; Boise; South Bend; Kansas City; Baltimore; Southfield; Henderson; Toledo; Edmond; Oklahoma City; Boerne; CABA; La Plata; Buenos Aires; Rosario; Ciudad Autonoma Buenos Aires; Vitória; Salvador; Natal; Passo Fundo; Porto Alegre; São Paulo; Sorocaba; Brampton; Ottawa; Toronto; Trois-Rivières; Québec; Talca; Santiago; Quillota; Budapest; Edelény; Gödöllö; Hajdunánás; Mosonmagyaróvár; Püspökladány; Százhalombatta; Szombathely; Cona (FE); Rome; Napoli; Verona; Narita-shi; Kamakura-shi; Yokohama; Nankoku-shi; Kumamoto; Sakai-shi; Chuo-ku; Kiyose-shi; Shinagawa-ku; Shinjuku-ku; Tachikawa-shi; Toshima-ku; Fukuoka; Hiroshima; Guadalajara; Chihuahua City; Durango, Durango; Tlalnepantla; Yucatán; Poznan; Krakow; Bialystok; Elblag; Gdansk; Tarnów; Benoni; Cape Town; Durban; George; Johannesburg; Middelburg; Daegu; Seoul; Seongnam-si, Gyeonggi-do; Istanbul; Izmir; Kayseri; Kocaeli; Mersin; Bradford\n",
       "4  Miami; New York; San Antonio; Toronto; Québec; Copenhagen; Odense; Haifa; Jerusalem; Sankt Gallen; Bellinzona; Chur                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \n",
       "5  Calgary; Edmonton                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \n",
       "6  Saskatoon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \n",
       "7  Los Angeles; San Diego; Santa Rosa; Muncie; Kansas City; Boston; Grand Rapids; East Brunswick; Albuquerque; Commack; Cincinnati; Columbus; Portland; Nashville; Houston; Madison; Toronto; Montreal; Québec; Changsha; Chongqing; Guangzhou; Hangzhou; Hefei; Shanghai; Shenyang; Wuhan; Xi'an; Zhengzhou; Bordeaux; Lyon; Marseille; Suresnes; Berlin; Essen; Hanover; München; Regensburg; Florence; Genova; Milan; Napoli; Rome; Chūōku; Kashiwa; Kōtoku; Nagoya; Shinagawa-ku; Suita-shi; Gliwice; Krakow; Lodz; Poznan; Warsaw; Seoul; Barcelona; Córdoba; Madrid; Málaga; Pamplona; Seville; Basel; Bellinzona; Sankt Gallen; Liou Ying Township; Taipei; Taoyuan District; Ankara; Edirne; Kadıkoy/Istanbul; Karşıyaka; Konya; Pamukkale; Samsun; Cambridge; Dundee; London; Manchester                                                                                                                                                                                                                                                                  \n",
       "8  Birmingham; Scottsdale; Irvine; Washington D.C.; Miami; West Seneca; Chapel Hill; Ashtabula; Bexley; Dallas; Murray; Seattle; Waterloo; Québec                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \n",
       "9  Boston; Hackensack; Houston; Edmonton; Hamilton; Ottawa; Toronto; Bordeaux; Villejuif; Marseille; Toulouse; Málaga; Madrid; Sankt Gallen; Basel; Geneva                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \n",
       "10 Birmingham; Duarte; Greenbrae; Los Angeles; New Haven; Washington D.C.; Atlanta; Fort Wayne; Paducah; New Orleans; Baltimore; Boston; St Louis; Reno; East Brunswick; Hackensack; New York; Stony Brook; The Bronx; Chapel Hill; Durham; Greenville; Wilson; Memphis; Houston; Salt Lake City; Charlottesville; Seattle; Calgary; Vancouver; Hamilton; Toronto                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  \n",
       "   n_references pmids   \n",
       "1  0            NA      \n",
       "2  0            NA      \n",
       "3  0            NA      \n",
       "4  0            NA      \n",
       "5  0            NA      \n",
       "6  0            NA      \n",
       "7  0            NA      \n",
       "8  0            NA      \n",
       "9  0            NA      \n",
       "10 1            40330782\n",
       "   citations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \n",
       "1  NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \n",
       "2  NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \n",
       "3  NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \n",
       "4  NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \n",
       "5  NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \n",
       "6  NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \n",
       "7  NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \n",
       "8  NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \n",
       "9  NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \n",
       "10 Masarova L, Reeves BN, El Chaer F, Foltz L, Tashi T, Abu-Zeinah G, Lucas J, Halpern AB, Maze D, Qin A, Safah H, Lan F, O'Connell CL, Goel S, Rein L, Fang B, How J, Babu S, Li Z, Cerquozzi S, Oh ST, Hunter AM, Podoltsev N, Vachhani P, Yacoub A, Cunningham JM, Hillis C, Otoukesh S, Zagrijtschuk O, Castro H, Bose P. A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. Front Med (Lausanne). 2025 Apr 17;12:1548590. doi: 10.3389/fmed.2025.1548590. eCollection 2025."
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "tbl_all"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "f2217e2b-d0e2-4ffb-b40a-ff6e56c466c6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<style>\n",
       ".list-inline {list-style: none; margin:0; padding: 0}\n",
       ".list-inline>li {display: inline-block}\n",
       ".list-inline>li:not(:last-child)::after {content: \"\\00b7\"; padding: 0 .5ex}\n",
       "</style>\n",
       "<ol class=list-inline><li>'studies'</li><li>'modules'</li></ol>\n"
      ],
      "text/latex": [
       "\\begin{enumerate*}\n",
       "\\item 'studies'\n",
       "\\item 'modules'\n",
       "\\end{enumerate*}\n"
      ],
      "text/markdown": [
       "1. 'studies'\n",
       "2. 'modules'\n",
       "\n",
       "\n"
      ],
      "text/plain": [
       "[1] \"studies\" \"modules\""
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "names(formals(studies_to_table))\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "231e4792-435d-4b94-a043-ab7fed00770e",
   "metadata": {},
   "source": [
    "## Jan-30"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7f744e5c-0f1c-4b7f-8035-521355791a6c",
   "metadata": {},
   "source": [
    "tested it out again"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "0906b21c-3339-43bc-b9b6-ac1b40f19418",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\u001b[1m\u001b[22m\u001b[36mℹ\u001b[39m Loading \u001b[34mtidytrials\u001b[39m\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A tibble: 10 × 5</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>nct_id</th><th scope=col>org_study_id</th><th scope=col>brief_title</th><th scope=col>official_title</th><th scope=col>acronym</th></tr>\n",
       "\t<tr><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td>NCT05488314</td><td>CR109260      </td><td>A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer                                                                     </td><td>A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer                                                                                                                                </td><td>METalmark   </td></tr>\n",
       "\t<tr><td>NCT05402124</td><td>CRC-CHAMP01   </td><td>The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study                                                                                       </td><td>The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study                                                                                                                                                                                               </td><td>NA          </td></tr>\n",
       "\t<tr><td>NCT05242471</td><td>CR109178      </td><td>A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease                                                     </td><td>A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease </td><td>DUET-CD     </td></tr>\n",
       "\t<tr><td>NCT04888481</td><td>CC-19-0369    </td><td>68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors                                                                                                         </td><td>68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors                                                                                                                                                                                                                 </td><td>NA          </td></tr>\n",
       "\t<tr><td>NCT05372354</td><td>CA057-003     </td><td>A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma</td><td>An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma</td><td>NA          </td></tr>\n",
       "\t<tr><td>NCT05419375</td><td>BX43361       </td><td>Screening Study for Participants With Malignant Tumors                                                                                                                              </td><td>Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors                                                                                                                                                                     </td><td>NA          </td></tr>\n",
       "\t<tr><td>NCT05403385</td><td>A2A-005       </td><td>Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer                                                              </td><td>A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy                                       </td><td>NA          </td></tr>\n",
       "\t<tr><td>NCT05099003</td><td>NCI-2021-11337</td><td>A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)                           </td><td>A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)                                                                                                                             </td><td>NA          </td></tr>\n",
       "\t<tr><td>NCT05070845</td><td>C1131003      </td><td>Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia                                                                                                         </td><td>AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA                                                                                                      </td><td>NA          </td></tr>\n",
       "\t<tr><td>NCT05174169</td><td>NRG-GI008     </td><td>Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease                                                                                                                 </td><td>Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease                                                                                                                                                                                                                         </td><td>CIRCULATE-US</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A tibble: 10 × 5\n",
       "\\begin{tabular}{lllll}\n",
       " nct\\_id & org\\_study\\_id & brief\\_title & official\\_title & acronym\\\\\n",
       " <chr> & <chr> & <chr> & <chr> & <chr>\\\\\n",
       "\\hline\n",
       "\t NCT05488314 & CR109260       & A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer                                                                      & A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer                                                                                                                                 & METalmark   \\\\\n",
       "\t NCT05402124 & CRC-CHAMP01    & The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study                                                                                        & The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study                                                                                                                                                                                                & NA          \\\\\n",
       "\t NCT05242471 & CR109178       & A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease                                                      & A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease  & DUET-CD     \\\\\n",
       "\t NCT04888481 & CC-19-0369     & 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors                                                                                                          & 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors                                                                                                                                                                                                                  & NA          \\\\\n",
       "\t NCT05372354 & CA057-003      & A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma & An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma & NA          \\\\\n",
       "\t NCT05419375 & BX43361        & Screening Study for Participants With Malignant Tumors                                                                                                                               & Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors                                                                                                                                                                      & NA          \\\\\n",
       "\t NCT05403385 & A2A-005        & Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer                                                               & A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy                                        & NA          \\\\\n",
       "\t NCT05099003 & NCI-2021-11337 & A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)                            & A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)                                                                                                                              & NA          \\\\\n",
       "\t NCT05070845 & C1131003       & Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia                                                                                                          & AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA                                                                                                       & NA          \\\\\n",
       "\t NCT05174169 & NRG-GI008      & Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease                                                                                                                  & Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease                                                                                                                                                                                                                          & CIRCULATE-US\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A tibble: 10 × 5\n",
       "\n",
       "| nct_id &lt;chr&gt; | org_study_id &lt;chr&gt; | brief_title &lt;chr&gt; | official_title &lt;chr&gt; | acronym &lt;chr&gt; |\n",
       "|---|---|---|---|---|\n",
       "| NCT05488314 | CR109260       | A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer                                                                      | A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer                                                                                                                                 | METalmark    |\n",
       "| NCT05402124 | CRC-CHAMP01    | The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study                                                                                        | The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study                                                                                                                                                                                                | NA           |\n",
       "| NCT05242471 | CR109178       | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease                                                      | A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease  | DUET-CD      |\n",
       "| NCT04888481 | CC-19-0369     | 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors                                                                                                          | 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors                                                                                                                                                                                                                  | NA           |\n",
       "| NCT05372354 | CA057-003      | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma | NA           |\n",
       "| NCT05419375 | BX43361        | Screening Study for Participants With Malignant Tumors                                                                                                                               | Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors                                                                                                                                                                      | NA           |\n",
       "| NCT05403385 | A2A-005        | Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer                                                               | A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy                                        | NA           |\n",
       "| NCT05099003 | NCI-2021-11337 | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)                            | A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)                                                                                                                              | NA           |\n",
       "| NCT05070845 | C1131003       | Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia                                                                                                          | AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA                                                                                                       | NA           |\n",
       "| NCT05174169 | NRG-GI008      | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease                                                                                                                  | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease                                                                                                                                                                                                                          | CIRCULATE-US |\n",
       "\n"
      ],
      "text/plain": [
       "   nct_id      org_study_id  \n",
       "1  NCT05488314 CR109260      \n",
       "2  NCT05402124 CRC-CHAMP01   \n",
       "3  NCT05242471 CR109178      \n",
       "4  NCT04888481 CC-19-0369    \n",
       "5  NCT05372354 CA057-003     \n",
       "6  NCT05419375 BX43361       \n",
       "7  NCT05403385 A2A-005       \n",
       "8  NCT05099003 NCI-2021-11337\n",
       "9  NCT05070845 C1131003      \n",
       "10 NCT05174169 NRG-GI008     \n",
       "   brief_title                                                                                                                                                                         \n",
       "1  A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer                                                                     \n",
       "2  The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study                                                                                       \n",
       "3  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease                                                     \n",
       "4  68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors                                                                                                         \n",
       "5  A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma\n",
       "6  Screening Study for Participants With Malignant Tumors                                                                                                                              \n",
       "7  Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer                                                              \n",
       "8  A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)                           \n",
       "9  Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia                                                                                                         \n",
       "10 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease                                                                                                                 \n",
       "   official_title                                                                                                                                                                                                                                                                              \n",
       "1  A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer                                                                                                                                \n",
       "2  The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study                                                                                                                                                                                               \n",
       "3  A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease \n",
       "4  68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors                                                                                                                                                                                                                 \n",
       "5  An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma\n",
       "6  Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors                                                                                                                                                                     \n",
       "7  A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy                                       \n",
       "8  A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)                                                                                                                             \n",
       "9  AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA                                                                                                      \n",
       "10 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease                                                                                                                                                                                                                         \n",
       "   acronym     \n",
       "1  METalmark   \n",
       "2  NA          \n",
       "3  DUET-CD     \n",
       "4  NA          \n",
       "5  NA          \n",
       "6  NA          \n",
       "7  NA          \n",
       "8  NA          \n",
       "9  NA          \n",
       "10 CIRCULATE-US"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<table class=\"dataframe\">\n",
       "<caption>A tibble: 10 × 9</caption>\n",
       "<thead>\n",
       "\t<tr><th scope=col>nct_id</th><th scope=col>study_type</th><th scope=col>phases</th><th scope=col>allocation</th><th scope=col>intervention_model</th><th scope=col>primary_purpose</th><th scope=col>masking</th><th scope=col>enrollment_count</th><th scope=col>enrollment_type</th></tr>\n",
       "\t<tr><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th><th scope=col>&lt;chr&gt;</th></tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "\t<tr><td>NCT05488314</td><td>INTERVENTIONAL</td><td>PHASE1, PHASE2</td><td>NON_RANDOMIZED</td><td>SEQUENTIAL  </td><td>TREATMENT               </td><td>NONE     </td><td>57   </td><td>ACTUAL   </td></tr>\n",
       "\t<tr><td>NCT05402124</td><td>INTERVENTIONAL</td><td>PHASE2        </td><td>NA            </td><td>SINGLE_GROUP</td><td>HEALTH_SERVICES_RESEARCH</td><td>NONE     </td><td>100  </td><td>ESTIMATED</td></tr>\n",
       "\t<tr><td>NCT05242471</td><td>INTERVENTIONAL</td><td>PHASE2        </td><td>RANDOMIZED    </td><td>PARALLEL    </td><td>TREATMENT               </td><td>DOUBLE   </td><td>703  </td><td>ACTUAL   </td></tr>\n",
       "\t<tr><td>NCT04888481</td><td>INTERVENTIONAL</td><td>PHASE2        </td><td>NA            </td><td>SINGLE_GROUP</td><td>DIAGNOSTIC              </td><td>NONE     </td><td>600  </td><td>ESTIMATED</td></tr>\n",
       "\t<tr><td>NCT05372354</td><td>INTERVENTIONAL</td><td>PHASE1, PHASE2</td><td>RANDOMIZED    </td><td>PARALLEL    </td><td>TREATMENT               </td><td>NONE     </td><td>260  </td><td>ESTIMATED</td></tr>\n",
       "\t<tr><td>NCT05419375</td><td>INTERVENTIONAL</td><td>PHASE2        </td><td>NA            </td><td>SINGLE_GROUP</td><td>OTHER                   </td><td>NONE     </td><td>15000</td><td>ESTIMATED</td></tr>\n",
       "\t<tr><td>NCT05403385</td><td>INTERVENTIONAL</td><td>PHASE2        </td><td>RANDOMIZED    </td><td>PARALLEL    </td><td>TREATMENT               </td><td>QUADRUPLE</td><td>36   </td><td>ACTUAL   </td></tr>\n",
       "\t<tr><td>NCT05099003</td><td>INTERVENTIONAL</td><td>PHASE1, PHASE2</td><td>NA            </td><td>SINGLE_GROUP</td><td>TREATMENT               </td><td>NONE     </td><td>132  </td><td>ESTIMATED</td></tr>\n",
       "\t<tr><td>NCT05070845</td><td>INTERVENTIONAL</td><td>PHASE2        </td><td>NA            </td><td>SINGLE_GROUP</td><td>TREATMENT               </td><td>NONE     </td><td>61   </td><td>ESTIMATED</td></tr>\n",
       "\t<tr><td>NCT05174169</td><td>INTERVENTIONAL</td><td>PHASE2, PHASE3</td><td>RANDOMIZED    </td><td>PARALLEL    </td><td>TREATMENT               </td><td>NONE     </td><td>1912 </td><td>ESTIMATED</td></tr>\n",
       "</tbody>\n",
       "</table>\n"
      ],
      "text/latex": [
       "A tibble: 10 × 9\n",
       "\\begin{tabular}{lllllllll}\n",
       " nct\\_id & study\\_type & phases & allocation & intervention\\_model & primary\\_purpose & masking & enrollment\\_count & enrollment\\_type\\\\\n",
       " <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr> & <chr>\\\\\n",
       "\\hline\n",
       "\t NCT05488314 & INTERVENTIONAL & PHASE1, PHASE2 & NON\\_RANDOMIZED & SEQUENTIAL   & TREATMENT                & NONE      & 57    & ACTUAL   \\\\\n",
       "\t NCT05402124 & INTERVENTIONAL & PHASE2         & NA             & SINGLE\\_GROUP & HEALTH\\_SERVICES\\_RESEARCH & NONE      & 100   & ESTIMATED\\\\\n",
       "\t NCT05242471 & INTERVENTIONAL & PHASE2         & RANDOMIZED     & PARALLEL     & TREATMENT                & DOUBLE    & 703   & ACTUAL   \\\\\n",
       "\t NCT04888481 & INTERVENTIONAL & PHASE2         & NA             & SINGLE\\_GROUP & DIAGNOSTIC               & NONE      & 600   & ESTIMATED\\\\\n",
       "\t NCT05372354 & INTERVENTIONAL & PHASE1, PHASE2 & RANDOMIZED     & PARALLEL     & TREATMENT                & NONE      & 260   & ESTIMATED\\\\\n",
       "\t NCT05419375 & INTERVENTIONAL & PHASE2         & NA             & SINGLE\\_GROUP & OTHER                    & NONE      & 15000 & ESTIMATED\\\\\n",
       "\t NCT05403385 & INTERVENTIONAL & PHASE2         & RANDOMIZED     & PARALLEL     & TREATMENT                & QUADRUPLE & 36    & ACTUAL   \\\\\n",
       "\t NCT05099003 & INTERVENTIONAL & PHASE1, PHASE2 & NA             & SINGLE\\_GROUP & TREATMENT                & NONE      & 132   & ESTIMATED\\\\\n",
       "\t NCT05070845 & INTERVENTIONAL & PHASE2         & NA             & SINGLE\\_GROUP & TREATMENT                & NONE      & 61    & ESTIMATED\\\\\n",
       "\t NCT05174169 & INTERVENTIONAL & PHASE2, PHASE3 & RANDOMIZED     & PARALLEL     & TREATMENT                & NONE      & 1912  & ESTIMATED\\\\\n",
       "\\end{tabular}\n"
      ],
      "text/markdown": [
       "\n",
       "A tibble: 10 × 9\n",
       "\n",
       "| nct_id &lt;chr&gt; | study_type &lt;chr&gt; | phases &lt;chr&gt; | allocation &lt;chr&gt; | intervention_model &lt;chr&gt; | primary_purpose &lt;chr&gt; | masking &lt;chr&gt; | enrollment_count &lt;chr&gt; | enrollment_type &lt;chr&gt; |\n",
       "|---|---|---|---|---|---|---|---|---|\n",
       "| NCT05488314 | INTERVENTIONAL | PHASE1, PHASE2 | NON_RANDOMIZED | SEQUENTIAL   | TREATMENT                | NONE      | 57    | ACTUAL    |\n",
       "| NCT05402124 | INTERVENTIONAL | PHASE2         | NA             | SINGLE_GROUP | HEALTH_SERVICES_RESEARCH | NONE      | 100   | ESTIMATED |\n",
       "| NCT05242471 | INTERVENTIONAL | PHASE2         | RANDOMIZED     | PARALLEL     | TREATMENT                | DOUBLE    | 703   | ACTUAL    |\n",
       "| NCT04888481 | INTERVENTIONAL | PHASE2         | NA             | SINGLE_GROUP | DIAGNOSTIC               | NONE      | 600   | ESTIMATED |\n",
       "| NCT05372354 | INTERVENTIONAL | PHASE1, PHASE2 | RANDOMIZED     | PARALLEL     | TREATMENT                | NONE      | 260   | ESTIMATED |\n",
       "| NCT05419375 | INTERVENTIONAL | PHASE2         | NA             | SINGLE_GROUP | OTHER                    | NONE      | 15000 | ESTIMATED |\n",
       "| NCT05403385 | INTERVENTIONAL | PHASE2         | RANDOMIZED     | PARALLEL     | TREATMENT                | QUADRUPLE | 36    | ACTUAL    |\n",
       "| NCT05099003 | INTERVENTIONAL | PHASE1, PHASE2 | NA             | SINGLE_GROUP | TREATMENT                | NONE      | 132   | ESTIMATED |\n",
       "| NCT05070845 | INTERVENTIONAL | PHASE2         | NA             | SINGLE_GROUP | TREATMENT                | NONE      | 61    | ESTIMATED |\n",
       "| NCT05174169 | INTERVENTIONAL | PHASE2, PHASE3 | RANDOMIZED     | PARALLEL     | TREATMENT                | NONE      | 1912  | ESTIMATED |\n",
       "\n"
      ],
      "text/plain": [
       "   nct_id      study_type     phases         allocation     intervention_model\n",
       "1  NCT05488314 INTERVENTIONAL PHASE1, PHASE2 NON_RANDOMIZED SEQUENTIAL        \n",
       "2  NCT05402124 INTERVENTIONAL PHASE2         NA             SINGLE_GROUP      \n",
       "3  NCT05242471 INTERVENTIONAL PHASE2         RANDOMIZED     PARALLEL          \n",
       "4  NCT04888481 INTERVENTIONAL PHASE2         NA             SINGLE_GROUP      \n",
       "5  NCT05372354 INTERVENTIONAL PHASE1, PHASE2 RANDOMIZED     PARALLEL          \n",
       "6  NCT05419375 INTERVENTIONAL PHASE2         NA             SINGLE_GROUP      \n",
       "7  NCT05403385 INTERVENTIONAL PHASE2         RANDOMIZED     PARALLEL          \n",
       "8  NCT05099003 INTERVENTIONAL PHASE1, PHASE2 NA             SINGLE_GROUP      \n",
       "9  NCT05070845 INTERVENTIONAL PHASE2         NA             SINGLE_GROUP      \n",
       "10 NCT05174169 INTERVENTIONAL PHASE2, PHASE3 RANDOMIZED     PARALLEL          \n",
       "   primary_purpose          masking   enrollment_count enrollment_type\n",
       "1  TREATMENT                NONE      57               ACTUAL         \n",
       "2  HEALTH_SERVICES_RESEARCH NONE      100              ESTIMATED      \n",
       "3  TREATMENT                DOUBLE    703              ACTUAL         \n",
       "4  DIAGNOSTIC               NONE      600              ESTIMATED      \n",
       "5  TREATMENT                NONE      260              ESTIMATED      \n",
       "6  OTHER                    NONE      15000            ESTIMATED      \n",
       "7  TREATMENT                QUADRUPLE 36               ACTUAL         \n",
       "8  TREATMENT                NONE      132              ESTIMATED      \n",
       "9  TREATMENT                NONE      61               ESTIMATED      \n",
       "10 TREATMENT                NONE      1912             ESTIMATED      "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "suppressWarnings(devtools::load_all())\n",
    "spec <- list(\n",
    "  query = \"cancer\",\n",
    "  max_records = 10,\n",
    "  phase = \"Phase 2\",\n",
    "  country = \"Canada\",\n",
    "  from_date = \"2022-01-01\",\n",
    "  to_date = \"2023-01-01\",\n",
    "  date_filter = \"StartDate\"\n",
    ")\n",
    "result <- trials_run_spec(spec)\n",
    "\n",
    "tabs <- studies_to_tables_by_module(result$studies, modules = c(\"identificationModule\",\"designModule\"))\n",
    "\n",
    "tabs$identificationModule\n",
    "tabs$designModule"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "56c1b56d-8165-43d8-b8ee-375c0c5f9853",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "R",
   "language": "R",
   "name": "ir"
  },
  "language_info": {
   "codemirror_mode": "r",
   "file_extension": ".r",
   "mimetype": "text/x-r-source",
   "name": "R",
   "pygments_lexer": "r",
   "version": "4.5.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
